

Please type a sign(+) inside this box



PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No 1294 0010001/RWE/LBB
First Inventor or Application Identifier VON SEGGERN et al.
Title ADENOVIRUS VECTORS, PACKAGING CELL LINE COMPOSITIONS, AND METHODS FOR PREPARATION AND USE
Express Mail Label No.

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☐ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- ☒ Specification [Total Pages 138]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 30]
- ☐ Oath or Declaration [Total Pages _____]
 - ☐ Newly executed (original or copy)
 - ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
- ☐ Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☒ Computer Readable Copy
 - ☒ Paper Copy (identical to computer copy)
 - ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- ☐ *Small Entity Statement(s) (PTO/SB/09-12) ☐ Statement filed in prior application, Status still proper and desired
- ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- ☒ Other 37 CFR § 1.136(a)(3) Authorization ☐ Other

*NOTE FOR ITEMS 1 & 14. IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☐ Continuation ☐ Divisional ☒ Continuation-in-Part (CIP) of prior application No: 09/423,783

Prior application information: Examiner _____ Group/Art Unit: _____

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX P L L C				
	Attorneys at Law				
ADDRESS	Suite 600, 1100 New York Avenue, N.W.				
CITY	Washington	STATE	DC	ZIP CODE	20005-3934
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX	(202) 371-2540

NAME (Print/Type)	Lawrence B Bugaisky	Registration No (Attorney/Agent)	35,086
SIGNATURE	<i>Lawrence B Bugaisky</i>	Date	January 14, 2002

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

B. S. S. S. S. S.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE (202) 371-2540 (202) 371-6566

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL Q. LEE

STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*

HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL

TERESA U. MEDLER
JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
MATTHEW M. CATLETT*
NATHAN K. KELLEY*
ALBERT J. FASULO II *

KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
ANDREA J. KAMAGE**
NANCY J. LEITH**
TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

January 14, 2000

WRITER'S DIRECT NUMBER:

(202) 371-2589

INTERNET ADDRESS:

LARRYB@SKGF.COM

BOX PATENT APPLICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
(Continuation-In-Part of U.S. Appl. No. 09/423,783 and claims benefit of U.S.
Provisional Appl. No. 60/115,920)
Appl. No. *To be assigned*; Filed: Herewith
For: **Adenovirus Vectors, Packaging Cell Lines, Compositions, and
Methods for Preparation and Use**
Inventors: Von Seggern *et al.*
Our Ref: 1294.0010001/RWE/LBB

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office:

1. U.S. Utility Patent Application entitled:

**ADENOVIRUS VECTORS, PACKAGING CELL LINES,
COMPOSITIONS, AND METHODS FOR PREPARATION AND
USE**

01/14/00
jc639 U.S. PRO

Assistant Commissioner for Patents

January 14, 2000

Page 2

and naming as inventors:

Daniel J. VON SEGGERN

Glen R. NEMEROW

Paul HALLENBECK

Susan STEVENSON

Yelena SKRIPCHENKO

the application comprising:

a. A specification containing:

(i) 123 pages of description prior to the claims;

(ii) 14 pages of claims (94 claims);

(iii) a one (1) page abstract;

b. 30 sheets of drawings: (Figures 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30);

c. 59 pages of a paper copy of the sequence listing;

d. A computer readable copy of the sequence listing. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same;

2. USPTO Utility Patent Application Transmittal Form PTO/SB/05 (*in duplicate*)
3. 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time (*in duplicate*); and
4. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

Assistant Commissioner for Patents

January 14, 2000

Page 3

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Luciano B. Buzicki,

Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

LBB/ybh

P:\USERS\Yharris\LBB\PTO\129411\skgf tr
SKGF Rec 9/22/98dcw

Adenovirus Vectors, Packaging Cell Lines, Compositions, and Methods for Preparation and Use

This application is a continuation-in-part of U.S. Application
09/423,783 filed November 12, 1999 and claims the benefit of the filing date of
U.S. Provisional Application 60/115,920 filed January 14, 1999. The contents
of each application are incorporated herein by reference.

Statement as to Rights to Inventions Made Under Federally Sponsored Research and Development

This invention was made with U.S. government support under NIH Grant
No. HL 54352. The government has certain rights in the invention.

Technical Field of the Invention

The present invention relates to gene therapy, especially to adenovirus-
based gene therapy. In particular, novel packaging cell lines are disclosed, for use
in facilitating the development of high-capacity and targeted vectors. High-
capacity adenovirus vectors are also disclosed herein, as are related compositions,
kits, and methods of preparation and use of the disclosed vectors, cell lines and
kits.

Background of the Invention

Enhanced transfer of DNA conjugates into cells has been achieved with
adenovirus, a human DNA virus which readily infects epithelial cells (Horwitz,
“Adenoviridae and Their Replication”, in *Virology*, Fields and Knipe, eds., Raven
Press, NY (1990) pp. 1679-1740).

Although adenovirus-mediated gene therapy represents an improved
method of DNA transfer into cells, a potential limitation of this approach is that
adenovirus replication results in disruption of the host cell. In addition,

adenovirus also possesses oncogenic properties including the ability of one of its proteins to bind to tumor suppressor gene products. The use of so-called replication defective strains of adenovirus (which typically possess E1A and/or E1B deletions that render the virus unable to replicate in host cells) is in principle more suitable for *in vivo* therapy; however, the potential of co-infection of epithelial cells with wild-type strains of virus resulting in transactivation of the recombinant virus may represent a significant safety concern for *in vivo* applications.

Another undesirable aspect of using intact or replication-competent adenovirus as a gene transfer means is that it is an oncogenic virus whose gene products are known to interfere with the function of host cell tumor suppressor proteins as well as immune recognition molecules, such as the major histocompatibility complex (MHC). In addition, pre-existing circulating antibodies to adenovirus may significantly reduce the efficiency of *in vivo* gene delivery. Lastly, only a foreign gene of 6 kilobases (kb) or less can be incorporated into the intact adenovirus genome for gene transfer experiments, whereas DNA segments of greater than 12 kb can be transferred using the methods of this invention.

In order to make Ad vectors more replication-incompetent, some investigators have attempted to construct recombinant Ad-derived vectors which have nearly all of their genome deleted, except for portions known to be required for packaging of virus particles. For example, helper-dependent vectors lacking all viral ORFs but including essential *cis* elements (the inverted terminal repeats -- ITRs -- and the contiguous packaging sequence) have been constructed, but the virions package less efficiently than the helper and package as multimers part of the time, which suggests that the virus may "want" to package a fuller DNA complement (see, *e.g.*, Fisher, *et al.*, *Virology* 217: 11-22, 1996). Mitani *et al.* (*Proc. Natl. Acad. Sci. USA* 92: 3854-3858, 1995) also describe a helper-dependent Ad vector that was apparently not completely replication-defective.

Amalfitano, *et al.* (*Proc. Natl. Acad. Sci. USA* 93: 3352-3356, 1996) describe the construction of Ad packaging cell lines that support the growth of

E1- and polymerase-deleted Ad vectors, in an effort to block the replication of Ad vectors *in vivo*. Similarly, Armentano, *et al.* (*Hum. Gene Ther.* 6: 1343-53, 1995) describes Ad vectors with most -- but not all -- of the E4 sequence deleted therefrom. However, since such a small amount of genetic material is deleted from the vectors, their ability to transport therapeutic sequences is rather limited. Published International App. No. WO96/14061 describes efforts to construct packaging cell lines containing nucleotide sequences encoding E1 and ORF6 of E4.

In addition to being able to incorporate large amounts of DNA into a vector, the ability to target the vectors to specific cell types will result in more efficient administration of desired therapeutics. Such targeting of adenovirus in a relatively simple system is one of the advantages of the current invention.

Thus, there is a need in the art to obtain Adenovirus vectors 1) capable of incorporating large segments of foreign DNA and capable of being targeted to specific cells, as well as to obtain cell lines which can package such adenovirus-gene deficient vector or targeted vectors. These needs, as well as others, are met by the invention.

Brief Summary of the Invention

This invention utilizes recombinant adenovirus constructs which duplicate the cell receptor binding and DNA delivery properties of intact adenovirus virions and thus represents an improved method for gene therapy and cell targeting as well as for antisense-based antiviral therapy.

In contrast to the disadvantages of using intact adenovirus, modified adenovirus vectors requiring a helper plasmid or virus, or so-called replication-deficient adenovirus in the art, the use of recombinant adenovirus-derived vectors according to one aspect of the present invention provides certain advantages for gene delivery. First, the Ad-derived vectors of the present invention possess all of the functional properties required for gene therapy including binding to

epithelial cell receptors and penetration of endocytic vesicles. Therapeutic viral vectors of the present invention may also be engineered to target the receptors of and achieve penetration of non-epithelial cells; means of engineering viral vectors to accomplish these ends are described in detail herein below.

5 Second, the vectors of the present invention have deletions of substantial portions of the Ad genome, which not only limits the ability of the Ad-derived vectors to “spread” to other host cells or tissues, but allows significant amounts of “foreign” (or non-native) nucleic acids to be incorporated into the viral genome without interfering with the reproduction and packaging of the viral genome. Therefore, the vectors of the present invention are ideal for use in a wide variety of therapeutic applications.

10 Third, while the vectors disclosed herein are safe for use as therapeutic agents in the treatment of a variety of human afflictions, some of these vectors do not require the presence of any “helpers” for propagation and packaging, largely because of the novel cell lines in which they are reproduced. Such cell lines -- referred to herein as packaging cell lines -- comprise yet another aspect of the invention.

15 To reduce the frequency of contamination with wild-type adenovirus, it is desirable to improve either the viral vector or the cell line to reduce the probability of recombination. For example, an adenovirus from a group with less homology to the group C viruses may be used to engineer recombinant viruses with little propensity for recombination with the Ad5 sequence contained in the packaging lines. The invention describes the preparation of packaging cells lines which stably expresses adenovirus proteins or polypeptides. These cell lines are useful for complementing viral vectors bearing deletions of regulatory and/or structural genes, irrespective of the serotype from which such a vector was derived.

20 It is also contemplated that the constructs and methods of the present invention will support the design and engineering of chimeric viral vectors which express amino acid residue sequences derived from two or more Ad serotypes.

Thus, unlike methods and constructs available prior to the advent of the present disclosure, this invention allows the greatest possible flexibility in the design and preparation of useful viral vectors and cell lines which support their construction and propagation -- all with a decreased risk of recombining with wild-type Ad to produce potentially-harmful recombinants.

In part, the present invention discloses a simpler, alternative means of reducing the recombination between viral and cellular sequences than those discussed in the art. One such means is to increase the size of the deletion in the recombinant virus and thereby reduce the extent of shared sequences between that virus and any Ad genes present in a packaging cell line *e.g.*, the Ad5 genes in 293 cells, or the various Ad genes in the novel cell lines of the present invention.

Deletions of all or portions of structural genes of the adenovirus have been considered undesirable because of the anticipated deleterious effects such deletions would have on viral reproduction and packaging. Indeed, the use of "helper" viruses or plasmids has often been recommended when using Ad-derived vectors containing large deletions in structural protein sequences precisely for this reason.

Contrary to what has been suggested in the art, however, this invention discloses the preparation, propagation and use of recombinant Ad-derived vectors having deletions of all or part of various gene sequences encoding Ad structural proteins, both as a way of reducing the risk of wild-type adenovirus contamination in virus preparations, as a way of allowing foreign DNA to be packaged in such vectors for a variety of diagnostic and therapeutic applications and as a way of targeting an adenovirus vector to a specific cell type.

The invention further discloses a wide variety of nucleic acid sequences and viral vectors. Thus, in one embodiment, the invention discloses a nucleic acid sequence encoding any one of the adenovirus fiber proteins mentioned in the specification, polypeptides or fragments thereof -- including, without limitation, those that include deletions or other mutations; those that are chimeric; and those that have linkers, foreign amino acid residues, or other molecules attached for various purposes as disclosed herein. Nucleic acid sequences encoding various

other adenovirus structural and/or regulatory proteins or polypeptides are also within the scope of the present invention.

In various embodiments, the adenovirus is a Group C adenovirus selected from serotypes 1, 2, 5 or 6; while in other embodiments, adenovirus selected from other serotypes, such as for example Ad37 (subgroup D) are useful as disclosed herein.

The invention is also directed to an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. A preferable embodiment of the invention may further comprise an intron operatively linked to the TPL, wherein said intron also contains requisite processing signals for the intron's removal. Another preferable embodiment of the invention is directed to the isolated nucleic acid molecule wherein said TPL nucleotide sequence consists essentially of complete TPL exon 1 operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. A related embodiment may further include an intron and appropriate processing signals. Additional embodiments of the invention are directed to nucleic acid molecules contained in plasmids selected from the group; consisting of pCLF, pDV60, pDV67, pDV69, pDV80 and PDV90. Packaging cell lines and adenovirus particles containing the nucleic acids described above are also included in the invention.

The invention is further directed to methods for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome comprising providing a) a packaging cell line which complements replication and packaging of said genome and b) a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles. The genome is introduced into the cell line. Additional embodiments of the invention

may also include the following steps; a) growing the cell line produced under conditions for producing particles; and/or b) harvesting an adenovirus vector particle containing said helper-independent fiberless recombinant adenovirus vector genome. The method may also include a cell line that expresses a fiber protein and complements a fiber mutation in the vector.

The invention is also directed to an adenovirus vector packaging cell line comprising a stably integrated nucleic acid molecule as described above, an operatively-linked promoter and a nucleic acid sequence which encodes an adenovirus structural protein, wherein said TPL sequence consists essentially of a first TPL exon operatively linked to a complete second TPL exon operatively linked to a complete third TPL exon. Preferably, the cell line may have a complete or partial first TPL exon. Another embodiment of the invention comprises adenovirus structural protein, such as adenovirus fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.

The invention is further directed to a recombinant adenovirus particle comprising a recombinant adenovirus vector genome wherein said genome: (a) does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, and (b) encodes an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication. The invention is also directed to a helper-independent fiberless recombinant adenovirus vector genome comprising genes which (a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene and (b) encodes an exogenous protein. Either of the above embodiments may substitute a helper-dependent for a helper-independent recombinant adenovirus vector genome. In a preferable embodiment, no fiber protein is expressed. In yet another embodiment of the invention, the recombinant adenovirus particle fails to express sufficient fiber protein to allow fiber

incorporation into the particle such that the particle can use the fiber pathway for infection.

5 The invention is further directed to a method for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome, said method comprising providing a packaging cell line which complements replication and packaging of said genome and a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles and harvesting said particles produced by said cell line. The method may also
10 comprise a step of coating (i.e. providing fiber protein in any way) to a particle with an adenovirus fiber protein. In a preferable embodiment the adenovirus particle comprises an exogenous protein or a modified fiber protein.

15 Another aspect of the invention is directed to a method for pseudotyping recombinant viral vectors comprising complementing a missing fiber gene of a helper-independent fiberless recombinant adenovirus vector genome by expressing in packaging cells a fiber gene from a different adenoviral serotype than said recombinant adenovirus vector, thereby pseudotyping said vector. An additional embodiment of the invention is directed to the method for pseudotyping recombinant viral vectors comprising: a) providing a packaging cell line for propagating a fiber gene deleted recombinant adenovirus vector, b) introducing
20 into said cell line a helper-independent fiberless recombinant adenovirus vector genome, and c) complementing the missing fiber gene by expression in the cells of a fiber gene from a different adenoviral serotype thereby pseudotyping the vector.

25 The invention is further directed to a method for specifically targeting an adenovirus vector to a cell of choice comprising providing a packaging cell line for producing a fiber gene-deleted adenovirus vector and providing a helper-independent fiberless recombinant adenovirus vector genome, wherein said gene for a missing fiber protein is complemented with a gene for a desired modification
30 for targeting the vector to a cell of choice.

The invention is further directed to a method for producing a modified adenovirus comprising providing *in vitro* an exogenous fiber protein to a fiberless adenovirus. Additional embodiments of the invention may provide any combination of all of the following steps such that the invention be directed to a method for producing a modified adenovirus comprising: a) providing a packaging cell line for producing a fiberless adenovirus vector, b) introducing into said cell line a helper-independent fiberless or helper-dependent fiberless recombinant adenovirus vector genome, c) growing and harvesting a fiberless adenovirus, d) maintaining the fiberless adenovirus in any suitable buffer, and e) providing exogenous fiber, wherein said fiber may be a modified fiber, to the fiberless adenovirus by adding conditioned media or a soluble fiber preparation or a fiber in any suitable buffer to a virus preparation thereby producing the modified adenovirus.

The invention is further directed to a method for producing a modified adenovirus comprising providing a packaging cell line for producing a helper-dependent fiberless adenovirus vector genome and providing a helper virus vector, wherein said cell line complements at least a deficient fiber protein gene, thereby producing the modified adenovirus. Another aspect of the invention is directed to a method for producing a modified adenovirus comprising: a) providing a packaging cell line for producing a fiberless adenovirus vector, b) introducing into said cell line a helper dependent fiberless recombinant adenovirus vector genome and a fiberless helper virus vector, c) growing and harvesting a fiberless adenovirus, and d) maintaining the fiberless adenovirus in infectious media, and e) providing exogenous fiber to the fiberless adenovirus by adding conditioned media or a soluble fiber preparation to a virus preparation thereby producing the modified adenovirus.

Additional aspects of the invention are directed to hybrid Ad/AAV vectors and to new helper-dependent vectors used with fiberless adenovirus vectors.

The invention is also directed to a method for delivering a heterologous gene to an EBV-infected B cells comprising infecting said B cells with a

pseudotyped Ad5 β gal. Δ F particle or other fiber-deleted adenovirus particle, said particle having a chimeric fiber with the receptor-binding knob domain of the adenovirus type 3 fiber.

The invention is also directed to an isolated nucleic acid comprising a post-transcriptional regulatory element (PRE) and a TPL. Preferably the PRE is the woodchuck hepatitis virus PRE (WPRE).

The invention is further directed to a composition for preparing a therapeutic vector, said composition comprising a plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding a fiber protein or a genome that is incapable of expressing sufficient fiber to result in packaging.

Another aspect of the invention is directed to a method of delivering a heterologous gene to a human or any animal comprising providing an exogenous gene to a target cell comprising contacting said cell *in vivo* or *ex vivo* with an amount of a recombinant adenovirus particle sufficient to infect said cell.

The invention is also directed to A method for producing a gutless adenoviral vector particle comprising: a) delivering a helper adenovirus vector genome to an adenovirus vector packaging cell, wherein said helper adenovirus vector genome lacks any gene encoding adenovirus fiber protein or lacks the ability to encode sufficient adenovirus fiber protein to produce an adenoviral vector comprising fiber protein in the absence of complementation by said packing cell and wherein said packaging cell comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to an adenoviral fiber protein or to a chimeric protein that includes an adenovirus fiber protein tail domain; (b) delivering a gutless adenovirus vector genome to said packaging cell; and (c) recovering the gutless adenoviral vector particle produced by said cell.

Another aspect of the invention is directed to a helper adenovirus particle comprising an adenovirus vector genome that does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, wherein said genome has a mutation in its packaging sequence that renders said genome

substantially incapable of being packaged. Packaging sequence are those sequences are those sequences involved in packaging the viral particle.

5 The invention is further directed to a helper adenovirus particle comprising an adenovirus vector genome with recombinase sites flanking its packaging sequence, wherein said vector genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.

10 The invention is also directed to an adenovirus particle comprising a gutless adenoviral vector genome and a fiberless capsid, as well as an adenovirus particle comprising a gutless adenoviral vector genome and a capsid comprising a modified fiber protein.

15 Another aspect of the invention is directed to a packaging cell for the production of a fiberless or fiber-modified gutless adenovirus particle comprising an adenovirus vector complementing plasmid and a nucleotide sequence encoding a recombinase, wherein said complementing plasmid comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to a nucleotide sequence encoding an adenoviral fiber protein or a chimeric adenoviral fiber protein. Preferably the cell line may comprise a recombinase. In an embodiment of the invention the recombinase may be Cre.

20 In another embodiment of the invention, the fiber-deleted adenovirus vectors of the invention and the fiber-complementing adenovirus packaging cells of the invention are used to produce a gutless adenovirus vector particle. Such particle comprises a gutless adenoviral vector genome in an adenoviral capsid. The fiber proteins of the capsid may be wild-type fiber, or the modified fiber proteins disclosed herein. Alternatively, such particle may have a fiberless capsid as disclosed herein. Preferably, the gutless genome contains at least one heterologous gene as described herein. As used herein, the term "gutless adenoviral vector genome" means an adenoviral vector genome from which all of the viral genes have been deleted.

25

The invention also discloses systems or kits for use in any of the
aforementioned methods. The systems or kits may contain any appropriate
combination of the within-described vectors, plasmids, cell lines, virus particles
and additional therapeutic agents as disclosed. Preferably, each such kit or system
5 includes a quantity of the appropriate therapeutic substance or sequence sufficient
for at least one administration, and instructions for administration and use. Thus,
one system further comprises an effective amount of a therapeutic agent which
enhances the therapeutic effect of the therapeutic viral vector-containing
composition. Another variation discloses that the composition and the therapeutic
10 agent are each included in a separate receptacle or container.

It will also be appreciated that any combination of the preceding elements
may also be efficacious as described herein, and that all related methods are also
within the scope of the present invention.

Brief Description of the Drawings

Figure 1 is a schematic diagram of the entire adenoviral E4 transcriptional
unit with the open reading frames (ORF) indicated by blocked segments along
with the promoter and terminator sequences. The location of primers for
amplifying specific portions of E4 are also indicated as further described in
Example 1A.
15

Figure 2 is a schematic map of plasmid pE4/Hygro as further described in
Example 1B.
20

Figure 3 is a schematic map of plasmid pCDNA3/Fiber as further described
in Example 1B.

Figure 4 is a schematic map of plasmid pCLF as further described in
Example 1B.
25

Figure 5 is a photograph of a Southern blot showing the presence of intact
adenovirus E4 3.1 kilobase (kb) insert in the 211 cell line as further described in
Example 1C.

Figure 6 is an autoradiograph showing labeled fiber protein immunoprecipitated from cells and electrophoresed under native and denaturing electrophoresis conditions as described in Example 1C. The 293 cells lack fiber while the sublines 211A, 211B and 211R contain fiber protein detectable in functional trimerized form and denatured monomeric form.

Figure 7 is a schematic map of plasmid pDEX/E1 as further described in Example 1D.

Figure 8 is a schematic map of plasmid pE1/Fiber as further described in Example 1F1.

Figure 9 is a schematic map of plasmid pE4/Fiber as further described in Example 1F2).

Figure 10 is a schematic illustration of linearized pD E1Bb gal delivery plasmids for use in cotransfection and recombination to form a recombinant adenoviral vector having multiple adenoviral gene deletions. The plasmids and recombination event are more fully described in Example 2A.

Figure 11 is a schematic of plasmid p11.3 as further described in Example 2A used in the construction of pDV44 delivery plasmid.

Figure 12 is a schematic of plasmid 8.2.

Figure 13 shows the trimeric structure of the recombinant fiber. 293, 211A, 211B, or 211R cells as indicated were metabolically labeled with [³⁵S]methionine, soluble protein extracts prepared, and fiber was immunoprecipitated. A portion of the precipitated protein was electrophoresed on an 8% SDS-PAGE gel under either semi-native or denaturing conditions. The positions of trimeric (T) and monomeric (M) fiber are indicated. As a control for electrophoretic conditions, recombinant Ad2 fiber produced in baculovirus-infected cells was run under identical conditions and stained with Coomassie blue.

Figure 14 shows the complementation of a fiber mutant adenovirus by fiber-producing cells. The cell lines indicated (2x10⁶ cells per sample) were infected with the temperature-sensitive fiber mutant adenovirus H5ts142 at 10 PFU/cell and incubated at either the permissive (32.5°C, stippled bars) or the

restrictive (39.5°C, solid bars) temperature. 48 hours post-infection, virus was isolated by freeze-thaw lysis and yields determined by fluorescent focus assay on SW480 cells. Each value represents the mean of duplicate samples, and the data shown is representative of multiple experiments.

Figure 15 shows the incorporation of the recombinant Ad5 fiber into Ad3 particles. In Figure 15A, the alignment of the N-terminal (penton base-binding) domains of fiber proteins from several different adenovirus serotypes is shown. From top to bottom, the five different serotypes are listed as SEQ ID NOs 21-25. In Figure 15B, type 3 adenovirus was propagated in 293, 211B, or 211R cells as indicated and purified by two sequential CsCl centrifugations. 10 µg of the purified viral particles was then electrophoresed under denaturing conditions and transferred to a PVDF membrane. Ad5 fiber was detected with a polyclonal rabbit antibody raised against recombinant Ad2 fiber. As a positive control for detection, 400 ng of wild-type Ad2 was run in the lane marked "Ad2". Under these conditions, the mobilities of the Ad2 and Ad5 fibers are indistinguishable and the antibody reacts with both proteins.

Figure 16 shows the fiber deletion in pDV44 and the genomic structures of the Ad5.βgal.ΔF and Ad5.βgal.wt vectors: Figure 16A shows pDV44 that was constructed by removing the fiber gene and residual E3 sequences (nt 30819:32743 of AD5) from pBHG10. Figures 16B shows viruses constructed by cotransfection of either pBHG10 or pDV44 with pΔE1Bβgal. Both are E1/E3 deleted Ad5 vectors, and Ad5.βgal.ΔF has the additional fiber (L5) deletion as in pDV44.

Figure 17 shows the analysis of the viral chromosomes. Figure 17A shows the predicted EcoRI restriction maps of Ad5.βgal.wt and Ad5.βgal.ΔF. The 5.9 kb fragment at the right end of the Ad5.βgal.wt genome is reduced to 4.0 kb by the deletion of fiber sequences in Ad5.βgal.ΔF. Figure 17B shows an ethidium bromide-stained gel of EcoRI-digested viral DNA. Figure 17C shows a Southern blot of the gel as described in Example 2 probed either with labeled fiber or E4 sequences.

Figure 18 shows the analysis of vertex proteins in the viral particles. 293 (non-fiber expressing) or 211B (fiber-expressing) cells were infected with Ad5.βgal.wt ('wt') or with Ad5.βgal.ΔF ('ΔF') and the resulting viral particles were purified on CsCl gradients. 10 μg of purified virions was then electrophoresed on 5-16% gradient gels and Western blotted. Proteins were detected with polyclonal anti-fiber or anti-penton base antibodies.

Figure 19 shows the infectivity of Ad particles on THP-1 monocytic cells. Figure 19A shows THP-1 cells that were infected with Ad5.βgal.wt or with fiberless Ad5.βgal.ΔF at 100,000 particles/cell. Forty-eight hours after infection, cells were fixed and stained with X-gal and the fraction of infected cells was determined by light microscopy. Figure 19B shows cells that were infected with 1000 particles per cell of Ad5.βgal.wt or with 100,000 particles/cell of Ad5.βgal.ΔF. As indicated, cells were pretreated with 100 μg/ml of recombinant penton base or with 20 μg/ml of recombinant Ad2 fiber.

Figure 20 shows a schematic of improved fiber-complementing cell lines, 633 and 644 as further described in the Examples.

Figures 21 and 22 illustrates pseudotyping of fiberless particles with fiber proteins and infectivity data as further described in the Examples.

Figure 23 shows the ClaI to BglII fragment of Ad5.

Figure 24 shows the plasmid pGRE5-2/EBV

Figure 25 shows the plasmid pGRE5-E1.

Figure 26 shows the plasmid pSE280-E2 BamHI-SmaI.

Figure 27. The fiber-deleted adenovirus vector Ad5.βgal.ΔF was grown in cells expressing either no fiber (293; 'Ad5.βgal.ΔF/0'), the Ad5 fiber (633; 'Ad5.βgal.ΔF/5F'), or the Ad37 fiber with modifications as described in the text (705; 'Ad5.βgal.ΔF/37F') and CsCl-purified. 10 μg of the purified particles were electrophoresed and transferred to a nylon membrane. As controls, 10 μg of wild-type Ad37 or the fiber gene-containing vector Ad5.βgal.wt or a sample of purified recombinant Ad37 fiber knob were also run. The blot was probed with polyclonal antisera against recombinant Ad37 fiber or Ad2 fiber proteins. As a

loading control, the same filter was reprobed with an antibody against the Ad2 penton base (the anti-Ad2 sera cross-recognized the very similar Ad5 fiber and Ad5 penton base proteins).

Figure 28 shows PCR analysis for fiber presence.

Figure 29 shows the transduction efficiency for fiberless virus with and without soluble fiber.

Figure 30 shows the transduction efficiency of AD5BgF⁻ on HDF cell line with the presence of different amounts of 633 conditioned media.

Detailed Description of the Invention

To reduce the frequency of contamination with wild-type adenovirus, it is considered desirable to improve either the viral vector or the cell line to reduce the probability of recombination. For example, an adenovirus from a group with less homology to the group C viruses may be used to engineer recombinant viruses with little propensity for recombination with the Ad5 sequence in 293 cells. Similarly, an epithelial cell line -- e.g. the cell line known as 293 -- may be used or further modified according to within-disclosed methods which stably expresses adenovirus proteins or polypeptides from Ad3 and/or proteins or polypeptides from another non-group-C or group C serotype; such a cell line would be useful to support adenovirus-derived viral vectors bearing deletions of regulatory and/or structural genes, irrespective of the serotype from which such a vector was derived.

It is also contemplated that the constructs and methods of the present invention will support the design and engineering of chimeric viral vectors which express amino acid residue sequences derived from two or more Ad serotypes. Thus, unlike methods and constructs available prior to the advent of the present disclosure, this invention allows the greatest possible flexibility in the design and preparation of useful viral vectors and cell lines which support their construction

and propagation -- all with a decreased risk of recombining with wild-type Ad to produce potentially-harmful recombinants.

In part, the present invention discloses a simpler, alternative means of reducing the recombination between viral and cellular sequences than those discussed in the art. One such means is to increase the size of the deletion in the recombinant virus and thereby reduce the extent of shared sequences between that virus and any Ad genes present in a packaging cell line -- e.g., the Ad5 genes in 293 cells, or the various Ad genes in the novel cell lines of the present invention.

Therefore, the present invention makes it feasible to engineer and produce novel viral vectors that are able to package and deliver significantly larger foreign nucleic acid sequences for efficacious use in a variety of therapeutic applications, without endangering the subject to whom they are administered, due to their impaired ability to self-replicate in non-complementing cell lines. Due to the fact that "helper" viruses or plasmids need not be used in conjunction with many of the viral vectors of the present invention, those vectors of the present invention are also simpler to use than those previously described in the art.

I. Definitions

In order to provide a clearer understanding of the specification and claims, the following definitions are provided.

Adenoviral Vector or Ad-Derived Vector: Any adenovirus-derived plasmid, genome or virus into which a foreign DNA may be inserted or expressed. This term may also be used interchangeably with "viral vector." This "type" of vector may be utilized to carry nucleotide sequences encoding therapeutic proteins or polypeptides to specific cells or cell types in a subject in need of treatment, as described further herein below.

Amino Acid Residue: An amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues

described herein are preferably in the “L” isomeric form. However, residues in the “D” isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. § § 1.821 - 1.822, abbreviations for amino acid residues are shown in the following Table of Correspondence:

Table of Correspondence

SYMBOL		AMINO ACID
<u>1-Letter</u>	<u>3-Letter</u>	
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine
A	Ala	alanine
S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
T	Thr	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
Q	Gln	glutamine
E	Glu	glutamic acid
Z	Glx	Glu and/or Gln
W	Trp	tryptophan

R	Arg	arginine
D	Asp	aspartic acid
N	Asn	asparagine
B	Asx	Asn and/or Asp
C	Cys	cysteine
X	Xaa	Unknown or other

Table 1

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase “amino acid residue” is broadly defined to include the amino acids listed in the Table of Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. §§ 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues or to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

Complementing Plasmid: This term is generally used herein to describe plasmid vectors used to deliver particular nucleotide sequences into a packaging cell line, with the intent of having said sequences stably integrate into the cellular genome.

Delivery Plasmid: This term is generally used herein to describe a plasmid vector that carries or delivers nucleotide sequences in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors of the present invention.

DNA Homolog: A nucleic acid having a preselected conserved nucleotide sequence and a sequence encoding a preferred polypeptide according to the present invention, where the nucleic acid is substantial homologous to a named

preferred embodiment. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith.

The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482 (1981)). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

Whether any two nucleic acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the National Center for Biotechnology Information database may be used to determine identity

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics*

and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(I):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990)).

Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid

difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or deletions.

An embodiment of the invention may use polynucleotides at least 90% or 95% identical to those encoding the TPL nucleic acid sequences. A further embodiment of the invention may include those polynucleotides that encode a polypeptide of interest that are at least 95% identical when the variation in such a polynucleotide is due to more than merely degenerate changes.

Expression or Delivery Vector: Any plasmid or virus into which a foreign DNA may be inserted for expression in a suitable host cell -- *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors which allow cloning of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

Foreign Gene: This term is used to identify a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or from another Ad serotype.

Gene: A nucleic acid whose nucleotide sequence encodes an RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

Isolated: This term is used to indicate a nucleic acid or polypeptide sequence separated from the genetic environment from which the sequences were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present

invention. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compounds can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988). The terms isolated and purified are sometimes used interchangeably.

By "isolated" is meant that the DNA is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) from which the DNA of the invention is derived, immediately flank the gene encoding the DNA of the invention. The isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

Isolated or purified as it refers to preparations made from biological cells or hosts should be understood to mean any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange change chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

A preparation of DNA or protein that is "pure" or "isolated" should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

A cell extract that contains the DNA or protein of interest should be understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term “cell extract” is intended to include culture media, especially spent culture media from which the cells have been removed.

Packaging Cell line: A packaging cell line is a cell line that provides a missing gene product or its equivalent.

Particle: The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures. The particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of particles or a viral genome.

Penton: The terms “penton” or “penton complex” are preferentially used herein to designate a complex of penton base and fiber. The term “penton” may also be used to indicate penton base, as well as penton complex. The meaning of the term “penton” alone should be clear from the context within which it is used.

Plasmid: An autonomous self-replicating extrachromosomal circular DNA

Post-transcription Regulatory Element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA sequence.

Pseudotyping: This term as generally used herein describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing a chimeric Ad3/Ad5 fiber protein. This may be accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

Promoter: Useful promoters according to the present invention may be inducible or constitutive. Inducible promoters will initiate transcription only in the

presence of an additional molecule; constitutive promoters, on the other hand, do not require the presence of any additional molecule to regulate gene expression. A regulatable or inducible promoter may also be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Receptor: Receptor is a term used herein to indicate a biologically active molecule that specifically binds to (or with) other molecules. The term “receptor protein” may be used to more specifically indicate the proteinaceous nature of a specific receptor.

Recombinant: As used herein, the term is intended to refer to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

Transgene or Therapeutic Nucleotide Sequence: As described and claimed herein, such a sequence includes DNA and RNA sequences encoding an RNA or polypeptide. Such sequences may be “native” or naturally-derived sequences; they may also be “non-native” or “foreign” sequences which are naturally- or recombinantly-derived. The term “transgene,” which may be used interchangeably herein with the term “therapeutic nucleotide sequence,” is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

Therefore, therapeutic nucleotide sequences may also include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) further comprise sequences which function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic nucleotide sequence may encode a functional protein intended for delivery into a cell which is unable to produce that functional protein.

II. Adenovirus

Fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on the cell surface. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber consists of three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus. (See, *e.g.*, Hong and Engler, *Virology* 185: 758-761, 1991). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery. This has great utility for a variety of gene therapy applications and is one of the objects of the present invention.

Hexon, penton and fiber capsomeres are the major components on the surface of the virion. Their constituent polypeptides, nos. II, III and IV, contain tyrosine residues that are exposed on the surface of the virion and can be labeled -- *e.g.*, by iodination of intact particles.

The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described. (See, *e.g.*, Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Viol.* 161: 549-554, 1987).

The sequence of Ad5 DNA was completed more recently; its sequence includes a total of 35,935 bp. Portions of many other adenovirus genomes have also been sequenced. It is presently understood that the upper packaging limit for

adenovirus virions is about 105% of the wild-type genome length. (See, *e.g.*, Bett, *et al.*, *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats enable single strands of viral DNA to circularize by base-pairing of their terminal sequences, and the resulting base-paired "panhandle" structures required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and contiguous packaging sequence) have been constructed, but the virions package less efficiently than the helper and package as multimers part of the time, which suggests that the virus may "want" to package a fuller DNA complement (see, *e.g.*, Fisher, *et al.*, *Virology* 217: 11-22, 1996).

The viral vectors of the present invention may retain their ability to express the genome packaged within -- *i.e.*, they may retain their "infectivity" -- they do not act as infectious agents, however, to the extent that they cause disease in the subjects to whom they are administered for therapeutic purposes.

It is to be appreciated that Ad vectors have several distinct advantages over other viral vectors in the art. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins.

An extension of this invention is that the Ad-derived viral vectors disclosed herein may be used to target and deliver genes into specific cells by incorporating the attachment sequence for other receptors (such as CD4) onto the fiber protein by recombinant DNA techniques, thus producing a chimeric molecule. This

should result in the ability to target and deliver genes into a wide range of cell types with the advantage of evading recognition by the host's immune system. The within-disclosed delivery systems thus provide for increased flexibility in gene design to enable gene delivery into proliferating and nonproliferating cell types.

5 For example, U.S. Patent Nos. 5,756,086, and 5,543,328 as well as WO95/26412 and WO 98/44121 and Krasnykh, *et al.* (*J. Virol.* 70: 6839-46, 1996), the disclosures of which are incorporated by reference herein, describe modifications that may be made to the adenovirus fiber protein. Such modifications are useful in altering the targeting mechanism and specificity of adenovirus and could readily be utilized in conjunction with the constructs of the present invention to target the novel viral vectors disclosed herein to different receptors and different cells. Moreover, modifications to fiber protein which alter its tropism may permit greater control over the localization of viral vectors in therapeutic applications.

10 Similarly, incorporation of various structural proteins into cell lines of the present invention, whether or not those proteins are modified, is also contemplated by the present invention. Thus, for example, modified penton base polypeptides such as those described in Wickham, *et al.* (*J. Virol.* 70: 6831-8, 1996) may have therapeutic utility when used according to the within-disclosed methods.

15 While some of the Examples appearing below specifically recite fiber proteins, polypeptides, and fragments thereof, it is expressly provided herein that other structural and non-structural Ad proteins and polypeptides (*e.g.*, regulatory proteins and polypeptides) may be used as components of the various disclosed vectors and cell lines. Moreover, chimeric molecules comprised of proteins, polypeptides, and/or fragments thereof which are derived from different Ad serotypes may be used in any of the within-disclosed methods, constructs and compositions. Similarly, recombinant DNA sequences of the present invention may be prepared using nucleic acid sequences derived from different Ad serotypes, in order to design useful constructs with broad applicability, as disclosed and claimed herein.

20

25

30

It should also be appreciated that, while the members of Group C or Group D adenovirus -- *i.e.*, Ad serotypes 1, 2, 5, 6 or 37 -- are specifically recited in various examples herein, the present invention is in no way limited to those serotypes alone. In view of the fact that the adenovirus serotypes are all closely-related in structure and functionality, therapeutic viral vectors, packaging cell lines, and plasmids of the present invention may be constructed from components of any and all Ad serotypes -- and the within-disclosed methods of making and using the various constructs and cell lines of the present invention apply to all of said serotypes.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses, and members of the Aviadenovirus genus, including bird viruses, e.g. CELO. Thus it is contemplated that the disclosed inventions can be applied to any adenovirus species, and the invention need not be so limited. One of skill in the art would have knowledge of the different adenoviruses as evidenced by (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) which is herein incorporated by reference.

III. Packaging Cell Lines

A. Adenovirus Complementation Genetics

The first generation of recombinant adenoviral vectors currently available typically have a deletion in the first viral early gene region which is generally referred to as E1, which comprises the E1a and E1b regions. (These regions span genetic map units 1.30 to 9.24.) Figure 3 in chapter 67 of *Fields Virology*, 3d Ed. (Fields *et al.* eds, Lippincott-Raven Publ., Philadelphia, 1996, p. 2116) illustrates a transcription and translation map of adenovirus type 2 (Ad2).

Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293.

Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, *e.g.*, Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378). Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106). Nevertheless, inherent problems exist concerning first-generation recombinant adenoviruses.

B. Adenovirus Particle Packaging Cell Lines

Packaging cell lines disclosed herein support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses. Additionally, the invention provides novel cell lines and helper viruses for use with helper-dependent vectors.

Thus, in one embodiment of the present invention, a packaging cell line is disclosed having DNA sequences stably integrated into the cellular genome wherein the DNA sequences encode one or more adenovirus regulatory and/or structural polypeptides which complement the genes deleted or mutated in the adenovirus vector genome to be replicated and packaged.

In another embodiment, the packaging cell line expresses one or more adenovirus structural proteins, polypeptides, or fragments thereof, wherein said structural protein is selected from the group consisting of penton base, hexon,

fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof.

In one variation, the sequences are constitutively expressed; in another, one or more sequences is under the control of a regulatable promoter. In a preferred embodiment expression is constitutive. In various preferred embodiments, the polypeptides expressed by the DNA sequences are biologically active.

In a further and preferred embodiment the packaging cell line of the present invention supports the production of a viral vector. In a preferred embodiment the viral vector is a therapeutic vector.

The present invention also discloses a packaging cell line which complements a viral vector having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

Various useful packaging cells are contemplated which complement adenovirus. In one aspect of the present invention, each DNA sequence is introduced into the genome of the within-disclosed cell lines via a separate complementing plasmid. In other embodiments, two or more DNA sequences were introduced into the genome via a single complementing plasmid. In one variation, the complementing plasmid comprises a DNA sequence encoding adenovirus fiber protein, polypeptide or fragment thereof. An example of a useful complementing plasmid according to the present invention is a plasmid having the characteristics of pCLF (for deposit details, see Example 3)

One embodiment discloses a packaging cell useful in the preparation of recombinant adenovirus viral vectors comprising a delivery plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding fiber. In one variation, the delivery plasmid further comprises a nucleotide sequence encoding a foreign polypeptide. A preferred delivery plasmid is pDV44, pE1B gal, or

pE1sp1B. In another variation, the cell further comprises a complementing plasmid containing a nucleotide sequence encoding fiber, the plasmid being stably integrated into the cellular genome of the cell.

5 In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

10 In another variation, the first and second delivery plasmids interact within the cell to produce a therapeutic viral vector. In yet another variation, the cell further comprises a complementing plasmid containing a nucleotide sequence encoding fiber, the plasmid being stably integrated into the cellular genome of the cell. In still another, the first or second delivery plasmid further comprises a nucleotide sequence encoding a foreign polypeptide. In various embodiments, the polypeptide is a therapeutic molecule.

15 Another embodiment discloses a composition as before, wherein the first delivery plasmid lacks adenovirus packaging signal sequences. In another aspect, the second delivery plasmid contains a LacZ reporter construct. In another variation, the second delivery plasmid further lacks a nucleotide sequence encoding an adenovirus regulatory protein. In one variation, the regulatory protein is E1. In one embodiment of the above-noted compositions, the complementing plasmid has the characteristics of pCLF.

20 In another embodiment, a composition is disclosed wherein the first delivery plasmid lacks a nucleotide sequence encoding an adenovirus structural protein and the second delivery plasmid lacks a nucleotide sequence encoding adenovirus E1 protein. In another, the first delivery plasmid lacks a nucleotide sequence encoding adenovirus E4 protein and the second delivery plasmid lacks a nucleotide sequence encoding adenovirus E1 protein. In still another, the cell

25

30

contains at least one complementing plasmid encoding an adenoviral regulatory protein and a structural protein.

In one preferred variation of the present invention, a packaging cell line expresses fiber protein. In one embodiment, the fiber protein has been modified to include a non-native amino acid residue sequence which targets a specific receptor, but which does not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. In still another embodiment, the structural protein is fiber comprising amino acid residue sequences from more than one adenovirus serotype. As disclosed herein, the nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein -- and indeed, any of the adenovirus structural proteins, as taught herein -- may be modified "internally" as well as at the termini.

In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In yet another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker. A suitable ligand may be selected from the group consisting of ligands that specifically bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, any of the packaging cell lines of this invention may have a DNA sequence encoding all or part of a fiber protein -- including modified or chimeric proteins -- stably integrated into the genome.

In various aspects of the present invention, a packaging cell line of the present invention is derived from a procaryotic cell line; in another, it is derived from a eucaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from the group consisting of

293, A549, W162, HeLa, Vero, 211, and 211A cell lines, it is understood that various other cell lines are likewise contemplated for use as disclosed herein.

IV. Therapeutic Viral Vectors and Related Systems

A. Nucleic Acid Segments

5 A therapeutic viral vector or composition of the present invention comprises a nucleotide sequence, nucleic acid molecule or segment as described herein. Typically, the nucleic acid molecule or molecule encodes a protein or polypeptide molecule -- or a biologically active fragment thereof -- which may be used for therapeutic applications. A nucleotide sequence may further comprise an enhancer element or a promoter located 3' or 5' to and controlling the expression of such a therapeutic nucleotide sequence or gene.

10 A subject nucleotide sequence consists of a nucleic acid molecule that comprises at least 2 different operatively linked DNA segments. The DNA can be manipulated and amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce a nucleotide sequence of the present invention, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous replication in a cell either *in vivo* or *in vitro*. By operatively linking the enhancer element or promoter and the nucleotide sequence to the vector, the attached segments are replicated along with the vector sequences.

20 Thus, a recombinant DNA molecule (rDNA) of the present invention is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. Stated another way, a nucleotide sequence of the present invention is one that

25

encodes an expressible protein, polypeptide or fragment thereof, and it may further include an active constitutive or regulatable (*e.g.* inducible) promoter sequence.

A nucleotide sequence of the present invention is optimally from about 20 base pairs to about 40,000 base pairs in length. Preferably the nucleotide sequence is from about 50 bp to about 38,000 bp in length. In various embodiments, the nucleotide sequence is of sufficient length to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, corresponding nucleotide sequences will range from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic nucleotide sequences of the present invention.

1. Tripartite Leader (TPL) Nucleic Acid Sequences

In one aspect of the invention, it has been discovered that expression of adenovirus late proteins such as the structural proteins in a packaging cell line according to the present invention is substantially improved when the expression cassette present on the complementing plasmid or in the packaging cell line's genome contains an adenovirus tripartite leader (TPL) nucleic acid sequence.

Thus, the invention contemplates a nucleic acid molecule comprising a TPL nucleotide sequence. Preferably, the TPL nucleotide sequence may be operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron.

In one embodiment, a subject nucleic acid molecule of this invention is isolated, *i.e.*, separated from the genetic environment from which the component sequences were obtained. Thus, molecular cloning of fragments of a gene will

produce an isolated nucleic acid, as will the chemical synthesis of an oligonucleotide to build a nucleic acid molecule.

The intron useful in the present invention is any nucleotide sequence which functions in the packaging cell line to provide RNA processing signals, as are well known in the art, including splicing signals. Introns have been well characterized from a large number of structural genes, and therefor the invention should not be considered as limited. Well characterized and preferred introns include a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs. See, for example, Petitclerc *et al.*, *J. Biothechnol.*, 40:169, 1995, and Choi *et al.*, *Mol. Cell. Biol.*, 11:3070, 1991.

The TPL nucleotide sequence comprises either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples. The use of a TPL with a partial exon 1 has been reported (WO98/13499).

The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence, although in some embodiments of the invention, an intron may not be a part of the construct. For example, the intron can be positioned between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment, complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and

complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an adenovirus TPL nucleotide sequence as described herein. Preferred packaging cell lines containing the subject nucleic acid molecules also contain a TPL nucleotide sequence of the invention.

2. Complementing Plasmids

The invention describes in a related embodiment nucleic acid molecules and nucleotide sequences, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are used to complement the defective genes of a recombinant adenovirus vector genome of this invention, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product off the gene encoded by the nucleotide sequence. Expression cassettes are described in more detail herein, but typically contain a promoter and a structural gene operatively linked to the promoter and whose expression is controlled by the promoter. A preferred complementing plasmid further includes a TPL nucleotide sequence described

herein to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

In one embodiment, a complementing plasmid comprises a promoter nucleotide sequence operatively linked to a nucleotide sequence encoding an adenovirus structural polypeptide. The adenovirus structural polypeptide is selected from the group consisting of penton base; hexon; fiber; polypeptide IIIa; polypeptide V; polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid further comprises a nucleotide sequence encoding a first adenovirus regulatory polypeptide, a nucleotide sequence encoding a second regulatory polypeptide, a nucleotide sequence encoding a third regulatory polypeptide; or any combination of the foregoing.

The present invention also discloses a complementing plasmid comprising a promoter nucleotide sequence operatively linked to a nucleotide sequence encoding an adenovirus structural protein, polypeptide or fragment thereof and a nucleotide sequence encoding an adenovirus regulatory protein, polypeptide or fragment thereof. In one variation, the early region polypeptide is E4; in another, the plasmid comprises pE4/Hygro. In still another variation, the early region polypeptides are E1 and E4.

In another aspect of the present invention, the complementing plasmid used to transform a cell line of the present invention further comprises a DNA sequence encoding an adenovirus regulatory protein, polypeptide or fragment thereof. In one variation, the regulatory protein is selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4 and L4 (also referred to as "the 100K protein"); an exemplary complementing plasmid has the characteristics of is pE4/Hygro (for deposit details, see the Examples). In another aspect, the complementing plasmid used to transform a cell line of the present invention further comprises a DNA sequence encoding two or more of the above mentioned adenovirus regulatory proteins, polypeptides or fragments thereof.

Preferred complementing plasmids include pCLF, pDV60, pDV61, pDV67, pDV69, pDV80, pDV90 and the like plasmids described in the Examples. The nucleic acid sequence of particularly preferred complementing plasmids are shown in SEQ ID NO: 43 for pDV60, SEQ ID NO: 44 for pDV67 and SEQ ID NO: 47 for pDV69, SEQ ID NO: 64 for pDV80 and SEQ ID NO: 65 for pDV90.

3. Nucleic Acid Molecule Synthesis

A nucleic acid molecule comprising synthetic oligonucleotide sequences of the present invention can be prepared using any suitable method, such as, the phosphotriester or phosphodiester methods. See Narang *et al.*, *Meth. Enzymol.*, 68:90, (1979); U.S. Patent No. 4,356,270; and Brown *et al.*, *Meth. Enzymol.*, 68:109, (1979), the disclosures of which are incorporated by reference herein.

For oligonucleotide sequences in which a family of variants is preferred, the synthesis of the family members can be conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants.

This manner of simultaneous synthesis of a family of related oligonucleotides has been previously described for the preparation of "Degenerate Oligonucleotides" by Ausubel *et al.* (*Current Protocols in Molecular Biology*, Suppl. 8. p.2.11.7, John Wiley & Sons, Inc., New York, 1991), and can readily be applied to the preparation of the therapeutic oligonucleotide compositions described herein.

Nucleotide bases other than the common four nucleotides (A, T, G or C), or the RNA equivalent nucleotide uracil (U), can also be used in the present invention. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures are contemplated. The composition can contain four members, where a preselected position contains A, T, G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and ligation, as is well known.

B. Adenovirus Expression Vector Systems

One key component of the present invention for producing gene therapy reagents comprised of recombinant adenovirus particles is the recombinant

adenovirus vector genome which is encapsulated in the virus particle and which expresses exogenous genes in a gene therapy setting. Thus, the components of an recombinant adenovirus vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat containing an adenovirus origin of replication, as is well known and described herein.

According to the present invention, a preferred recombinant adenovirus vector genome is "helper independent" which means the genome can replicate and be packaged without the help of a second, complementing helper virus. Instead, the complementation is provided by a packaging cell line of the present invention. Additional embodiments of the invention, however, are drawn to a vector genome referred to as "gutless" which is "helper dependent."

In a preferred embodiment, the adenovirus vector genome does not encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

Thus, the invention describes a helper-independent fiberless recombinant adenovirus vector genome comprising genes which (a) express all adenovirus structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contains an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

The introduction of exogenous DNA into eucaryotic cells has become one of the most powerful tools of the molecular biologist. The term "exogenous" encompasses any therapeutic composition of this invention which is administered by the therapeutic methods of this invention. Thus, "exogenous" may also be referred to herein as "foreign," "non-native," and the like. The methods of this invention preferably require efficient delivery of the DNA into the nucleus of the recipient cell and subsequent identification of cells that are expressing the foreign DNA.

The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

A widely-used plasmid is pBR322, a vector whose nucleotide sequence and endonuclease cleavage sites are well known. Various other useful plasmid vectors are described in the Examples that follow.

A nucleic acid vector of the present invention comprises a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, *e.g.*, a gene or polynucleotide, can be operatively linked so as to bring about replication of the attached segment. In the present invention, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule -- in effect, a nucleic acid sequence that encodes one or more therapeutic proteins or polypeptides, or fragments thereof.

As one of skill in the art will note, in various embodiments of the present invention, different "types" of vectors are disclosed. For example, one "type" of vector is used to deliver particular nucleotide sequences into a packaging cell line, with the intent of having said sequences stably integrate into the cellular genome; these "types" of vectors are generally identified herein as complementing plasmids. A further "type" of vector described herein carries or delivers nucleotide

sequences in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors of the present invention; hence, these vectors are generally referred to herein as delivery plasmids. A third “type” of vector described herein is utilized to carry nucleotide sequences encoding therapeutic proteins or polypeptides to specific cells or cell types in a subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or Ad-derived vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette nucleic acid sequence for expressing the therapeutic gene.

1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least a portion of a therapeutic nucleotide sequence operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

As used herein with regard to DNA sequences or segments, the phrase “operatively linked” generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form.

The choice of viral vector into which a therapeutic nucleotide sequence of this invention is operatively linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, vector replication and protein expression, and the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain

adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the present invention contemplates the use of *any* adenovirus serotype, including hybrids and derivatives thereof. As one will observe, it is not unusual or outside the scope of the present invention to utilize nucleotide and/or amino acid residue sequences of two or more serotypes in constructs, compositions and methods of the invention.

A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the nucleic acid material and any polypeptides that are to be inserted into the cell.

2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector of the present invention may also include a promoter sequence.

In general, promoters are DNA segments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences which direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance efficiency of expression. For purposes of the present invention, regulatable (inducible) as well as constitutive promoters may be used, either on separate vectors or on the same vector.

Both constitutive and regulatable (often called "inducible") promoters are useful in constructs and methods of the present invention. For example, some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, *e.g.*, published International App. No. WO96/14061, the disclosure of which is incorporated by reference herein.)

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (See U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters. Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then it is expressed appropriately in the correct cell types (see, *e.g.*, Palmiter *et al.*, *Ann. Rev. Genet.* 20: 465-499, 1986).

When a tissue-specific promoter controls the expression of a gene, that gene will be expressed in a small number of tissues or cell types rather than in substantially all tissues and cell types. Examples of tissue-specific promoters include the immunoglobulin promoter described by Brinster *et al.*, *Nature* 306: 332-336 (1983) and Storb *et al.*, *Nature* 310: 238-231 (1984); the elastase-I promoter described by Swift *et al.*, *Cell* 38: 639-646 (1984); the globin promoter described by Townes *et al.*, *Mol. Cell. Biol.* 5: 1977-1983 (1985), and Magram *et al.*, *Mol. Cell. Biol.* 9: 4581-4584 (1989), the insulin promoter described by Bucchini *et al.*, *PNAS USA*, 83: 2511-2515 (1986) and Edwards *et al.*, *Cell* 58: 161 (1989); the immunoglobulin promoter described by Ruscon *et al.*, *Nature*

314: 330-334 (1985) and Grosscheld *et al.*, *Cell* 38: 647-658 (1984); the alpha actin promoter described by Shani, *Mol. Cell. Biol.* 6: 2624-2631 (1986); the alpha crystalline promoter described by Overbeek *et al.*, *PNAS USA* 82: 7815-7819 (1985); the prolactin promoter described by Crenshaw *et al.*, *Genes and Development* 3: 959-972 (1989); the propiomelanocortin promoter described by Tremblay *et al.*, *PNAS USA* 85: 8890-8894 (1988); the beta-thyroid stimulating hormone (BTSH) promoter described by Tatsumi *et al.*, *Nippon Rinsho* 47: 2213-2220 (1989); the mouse mammary tumor virus (MMTV) promoter described by Muller *et al.*, *Cell* 54: 105 (1988); the albumin promoter described by Palmiter *et al.*, *Ann. Rev. Genet.* 20: 465-499 (1986); the keratin promoter described by Vassar *et al.*, *PNAS USA* 86: 8565-8569 (1989); the osteonectin promoter described by McVey *et al.*, *J. Biol. Chem.* 263: 11,111-11,116 (1988); the prostate-specific promoter described by Allison *et al.*, *Mol. Cell. Biol.* 9: 2254-2257 (1989); the opsin promoter described by Nathans *et al.*, *PNAS USA* 81: 4851-4855 (1984); the olfactory marker protein promoter described by Danciger *et al.*, *PNAS USA* 86: 8565-8569 (1989); the neuron-specific enolase (NSE) promoter described by Forss-Pelter *et al.*, *J. Neurosci. Res.* 16: 141-151 (1986); the L-7 promoter described by Sutcliffe, *Trends in Genetics* 3: 73-76 (1987) and the protamine 1 promoter described Peschon *et al.*, *Ann. New York Acad. Sci.* 564: 186-197 (1989) and Braun *et al.*, *Genes and Development* 3: 793-802 (1989). (The disclosures of all references cited are incorporated by reference herein.)

3. Adenovirus Vectors

Although adenovirus consists of many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector) of this invention. Thus, deletion of the appropriate genes from a recombinant Ad vector as taught herein will thus allow the vector to accommodate even larger "foreign" DNA segments. Thus, if the sequences encoding one or more adenovirus

polypeptides or proteins are supplanted by a recombinant nucleotide sequence of the present invention, the length of the recombinant sequence can conceivably extend nearly to the packaging limit of the relevant adenovirus-derived vector.

In view of the fact that preferred embodiments disclosed herein are helper-independent Ad-derived vectors, the entire wild-type Ad genome cannot be completely supplanted by recombinant nucleic acid molecules without transforming such a vector into a vector requiring "help" of some kind. However, most of the Ad-derived vectors of the present invention do not depend on a helper virus; instead, the vectors of the present invention are propagated in cell lines stably expressing proteins or polypeptides that have been removed from said vectors to allow the addition of "foreign" DNA into the vectors. In various disclosed embodiments, specific early region and structural polypeptides are deleted from the vectors of the present invention, thereby enabling the vectors to accommodate recombinant nucleic acid sequences (or cassettes) of various lengths. For example, Ad-derived vectors of the present invention may easily include 12 kb or more of foreign (or "therapeutic") DNA sequences.

Thus, adenovirus viral vectors are also disclosed which comprise nucleotide sequences encoding a packaging signal and a foreign protein or polypeptide, wherein the nucleotide sequence encoding an adenovirus structural protein has been deleted.

In one variation, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 3 kb in length; in another, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 9.5 kb in length; in still another, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 12.5 kb in length. Nucleotide sequences of intermediate lengths are also contemplated by the present invention, as are sequences in excess of 12.5 kb.

The invention also discloses viral vectors wherein the sequence encoding a foreign protein or polypeptide is a sequence encoding an anti-tumor agent, a tumor suppressor protein, a suicide protein, or a fragment or functional equivalent

thereof. In one variation, nucleotide sequences encoding one or more regulatory proteins have also been deleted from the vector. In another, the regulatory proteins are selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4, and L4 (100K protein).

5 A wide variety of therapeutic viral vectors are also embodiments of the present invention. In one embodiment, a therapeutic viral vector is disclosed which lacks a DNA sequence encoding fiber protein, or a portion thereof. In another variation, a therapeutic viral vector may further or alternatively comprise deletion of a DNA sequence encoding one or more regulatory proteins, polypeptides, or fragments thereof. In various embodiments, foreign DNA sequences are inserted in place of the DNA sequence encoding fiber protein in the viral vectors of the present invention. In other embodiments, the therapeutic viral vectors further comprise foreign DNA sequences inserted in place of the DNA sequences encoding one or more regulatory proteins, polypeptides, or fragments thereof, and/or one or more structural proteins, polypeptides, or fragments thereof.

10 The present invention further discloses a number of viral vectors. In one variation, a viral vector comprises a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, polypeptide, or fragment thereof. A vector may further comprise deletion or mutation of the DNA sequences encoding regulatory polypeptides E1A and E1B; and it may still further comprise deletion or mutation of the DNA sequence encoding one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof. In another variation, in a viral vector of the present invention, the structural protein comprises fiber. Any combination of the foregoing is also contemplated by the present invention. The viral vectors of the present invention are suitable for the preparation of pharmaceutical compositions comprising any of the therapeutic viral vectors disclosed herein -- including combinations thereof -- are also disclosed herein. A further use of the viral vectors of the present invention is for targeting specific cells in a cell population comprising different cell types.

Yet another variation discloses that a foreign DNA sequence encoding one or more foreign proteins, polypeptides or fragments thereof has been inserted in place of any of the deletions in the therapeutic viral vector. In one embodiment, the foreign DNA encodes a tumor-suppressor protein or a biologically active fragment thereof. In another embodiment, the foreign DNA encodes a suicide protein or a biologically active fragment thereof.

The invention further contemplates that a viral vector comprises a foreign DNA sequence encoding one or more foreign proteins, polypeptides or fragments thereof wherein said DNA sequence has been inserted in place of any structural and/or regulatory proteins (or portions thereof) that have been deleted. Thus, in one embodiment, the foreign DNA encodes a therapeutic molecule such as a tumor-suppressor protein; a suicide protein; a cystic fibrosis transmembrane conductance regulator (CFTR) protein; or a biologically active fragment of any of them.

The therapeutic (or foreign) nucleotide sequence can be a gene or gene fragment that encodes a protein or polypeptide -- or a biologically active fragment thereof. (See, *e.g.*, Crystal, *et al.*, *Nature Genetics* 8: 42-51 (1994); Zabner, *et al.*, *Cell* 75: 207-216 (1993); Knowles, *et al.*, *NEJM* 333(13): 823-831 (1995); and Rosenfeld, *et al.*, *Cell* 68: 143-155 (1992), the disclosures of which are incorporated by reference herein.)

It is further contemplated that a therapeutic protein or polypeptide expressed by a therapeutic viral vector of the present invention may be used in conjunction with another therapeutic agent when appropriate -- *e.g.*, a thymidine kinase metabolite may be used in conjunction with the gene encoding thymidine kinase and its gene product -- in order to be even more effective.

Alternatively, a therapeutic viral vector can include a DNA or RNA oligonucleotide sequence that exhibits therapeutic activity without needing to be translated into a polypeptide product before exerting a therapeutic effect. Examples of the latter include antisense oligonucleotides that will inhibit the transcription of deleterious genes or ribozymes that act as site-specific

ribonucleases for cleaving selected mutated gene sequences. In another variation, a therapeutic nucleotide sequence of the present invention may comprise a DNA construct capable of generating therapeutic nucleotide molecules, including ribozymes and antisense DNA, in high copy numbers in target cells, as described in published PCT application No. WO 92/06693 (the disclosure of which is incorporated herein by reference). Other preferred therapeutic nucleotide sequences according to the present invention are capable of delivering HIV antisense oligonucleotides to latently-infected T cells via CD4. Similarly, delivery of Epstein-Barr Virus (EBV) EBNA-1 antisense oligonucleotides to B cells via CR2 is capable of effecting therapeutic results.

A preferred recombinant adenovirus vector genome is based on the vector described in the Examples and designated Ad5.Bgal.ΔF. This vector is a helper independent, fiberless vector genome which can host, upon insertion, an exogenous gene for expression of an exogenous or therapeutic protein. The genome of Ad5.Bgal.ΔF has a nucleotide sequence shown in SEQ ID NO: 27. A virus particle containing Ad5.Bgal.ΔF vector genome has been prepared as described in the Examples and is deposited with the ATCC as Accession No. VR-2636

The Ad5.Bgal.ΔF genome nucleic acid can be manipulated to contain any exogenous gene in place of the beta-galactosidase gene present in the construct, as described herein.

V. Construction of Therapeutic Viral Vectors for Gene Delivery

A. Adenovirus Particles

Various methods of making and using the vectors, plasmids, cell lines and other compositions and constructs of the present invention are also disclosed herein. The following methods are considered exemplary and not limiting.

Thus, in one variation, the invention discloses a method of constructing therapeutic viral vectors, comprising introducing a delivery plasmid into an Ad fiber-expressing complementing cell line, wherein the DNA sequence encoding Ad fiber protein has been deleted from the delivery plasmid. In one variation, the delivery plasmid further includes a DNA sequence encoding a foreign protein, polypeptide, or fragment thereof. In other embodiments, a combination of pDV44 and pDE1B β gal or a similar construct such as, for example, that found in pDV44, p Δ E1B β gal or the equivalent.

A recombinant adenovirus particle may be produced with a fiber protein, or it may be produced without a fiber protein ("fiberless particle") according to the present invention. Where the particle is made without fiber, such as by passaging the fiberless viral vector genome, e.g., Ad5.Bgal. Δ F in the 293 cells, a fiberless genome is replicated and packaged in a fiberless particle. In contrast, where the fiberless genome Ad5.Bgal. Δ F is passaged in the 211B or other fiber expressing cells, a fiberless genome is replicated and packaged into a fiber-containing particle.

Recombinant adenovirus particles may be made such that they include no fiber proteins, modified fiber proteins or other exogenous proteins. They may also be produced in systems using either helper-independent or helper-dependent adenovirus recombinant genomes, i.e. with or without helper viruses.

B. Targeting of Particles to Tissues - Virus Trophism

A preferred viral vector particle in which therapeutic nucleotide compositions of this invention are present is derived from adenovirus (Ad). As taught herein, viral vector particles of this invention may be designed and constructed in such a way that they specifically target a preselected recipient cell type, depending on the nature of therapy one seeks to administer. Methods of making and using therapeutic viral vectors that target specific cells are further described in the Examples that follow.

Novel vectors, viral particles or compositions may also be designed and prepared to preferentially target cells that might not otherwise be targeted by wild-type adenovirus virions. For example, in order to target non-epithelial cells, one following the teachings of the present specification may be able to prepare a therapeutic vector particle including a nucleotide sequence encoding a foreign protein, polypeptide or other ligand directed to a non-epithelial cell or to a different receptor than that generally targeted by a particular adenovirus. Examples of useful ligands directed to specific receptors (identified in parentheses) include the V3 loop of HIV gp120 (CD4); transferrin (transferrin receptor); LDL, apolipoprotein B100, apolipoprotein E (LDL receptors); and deglycosylated proteins (asialoglycoprotein receptor). Various useful ligands which may be added to adenovirus fiber -- and methods for preparing and attaching same -- are set forth in U.S. Patent Nos. 5,756,086 and 5,543,328, the disclosures of which are incorporated by reference herein.

In yet another embodiment, the non-native amino acid residue sequence is incorporated into the fiber amino acid residue sequence at a location other than one of the fiber termini. Alternatively, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. In other embodiments, the linker sequence alters the binding specificity of the fiber for a targeted cell type. The expressed fiber may, in various embodiments, bind to a specific targeted cell type not usually targeted by adenovirus and/or may comprise amino acid residue sequences from more than one adenovirus serotype.

Useful ligands may be encoded by a foreign nucleotide sequence contained within a viral vector of the present invention, or may be linked to proteins or polypeptides, include antibodies and attachment sequences, as well as receptors themselves. For example, antibodies to cell receptor molecules such as integrins and the like, MHC Class I and Class II, asialoglycoprotein receptor, transferrin receptors, LDL receptors, CD4, and CR2 are but a few which are useful according to the present invention. It is also understood that the ligands typically bound by

receptors, as well as analogs to those ligands, may be used as cellular targeting agents, as disclosed herein.

VI. Therapeutic Methods

5 The recombinant adenovirus vectors of the present invention, typically in the form of an adenovirus particle encapsulating a recombinant adenovirus vector genome containing an expression cassette for expressing a therapeutic gene, are particularly suited for gene therapy. Thus, various therapeutic methods are contemplated by the present invention.

10 For example, it has now been discovered that Ad-derived viral vectors are capable of delivering a therapeutic nucleotide sequence to a specific cell or tissue, based on the tissue tropism of the particle, thereby expanding and enhancing treatment options available in numerous conditions in which more conventional therapies are of limited efficacy. Accordingly, methods of gene therapy utilizing a recombinant adenovirus particle containing a modified fiber or chimeric fiber which targets a preselected tissue, as described herein, is within the scope of the invention. Vector particles are typically purified and then an effective amount is administered *in vivo* or *ex vivo* (*in vitro*) into the subject.

15 For *in vitro* or *ex vivo* gene transfer, administration is often accomplished by first isolating a selected cell population from a patient such as lung epithelial cells, lymphocytes and the like followed by *in vitro* or *ex vivo* gene transfer of the therapeutic compositions of this invention and the replacement of the cells into the patient. *In vivo* therapy is also contemplated, *e.g.*, via the administration of therapeutic compositions of this invention by various delivery means. For example, aerosol administration and administration via subcutaneous, intravenous, 20 intraperitoneal, intramuscular, ocular means and the like are also within the scope of the present invention.

25 Other gene-delivery methods are also useful in conjunction with the methods, compositions and constructs of the present invention; see, *e.g.*, published

International Application No. WO 95/11984, the disclosures of which are incorporated by reference herein.

5 The present invention also contemplates various methods of targeting specific cells -- *e.g.*, cells in a subject in need of diagnosis and/or treatment. As discussed herein, the present invention contemplates that the viral vectors and compositions of the present invention may be directed to specific receptors or cells, for the ultimate purpose of delivering those vectors and compositions to specific cells or cell types. The viral vectors and constructs of the present invention are particularly useful in this regard.

10 In general, adenovirus attachment and uptake into cells are separate but cooperative events that result from the interaction of distinct viral coat proteins with a receptor for attachment and α_v integrin receptors for internalization. Adenovirus attachment to the cell surface via the fiber coat proteins has been discovered to be dissociable and distinct from the subsequent step of internalization, and the present invention is able to take advantage of and function in conjunction with these differing receptors.

15 The invention also discloses methods of transforming a pathologic hyperproliferative mammalian cell comprising contacting the cell with any of the vectors described herein. In another embodiment, methods of infecting a mammalian target cell with a viral vector containing a preselected foreign nucleotide sequence are disclosed. One such variation comprises the following steps: (a) infecting the target cell with a viral vector of the present invention, the viral vector carrying a preselected foreign nucleotide sequence; and (b) expressing the foreign nucleotide sequence in the targeted cell.

20 The invention also encompasses mammalian target cells infected with a preselected foreign nucleotide sequence produced by the methods disclosed herein. In one variation, the target cells are selected from the group consisting of replicating, slow-replicating and non-replicating human cells.

25 Methods of treating an acquired or hereditary disease are also disclosed. One method comprises (a) administering a pharmaceutically acceptable dose of a

viral vector to a target cell, wherein the vector comprises a preselected therapeutic nucleotide sequence; and (b) expressing the therapeutic sequence in the target cell for a time period sufficient to ameliorate the acquired or hereditary disease in the cell. Method of gene therapy comprising administering to a subject an effective amount of a therapeutic viral vector produced by a packaging cell line of the present invention are also disclosed.

Also contemplated by the present invention are various methods of inhibiting the proliferation of a tumor in a subject comprising administering an effective amount of a therapeutic viral vector of the present invention under suitable conditions to the subject. In one variation, the gene encodes an anti-tumor agent. In another variation, the agent is a tumor-suppressor gene. In still another embodiment, the agent is a suicide gene or a functional equivalent thereof. In another variation, the vector is administered via intra-tumoral injection.

A composition of this invention may be used prophylactically or therapeutically *in vivo* to disrupt HIV infection and mechanisms of action by inhibiting gene expression or activation, via delivery of antisense HIV sequences or ribozymes to T cells or monocytes. Using methods of the present invention, one may target therapeutic viral vectors as disclosed herein to specific cells and tissues, including hematopoietic cells, as infection of such cells appears to be mediated by distinct integrins to which viral vectors of the present invention may readily be targeted. (See, *e.g.*, Huang, *et al.*, *J. Virol.* 70: 4502-8, 1996).

Other useful therapeutic nucleotide sequences include antisense nucleotide sequences complementary to EBV EBNA-1 gene. Use of such therapeutic sequences may remediate or prevent latent infection of B cells with EBV. As discussed herein and in the Examples below, targeting and delivery may be accomplished via the use of various ligands, receptors, and other appropriate targeting agents.

Thus, in one embodiment, a therapeutic method of the present invention comprises contacting the cells of a subject infected with EBV or HIV with a therapeutically effective amount of a pharmaceutically acceptable composition

comprising a therapeutic nucleotide sequence of this invention. In a related embodiment, the contacting involves introducing the therapeutic nucleotide sequence composition into cells having an EBV or HIV-mediated infection.

5 Methods of gene therapy are well known in the art (see, *e.g.*, Larrick and Burck, *Gene Therapy: Application of Molecular Biology*, Elsevier Science Publ. Co., Inc., New York, NY (1991); Kriegler, *Gene Transfer and Expression: A Laboratory Manual*, W. H. Freeman and Company, New York, 1990). The term “subject” should be understood to include any animal -- particularly mammalian -- patient, such as any murine, rat, bovine, porcine, canine, feline, equine, ursine, or human patient.

10 When the foreign gene carried in the vector encodes a tumor suppressor gene or another anti-tumor protein, the vector is useful to treat or reduce hyperproliferative cells in a subject, to inhibit tumor proliferation in a subject or to ameliorate a particular, related pathology.

15 The present invention also contemplates methods of depleting suitable samples of pathologic mammalian hyperproliferative cells contaminating hematopoietic precursors during bone marrow reconstitution via the introduction of a wild-type tumor suppressor gene into the cell preparation using a vector of this invention. As used herein, a suitable sample is defined as a heterogeneous cell preparation obtained from a patient, *e.g.*, a mixed population of cells containing both phenotypically normal and pathogenic cells.

20 Administration includes -- but is not limited to -- the introduction of therapeutic agents of the present invention into a cell or subject via various means, including direct injection, intravenously, intraperitoneally, via intra-tumor injection, via aerosols, or topically. Therapeutic agents as disclosed herein may also be combined for administration of an effective amount of the agents with a pharmaceutically-acceptable carrier, as described herein.

25 As used herein, “effective amount” generally means the amount of vector particle (or proteins produced/released thereby) which achieves a positive outcome in the subject to whom the vector is administered. The total volume

30

administered will necessarily vary depending on the mode of administration, as those of skill in the relevant art will appreciate, and dosages may vary as well.

The dose of a biologic vector (particle) is somewhat complex and may be described in terms of the concentration (in plaque-forming units per milliliter (pfu/ml)), the total dose (in pfus), or the estimated number of particles administered per cell (the estimated multiplicity of infection or MOI). Thus, if a vector is administered via infusion -- say, across nasal epithelium -- at a constant total volume, the respective concentration, etc. may be described as follows:

In general, when recombinant adenoviral vector particles are administered via infusion across the nasal epithelium (e.g. an area of nasal epithelium containing 2×10^7 cells,) administered amounts producing an estimated MOI (multiplicity of infection) of about 10 or greater are much more effective than lower

Concentration (pfu/ml)	Volume (ml)	Dose (pfu)	Estimated MOI
10^7	2	2×10^7	1
10^8	2	2×10^8	10
10^9	2	2×10^9	100
10^{10}	2	2×10^{10}	1000

Table 2

dosages. (See, e.g., Knowles, *et al.*, *New Eng. J. Med.* 333: 823-831, 1995). Similarly, when direct injection is the preferred treatment modality -- e.g., direct injection of a viral vector into a tumor -- doses of 1×10^9 pfu or greater are generally preferred. (See, e.g., published International App. No. WO95/11984.)

Thus, depending on the mode of administration, an effective amount administered in a single dose preferably contains from about 10^6 to about 10^{15} infectious units. A typical course of treatment would be one such dose per day over a period of five days. As those of skill in the art will appreciate, an effective amount may vary depending on (1) the pathology or other condition to be treated,

(2) the status and sensitivity of the patient, and (3) various other factors well known to those of skill in the art, such as the patient's tolerance to other courses of treatment that may have been applied previously. Thus, those of skill in the art may easily and precisely determine effective amounts of the agents/vectors of the present invention which may be administered to a particular patient, based on their understanding of and evaluation of such factors.

The present invention also contemplates methods of ameliorating pathologies characterized by hyperproliferative cells or genetic defects in a subject, by administering to the subject an effective amount of a vector as described herein. Such vectors preferably contain a foreign gene encoding a gene product (*e.g.* polypeptide or protein) having the ability to ameliorate the pathology, under suitable conditions. As used herein, the term "genetic defect" means any disease, condition or abnormality which results from inherited factors, *e.g.* Huntington's Disease, Tay-Sachs Disease, or Sickle Cell Disease.

The present invention further provides methods for reducing the proliferation of tumor cells in a subject by introducing into the tumor mass an effective amount of an adenoviral expression vector containing an anti-tumor gene other than a tumor suppressor gene. The anti-tumor gene can encode, for example, thymidine kinase (TK). An effective amount of a therapeutic agent is then administered to the subject; the therapeutic agent, in the presence of the anti-tumor gene, is toxic to the cell.

Using thymidine kinase as exemplary, the therapeutic agent is a thymidine kinase metabolite such as ganciclovir (GCV), 6-methoxypurine arabinonucleoside (araM), or a functional equivalent thereof. Both the thymidine kinase gene and the thymidine kinase substrate must be used concurrently in order to exert a toxic effect on the host cell. In the presence of the TK gene, GCV is phosphorylated and becomes a potent inhibitor of DNA synthesis, whereas araM is converted to the cytotoxic anabolite araATP. Thus, the precise method of action or synergism is not relevant to therapeutic efficacy; what is relevant is the fact that the

concurrent use of appropriate genes and therapeutic agents may effectively ameliorate a specific disease condition.

Another useful example contemplates use of a vector of the present invention which expresses the enzyme cytosine deaminase. Such a vector could be used in conjunction with administration of the drug 5-fluorouracil (Austin and Huber, *Mol. Pharm.* 43: 380-387, 1993) or the recently-described *E. coli* Deo gene in combination with 6-methyl-purine-2'-deoxyribonucleoside (Sorscher *et al.*, *Gene Therapy* 1: 233-238, 1994).

As with the use of the tumor suppressor genes described previously, the use of other anti-tumor genes, either alone or in combination with the appropriate therapeutic agent, provides a treatment for the uncontrolled cell growth or proliferation characteristic of tumors and malignancies. Thus, the present invention provides therapies to halt the uncontrolled cellular growth in a patient, thereby alleviating the symptoms or the disease or cachexia present in the patient. The effect of this treatment includes, but is not limited to, prolonged survival time of the patient, reduction in tumor mass or burden, apoptosis of tumor cells, or the reduction in the number of circulating tumor cells. Means of quantifying the beneficial effects of this therapy are well known to those of skill in the art.

The present invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of one or more adenoviral structural protein genes, such as the gene encoding fiber, which allows the vector to accommodate a therapeutic, foreign nucleic acid sequence encoding a functional foreign polypeptide, protein, or biologically active fragment thereof.

A therapeutic gene sequence may be introduced into a tumor mass by combining the adenoviral expression vector with a suitable pharmaceutically acceptable carrier. Introduction can be accomplished, for example, via direct injection of the recombinant Ad vector into the tumor mass.

A method of tumor-specific delivery of a tumor-suppressor gene is accomplished by contacting target tissue in a subject with an effective amount of a recombinant Ad-derived vector of this invention. In the case of anti-tumor

therapy, the gene is intended to encode an anti-tumor agent, such as a functional tumor suppressor gene product or suicide gene product. The term “contacting” is intended to encompass any delivery method for the efficient transfer of the vector, such as via intra-tumoral injection.

5 In another example, adenovirus vectors of the present invention can be used to transfer genes to central nervous system (CNS) tumors *in vivo*.

10 The present invention also contemplates methods for determining the efficacy of the within-disclosed therapeutic compositions and methods. One such method for confirming efficacy utilizes the human/SCID (severe combined immunodeficient) mouse model of EBV-induced LPD (lymphoproliferative disease) to ascertain whether EBV-antisense therapeutic nucleotide sequences block tumor formation. (See, *e.g.*, Pisa, *et al.*, *Blood* 79: 173-179 (1992); Rowe, *et al.*, *Curr. Top. Microbiol. Immunol.* 166: 325 (1990); and Cannon, *et al.*, *J. Clin. Invest.* 85: 1333-1337 (1990), the disclosures of which are incorporated by reference herein.)

15 Finally, the use of Ad vectors of the present invention to prepare medicaments for the treatment, therapy and/or diagnosis of various diseases is also contemplated by this invention. Moreover, other anti-tumor genes may be used in combination with the corresponding therapeutic agent to reduce the proliferation of tumor cells. Such other gene-and-therapeutic-agent combinations are known to those of skill in the art and may be applied as taught herein.

A. Therapeutic Compositions

25 In various alternative embodiments of the present invention, therapeutic sequences and compositions useful for practicing the therapeutic methods described herein are contemplated. Therapeutic compositions of the present invention may contain a physiologically tolerable carrier together with one or more therapeutic nucleotide sequences of this invention, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the composition is not

immunogenic or otherwise able to cause undesirable side effects when administered to a subject for therapeutic purposes.

As used herein, the terms “pharmaceutically acceptable,” “physiologically tolerable” and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a subject -- *e.g.*, a mammal -- without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

For example, the present invention comprises therapeutic compositions useful in the specific targeting of epithelial or non-epithelial cells as well as in delivering a therapeutic nucleotide sequence to those cells. Therapeutic compositions designed to preferentially target to epithelial cells may comprise a recombinant adenovirus-derived vector particle including a therapeutic nucleotide sequence. As described herein, a number of adenovirus-derived moieties are described, including particles lacking fiber, particles that contain wild type adenovirus fiber, and particles that contain modified or chimeric fiber, each type providing a different tissue tropism to the particle.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as injectables -- either as liquid solutions or suspensions -- however, solid forms suitable for solution or suspension in liquid prior to use can also be prepared. A preparation can also be emulsified, or formulated into suppositories, ointments, creams, dermal patches, or the like, depending on the desired route of administration.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well

as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin,
5 vegetable oils such as cottonseed oil, and water-oil emulsions.

A therapeutic composition typically contains an amount of a therapeutic material, *i.e.*, a nucleotide sequence or adenovirus vector particle of the present invention, sufficient to deliver a therapeutically effective amount to the target tissue, typically an amount of at least 0.1 weight percent to about 90 weight percent of therapeutic material per weight of total therapeutic composition. A
10 weight percent is a ratio by weight of therapeutic material, *e.g.*, a nucleotide sequence, to total composition. Thus, for example, 0.1 weight percent is 0.1 grams of DNA segment per 100 grams of total composition.

VII. Other Applications

The cell lines, viral vectors and methods of the present invention may also be used for purposes other than the direct administration of therapeutic nucleotide sequences. In one such application, the production of large quantities of biologically active proteins or polypeptides in cells transfected with the within-disclosed viral vectors is contemplated herein. For example, human
15 lymphoblastoid cells may be transfected with a viral vector of the present invention carrying a human hematopoietic growth factor such as the gene for erythropoietin (EPO); cells so transfected are thus able to produce biologically active EPO. (See, *e.g.*, Lopez *et al.*, *Gene 148*: 285-91, 1994).

Various other applications and uses of the within-described methods, cell
25 lines, plasmids, vectors, and compositions of the present invention shall become apparent upon closer examination of the Examples that follow.

Examples

The following examples are intended to illustrate, but not limit, the present invention. As such, the following description provides details of the manner in which particular embodiments of the present invention may be made and used. This description, while exemplary of the present invention, is not to be construed as specifically limiting the invention. Variations and equivalents, now known or later developed, which would be within the understanding and technical competence of one skilled in this art are to be considered as falling within the scope of this invention.

Example 1

Preparation of Adenovirus Packaging Cell Lines

Cell lines that are commonly used for growing adenovirus are useful as host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and the like epithelial-derived cell lines. As a result of the adenovirus transformation, the 293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

The cell lines of this invention allow for the production and propagation of novel adenovirus-based gene delivery vectors having deletions in preselected gene regions, that are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a novel viral vector of the present invention, plasmid vectors that contain preselected functional units were designed as described herein. Such

units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such complementation, thereby being “complementary plasmids or constructs,” that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit which is alternately spliced to produce several different mRNAs. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcriptional unit as shown in Figure 1. A DNA fragment extending from 175 nucleotides upstream of the E4 transcriptional start site including the natural E4 promoter to 153 nucleotides downstream of the E4 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Virology*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of the primers used were 5'CGGTACACAGAAATTCAGGAGACACAACTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAAC3' (SEQ ID NO: 2) (backward or 3' primer referred to as E4R). To facilitate cloning of the PCR fragment, these oligonucleotides were designed to create novel sites for the restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute, 50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette

including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment.

The isolated BamHI-modified fragment was then cloned into the BamHI site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp (Figure 2). The pE4/Hygro plasmid has been deposited with the ATCC as described in Example 3. The complete nucleotide sequence of pE4/Hygro is listed in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone as shown in Figure 2 as a thin line between the 3' BamHI site in the hygromycin insert and the 3' EcoRI site in the E4 insert. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon

(C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp, the plasmid map of which is shown in Figure 3. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter provided by the pcDNA vector, a BglII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp, the plasmid map of which is shown in Figure 4. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is listed in SEQ ID NO: 8 bordered by BamHI/BglII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial TPL of the present invention is also listed separately as SEQ ID NO: 26 with the noted 5' and 3' restriction sites and with the following

nucleotide regions identified: 1-6 nt BglII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1); 28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BglII site.

The pCLF plasmid has been deposited with the ATCC as described in Example 3. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA. The rest of the vector construct has been previously described above.

C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins

The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*, 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10⁶ cells were electroporated with 20 µg each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 µF. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).

Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200 µg/ml Hygromycin B (Sigma, St. Louis, MO).

From expanded colonies, genomic DNA was isolated using the "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near

adenovirus 5 open reading frame 6. Refer to Figure 1 for position of the primers relative to the E4 genes.

One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the expected product, indicating the presence of inserted DNA corresponding to most, if not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 3. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected. Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell line, the expected labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event (Figure 5).

Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional electroporation with the fiber-encoding pCLF plasmid as described above.

Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 μ g/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate sublines of 211 were then screened for fiber protein expression by indirect immunofluorescence as described above. The three sublines screened, 211A,

211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSV β gal (1 pfu/cell) and stained 24 hours post-infection.

Lines positive for nuclear staining in this assay were then subjected to Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the expected molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including 211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 3.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a semipreparative electrophoresis system demonstrated that the fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein as shown in Figure 6. The predicted molecular weight of a trimerized fiber is 186 kd. The lane marked 293 lacks fiber while the sublines contain detectable fiber. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers as shown in Figure 6. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses

In order to prepare adenoviral packaging cell lines other than those based on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC

GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and XhoI as indicated by the underlines. The sites are used to clone the amplified E1 gene fragment into the NheI/XhoI sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp, the plasmid map of which is shown in Figure 7.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the *E. coli gpt* gene that allows stable transfectants to be isolated using hypoxanthine/aminopterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C, alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R, as described above. Functional insertion of the

fiber gene is assayed by staining with the anti-fiber antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments contemplated for use with the methods of this invention, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for use in generating recombinant adenovirus viral vectors of this invention thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer 5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is

amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides both dexamethasone-inducible E1 function as described for DEX/E1 and expression of Ad5 fiber protein as described above. A schematic plasmid map of pE1/Fiber, having 14455 bp, is shown in Figure 8.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately to 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions preformed as previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes

pCLF prepared as described in Example 1B is partially digested with BglII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form

plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp, is shown in Figure 9. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4 gene are located at respective nucleotide positions 21 and 3149 followed by fused BglII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BglII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BglII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

Example 2

Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines

Adenoviral delivery vectors of this invention are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector of this invention that is replication competent but only via a non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, the adenovirus delivery vectors of this invention have a higher capacity for insertion of foreign DNA.

A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use

To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid pΔ E1Bβgal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli* β-galactosidase gene was isolated from pSVβgal (Promega) by digesting with VspI, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with Bam HI. The resulting fragment was cloned into the EcoRV and BamHI sites in the polylinker of pΔ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form pΔ E1B βgal that therefore contained the left end of the adenovirus genome with the Ela region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSVβ gal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)

The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994), now described in International Application Publication Number WO 9500655, with methodology well known to one of ordinary skill in the art and also is commercially available from Microbix, which contains an Ad5 genome with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme PacI. An 11.9 kb BamHI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the BamHI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. A schematic of the plasmid map is shown in Figure 13. The p11.3 plasmid

was then digested with PacI and SalI to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

This fragment was replaced with a 3,4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences (5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17) and (5'CACAACGAGCTC AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18). These primers incorporated sites for PacI and BamHI. Cloning this fragment into the PacI and blunt ended SalI sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resultant p11.3 plasmid containing the ITR and E4 regions, now called plasmid pDV43a, was then digested with BamHI. This BamHI fragment was then used to replace a BamHI fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb BamHI fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3. The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a SalI restriction site. pDV42 was then digested with PacI, which cuts at a unique site (bold type) in one of the PCR primers, and with SalI, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding PacI/XhoI fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique XhoI site), creating pDV43. Finally,

pDV44 was constructed by replacing the 11.9 kb BamHI fragment of pBHG10 by the analogous BamHI fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Figure 16A). pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Both pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with pΔE1Bβgal, which contains the left end of the Ad5 genome with an SV40-driven β-galactosidase reporter gene inserted in place of the E1 region.

In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences corresponding to viral gene delivery vectors.

A selected cell line is plated in dishes and cotransfected with pDV44 and pΔE1Bβ gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a full-length viral chromosome where pDV44 and pΔE1Bβ gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the

sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of the recombinant virus are produced by standard methods.

5 A pDV44-derived virus is expected to be replication-defective due to the fiber deletion, so that the cells in which it is grown must complement this defect. The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 3) was used for rescue and propagation of the virus described here. pDV44 and pΔE1βgal were cotransfected into 211B cells, and the monolayers were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

10 One of a total of 58 transfected dishes showed evidence of spreading cell death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5.βgal.ΔF) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B cells were plated in DMEM plus 10% fetal calf serum at approximately 1×10^7 cells/150 cm² flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5.βgal.ΔF, at approximately 100 particles/cell. At day two, an equal volume of medium was added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis via
15 four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at - 70°C. Purified Ad5.βgal.ΔF virus particles containing human adenovirus Ad5.βgal.ΔFgenome (described
20
25

further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 3.

For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at 1.5×10^6 cells/well. Duplicate dilutions of virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C , virus was removed and the wells overlaid with 2 ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. β gal.wt, which is identical to Ad5. β gal. Δ F except for the fiber deletion, was constructed by cotransfection of pBHG10 and p Δ E1B β gal (Figure 16B). In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p Δ E1B β gal and pBHG10 produced virus.

In a preferred embodiment of this invention as more fully described herein and below, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to prepare a viral vector lacking fiber. In a preferred aspect of this invention, the fiber gene is replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Other embodiments including production of fiberless vector with a complete TPL are described in Example 5.

Vectors for the delivery of any desired gene and preferably a therapeutic gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p Δ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing p E1B β gal as described above.

The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later Examples.

1. Characterization of the Ad5.βgal.ΔF Genome

To confirm that the vector genomes had the expected structures and that the fiber gene was absent from the Ad5.βgal.ΔF chromosome, the DNA isolated from viral particles was analyzed. Briefly, purified viral DNA was obtained by adding 10 μl of 10 mg/ml proteinase K, 40 μl of 0.5 M EDTA and 50 μl of 10% SDS to 800 μl of adenovirus-containing culture supernatant. The suspension was then incubated at 55°C for 60 minutes. The solution was then extracted once with 400 μl of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 μl of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from both Ad5.βgal.wt and Ad5.βgal.ΔF produced the expected restriction patterns (Figure 17A) following digestion with either EcoRI (Figure 17B) or with NdeI (data not shown). Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the presence of fiber sequence in Ad5.βgal.wt but not in Ad5.βgal.ΔF DNA (Figure 17C). As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. As expected, E4 signal was readily detectable in both genomes at equal intensities (Figure 17C).

The complete nucleotide sequence of Ad5.βgal.ΔF is presented in SEQ ID NO: 27 and is contained in the virus particle on deposit with ATCC.

2. Characterization of the Fiberless Adenovirus Ad5.βgal.ΔF

To verify that Ad5.βgal.ΔF was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5.βgal.ΔF or with Ad5.βgal.wt. Twenty-four hours post infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5.βgal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

3. Growth of the Fiber-Deleted Ad5.βgal.ΔF Vector in Complementing Cells

Ad5.βgal.ΔF was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5.βgal.ΔF or Ad5.βgal.wt contained similar numbers of viral particles (Table 1), and the particles appeared to band normally on CsCl gradients. However, infectivity of the Ad5.βgal.ΔF particles was lower than the Ad5.βgal.wt control, as indicated by an increased particle/PFU ratio (Table 1). This is likely due to a reduced amount of fiber protein incorporated into mutant particles during growth in the

Virus	CsCl-purified prepn	Cell line	Particles/ml ^a	PFU/ml ^b	Particle/PFU ratio	Fiber source
Ad5.βgal wt	1	211B	7.4 x 10 ¹¹	7.5 x 10 ¹⁰	10	Ad chromosome
	2	211B	3.0 x 10 ¹¹	5.0 x 10 ⁹	60	Ad chromosome
Ad5.βgal.ΔF	3	211B	7.7 x 10 ¹¹	3.5 x 10 ⁸	2,200	Packaging cells

	4	211B	1.9×10^{12}	2.3×10^9	808	Packaging cells
	5	293	4.5×10^{11}	9.5×10^6	47,400	None
	6	293	3.4×10^{11}	3.5×10^7	9,700	None

^aCalculated from viral protein concentration (1 μ g of protein = 4×10^9 particles).

^bAssayed by plaquing on 211B cells.

Table 3

*Particle numbers and infectious titers of representative adenovirus preps. Each line represents a single CsCl-purified preparation of the indicated virus. Particle numbers were calculated from viral protein concentration (1 μ g protein = 4×10^9 particles). Pfu was assayed by plaquing on 211B cells (see above).

211B cells (see below). Ad5. β gal. Δ F was also found to plaque more slowly than the control virus. When plated on 211B cells, Ad5. β gal.wt plaques appeared within 5-7 days, while plaques of Ad5. β gal. Δ F continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5. β gal. Δ F plaques was essentially normal.

4. Production of Fiberless Ad5. β gal. Δ F Particles

As Ad5. β gal. Δ F represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the determination of whether such particles would be stable and/or infectious. Either Ad5. β gal.wt or Ad5. β gal. Δ F was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5. β gal. Δ F particles were readily produced in 293 cells at approximately

the same level as the control virus and behaved similarly on the gradients, indicating that there was not a gross defect in morphogenesis of fiberless capsids (Table 1).

As shown in Figure 18, particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. However, as predicted, the Ad5.βgal.ΔF particles produced in 293 cells did not contain fiber protein. 211B-grown Ad5.βgal.ΔF also contained less fiber than the Ad5.βgal.wt control virus (Figure 18). Importantly, the infectivities of the different viral preparations on epithelial cells (Table 1) correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5.βgal.ΔF was only 50-100 fold less than that of Ad5.βgal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

5. Composition and Structure of the Fiberless Ad5.βgal.ΔF Particles

The proteins contained in particles of 293-grown Ad5.βgal.ΔF were compared to those in Ad5.βgal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant (data not shown). The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a first-generation vector, with the exception of reduced intensity of the composite band resulting from both proteins IIIa and IV (fiber) (data not shown). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5.βgal.ΔF and of Ad5βgal.wt. The fiber, which consists of an extended stalk with a knob at the end, was faintly visible in favorable orientations of

wild-type Ad5 particles, but not in images of the fiberless particles (data not shown). Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

5 Three-dimensional image reconstructions of fiberless and wild-type particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

6. Integrin-Dependent Infectivity of Fiberless Ad5.βgal.ΔF Particles

20 While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates both binding to the cells (via β2 integrins) and internalization (through interaction with αv integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial cells.

25 To investigate this, THP-1 monocytic cells were infected with Ad5.βgal.wt or with Ad5.βgal.ΔF grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2×10^5 cells at the indicated m.o.i. in 0.5 ml of complete RPMI.

Forty-eight hours post-infection, the cells were fixed with glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy.

The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells (Figure 19A). In contrast to this, very large differences were seen in plaquing efficiency on epithelial (211B) cells (Table 1). Infection of THP-1 cells by either Ad5.βgal.ΔF or Ad5.βgal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base (Figure 19B). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5.βgalΔF from internalizing into the cells and delivering its genome to the nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools both in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T lymphocytes directed against the vector, and the nature and magnitude of the antibody response directed against viral proteins.

Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression.

Following this evaluation, they are used as experimental therapeutic agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins

5 As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.

10 In one aspect of invention, chimeric fiber proteins are produced according to the methods of Stevenson *et al.*, *J. Virol.*, 69:2850-2857 (1995). The authors showed that the determinants for fiber receptor binding activity are located in the head domain of the fiber and that isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods of this invention are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in Example 1 as a complementing viral vector in adenoviral packaging cells, the constructs described

15

20 herein are used to transfect cells along with E4 and/or E1-encoding constructs.

Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotides sequences are available with the respective GenBank Accession Numbers M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

25

The resultant products are then used to construct chimeric fiber constructs by PCR gene overlap extension, as described by Horton *et al.*, *BioTechniques*, 8:525-535 (1990). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1. The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as previously described. Other fiber chimeric constructs are obtained using a similar approach with the various adenovirus serotypes known.

In an alternative embodiment, the methods of this invention contemplate the use of the modified proteins including novel epitopes as described by Michael *et al.*, *Gene Therapy*, 2:660-668 (1995) and in International Publication WO 95/26412, the disclosures of which are incorporated by reference herein. Both publications describe the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity. In particular, the authors described the production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following synthesis.

Based on the teachings in the paper and International Publication, similar constructs are contemplated for use in the complementing adenoviral packaging cell systems of this invention for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic. Heterologous ligands contemplated for use herein to redirect fiber specificity range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end. One of ordinary skill in the art is familiar with the preparation of linkers to accomplish sufficient protein presentation and for altering the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this invention, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example 1.

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20) followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop

codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site.

The resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral vector packaging systems for use with the methods of this invention.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

Example 3

Deposit of Materials

The following cell lines and plasmids have been deposited on September 25, 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty): Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737), 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5.βgal.ΔF, was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were deposited at the ATCC on January 5, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

Example 4

Complementation of Fiber-Defective and Fiber-Modified Virus

The native fiber protein is a homotrimer (Henry L.J. *et al.*, *J. Virol.* 68:5239-5246 (1994)), and trimerization is essential for assembly of the penton/fiber complex (Novelli A *et al.*, *J. Biol. Chem.* 266:9299-9303 (1991)). To assess the multimeric structure of the recombinant fiber protein produced by the cell lines, cells were labeled with 50 μCi/ml [³⁵S] Translabel (ICN) for two hours at 37°C, lysed in RIPA buffer, and fiber protein was immunoprecipitated as described (Harlow E *et al.*, *Antibodies*. Cold Spring Harbour Laboratory, Cold Spring Harbor (1988). Immune complexes were collected on Protein A-Sepharose beads (Pierce), extensively washed with RIPA buffer, and incubated at room temperature in 0.1 M triethylamine, pH 11.5 to release bound fiber protein. A portion of the precipitated fiber was electrophoresed on a 8% SDS-PAGE gel under denaturing (1% SDS in loading buffer, samples boiled for 5 minutes) or semi-native (0.1% SDS in loading buffer, samples not heated) conditions.

As seen in Fig. 13, lines 211A, 211B, and 211R, but not the control 293 cells, expressed an immunologically reactive protein which migrated at the predicted molecular weight for trimer (186 kD) under seminative conditions and for monomer (62 kD) under denaturing conditions. The behavior of the precipitated fiber was indistinguishable from that of purified baculovirus-produced recombinant Ad2 fiber (Wickham T *et al.*, *Cell* 73:309-319 (1993)) (the 58 kD Ad2 and 62 kD Ad5 fibers have very similar mobilities under these conditions).

To determine whether the fiber-expressing lines could support the growth of a fiber-defective adenovirus, we performed one-step growth experiments using the

temperature-sensitive fiber mutant Ad H5ts142 (the gift of Harold Ginsberg). At the restrictive temperature (39.5°C), this mutant produces an underglycosylated fiber protein which is not incorporated into mature virions (Chee-Sheung C. C *et al.*, *J. Virol* 42: 932-950 (1982)). This results in the accumulation of non-infectious viral particles. We asked whether the recombinant fiber protein expressed by our cell lines could complement the H5ts142 defect and rescue viral growth.

Cell lines 293, 211A, 211B and 211R (2 x 10⁶ cells/sample) were infected with H5ts142 at 10 pfu/cell. 48 hours later, cells were detached with 25 mM EDTA and virus was harvested by four rapid freeze-thaw cycles. Debris was removed by a 10 minute spin at 1500 x g, and viral titers determined by fluorescent focus assay (Thiel J.F *et al.*, *Proc. Soc. Exp. Biol. Med.* 125:892-895 (1967)) on SW480 cells with a polyclonal anti-penton base Ab (Wickham T *et al.*, *Cell* 73:309-319 (1993)). As shown in Fig. 14, the fiber mutant virus replicated to high titers in 293 cells at 32.5°C (the permissive temperature), but to a much lower extent at the restrictive temperature of 39.5°C. The fiber-producing packaging lines 211A, 211B, or 211R supported virus production at 39°C to levels within two- to three-fold of those seen at the permissive temperature in 293 cells, indicating that these cells provided partial complementation of the fiber defect.

Interestingly, virus yields from the fiber-producing cell lines were also somewhat higher than those from 293 cells at 32.5°C (the 'permissive' temperature). This suggests that fiber produced by the ts142 virus may be partially defective even at the permissive temperature. Alternatively, a non-specific increase in adenoviral titer could result when viruses are grown in the packaging cells, by a mechanism not involving fiber complementation. However, it was found that viruses with wild type fiber genes (such as Ad.RSVβgal) replicate to identical levels either in our packaging lines or in 293 cells (data not shown). Taken together, these results demonstrate that the observed increase in H5ts142 growth is due to specific complementation of the fiber mutation.

Even in the fiber-expressing cell lines, the fiber mutant grows to higher titers at 32°C than at 39.5°C. This incomplete complementation may be due to the packaging lines' expression of fiber at a level somewhat below that seen in a wild-type infection

(data not shown). A recent study reported an E4-deleted vector which coincidentally reduced fiber protein expression, resulting in a large reduction in the titer of virus produced (Brough *et al.*, *J. Virol.* 70:6497-6501 (1996)). Another possibility is that the defective *ts142* fiber protein produced at the restrictive temperature might form complexes with some of the wild type protein produced by the cells and prevent its assembly into particles.

Although the fiber proteins of different Ad serotypes differ in the length of their shaft domains and in their receptor-binding knob domains, the N-terminal regions responsible for interaction with the viral penton base are highly conserved (Arnberg *et al.*, *Virology* 227:239-244 (1997)) (Figure 15A). This suggests that fibers from many viral serotypes, with their different cell-binding specificities, may be amenable for use in producing gene delivery vectors.

In order to determine whether the recombinant Ad5 fiber produced by the packaging cells could be incorporated into particles of another adenovirus serotype, adenovirus type 3 was grown either in fiber-producing cell lines or in 293 cells. Viral particles were purified by two sequential centrifugations (3 h at 111,000 x g) on preformed 15-40% CsCl gradients to remove soluble cellular proteins and then dialyzed extensively against 10 mM Tris-HCl, pH 8.1, 150 mM NaCl, 10% glycerol. Ad5 fiber protein was detected by immunoblotting using the polyclonal anti-fiber serum, followed by detection with a horseradish peroxidase-conjugated goat anti-rabbit antibody (Kirkegaard and Perry Laboratories) and the ECL chemiluminescence substrate (Amersham). The purified Ad3 particles contained Ad5 fiber protein after a single passage through a fiber-expressing cell line but not after passage through 293 cells (Figure 15B). Previous work has demonstrated that Ad2 fiber is capable of interacting *in vitro* with Ad3 penton base (Fender *et al.*, *Nature Biotech.* 15:52-56 (1997)), and our result demonstrates that the type 5 fiber protein produced by the cells is capable of assembling into complete Ad3 particles.

A vector based on Ad5 but containing the gene for the Ad7 fiber protein has been described (Gall *et al.*, *J. Virol.* 70:2116-2123 (1996)), as well as Ads containing chimeric fiber genes (Krasnykh *et al.*, *J. Virol.* 70:6839-6846 (1996) and Stevenson *et al.*, *J. Virol.* 69:2850-2857 (1995)). Chimeric Ad5/Ad3 vectors have also been

reported (Stevenson, S. *et al.*, *J. Virol.* 71:4782-4790, (1997). Addition of a short peptide linker to the fiber in order to confer binding to a different cellular protein has also been reported (Michael *et al.*, *Gene Therapy* 2:660-668 (1995). By using packaging technology such as that presented here, Ad vectors equipped with different fiber proteins may be produced simply by growth in cells expressing the fiber of interest, without the time-consuming step of generating a new vector genome for each application.

Replacing or modifying the fiber gene in the vector chromosome would also require that the new fiber protein bind a receptor on the surface of the cells it is to be grown. The packaging cell approach will allow the generation of Ad particles containing a fiber which can no longer bind to its host cells, by a single round of growth in cells expressing the desired fiber gene. This will greatly expand the repertoire of fiber proteins which can be incorporated into particles, as well as simplifying the process of retargeting gene delivery vectors.

Finally, a novel fiber-independent pathway of infection has recently been described in hematopoietic cells, in which penton base provides the initial virus-cell interaction by binding to integrin $\alpha_m\beta_2$ (Huang S. *et al.*, *J. Virol* 70: 4502-4508 (1996)). This suggests that viral particles lacking fiber protein may be useful in targeting gene delivery to specific cell types via this pathway.

Example 5

Preparation of Alternative TPLs

The present invention contemplates the use of tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector. One preferred TPL is the complete Ad5 tripartite leader contained in complementing vectors such as pDV67 and pDV69, both of which are prepared as described below. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5 genomic DNA using the synthetic oligonucleotide primers

5'CTCAACAATTGT**GGATCC**GTACTCC3'(SEQ ID NO: 28) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 29). The resulting product was cloned to the BamHI and BglII sites of pΔE1Sp1a (Microbix Biosystems) using novel sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then amplified using primers 5'GGCGCGTTC**GGATCC**ACTCTCTTCC3' (SEQ ID NO:30) and 5'CTA CATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID NO: 31), and cloned into the BamHI site of pDV52 (again using novel sites in the primers) to create pDV55. This plasmid contains a 1.2 kb BamHI/BglII fragment consisting of the first TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID NO: 32 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2); 1141-1146 nt fused BamHI and BglII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BglII site.

TPLs fragments containing two of the three exons, exons in non-native order, or containing either the first or second TPL intron are also constructed for use in preparing complementing plasmids for use in the methods of the present invention.

Briefly, DNA fragments containing any combination of 2 TPL exons can be constructed as follows: Exon 1 is amplified from genomic DNA as prepared above by using the oligonucleotides 5'GGCGCGTTC**GGATCC**ACTCTCTTCC3'(SEQ ID NO: 33) and 5'GGGAGTAGATCTCCCAACAG3' (SEQ ID NO: 34). Exon 2 is similarly amplified from the same genomic DNA using oligonucleotides 5'CCCTTTTTTTTT**GGATCC**CTCGCGG3' (SEQ ID NO: 35) and 5'CTACATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID NO: 36). Exon 3 is amplified using the oligonucleotides 5'CTCAACAATTGTT**GGATCC**GTACTCC3' (SEQ ID NO: 37) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 38).

The amplified exons are ligated together in any desired number and/or order by virtue of the unique BamHI and BglII restriction sites (bold) in the primers for

subsequent ligation into a construct analogous to pDV67, prepared as described below, for expression of viral structural genes.

Similarly, a fragment consisting of the first TPL exon (exon 1), the native first intron (intron 1), and the second TPL exon (exon 2) is produced by amplification from Ad5 genomic DNA with the oligonucleotide pair 5'GGCGCGTTTCGGATCC ACTCTCTTCC3' (SEQ ID NO: 39) and 5'CTACATGCTAGGCAGATCT CGTTCGGAG3' (SEQ ID NO: 40). Finally, a fragment consisting of the second TPL exon (exon 2), the native second intron (intron 2), and the third TPL exon (exon 3) is produced by amplification using the oligonucleotides 5'CCCTTTTTTTTGGATCC CTCGCGG3' (SEQ ID NO: 41) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 42). Either of the intron-containing fragments are used either alone or in combination with another TPL fragment(s) in constructs analogous to pDV67. Introns in addition to adenoviral intron 1 used herein that have been shown to increase the expression of recombinant proteins when included in expression constructs include SV40 VP1 intron, rabbit β -globin intron among others. The use of these alternative intron sequences are contemplated for use in preparing a TPL in the present invention.

Example 6

Preparation and Use of Adenoviral Packaging Cell Lines Containing Plasmids Containing Alternative TPLs

Plasmids were first constructed as described below that contained TPLs are described above. The resultant plasmids containing different selectable markers such as neomycin or zeocin were then used to prepare stable cell lines for use as complementing vectors for preparing adenoviral vectors for use in the present invention. In a preferred embodiment, the resulting cell lines represent improvements over preexisting fiber-complementing cell lines in that fiber expression is enhanced with the use of alternative TPLs.

A. pDV60

pDV60 was constructed by inserting this TPL cassette of SEQ ID NO: 32 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a neomycin selectable plasmid, prepared as described in Example 1 and also as described by Von Seggern *et al.*, *J. Gen Virol.*, 79: 1461 (1998). The nucleotide sequence of pDV60 is listed in SEQ ID NO: 43.

B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone terminator was transferred from pCLF, prepared as described in Example 1 and also as described by Von Seggern *et al.*, *J. Gen Virol.*, 79: 1461 (1998), to a zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially available from Invitrogen and the sequence is also available).

C. pDV67

In an analogous process, pDV67 containing complete TPL was constructed by transferring an Asp 718/XbaI fragment from pDV60 to the pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is listed in SEQ ID NO: 44.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.*, *J. Virol.*, 69: 2850-2857, 1995)) using the primers 5'ATGGGATCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 45) and 5'CACTATAGCGGCCGCATTCTCAGTCATCTT3' (SEQ ID NO: 46), and cloned to the BamHI and NotI sites of pcDNA3.1/Zeo(+) via novel BamHI and NotI sites

engineered into the primers to create pDV68. Finally, the complete TPL fragment described above was then added to the unique BamHI site of pDV68 to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID NO: 47.

E. Preparation of Stable Adenovirus Packaging Cell Lines

5 E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC # CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID NO: 48) and pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in SEQ ID NO: 49), which provide complementation of the adenoviral E1 and E2a functions, respectively. This line and its derivatives were grown in Richter's modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were electroporated as previously described (Von Seggern *et al.*, *J. Gen Virol.*, 79: 1461 (1998)) with pDV61, pDV67, or with pDV69, and stable lines were selected with zeocin (600 µg/ml). The cell line generated with pDV61 is designated 601. The cell line generated with pDV67 is designated 633 while that generated with pDV69 is designated 644. Candidate clones were evaluated by immunofluorescent staining with a polyclonal antibody raised against the Ad2 fiber. Lines expressing the highest level of fiber protein were further characterized.

For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM of dexamethasone was added to cell cultures 16-24 hours prior to challenge with virus for optimal growth kinetics. For preparing viral plaques, 5 X 10⁵ cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone the day prior to infection with 0.5 µM included at a final concentration in the agar overlay after infection.

F. Development of Cell Lines for Complementation of E1⁻/E2a⁻ Vectors

25 This example shows the construction of S.8 cells

The Adenovirus 5 genome was digested with ScaI enzyme, separated on an agarose gel, and the 6,095 bp fragment comprising the left end of the virus genome was

isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A., under accession number VR-5. The ScaI 6,095 bp fragment was digested further with ClaI at bp 917 and BglII at bp 3,328. The resulting 2,411 bp ClaI to BglII fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with ClaI and BglII, to form pSE280-E. (Figure 23).

Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an XhoI and Sall restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:

5' end, Ad5 bp 552-585:

5'-GTCACCTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCA
CGGACC-3' (SEQ ID NO: 66)

3' end, Ad5 bp 922-891:

5'-CGAGATCGATCACCTCCGGTACAAGGTTTGGCATAG-3' (SEQ ID NO: 67)

This amplified DNA fragment (sometimes hereinafter referred to as Fragment A) then was digested with XhoI and ClaI, which cleaves at the native ClaI site (bp 917), and ligated to the XhoI and ClaI sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.

PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an EcoRI restriction site. The primers which were employed were as follows:

5' end, Ad5 bp 3323-3360:

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID NO: 68)

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAA
ATCC-3' (SEQ ID NO: 69)

This amplified DNA fragment (sometimes hereinafter referred to as Fragment B) was digested with BglII, thereby cutting at the Adenovirus 5 BglII site (bp 3,382) and EcoRI, and ligated to the BglII and EcoRI sites of pSE280-AE to reconstruct the

complete E1a and E1b region from Adenovirus 5 bp 552 through 4,090. The resulting plasmid is referred to as pSE280-E1 (Figure 23).

A construct containing the intact E1a/b region under the control of the synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was excised from pSE280-E1, which was modified previously to contain a BamHI site 3' to the E1 gene, by digesting with XhoI and BamHI. The XhoI to BamHI fragment containing the E1a/b fragment was cloned into the unique XhoI and BamHI sites of pGRE5-2/EBV (Figure 4, U.S. Biochemicals, Cleveland, Ohio) to form pGRE5-E1 (Figure 24).

Bacterial transformants containing the final construct were identified. Plasmid DNA was prepared and purified by banding in CsTFA prior to use for transfection of cells.

Construction of plasmid including Adenovirus 5 E2A sequence.

The Adenovirus 5 genome was digested with BamHI and SpeI, which cut at bp 21,562 and 27,080, respectively. Fragments were separated on an agarose gel and the 5,518 bp BamHI to SpeI fragment was isolated. The 5,518 bp BamHI to SpeI fragment was digested further with SmaI, which cuts at bp 23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI (Figure 26).

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites. The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID NO: 70)

3' end, Ad5 bp 23,912-23,934:

5'-CACCCCGGGGAGGCGGCGGCGACGGGGACGGG-3' (SEQ ID NO: 71)

This amplified DNA fragment was digested with SmaI and EcoRI, and ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the complete E2a region from Ad5 bp 24,730 through 21,562. The resulting construct is pSE280-E2a (Figure 27.)

In order to convert the BamHI site at the 3' end of E2a to a SalI site, the E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and recloned into the unique BamHI and NheI sites of pSE280. (Figure 27.) Subsequently, the E2a region was excised from this construction with NheI and SalI in order to clone into the NheI and SalI sites of the pMAMneo (Clonotech, Palo Alto, CA) multiple cloning site in a 5' to 3' orientation, respectively. The resulting construct is pMAMneo E2a. (Figure 27).

Bacterial transformants containing the final pMAMneo-E2a were identified. Plasmid DNA was prepared and purified by banding in CsTFA. Circular plasmid DNA was linearized at the XmnI site within the ampicillin resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform extraction and ethanol precipitation prior to use for transfection of cells.

Transfection and selection of cells.

In general, this process involved the sequential introduction, by calcium phosphate precipitation, or other means of DNA delivery, of two plasmid constructions each with a different viral gene, into a single tissue culture cell. The cells were transfected with a first construct and selected for expression of the associated drug resistance gene to establish stable integrants. Individual cell clones were established and assayed for function of the introduced viral gene. Appropriate candidate clones then were transfected with a second construct including a second viral gene and a second selectable marker. Transfected cells then were selected to establish stable integrants of the second construct, and cell clones were established. Cell clones were assayed for functional expression of both viral genes.

In order to determine the most suitable cell lines for the above-mentioned transfections, sequential transfections and selections were carried out with the following parental cell types:

A549 (ATCC Accession No. CCL-185);
Hep-2 (ATCC Accession No. CCL-23); or
KB (ATCC Accession No. CCL-17).

Appropriate selection conditions were established for both G418 and hygromycin B for all three cell lines by standard kill curve determination.

Transfection of cell lines with plasmids including E1 and E2a regions.

pMAMNeo-E2a was linearized with XmnI with the Amp^R gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, and visualizing by immunofluorescence. E2a function was screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1 (Figure 5), which contains the GRE5 promoted E1a/b region plus the hygromycin^R gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus establishing the expression of both E1a/b and E2a in the positive cell clones.

One of the transfected A549 cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

G. Preparation of Adenoviral Vectors Containing Ad5.βgal.ΔF Genome in S8 Improved Fiber-Complementing Cell Lines

To prepare adenoviral vectors containing Ad5.βgal.ΔF in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5.βgal.ΔF in 211B cells was followed with the exception of pretreatment with 0.3 μM dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless Ad5.βgal.ΔF genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5.βgal.ΔF genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

The preparation of the cell lines and demonstration of stable nuclear expression of either wild-type Ad5 fiber protein or chimeric Ad5/Ad3 protein is shown in Figure 20. In the figure, schematic diagrams are presented of the constructs used to generate the cell lines as well as immunofluorescence results indicating the presence of expressed fiber protein in the nucleus of the cells.

Thus, these viral preparations, prepared as described herein and in Example 2, are useful for targeting delivery of Ad5.βgal.ΔF fiberless genome with either wild-type or modified fibers, embodiments of which uses have been previously discussed and as further exemplified with the pseudotyping and infectivity results described in Example 7.

Example 7

Pseudotyping and Infectivity of Recombinant Adenoviral Vectors Produced with Improved Fiber-Complementing Cell Lines

A. Pseudotyping of Ad5.βgal.ΔF

To verify that adenoviral vectors were produced had altered tropisms, viral particles were purified from either 633 or 644 cells and were then Western blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects both the Ad5 and chimeric 5T3H fiber proteins.). The results are shown in Figure 21 where both fiber proteins were detectable confirming pseudotyping.

B. Infectivity of Cells with 633 or 644 Generated Virus Particles

The cell lines, 633 or 644, prepared as described above, were infected with the indicated number of particles/cell of Ad5.βgal.ΔF and virus particles produced. Virus was then used to infect, as previously described, selected cell lines as shown in Figure 22, including 211B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light microscopy where all experiments were done in triplicate.

The results shown in Figure 22 indicate that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber proteins. The data marked with "none" indicates virus grown in 293 cells and lacking fiber, while "Ad5" indicates virus prepared in 633 cells (containing the wild type fiber) and Ad3 indicates virus prepared in 644 cells (containing the chimeric 5T3H fiber.) Particles containing either fiber were equally infectious on 211B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.

Example 8

Targeted Gene Delivery Using Viral Vector Particles Lacking Fiber Protein

An alternative mode of entry for adenoviral infection of hematopoietic cells has been described by Huang, *et al.*, *J. Virol.*, 69:2257-2263 (1995) which does not involve the fiber protein-host cell receptor interaction. As infection of most other cell types does require the presence of fiber protein, vector particles which lack fiber may preferentially infect hematopoietic cells, such as monocytes or macrophages.

To produce a fiber-free adenovirus vector particle, a vector lacking the fiber gene as described above in Example 2A but containing a gene of interest for delivery is amplified by growth in cells which do not produce a fiber protein, such as the 211 cells prepared in Example 1 or 293 or S8 cells as described herein, thereby producing large numbers of particles lacking fiber protein. The recovered fiber-free viral particles are then used to deliver the inserted gene of interest following the methods of this invention via targeting mechanisms provided by other regions of the adenoviral vector, *i.e.*, via the native penton base.

A. Construction of an Adenovirus Vector Deleted for E1, E3, and Fiber, and Carrying a Therapeutic Gene of Interest

A general method of constructing a fiber-deleted Ad vector containing a therapeutic gene of interest (in this example, the Herpes Simplex Virus Thymidine Kinase (TK) gene) is described here. Linear viral DNA is isolated from a preparation of Ad5.βgal.ΔF particles. This DNA is digested with the restriction enzyme ClaI, which removes the leftmost viral sequences including the left ITR, the packaging signals, and part of the SV40-driven β-galactosidase gene. The large ClaI fragment with the remainder of the fiber-deleted viral genome is then isolated by centrifugation on a sodium chloride or sucrose gradient. The plasmid pAdShuttleTK, which contains the left part of the Ad chromosome with an RSV-driven TK gene inserted in place of the E1 region, is linearized by digestion with NotI. The nucleotide sequence of the pAdShuttleTK is shown in SEQ ID NO: 50. The large ClaI fragment of Ad5.βgal.ΔF and the linearized pAdShuttleTK are cotransfected into 211B cells, and an infectious adenovirus genome is generated by homologous recombination. A virus deleted for E1, E3, and fiber that contains the TK cassette in the place of the E1 deletion is thus recovered. A virus containing any desired therapeutic gene of interest can be created in this manner by replacing the TK gene of the example with the gene of interest.

An alternative method of constructing a fiber-deleted genome containing a therapeutic gene (in this example the *retinal degeneration-slow (RDS)* gene driven by the CMV immediate early promoter) is described here. RDS is a protein expressed in photoreceptors, and essential for their proper development and functioning. RDS mutations have been implicated in retinal degenerative disorders, and transfer of the wildtype RDS gene by means of an Ad vector provides an avenue towards treating such disorders.

A plasmid (pDV50) analogous to pΔE1Bβgal but containing a CMV-driven RDS gene was constructed as follows. First, a fragment containing the CMV promoter and enhancer was excised from pChAMIEP by digestion with HindIII, filling the overhanging ends with the large fragment of *E. coli* DNA polymerase 1, ligation of BamHI linkers (5'CGCGGATCCCG3' SEQ ID NO: 51) to the blunt ends, and digesting with BamHI. The resulting fragment was then ligated into the BamHI site

of pΔE1spl1a (Mikrobix) to create pDV45. A fragment containing the SV40 polyadenylation signal was amplified from pSVβgal (Promega) using the oligonucleotides 5'CTGACAAACTCAGATCTTGTATTG3' (SEQ ID NO: 51) and 5'GTCGACTCTAGAGGATCCAGA3' (SEQ ID NO: 52). This fragment was ligated into the BglII site of pDV45 to create pDV46, using the unique BamHI and BglII sites (bold type) in the primers. Finally, the human *RDS* open reading frame was amplified from the plasmid pRDS-T7 using the oligonucleotides 5'CCGGACTCTAGATGGCAACCATGGCGCTAC3' (SEQ ID NO: 53) and 5'GGA GGGGAAGCTTGGCCCTCAGCCAGCCTCT3' (SEQ ID NO: 54). This fragment was inserted into the HindIII and XbaI sites of pDV46, again using unique restriction sites in the primers, to create pDV50. pDV50 therefore contains a cassette consisting of the CMV promoter, the *RDS* open reading frame, and the SV40 terminator sequences inserted in place of the Ad5 E1 region.

In a manner analogous to the construction of Ad5.βgal.ΔF, pDV50 and pDV44 are then co-transfected into 211B cells, and an infectious Ad genome (Ad5.*RDS*.ΔF) is recovered. A fiber-deleted Ad vector containing any desired gene to be expressed can be constructed by replacing the *RDS* gene of this example with the gene of interest.

Example 9

Transient Transcomplementation

Human adenovirus type 5 (Ad5) is being developed as a vector for gene therapy. Its ability to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it can be difficult to use adenoviruses to deliver genes to specific cell types. One way to address this is to target the virus to a particular cell type by genetically altering the fiber. However, the genetic manipulations involved in cloning and production of the viruses with altered fibers can be time-consuming. Thus it would be a significant advancement in the field of adenoviral gene therapy to have a more streamlined system for testing modified fiber

genes. An *in vitro* system has thus been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate such modified fibers in the context of a viral particle easily and quickly. In addition this system can be envisioned to actually produce therapeutic quantities of adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

Plasmids used were pDV60 and pDV55, prepared as described herein. pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5.βgal.ΔF and 211B are described above. 293T cells are identical to 293 cells except they express an integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine serum.

The fiber deletion mutation of Ad5.βgal.ΔF is complemented in *trans* by passaging virions through 211B, a cell line that stably expresses functional Ad5 fiber. The present system was designed to complement Ad5.βgal.ΔF by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5.βgal.ΔF genome that does not require propagation of the virus.

The feasibility of transcomplementation of Ad5.βgal.ΔF with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists for at least six days, suggesting that the plasmid is stable as an episome for this amount of time. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5.βgal.ΔF passaged through 211B cells. Seventy-two hours later, a crude viral

lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

To demonstrate the functionality of these virions, the transduction efficiency was tested. The virions containing no fiber (pDV55) or wildtype fiber (pDV60) were applied to monolayers of 293T and HDF cells at different multiplicity of infection (MOI's). 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. After 2 days, the cells were fixed and stained with X-gal to detect the β -galactosidase reporter gene activity. The results showed low transduction efficiency for the pDV55-complemented virions in both cell lines. As expected, the pDV60-complemented virions transduced 293T cells to a high degree but did not transduce HDF cells, indicating that functional fiber proteins had been expressed from the episomal plasmids and incorporated into the virions. This transduction efficiency was comparable to or better than that of Ad5. β gal. Δ F virions passaged through the 211B cells.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility for quickly evaluating a bank of modified fibers for other binding properties, including novel tropism and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. β gal. Δ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber with which you want to complement Ad5. β gal. Δ F. Because the Ad5. β gal. Δ F is deleted in E1, E3 and fiber, there is an additional gene deletion compared to other first generation vectors. This makes t Ad5. β gal. Δ F more replication defective and presumably safer. In addition, the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. In terms of production a single Ad vector prep could be

retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

Example 10

Adenoviral Gene Delivery Vectors Containing the Ad37 Fiber Protein

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract, and may be useful for targeting these tissues or other mucous membranes, as well as other cell types. The tropism of Ad37 is due to the binding preference of its fiber protein, which binds to an as yet-unidentified receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang *et al.*, *J. Virology* 73(4):2798-2802 (1999)). As this fiber directs viral infection to cell types different than those infected by Ad5, it is likely to provide a method for targeting gene delivery. This example describes construction of packaging cell lines expressing the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as Ad5.βgal.ΔF) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would efficiently bind the Ad5 penton base in these vectors.

1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)

This plasmid uses the same regulatory elements as contained in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines, and was constructed in two steps. First, the Ad37 fiber open reading frame was amplified from Ad37 genomic DNA (obtained from the ATCC - accession number VR-929) using the synthetic oligonucleotides primers L37 (5' TGT CTT **GGA TCC AAG ATG AAG CGC GCC CGC CCC AGC** GAA GAT GAC TTC 3') (SEQ ID NO: 56) and 37FR (5' AAA CAC **GGC GGC CGC** TCT TTC ATT CTT G 3') (SEQ ID NO: 57). L37

contains nucleotides that differ from the Ad37 genomic sequence in order to add an unique *Bam* H1 site (bold in the above sequence) and create point mutations to make the N-terminal sequence of the fiber more closely match that of the Ad6 protein (underlined in the above sequence; the start codon is italicized). 37FR incorporates changes to create a unique *Not* I site (bold). The PCR product was inserted into the *Bam* H1 and *Not* I sites of pCDNA3.1zeo(+) (Invitrogen) to create pDV78. The correct sequence of the Ad37 fiber gene, including the predicted changes, was confirmed by sequencing.

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5 tripartite leader was excised from pDV55 (DVS 1999) and inserted into the *Bam* H1 site of pDV78 to create pDV80 (SEQ ID NO:64).

2. Isolation of Cell Lines Expressing the Ad37 Fiber Protein

pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (Gorziglia *et al.*, *J. Virology* 70(5):4173-4178 (1996)) as previously described (Von Seggern, *et al.*, *J. Gen. Virol.* 79:1461-1418), and stable clones were selected with 600 µg/ml zeocin (Invitrogen). Clones were expanded and screened for fiber expression by indirect immunofluorescence using a rabbit polyclonal antibody directed against the Ad37 fiber. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected for further study.

3. Production of Pseudotyped Ad Vector Particles

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately 1000 particles/cell) with Ad5.βgal.ΔF or with Ad5.GFP.ΔF.

Ad5.βgal.ΔF is prepared as previously described. Ad5.GFP.ΔF was constructed by recombination in bacteria using a modification of the method of (He, *et al.*, *PNAS* 95:2509-2514 (1998)). First, a fiber-deleted genomic plasmid was constructed by removing the fiber gene from pAdEasy1 (He, *et al.*, *PNAS* 95:2509-2514 (1998)).

pDV43 (Von Seggern, *et al.*, *J. Virol.* 73:1601-1608 (1999)) was digested with *Pac* 1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated. The resulting plasmid, pDV76, is identical to pDV43 except for loss of the *Pac* 1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.2 kb fragment was amplified from pDV76 using the oligonucleotides primers 5' CGC GCT GAC TCT TA **GGA CTA** GTT TC 3' (SEQ ID NO: 58) (including the unique *Spe* 1 site in the Ad5 genome, bold) and 5' GCG **CTT AAT TAA** CAT CAT CAA TAA TAT ACC TTA TTT T 3' (SEQ ID NO: 59) (including a novel *Pac* 1 site (bold) adjacent to the right Ad5 ITR). This PCR fragment therefore contains nucleotides 27,082 to 35,935 of the Ad5 genome with a deletion of nucleotides 28133 to 32743 (the E3 and fiber genes), and was used to replace the corresponding *Spe* 1/*Pac* 1 fragment of PAdEasy1 to create pDV77.

E. coli strain BJ5183 was electroporated with a mixture of pDV77 and *Pme* 1-linearized pAdTrack as described (He et al., 1998), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete E1-, E3-, and fiber-deleted Ad5 genome with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full-length Ad chromosome was isolated by *Pac* 1 digestion, and transfected to the E1- and fiber-complementing 633 cells (Von Seggern *et al.*, *J. Virol* January 2000). The recovered virus was then plaque purified by plating on 633 cells and stocks were prepared.

Ad5-pseudotyped particles were generated by virus growth in 633 cells, which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients as previously described (Von Seggern et al., *J. Virol.* 73:1601-1608, 1999). For analysis of viral proteins, ten µg of the purified particles were electrophoresed on 8-16% gradient gels and the protein transferred to nylon membranes. The blot was then probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells (Figure 27).

Example 11

Construction of a Fiber Expression Construct Containing a Post-Transcriptional Regulatory Element

Previous studies have shown that mRNA transcribed from the woodchuck hepatitis virus (WHV) genome contains an element (the WHV post-transcriptional regulatory element, or WPRE) which can increase expression of a protein encoded by the mRNA via a post-transcriptional mechanism (Loeb *et al.*, *Human Gene Therapy* 10:2295-2305 (1999)). The WPRE has also been shown to enhance expression of transgenes delivered by retroviral vectors. (Zufferey, R. *et al.*, *J. Virol.* 73:2886-2892 (1999)). This example describes the construction of a fiber expression construct (pDV90) (SEQ ID NO:65) containing a WPRE as well as the promoter and TPL sequences as contained in pDV67.

A plasmid (pBS/WPRE) which contains the WPRE was obtained from Dr. Thomas Hope, Salk Institute. Digestion of pBS/WPRE with *Cla*I releases a 600 bp fragment containing the WPRE (nt 193-1684 of the WHV genome.) Following *Cla*I digestion, the ends of this fragment were filled by treatment with the large fragment of *E. coli* DNA polymerase 1 in the presence of dNTPs to render them blunt. pDV67 DNA was digested with *Xba*I (which cuts at a unique site in the transcribed region downstream of the Ad5 fiber open reading frame) and the ends filled by the same treatment. The filled WPRE fragment was then ligated into the filled *Xba* I site of pDV67 to create pDV90. The sequence is found at GenBank accession no. J04514 (entire genome) in Zufferey, R. *et al.*, *J. Virol.* 73:2886-2892 (1999).

pDV90 (SEQ ID NO:65) was electroporated into E1-2a S8 cells and stable clones expressing fiber isolated as described previously for pDV80.

Example 12

Construction of an Ad5 Fiber Protein with Heterologous Peptide Sequences Inserted in the HI Loop

The receptor-binding knob domain of the Ad5 fiber protein contains several

surface loops which are attractive candidates for the insertion of heterologous peptide sequence, as an additional ligand for vector targeting. This example describes the construction of a fiber gene which encodes a fiber protein containing a 6 amino acid peptide linker in the HI loop, and retains the ability to trimerize. The modified gene also contains a unique novel restriction site at the position of the linker insertion to facilitate addition of the targeting ligand into the HI loop.

The Ad5 fiber gene was amplified from Ad5 genomic DNA (ATCC accession number VR-5) using the primers Fiber ATG (5' TGA AGC GCG CAA GAC CGT CTG AAG 3') (SEQ ID NO: 60) and Fiber TAA (5' CAT AAC ACT **GCA** GAT TCT TTA TTC TTG G 3') (SEQ ID NO: 61), and cloned to the *Nde*1 (filled with the large fragment of *E. coli* DNA polymerase 1 in the presence of dNTPs) and *Pst* 1 sites of pT7-7 using a unique *Pst* 1 site (bold) in the 'Fiber TAA' oligo. The resulting plasmid, pT7/fiber, was digested with *Xba* 1 and *Pst* 1 to excise the fiber gene, which was then cloned into the *Pst* 1 and *Xba* 1 sites of pUC119 to create pUC/fiber. This pUC-derived plasmid contains an origin for single-stranded DNA replication and can therefore be used to create template DNA for site-directed mutagenesis.

Site-directed mutagenesis was carried out according to the method of Kunkel (T.A. Kunkel, *PNAS* 82:488-492 (1985)) using the oligonucleotide primer T542 (5' GGT ACA CAG GAA ACA GGA GGT TCC GGA GGT GGA GGA GAC ACA ACT CC 3') (SEQ ID NO: 62). This results in the addition of 18 new bases (underlined) encoding the sequence Gly Gly Ser Gly Gly Gly (SEQ ID NO: 63), with a novel BspE1 site (bold) for the addition of further sequences. The inserted sequence is between Thr542 and Gly543 of the Ad5 fiber protein, in the HI loop. The modified plasmid is termed pDV14.

Finally, the modified fiber gene was excised from pDV14 by digestion with *Pst* 1 and *Xba* 1 and cloned into the *Pst* 1 and *Xba* 1 sites of pGEM3Z (Promega) to create pDV18. *In vitro* transcription/translation experiments with pDV18 (using the TNT™ kit, Promega) demonstrated that the modified fiber gene encoded a protein which was capable of trimerizing.

Alternatively an Ad5 fiber open reading frame (ORF) is amplified from Ad5 genomic DNA (wildtype Ad5 was purchased from the ATCC) using the

oligonucleotides 5' ATG **GGA TCC** AAG ATG AAG CGC GCA AGA CCG 3' (SEQ ID NO: 72) and 5' CAT AAC **CTG CAG** GAT TCT TTA TTC TTG GGC 3' (SEQ ID NO: 73), and inserted into the *Bam*HI and *Pst* I sites of pGEM-3Zf(+) (Promega Inc., Madison, WI) via novel restriction sites (bold type) designed into the primers. The 5' oligonucleotide also contains a G to A change 3 nucleotides 5' of the initial ATG codon (underlined), designed to improve the consensus for translation initiation.

Site-directed mutagenesis is performed by the method of Kunkel (Proc. Nat. Acad. Sci. **82**:488-492 (1985)), using the synthetic oligonucleotide 5' GGT ACA CAG GAA ACA **GGA GGT TCC GGA** GGT GGA GGA GAC ACA ACT CC 3' (SEQ ID NO: 74). This operation introduced sequence (bold type) encoding 6 novel amino acids (Gly Gly Ser Gly Gly Gly) immediately following Threonine 542 of the Ad5 fiber, and including a unique restriction site for the insertion of further heterologous sequences (underlined). The resulting plasmid (pDV18A) contains the modified fiber gene under the control of the T7 promoter in the parental pGEM-3Zf(+) and can be used for *in vitro* transcription/translation reactions to produce labeled fiber protein.

Example 13

Use of the Fiber Expression System to Retarget ('Pseudotype') Hybrid Ad/AAV Vectors

Adenoviral vectors which lack essentially all Ad genes ('helper-dependent' or 'gutless' vectors) have recently been developed. In a modification of this idea, vectors ('hybrid' vectors) which contain an adeno-associated virus (AAV) or retroviral genome have been generated. As AAV and retroviral genomes integrate into the chromosome of the target cells, the hybrid Ad/AAV or Ad/retroviral vectors have the potential to provide very long-term gene expression.

Lieber *et al.*, (*J. Virol.* 73(11):9314-9324) describe an Ad vector (Ad.AAV1) which contains an AAV vector genome (a transgene insert flanked by the AAV inverted terminal repeats) inserted into the E1 region. When 293 cells are infected by Ad.AAV1, recombination between the AAV sequences generates a minimal Ad chromosome which carries the Ad inverted terminal repeats and packaging signal

flanking the AAV vector genome. This chromosome cannot direct the synthesis of Ad proteins, but can be packaged into Ad vector particles. The remaining unrecombined Ad chromosomes provide the Ad structural proteins in trans, and both the full-length and minimal genomes are packaged into particles. The particles carrying the minimal Ad/AAV hybrid vector are then isolated by CsCl centrifugation.

These particles have the capsid structure of adenovirus, and infect cells using the efficient fiber- and penton base-mediated pathway used by Ad. Following infection, the hybrid genome is able to integrate into the cell's chromosomes by virtue of its AAV sequences. In this example, the AAV vector genome is inserted into the E1 region of a fiber-deleted vector, and the resulting vector is grown in packaging lines expressing either the Ad5 or Ad37 fiber proteins. The particles recovered therefore have the tropisms expected from the respective fiber proteins combined with the ability to integrate their AAV genome into target cells. Such pseudotyping should be possible with any of a number of modified fiber proteins, as for the fiber-deleted vectors already described by us.

The Ad vector is constructed in a manner analogous to that described for Ad5.βgal.ΔF, by recombination between pAd.AAV1 (Lieber *et al. J. Virol.* 73:9314-9324, 1999) and pDV44 (as described earlier in the specification.) pAd.AAV1 carries an MLV promoter-driven secreted alkaline phosphatase gene (SEAP) as a reporter, and an SV40-driven neomycin phosphotransferase (neo) gene to allow the selection of cells stable transduced by the AAV cassette. The resulting vector (Ad.AAV1.ΔF) has the AAV vector cassette of Ad.AAV1 inserted into the E1 region of a genome with the fiber deletion of Ad5.βgal.ΔF. Growth of Ad.AAV1.ΔF in 633 cells results in particles carrying the AAV genome and the Ad5 fiber, and which have the tropism associated with Ad5. Growth of Ad.AAV1.ΔF in 705 cells produces particles bearing the Ad37 fiber and therefore having its associated different tropism.

Tropism is evaluated by infecting Chang C cells (which express the Ad37 receptor) and A549 cells which do not express this protein but do express the Ad5 receptor (CAR). The extent of infection is monitored by assaying alkaline phosphatase expression, and the fraction of cells stable transduced is assayed by selection with neomycin. By using purified recombinant Ad5 or Ad37 fiber proteins as competitors

during infection, the usage of the expected receptors by the pseudotyped particles is evaluated.

Example 14

Use of the Fiber Expression System to Retarget ('Pseudotype') Helper-dependent Ad Vectors

Gutted Ad vectors are those from which most or all viral genes have been deleted. They are grown by co-infection of the producing cells with a "helper" virus (using an E1-deleted Ad vector). The helper virus *trans*-complements the missing Ad functions, including production of the viral structural proteins needed for particle assembly. In one embodiment of this invention, the helper virus is a fiber-deleted Ad (such as that described in Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)). The vector is prepared in a fiber expressing cell line such as has been previously described by Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998), Von Seggern *et al.*, *J. Virol.* 74:354-362 (2000). All the necessary Ad proteins except fiber are provided by the fiber-deleted helper virus, and the particles are equipped with the particular fiber expressed by the host cells. A concern with gutted vectors has been contamination of a vector preparation with residual helper virus. As the helper virus in one aspect of this invention is deleted for both E1 and for fiber, it is more replication defective and therefore safer than those currently used.

A helper adenovirus vector genome and a gutless adenoviral vector genome are delivered to the packaging cells of the invention. The cells are maintained under standard cell maintenance or growth conditions, whereby the helper vector genome and the packaging cell together provide the complementing proteins for the packaging of the adenoviral vector particle. Such gutless adenoviral vector particles are recovered by standard techniques. The helper vector genome may be delivered in the form of a plasmid or similar construct by standard transfection techniques, or it may be delivered through infection by a viral particle containing the genome. Such viral particle is commonly called a helper virus. Similarly, the gutless adenoviral vector genome may be delivered to the cell by transfection or viral infection.

The helper virus genome is preferably the fiberless adenovirus vector genome as disclosed herein. Preferably, such genome also lacks the genes encoding the adenovirus E1A and E1B proteins. More preferably, the genome further lacks the adenovirus genes encoding the adenovirus E3 proteins. Alternatively, the genes encoding such proteins may be present but mutated so that they do not encode functional E1A, E1B and E3 proteins. Furthermore, such vector genome may not encode other functional early proteins, such as E2A, E2B, and E4 proteins. Alternatively, the genes encoding such other early proteins may be present but mutated so that they do not encode functional proteins.

The helper virus genome is used in conjunction with the packaging cell of the invention. As disclosed elsewhere herein, the packaging cell also provides proteins necessary for the complementation of the gutless vector so that an adenovirus particle containing the gutless vector genome may be produced. Thus, the packaging cell can provide wild-type or modified fiber protein as described herein. Alternatively, the cell could package a fiberless particle which could be used by itself or to which exogenously provided fiber could be added as described elsewhere herein.

In producing the gutless vectors, the helper virus genome is also packaged, thereby producing helper virus. In order to minimize the amount of helper virus produced and maximize the amount of gutless vector particles produced, it is preferable to delete or otherwise modify the packaging sequence in the helper virus genome, so that packaging of the genome is prevented or limited. Since the gutless vector genome will have a packaging sequence, it will be preferentially packaged.

One way to do this is to mutate the packaging sequence by deleting one or more of the nucleotides comprising the sequence or otherwise mutating the sequence to inactivate or hamper the packaging function. An alternative approach is to engineer the helper genome so that recombinase target sites flank the packaging sequence and to provide a recombinase in the packaging cell. The action of recombinase on such sites results in the removal of the packaging sequence from the helper virus genome. Preferably, the recombinase is provided by a nucleotide sequence in the packaging cell that encodes the recombinase. Most preferably, such sequence is stably integrated into the genome of the packaging cell. Various kinds of recombinase are known by those

skilled in the art. The preferred recombinase is Cre recombinase, which operates on so-called lox sites, which are engineered on either side of the packaging sequence as discussed above. Further information about the use of Cre-loxP recombination is found in U.S. Pat. No. 5,919,676 and Morsy and Caskey, *Molecular Medicine Today*, Jan. 1999, pgs. 18-24, both incorporated herein by reference.

This example demonstrates how the fiber-expressing packaging lines can be used to generate pseudotyped particles of helper-dependent or 'gutless' vectors with altered tropisms. As the gutless vectors lack many or all Ad genes, they must be grown as mixed cultures in the presence of a helper virus which can provide the missing functions. To date, such helper viruses have provided all Ad functions except E1, and E1 is complemented by growth in 293 cells or the equivalent. The resulting virus particles are harvested, and the helper virus is typically removed by CsCl gradient centrifugation (the vector chromosome is generally shorter than the helper chromosome, resulting in a difference in buoyant density between the two particles).

An example of a gutless vector is pAd Δ RSVDys (Haecker *et al.*, *Human Gene Therapy* 7:1907-1914 (1996)). This plasmid contains a full-length human dystrophin cDNA driven by the RSV promoter and flanked by Ad inverted terminal repeats and packaging signals. 293 cells are infected with a first-generation Ad which serves as a helper virus, and then transfected with purified pAd Δ RSVDys DNA. Both the helper Ad genome and the pAd Δ RSVDys DNA are replicated as Ad chromosomes, and packaged into particles using the viral proteins produced by the helper virus. Particles are isolated and the pAd Δ RSVDys-containing particles separated from the helper by virtue of their smaller genome size and therefore different density on CsCl gradients.

To generate pseudotyped particles containing the pAd Δ RSVDys genome, the vector is grown in either 633 or 705 cells and Ad5. β gal. Δ F is used as a helper virus. As in the published method, both the Ad5. β gal. Δ F and Ad Δ RSVDys genomes replicate and are packaged into particles. The Ad5. β gal. Δ F helper provides all the essential Ad proteins except fiber, and the fiber protein is that produced by the cells (Ad5 fiber in 633 cells and Ad37 fiber in the case of 705 cells). The particles containing Ad Δ RSVDys genomes are then isolated by centrifugation.

Tropism is evaluated by infecting Chang C cells (which express the Ad37 receptor) and A549 cells which do not express this protein but do express the natural Ad5 receptor (CAR). The extent of infection is assessed by immunofluorescence staining of the infected cells with an anti-dystrophin antibody. By using purified recombinant Ad5 and Ad37 fiber proteins as competitors during infection, the usage of the expected receptors by the pseudotyped particles is evaluated.

Example 15

Targeting EBV-Infected B Cells

There are a number of cell types, such as EBV-transformed B-lymphocytes, that are involved in human disease which are not transducible using standard Ad vectors. To address this problem 'pseudotyped' Ad5 β gal. Δ F particles containing either the wildtype Ad5 fiber protein or a chimeric fiber with the receptor-binding knob domain of the adenovirus type 3 (Ad3) fiber were generated. (Von Seggern *et al.*, *J. Virol.* January, 2000). The strategy used for targeting the B-cells should be broadly applicable for targeting gene delivery to other specific cell types.

Cells and Viruses. THP-1, MRC-5, FaDu, and A-10 cells were purchased from the ATCC. 211B is a 293-derived cell line that expresses the wild-type Ad5 fiber protein (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)). E1-2a (Gorziglia *et al.*, *J. Virol.* 70:4173-4178 (1996)) is an A549-derived cell line which complements adenoviral E1 and E2a functions. The JR, TO, and TL LCL lines were established as described (Huang *et al.*, *Proc. Natl. Acad. Sci.* 94:8156-8161 (1997) by EBV infection of lymphocytes from three normal donors. THP-1 and all LCL lines were maintained in RPMI 1640 medium (Gibco) + 10% fetal calf serum (FCS) (Hyclone). 211B, MRC-5, and A-10 cells were grown in DMEM + 10% FCS. E1-2a and its derivatives were grown in Richter's modified medium (BioWhitaker) + 10% FCS. Peripheral blood mononuclear cells were isolated from normal human blood (General Clinical Research Center, Scripps Clinic) by sedimentation on Ficoll-Paque (Pharmacia) per the manufacturer's instructions. Wild type Ad2 and Ad3 were purchased from the ATCC. Construction of Ad5. β gal.wt and Ad5. β gal. Δ F (Von Seggern *et al.*, *J. Virol.*

73:1601-1608 (1999)) has been previously described. Av1LacZ4 (Mitttereder *et al.*, *J. Virol.* 70:7498-7509 (1996)) is a first-generation Ad5 vector containing an RSV-driven β -galactosidase reporter gene. Av9LacZ4 (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)) is identical to Av1LacZ4 except that the fiber gene in the vector chromosome was replaced by a recombinant gene encoding a chimeric fiber protein with the receptor-binding domain of the Ad3 fiber (Stevenson *et al.*, *J. virol.* 69:2850-2857 (1995)). Accession numbers for the above are as follows. THP-1: TIB-202, MRC-5: CCL-171, FaDu: HTB-43, A-10: CRL-1476, Ad2: VR-846, Ad3: VR-3.

DNA constructs. The complete Ad5 tripartite leader contained in pDV67 and pDV69 was constructed by assembly of PCR fragments. pDV55 was constructed similar to Example 5. This plasmid contains a 1.2 kb *Bam* HI/*Bgl* II fragment consisting of the first TPL exon, the natural first intron, and the fused second and third TPL exons. Finally, pDV60 was constructed by inserting this TPL cassette into the *Bam* HI site upstream of the Ad5 fiber gene in pcDNA3/Fiber (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)). pDV61 and pDV67 were then constructed similar to example 6.

The chimeric Ad3/Ad5 fiber gene was amplified from pGEM5T3H (Stevenson *et al.*, *J. Virol.* 69:2850-2857 (1995)) using the primers 5' ATG **GGA TCC** AAG ATG AAG CGC GCA AGA CCG 3' (SEQ ID NO: 75) and 5' CAC TAT **AGC GGC CGC** ATT CTC AGT CAT CTT 3' (SEQ ID NO: 76), and cloned to the *Bam* HI and *Not* I sites of pcDNA3.1/Zeo(+) via novel *Bam* HI and *Not* I sites (bold) engineered into the primers to create pDV68. Finally, the complete TPL fragment described above was then added to the unique *Bam* HI site of this plasmid to create pDV69.

Construction of Stable Cell Lines. E1-2a cells were electroporated as previously described (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)) with pDV61, pDV67, or pDV69, and stable lines were selected with 600 μ g/ml Zeocin (Invitrogen). Candidate clones were evaluated by immunofluorescence (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)) using a polyclonal antibody generated against the Ad2 fiber (Wickham *et al.*, *Cell* 73:309-319 (1993)). Those lines expressing the highest level of nuclear fiber expression were further characterized. Line 601 and 633 were produced by transfection of pDV61 and pDV67, respectively, and therefore

express the wildtype Ad5 fiber. Line 644 contains pDV69 and expresses the chimeric 5T3H fiber.

Virus Growth and Analysis. Adenovirus stocks were prepared in the indicated cell lines, and plaque-titered on 633 cells essentially as described (Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)). E1-2a cells (Gorziglia *et al.*, *J. Virol.* 70:4173-4178 (1996). and their derivatives contain a dexamethasone-inducible construct for complementation of E1a. 601, 633, or 644 cells were therefore treated with 0.3 μ M dexamethasone for 24 hours prior to infection, and 0.5 μ M dexamethasone was included in the overlay for plaque assays. Protein concentration of viral preparations was determined using the BioRad Protein Assay (BioRad) with purified bovine serum albumin as a standard. Particle number was calculated using the formula 1 μ g protein = 4×10^9 viral particles. Western blotting was performed as described (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)) using polyclonal rabbit antibodies raised against either the Ad2 (Wickham *et al.*, *Cell* 73:309-319 (1993) or Ad3 fibers (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)).

Determination of infection and binding to receptor was performed using methods known to those of skill in the art. 2×10^5 cells in a total volume of 200 μ l were incubated with the indicated Ad preparation for three hours at 37 °C. Cells were then washed twice with fresh medium, and returned to 37 °C. Two days later, cells were fixed and stained with X-gal and counted by light microscopy as described (Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)). For competition assays, cells were pre-incubated on ice for one hour with either recombinant Ad3 fiber (10 μ g/ml) purified from baculovirus or with a crude baculovirus lysate (100 μ g/ml) containing the recombinant Ad2 fiber protein (Wickham *et al.*, *Cell* 73:309-319 (1997)). Expression of α_v integrins on cell surfaces was assayed by FACS assay using monoclonal antibodies (the gift of David Cheresh, TSRI) against either $\alpha_v\beta_3$ (LM609) or $\alpha_v\beta_5$ (P1F6) as previously described (Huang *et al.*, *Proc. Natl. Acad. Sci. USA* 94:8156-8161 (1997)). For virus binding assays, CsCl-purified Ad2 or Ad3 was labeled with 125 I using Iodogen tubes (Pierce). Free iodine was removed by filtration with a PD-10 Sephadex column (Pharmacia). Cells (1×10^6 cells in a volume of 200 μ l either with

or without a 100-fold excess of unlabeled virus) were rocked at 4 °C for two hours with 1×10^6 cpm of the labeled virus, washed three times with PBS and counted.

Altered in vitro tropism and infection of B lymphoid cell lines.

Experiments with genetically modified viruses showed that a number of different cell types are more readily infected through interaction with the Ad3 receptor than by the CAR-dependent pathway used by Ad5 (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)). In order to further evaluate the pseudotyping system, the ability of Ad5. β gal. Δ F carrying either the Ad5 or chimeric 5T3H fibers to infect several cell lines was assayed: FaDu (a head and neck tumor line), THP-1 monocytic cells, and MRC-5 fibroblasts were assayed. Consistent with the previous studies (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)), use of the chimeric Ad5/Ad3 fiber protein increased infection of all of these lines at equal particle/cell ratios. In contrast, the rat smooth muscle cell line A-10 was infected somewhat more readily by Ad5- than by Ad3-pseudotyped particles.

Gene delivery to EBV-infected B cells could allow the development of therapies for a variety of lymphoproliferative disorders. For example, *ex vivo* purging of donor marrow to eliminate infected cells could reduce the risk of EBV-associated lymphoproliferative disease, and EBV-induced malignancies such as AIDS-associated lymphoma are also potential targets. However, neither B cells nor EBV-transformed lymphoblastoid cell lines (LCLs) are efficiently infected by Ad5-based vectors. As the tropism of Ad3-pseudotyped particles appeared to be somewhat broader, it was asked whether EBV-infected LCLs could be infected using this system. The ability of Ad3-pseudotyped particles to infect LCLs generated by EBV infection of lymphocytes from three different normal human donors was tested. In agreement with previous reports, there was little or no infection of these by particles carrying the Ad5 fiber. In contrast, virus particles equipped with the chimeric fiber protein were able to efficiently infect all of these lines. At equal particle/cell ratios, all LCLs examined were at least 10-fold more infectible using the Ad3 receptor.

Further studies were performed to correlate the efficiency of infection with the level of attachment and internalization receptors expressed by the cells. The three LCL

lines tested all bound very low levels of radiolabeled Ad2 particles, indicating that they expressed little or no CAR. In contrast, all three were able to specifically bind labeled Ad3 particles. This result suggested that fiber receptor distribution was largely responsible for the increased infection of these cells by Ad3-pseudotyped particles.

5 *Selective gene delivery to EBV-infected cells.* The results above suggested that the minority of EBV-infected B cells present in donor marrow or peripheral blood would be preferentially infected by vectors using the Ad3 receptor. To test this hypothesis, a mixing experiment with normal uninfected peripheral blood mononuclear cells (PBMCs) and EBV-infected cells was performed. JR-LCL cells were mixed at
10 varying ratios with PBMCs isolated from a normal human donor, and the mixture was then infected with Ad5.βgal.ΔF particles containing the 5T3H fiber protein. No infection of normal PBMCs alone was detected. Moreover, the percent of total cells infected increased with the fraction of JR cells added. These experiments indicate that EBV-infected cells can be selectively infected *in vitro* by relatively short (3 hours)
15 exposure to a retargeted Ad vector.

Example 16

Production of Adenovirus Vectors by Addition of Exogenous Fiber

The production of fiberless viruses by growth in a complementing cell line may result in a preparation that also contains contaminating fiber genome resulting from recombination in the complementing cell lines. This disadvantage is eliminated by
20 addition of exogenous fiber to a fiberless adenovirus vector.

Production of fiberless virus by standard methods may include a two-step preparation protocol. This has been described in the earlier examples and is briefly described here again as follows:

25 Step I - amplification of fiber containing fiberless virus (Ad5/F⁻/F⁺ or Ad5.βgalΔF - fiberless, but there is fiber on the surface, not encoded in genome) on

211B cell line (which stably expresses fiber), followed by CsCl-purification and characterization.

Step II - preparation of virus particles lacking fiber (Ad5F⁻) by infection of S.8 cell line with Ad5/F⁻/F⁺, followed by CsCl purification and characterization. This produces a large stock of particles which do not contain fiber.

Step 1 is necessary because the infection efficiency of fiberless virus is extremely low, e.g. the dose of 20,000 particles/cell of Ad5/βgalF⁻ gives only 10% infected cells.

Contrary to the above, the production of fiberless virus by addition of exogenous fiber involves only a one-step protocol. The fiberless virus is amplified using the S.8 cell line with addition of exogenous fiber into infection media. The amount of exogenous fiber necessary for production is very low, no more than 75ng of purified fiber required per roller bottle. If desired the process may be followed by CsCl purification. As mentioned above, one advantage to this protocol is that it should provide no chance for recombination of adenovector during preparation.

A 10 roller bottle (RB) preparation of fiberless virus was made using the above two-step procedure. The yield of adenovector was 6.6×10^{12} particles - total Ad/βgalF⁻ (two step procedure.) A 1 RB preparation of fiberless adenovector was also made from the same initial material using a one-step procedure with exogenous fiber. The total yield was 2.5×10^{11} particles - Ad5βgalF⁻ (one step procedure).

DNA was isolated from both preparations and a PCR assay for fiber contamination was performed. (Figure 28). The PCR assay was developed for detection of very low amounts of fiber contamination, as low as 10^{-18} g. PCR assay showed much lower contamination for the preparation which was done by adding exogenous fiber (10^{-15} g one-step procedure) vs. 10^{-8} two-step procedure). Therefore, less contamination was obtained by simpler one-step approach.

Experiments were done using soluble purified fiber which does not have His-taq on the end (Ad5Fiber = 5F) and with His-taq on the end (Ad5Fiber His = 5FHis). These experiments showed that addition of Ad5Fiber can dramatically increase transduction efficiency of fiberless adenovector by simply adding it exogenously to a

fiberless vector. The presence of the His tag on the Ad5FiberHis doesn't have any effect.

5 The results of these experiments suggest that the fiber is self-assembling with the fiberless vector. This self-assembled virus can then infect cell through the normal entry pathway. (Figure 29) Also, an experiment was done using conditioned media from 633 cell line, which can stably express fiber. A Western blot analysis for 633 condition media, showed that soluble fiber was present in the media during the period of cultivation of this cell line. Presence of soluble fiber in the media gives the possibility to increase transduction efficiency of fiberless adenovector on the HDF cell line. (Figure 30) Because the HDF cell line doesn't have a CAR-receptor, it is especially difficult to transduce this particular cell line, not only with fiberless vector, but also with regular fiber containing adenovector. Different amounts of 633 conditioned media (250µl, 500µl or 1000µl) were added to infectious media during the incubation period with fiberless adenovector.

10 This experiment also showed a role of soluble fiber in the process of cell entry. The conclusion is that by adding any fiber (wild-type, mutated, with ligand fusions) as long as on has the wild-type shaft (or region necessary to bind penton) one can retarget fiberless vector with any genome inside (gutless, oncolytic, expressing any transgene, etc.) to any cell type that your fiber is specific to. The advantage of this approach is that one does not have to make vectors with each new ligand. Just one fiberless vector need be made that can then be used to make different backbones by adding an exogenous "targetable" fiber off the shelf.

15 The foregoing specification, including the specific embodiments and examples, is intended to be illustrative of the present invention and is not to be taken as limiting. Numerous other variations and modifications can be effected without departing from the true spirit and scope of the present invention. All publications, patents and patent applications cited herein are incorporated by reference in their entirety into the present disclosure.

What is claimed is:

1. An isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said
5 TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3.

2. The isolated nucleic acid molecule of claim 1, wherein said sequence is operatively linked to an intron containing an RNA processing signal.

3. The isolated nucleic acid molecule of claim 1 wherein said TPL
10 nucleotide sequence consists essentially of complete TPL exon 1 operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3.

4. The isolated nucleic acid molecule of claim 1 wherein said intron is native adenovirus intron 1.

5. The isolated nucleic acid molecule of claim 1 wherein said TPL
15 nucleotide sequence is shown in SEQ ID NO: 32.

6. The isolated nucleic acid molecule of claim 1 further comprising a promoter and a nucleic acid sequence which encodes an adenoviral structural protein, operatively linked to said promoter and said TPL sequence.

7. The isolated nucleic acid molecule of claim 6 wherein said adenoviral
20 structural protein is a fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.

8. The isolated nucleic acid molecule of claim 7 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.

5 9. The isolated nucleic acid molecule of claim 7 wherein said molecule is contained in a plasmid selected from the group consisting of plasmids pCLF, pDV60, pDV67, pDV69, pDV80 and pDV90.

10 10. The isolated nucleic acid molecule of claim 9 wherein said molecule has a nucleotide sequence selected from the group consisting of sequences shown in SEQ ID NO: 8, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 64 and SEQ ID NO: 65..

11. An adenovirus vector complementing plasmid comprising an isolated nucleic acid molecule according to claim 1.

15 12. An adenovirus vector packaging cell line comprising a stably integrated nucleic acid molecule of claim 1, an operatively-linked promoter and a nucleic acid sequence which encodes an adenovirus structural protein, wherein said TPL sequence consists essentially of a first TPL exon operatively linked to a complete second TPL exon operatively linked to a complete third TPL exon.

13. The cell line of claim 12 wherein said first TPL exon is a complete or partial first TPL exon.

20 14. The cell line of claim 13 wherein said TPL molecule comprises complete TPL exon 1 having the nucleotide sequence of SEQ ID NO: 32 or partial TPL exon 1 having the nucleotide of SEQ ID NO: 26.

15. The cell line of claim 12 wherein said promoter is an inducible promoter.

16. The cell line of claim 12 wherein said adenovirus structural protein is adenovirus fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.

17. The cell line of claim 12 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.

18. The cell line of claim 12 wherein said nucleic acid molecule is selected from the group consisting of plasmids pDV60, pDV67, pDV69, pDV80 and pDV90.

19. The cell line of claim 18 wherein said nucleic acid molecule has a nucleotide sequence from the group consisting of sequences shown in SEQ ID NO: 43, SEQ ID NO: 44 and SEQ ID NO: 47.

20. The cell line of claim 12 wherein said cell line is an epithelial cell line.

21. The cell line of claim 20 wherein said cell line supports the production of a recombinant adenovirus vector genome by complementation of a deficient viral gene in said vector genome.

22. The cell line of claim 21 wherein said cell line further produces an adenovirus protein and thereby complements a deficient adenovirus gene in said vector genome, and wherein said cell line complements an adenovirus early protein gene and a fiber gene.

23. The cell line of claim 22 wherein the deletion of said deficient adenovirus gene is complemented by the expression of said gene under the control of an inducible promoter.

24. A recombinant adenovirus particle comprising a recombinant adenovirus vector genome wherein said genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.

25. The recombinant adenovirus particle of claim 24 wherein said adenovirus vector genome does not encode one or more functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3 and E4 protein.

26. The particle of claim 24 wherein said adenovirus vector genome is Ad5.Bgal.ΔF.

27. The particle of claim 24 wherein said adenovirus vector genome is contained in the adenovirus particle deposited under ATCC accession # VR2636 and corresponding to Ad5.Bgal.ΔF.

28. The particle of claim 24 wherein said particle lacks fiber protein or contains a modified fiber protein.

29. The particle of claim 24 wherein said particle comprises an adenovirus fiber protein or a chimeric protein having an adenovirus fiber protein tail domain, said chimeric protein comprising an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.

30. The particle of claim 24 wherein said exogenous protein is a therapeutic gene product.

31. A helper-independent fiberless recombinant adenovirus vector genome comprising genes which:

(a) encodes all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle

without complementation of said fiber gene or said genome lacks at least the fibre gene,
and

(b) encodes an exogenous protein.

32. The adenovirus vector genome of claim 31 wherein said adenovirus
vector genome does not encode one or more functional proteins selected from the
group consisting of E1A, E1B, E2A, E2B, E3 and E4 protein.

33. The adenovirus vector genome of claim 31 wherein said adenovirus
vector genome is Ad5.Bgal.ΔF.

34. The adenovirus vector genome of claim 33 wherein said adenovirus
vector genome has a nucleotide sequence shown in SEQ ID NO:27 and corresponds
to Ad5.Bgal.ΔF.

35. The adenovirus vector genome of claim 31 wherein said adenovirus
vector genome is contained in the adenovirus particle deposited under ATCC accession
VR-2636 corresponding to Ad5.Bgal.ΔF.

36. The adenovirus vector genome of claim 31 wherein said exogenous
protein is a therapeutic gene product.

37. An isolated nucleic acid that comprises the adenovirus vector genome
of claim 31.

38. A method for producing an adenovirus vector particle containing a
helper-independent fiberless recombinant adenovirus vector genome, said method
comprising providing a packaging cell line which complements replication and
packaging of said genome and a helper-independent fiberless recombinant adenovirus
vector genome which is deficient in expressing sufficient functional fiber protein to

support assembly of fiber-containing particles and harvesting said particle produced by said cell line.

39. The method of claim 38 wherein said packaging cell line complements adenovirus fiber protein.

5 40. The method of claim 38 wherein said adenovirus vector genome comprises genes that:

(a) express all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and

(b) express an exogenous protein.

10 41. The method of claim 38 wherein said packaging cell line comprises a stably integrated first nucleic acid molecule alternatively operatively linked to a promoter, and said first nucleic acid is operatively linked to a second nucleic acid molecule encoding an adenovirus structural protein, wherein said first nucleic acid molecule comprises an adenovirus tripartite leader (TPL) nucleotide sequence operatively linked to an intron containing an RNA processing signal, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3.

15 42. The method of claim 38 wherein said helper-independent fiberless recombinant adenovirus vector genome is introduced by infecting said cell line with a virus particle containing said genome.

20 43. The method of claim 42 wherein said particle is a particle comprising a helper-independent recombinant adenovirus vector genome comprising genes that:

(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and

5 (b) encode an exogenous protein,
wherein said particle comprises an adenovirus fiber protein or a chimeric protein that includes an adenovirus fiber protein tail domain.

44. The method of claim 38 wherein said helper-independent fiberless recombinant adenovirus vector genome is introduced into said cell line by transfecting
10 said cell line with said helper-independent fiberless recombinant adenovirus vector genome

45. The method of claim 44 wherein said adenovirus vector genome comprises genes which:

(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene,
15 and

(b) encode an exogenous protein.

46. The method of claim 38 wherein said packaging cell line is transfected
20 with a nucleic acid molecule encoding adenovirus fiber protein.

47. The method of claim 46 wherein said nucleic acid molecule is a nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group
25 consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and said molecule further comprises a sequence encoding adenovirus fiber protein.

48. The method of claim 39 wherein said adenovirus fiber protein is a modified fiber protein.

49. The method of claim 38 further comprising the step of coating said particle with adenovirus fiber protein.

50. A method for delivery of an exogenous gene to a target cell comprising contacting said cell with an amount of a recombinant adenovirus particle of claim 24 sufficient to infect said cell.

51. The method of claim 50 wherein said exogenous gene encodes a therapeutic gene product.

52. The method of claim 51 wherein said recombinant adenovirus particle contains a modified fiber protein which binds a preselected target cell and directs delivery of the particle to said target cell.

53. The method of claim 50 wherein said recombinant adenovirus particle comprises a helper-independent fiberless recombinant adenovirus vector genome comprising genes that:

(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and

(b) encode an exogenous protein.

54. The method of claim 50 wherein said modified fiber protein has an amino terminal head domain which binds to α_v integrins and thereby targets cells with α_v integrin receptors.

55. The method of claim 50 wherein said contacting is conducted *in vitro*.

56. The method of claim 55 wherein said contacting is conducted on cells of a tissue which are first removed from the body of a patient, and the cells are subsequently returned to said patient.

5 57. The method of claim 50 wherein said contacting is conducted *in vivo* by administering said recombinant adenovirus particle to a tissue of said patient.

58. The method of claim 57 wherein said administering is intravenously, intraperitoneally, by aerosol, topically or by injection.

59. A method for pseudotyping recombinant viral vectors comprising complementing a missing fiber gene of a helper-independent or helper dependent fiberless recombinant adenovirus vector genome by expressing in packaging cells a fiber gene from a different adenoviral serotype than said recombinant adenovirus vector, thereby pseudotyping said vector.

60. A method for specifically targeting an adenovirus vector to a cell of choice comprising introducing a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome into a packaging cell line for producing a fiber gene-deleted adenovirus vector, wherein a gene for a missing fiber protein is complemented with a gene for a desired modification for targeting the vector to a cell of choice.

61. A method for producing a modified adenovirus comprising providing *in vitro* an exogenous fiber protein to a fiberless adenovirus.

62. The method of claim 61, wherein said fiber is provided by adding fiber protein in a suitable buffer to a fiberless virus preparation, thereby producing a modified adenovirus.

63. The method of claim 61, wherein a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome is introduced into a packaging cell line to produce a fiberless adenovirus to which exogenous fiber protein will be provided.

5 64. A method for delivering a heterologous gene to EBV-infected B cells comprising infecting said B cells with a pseudotyped Ad5 β gal. Δ F particle or other fiber-deleted adenovirus particle, said particle having a chimeric fiber including the receptor-binding knob domain of the adenovirus type 3 fiber.

10 65. The adenovirus particle of claim 24 wherein said adenovirus vector genome lacks a fibre gene or lacks a portion of the fibre gene sequence such that fibre protein is not expressed in sufficient quantities to support packaging.

66. The recombinant adenovirus particle of claim 24 comprising a helper-independent recombinant adenovirus vector genome comprising genes that:

15 (a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the gene encoding fibre, and

(b) optionally encodes an exogenous protein.

20 67. The recombinant adenovirus particle of claim 24 wherein said particle further comprises a nucleic acid encoding an exogenous protein.

25 68. A method for producing a modified adenovirus comprising providing a packaging cell line for producing a fiberless adenovirus helper-dependent fiberless recombinant adenovirus vector genome and a helper virus vector, wherein said cell line complements at least a deficient fiber protein gene, thereby producing the modified adenovirus.

69 The packaging cell line of claim 9 wherein said cell line is selected from the group consisting of 293, A549, W163, HeLa, Vero, 211, 211A and an epithelial cell line comprising the stably integrated nucleic acid molecule.

5 70. The recombinant adenovirus particle of claim 21 wherein said exogenous protein is selected from a group consisting of a tumor-suppressor protein, a biologically active fragment thereof, a suicide protein and a biologically active fragment thereof.

10 71. A composition for preparing a therapeutic vector, said composition comprising a plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding a fiber protein or a genome that is incapable of expressing sufficient fiber to result in packaging.

15 72. A method of delivering a heterologous gene to a human or any animal comprising providing heterologous gene to a target cell wherein said target cell is contacted *in vivo* or *ex vivo* with an amount of a recombinant adenovirus particle of claim 24 sufficient to infect said cell and thereby deliver the heterologous gene.

73. The recombinant adenovirus vector particle of claim 24, wherein no fiber protein is expressed.

74. The recombinant adenovirus vector genome of claim 31, wherein no fiber protein is expressed.

20 75. The recombinant adenovirus vector particle of claim 24, wherein said genome expresses insufficient fiber to allow incorporation of said protein into the particle such that the particle cannot use the fiber pathway for infection.

76. The recombinant adenovirus genome of claim 31, wherein said genome expresses insufficient fiber to allow incorporation of said protein into a particle such that the particle cannot use the fiber pathway for infection.

77. A method for producing a gutless adenoviral vector particle comprising:

5 a) delivering a helper adenovirus vector genome to an adenovirus vector packaging cell, wherein said helper adenovirus vector genome lacks any gene encoding adenovirus fiber protein or lacks the ability to encode sufficient adenovirus fiber protein to produce an adenoviral vector comprising fiber protein in the absence of complemetation by said packing cell and wherein said packaging cell comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to an adenoviral fiber protein or to a chimeric protein that includes an adenovirus fiber protein tail domain;

10 (b) delivering a gutless adenovirus vector genome to said packaging cell; and

15 (c) recovering the gutless adenoviral vector particle produced by said cell.

78. The method of claim 77, wherein said helper adenovirus vector genome is delivered by viral infection.

79. The method of claim 78, wherein said gutless adenovirus vector genome is delivered by transfection.

80. The method of claim 77, wherein said gutless adenovirus vector genome comprises an operable packaging sequence.

81. The method of claim 80, wherein said helper adenovirus vector genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged as an adenoviral vector particle by said packaging cell.

82. The method of claim 80, wherein said helper adenovirus vector genome comprises recombinase sites flanking its packaging sequence and said packaging cell further comprises a nucleotide sequence encoding a recombinase.

83. The method of claim 82, wherein said recombinase site is a lox site and said recombinase is Cre.

84. A helper adenovirus particle comprising an adenovirus vector genome that does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, wherein said genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged.

85. The helper adenovirus particle of claim 84, wherein said mutation comprises a deletion of at least one nucleotide in said packaging sequence.

86. The helper adenovirus particle of claim 85, wherein said adenovirus vector genome does not encode functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3, and E4 proteins.

87. A helper adenovirus particle comprising an adenovirus vector genome with recombinase sites flanking its packaging sequence, wherein said vector genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.

88. The helper adenovirus particle of claim 87, wherein said adenovirus vector genome does not encode functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3, and E4 proteins.

89. An adenovirus particle comprising a gutless adenoviral vector genome and a fiberless capsid.

90. An adenovirus particle comprising a gutless adenoviral vector genome and a capsid comprising a modified fiber protein.

5 91. A packaging cell for the production of a fiberless or fiber-modified gutless adenovirus particle comprising an adenovirus vector complementing plasmid and a nucleotide sequence encoding a recombinase, wherein said complementing plasmid comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to a nucleotide sequence encoding an adenoviral fiber protein or a chimeric adenoviral fiber protein.

10 92. The packaging cell of claim 91, wherein said complementing plasmid and said nucleotide sequence encoding a recombinase are stably integrated into the genome of said cell.

15 93. The packaging cell of claim 91, further comprising a helper adenovirus vector genome.

94. The packaging cell of claim 91, wherein said recombinase is Cre.

ABSTRACT

The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits.

P:\USERS\LARRYB\1294\A271-66h.wpd




Figure 1




Figure 2




FIGURE 3




Fig. 4




Figure 5




Figure 6




Figure 7




Figure 8





Figure 9



pAE1Bβgal

FIGURE 10

100% 99% 98% 97% 96% 95% 94% 93% 92% 91% 90% 89% 88% 87% 86% 85% 84% 83% 82% 81% 80% 79% 78% 77% 76% 75% 74% 73% 72% 71% 70% 69% 68% 67% 66% 65% 64% 63% 62% 61% 60% 59% 58% 57% 56% 55% 54% 53% 52% 51% 50% 49% 48% 47% 46% 45% 44% 43% 42% 41% 40% 39% 38% 37% 36% 35% 34% 33% 32% 31% 30% 29% 28% 27% 26% 25% 24% 23% 22% 21% 20% 19% 18% 17% 16% 15% 14% 13% 12% 11% 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0%




Figure 11




FIGURE 12

Labeled Cell Extracts

Recombinant Fiber




Figure 13




Figure 14

A

Ad25	M-KRARPSEDTFNPVVPYDTETGPPTVPFLTPPFVSPNGFOESP
Ad3	M-KKRAQLS-TSFPVVPYEDSIS-QHPFLINQFISQDGFQSPH
Ad18/37	M-KKRLQYEDC-FNPVVPYGTAKNO-KIPFLTPPFVSQDCKMFPP
Ad40 (1)	M-KKRAF-EDDFNPVVPYEHYN-PLDIPFITYPPFASNGLOQKPP
Ad40 (2)	M-KKTRQ-IEQDFNPVVPYDTSTPS-IDYVAPPFVSQDLOENPP

B




Figure 15

FIGURE 16




FIGURE 17






FIGURE 18





FIGURE 19

A



B






FIGURE 20

Improved Fiber-complementing Cell Lines



Indirect immunofluorescence assay of A549-based cell lines which stably express two different Ad fibers. Line 633 expresses the native Ad5 fiber protein, and line 644 expresses a chimeric fiber protein with the tail and shaft domains of the Ad5 protein and the knob domain of the Ad3 fiber. Previous work (Stevenson *et al.*, 1996) showed that a virus containing this protein had the tropism expected for Ad3.


Pseudotyping of Ad. β gal. Δ F




Viral particles were purified from either 633 cells (expressing wt Ad5 fiber) or from 644 cells (expressing the chimeric Ad5/Ad3 fiber). 10 μ g of the purified particles were Western blotted, and the blot was probed with a polyclonal rabbit antibody against the Ad2 fiber. Equal amounts of purified Ad. β gal.wt or Av9LacZ (which has the chimeric fiber gene in the viral chromosome) were run as controls.

FIGURE 22


211B Cells (Human Embryonic Kidney)



MRC-5 Human Fibroblasts



A-10 Rat Aortic Endothelial Cells



THP-1 Human Monocytic Cells






FIG. 23



F-1 G.24



F I G.25





FIG. 26







FIGURE 27

PCR analysis for fiber presence contamination of fiberless adenonovectors.



1. 100 bp ladder
2. positive control - 10ng
3. positive control - 1ng
4. positive control - 1pg
5. Positive control - 1fg
6. Positive control - 10⁻¹⁸g
7. Ad5BgF- one step preparation with soluble fiber on s.8 cell line
8. Ad5BgF- two step preparation (211B and S.8 cell lines).

Figure 28




FIGURE 29




FIGURE 30

SEQUENCE LISTING

<110> VON SEGGERN, DANIEL
NEMEROW, GLEN R.
HALLENBECK, PAUL
STEVENSON, SUSAN
SKRIPCHENKO, YELENA

<120> ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS,
AND METHODS FOR PREPARATION AND USE

<130> 1294.0010001

<140>

<141>

<160> 76

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

cggtacacag aattcaggag acacaactcc

30

<210> 2

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

gccttgatcc gggaagttac gtaacgtggg aaaac

35

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 3

cgcgatccg cg

12

<210> 4

<211> 8710

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 4

cacctaaatt	gtaagcggtta	atatatttgtt	aaaatttcgcg	ttaaatttttt	gttaaatacag	60
ctcatttttt	aaccaatagg	ccgaaatcgg	caaaatccct	tataaatcaa	aagaatagac	120
cgagataggg	ttgagtgttg	ttccagtttg	gaacaagagt	ccactattaa	agaacgtgga	180
ctccaacgtc	aaagggcgaa	aaaccgtcta	tcagggcgat	ggccactac	gtgaaccatc	240
accctaatac	agtttttttg	ggtcgaggtg	ccgtaaagca	ctaaatcgga	accctaaagg	300
gagccccga	tttagagctt	gacgggggaa	gccggcggaac	gtggcgagaa	aggaaggga	360
gaaagcgaaa	ggagcgggcg	ctagggcgct	ggcaagtgtg	gcggtcacgc	tgcgcgtaac	420
caccacacc	gccgcgctta	atgcgcgct	acagggcgcg	tcccattcgc	cattcaggct	480
gcgcaactgt	tgggaagggc	gatcggtgcg	ggcctcttcg	ctattacgcc	agctggcgaa	540
agggggatgt	gctgcaaggc	gattaagttg	ggtaacgcca	gggttttccc	agtcacgacg	600
ttgtaaaacg	acggccagtg	aattgtaata	cgactcacta	tagggcgaat	tgggtaccgg	660
gccccccctc	gaggtcgacg	gtatcgataa	gcttgatata	gaattcagga	gacacaactc	720
caagtgcata	ctctatgtca	ttttcatggg	actggctctg	ccacaactac	attaatgaaa	780
tatttgccac	atcctcttac	actttttcat	acattgcccc	agaataaaga	atcgtttgtg	840
ttatgtttca	acgtgtttat	ttttcaattg	cagaaaattt	caagtcattt	ttcattcagt	900
agtatagccc	caccaccaca	tagcttatac	agatcaccgt	accttaatac	aactcacaga	960
accctagtat	tcaacctgcc	acctccctcc	caacacacag	agtacacagt	cctttctccc	1020
cggtggcct	taaaaagcat	catatcatgg	gtaacagaca	tattcttagg	tgttatattc	1080
cacacggttt	cctgtcgagc	caaacgctca	tcagtgatat	taataaactc	cccgggcgag	1140
tcacttaagt	tcagtgcgct	gtccagctgc	tgagccacag	gctgctgtcc	aacttgcggt	1200
tgcttaacgg	gcggcggaagg	agaagtccac	gcctacatgg	gggtagagtc	ataatcgctc	1260
atcaggatag	ggcggtgggtg	ctgcagcagc	gcgcgaataa	actgctgccg	ccgcgcgctc	1320
gtcctgcagg	aatacaacat	ggcagtggtc	tcttcagcga	tgattcgcac	cgcccgacgc	1380
ataaggcgcc	ttgtcctccg	ggcacagcag	cgcaccctga	tctcacttaa	atcagcacag	1440
taactgcagc	acagcaccac	aattattgttc	aaaattcccac	agtgcaggcg	gctgtatcca	1500
aaagtctatg	cggggaccac	agaacccacg	tggccatcat	accacaagcg	caggtagatt	1560
aagtggcgac	ccctcataaa	cacgctggag	ataaacatta	cctcttttgg	catgttgtaa	1620
ttcaccacct	cccgggtacca	tataaacctc	tgattaaaca	tggcgccatc	caccaccatc	1680
ctaaaccagc	tggccaaaac	ctgcccgcgc	gctatacact	gcagggaacc	gggactggaa	1740
caatgacagt	ggagagccca	ggactcgtaa	ccatggatca	tcattgctcg	catgatatac	1800
atgtttggc	aacacaggca	cacgtgcata	cacttccctc	ggattacaag	ctcctcccgc	1860
gttagaacca	tatcccaggg	aacaacccat	tctgtaatac	gcgtaaatcc	cacactgcag	1920
ggaagacctc	gcacgttaact	cacgttgtgc	attgtcaaa	tgttacattc	gggcagcagc	1980
ggatgatcct	ccagtatggt	agcgcgggtt	tctgtctcaa	aaggaggtag	acgatcccta	2040
ctgtacggag	tgcgcggaga	caaccgagat	cgtgttggtc	gtagtgtcat	gccaaatgga	2100
acgcgggacg	tagtcatatt	tctgaagca	aaaccagggt	cgggcgtgac	aaacagatct	2160
gogtctccgg	tctcgccgct	tagatcgctc	tggtgtagtag	ttgtagtata	tccactctct	2220
caaagcatcc	aggcgcccc	tggcttcggg	ttctatgtaa	actccttcac	gcgcgcgctc	2280
cctgataaca	tccaccaccg	cagaataaag	cacacccagc	caacctacac	attcgtttctg	2340
cgagtacac	acgggaggag	cggaagagc	tggaagaacc	atgttttttt	ttttattcca	2400
aaagattatc	caaaacctca	aatgaagat	ctattaagt	aacgcgctcc	cctccggtgg	2460
cgtggtcaaa	ctctacagcc	aaagaacaga	taatggcatt	tgtaagatgt	tgacacatgg	2520
cttccaaaag	gcaaacggcc	ctcacgtcca	agtggacgta	aaggctaaac	ccttcagggt	2580
gaatctcctc	tataaacatt	ccagcacctt	caaccatgcc	caaataattc	tcattctcgc	2640
accttctcaa	tatatctcta	agcaaatccc	gaatattaag	tccggccatt	gtaaaaatct	2700
gctccagagc	gcccctccacc	ttcagcctca	agcagcgaat	catgattgca	aaaattcagg	2760
ttcctcacag	acctgtataa	gattcaaaag	cggaacatta	acaaaaatac	cgcgatccc	2820
taggtccctt	cgcagggccca	gctgaacata	atcgtgcagg	tctgcacgga	ccagcgcggc	2880
cacttccccg	ccagggaacct	tgacaaaaga	accacactg	attatgacac	gcatactcgg	2940
agctatgcta	accagcgtag	ccccgatgta	agctttgttg	catgggcggc	gatataaaaa	3000
gcaaggtgct	gctcaaaaaa	tcaggcaaa	cctcgcgcaa	aaaagaaagc	acatcgtagt	3060
catgctcatg	cagataaagg	caggtaagct	ccggaaccac	cacagaaaaa	gacaccattt	3120
ttctctcaaa	catgtctgcg	ggtttctgca	taaacacaaa	ataaaataac	aaaaaaacat	3180
ttaaacatta	gaagcctgtc	ttacaacagg	aaaaacaacc	cttataagca	taagacggac	3240
tacggccatg	ccggcggtgac	cgtaaaaaaa	ctggtcaccg	tgattaaaaa	gcaccaccga	3300
cagctcctcg	gtcatgtccg	gagtcataat	gtaagactcg	gtaaacacat	caggttgatt	3360
catcggtcag	tgctaaaaag	cgaccgaaat	agcccggggg	aatacatacc	cgcaggcgta	3420
gagacaacat	tacagccccc	ataggaggta	taacaaaatt	aataggagag	aaaaacacat	3480

aaacacctga aaaaccctcc tgcctaggca aaatagcacc ctcccgtccc agaacaacat 3540
acagcgcttc acagcggcag cctaacagtc agccttacca gtaaaaaaga aaacctatta 3600
aaaaaacacc actcgacacg gcaccagctc aatcagtcac agtgtaaaaa agggccaagt 3660
gcagagcgag tatatatagg actaaaaaat gacgtaacgg ttaaagtcca caaaaaacac 3720
ccagaaaacc gcacgcgaac ctacgcccag aaacgaaagc caaaaaaccc acaacttcct 3780
caaatcgta cttccgtttt cccacgttac gtaacttccc ggatccgcgg cattcacagt 3840
tctccgcaag aattgattgg ctccaattct tggagtgggt aatccgttag cgaggtgccg 3900
ccggttcca ttcaggtcga ggtggcccgg ctccatgcac cgcgacgcaa cgcggggagg 3960
cagacaaggt atagggcggc gcctacaatc catgccaacc cgttccatgt gctcgcgag 4020
gcggcataaa tcgccgtgac gatcagcggg ccaggtatcg aagttaggct ggtaagagcc 4080
gcgagcgatc cttgaagctg tccctgatgg tcgtcatcta cctgcctgga cagcatggcc 4140
tgcaacgcgg gcatcccgat gccgcgggaa gcgagaagaa tcataatggg gaaggccatc 4200
cagcctcgcg tcgcgaacgc cagcaagacg tagcccagcg cgtcggccgc catgccctgc 4260
ttcatccccg tggcccgttg ctgcggtttg ctggcgggtg ccccggaaga aatatatttg 4320
catgtcttta gttctatgat gacacaaacc ccgccagcg tcttgtcatt ggcgaattcg 4380
aacacgcaga tgcagtcggg gcggcgcggg ccaggtcca cttcgcatat taaggtgacg 4440
cgtgtggcct cgaacaccga agcgaccgcg ttaacagcgt caacagcgtg 4500
ccgcagatcc cgggcaatga gatatgaaaa agcctgaact caccgcgacg tctgtcgaga 4560
agtttctgat cgaaaagtgc gacagcgtct ccgacctgat gcagctctcg gagggcgaag 4620
aatctcgtgc tttcagcttc gatgtaggag ggcgtggata tgtcctgagg gtaaatagct 4680
gcgcgatgg tttctacaaa tttatcggca ctttgcacg gccgcgtccc 4740
cgattccgga agtgcttgac attggggaat tcagcgagag cctgacctat tgcattctcc 4800
gccgtgcaca ggggtgtcacg ttgcaagacc tgccgtgaaac cgaactgccc gctgttctgc 4860
agccgtcgcg ggaggccatg gatgcgatcg ctgcggccga tcttagccag acgagcgggt 4920
tcggcccatt cggaccgcaa ggaatcggtc aatacactac atggcgtgat ttcatatgcy 4980
cgattgctga tccccatgtg tatcactggc aaactgtgat ggacgacacc gtcagtgcgt 5040
ccgtcgcgca ggctctcgat gagctgatgc tttgggcccga ggactgcccc gaagtccggc 5100
acctcgtgca cgcggatttc ggctccaaca atgtcctgac ggacaatggc cgcataacag 5160
cgggtcatga cctggagcgag gcgatgttcg ggtattccca atacgaggtc gccaacatct 5220
tcttctggag gccgtggttg cctgttatgg agcagcagac gcgctacttc gagcggaggc 5280
atccggagct tgcaggatcg ccgcggctcc gggcgatatat gctccgcatt ggtcttgacc 5340
aactctatca gagcttggtt gacggcaatt tcgatgatgc agcttgggcy cagggtcgat 5400
gcgacgcaat cgtccgatcc ggagccggga ctgtcgggcy tacacaaatc gccgcagaa 5460
gcgcggccgt ctggaccgat ggctgtgtag aagtactcgc cgatagtgga aaccgacgcc 5520
ccagcactcg tccgagggca aaggaatagg ggagatgggg gaggtactaact gaaacacgga 5580
aggagacaat accggaagga acccgcgcta tgacggcaat aaaaagacag aataaaacgc 5640
acgggtgttg ggtcgtttgt tcataaacgc ggggttcggt cccagggctg gcactctgtc 5700
gataccccac cgagacccca ttggggccaa tacgcccgcg tttcttctt ttccccaccc 5760
caccocccaa gttcgggtga agggccaggg ctgcgagcca acgtcggggc ggcaggccct 5820
gccatagcca ctggcccccgt ggggttaggga cgggggtccc catggggaat ggtttatggt 5880
tcgtgggggt tattattttg ggcgttgcg tggggtctggt ccacgactgg actgagcaga 5940
cagacccatg gtttttgat ggcctgggca tggaccgcat gtactggcgc gacacgaaca 6000
ccgggcgtct gtgctgcca aacaccccgc accccaaaaa accaccgcgc ggatttctg 6060
cgcccagtg cgtcgaccgg tcatggctgc gcccgcacac ccgccaacac ccgctgacgc 6120
gccctgacgg gcttgtctgc tcccgccatc cgcttacaga caagctgtga ccgtctccg 6180
gagctgcatg tgcagagggt tttcacccgt atcacccgaa cgcgcgaggc agccggatca 6240
taatcagcca taccacattt gtagagggtt tacttgcttt aaaaaacctc cccacctccc 6300
cctgaacctg aaacataaaa tgaatgcaat tcttgttgtt aacttgttta ttgcagctta 6360
taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat ttttttact 6420
gcattctagt tgtgggtttg ccaaactcat caatgtatct tatcatgtct ggatccacta 6480
gttctagagc ggccgccacc gcggtggagc tccagctttt gttcccttta gtgagggtta 6540
atttcagagc tggcgtaatc atggctcatag ctgtttcctg tgtgaaattg ttatccgctc 6600
acaattccac acaacatacg agccgggaagc ataaagtgt aagcctgggg tgcctaata 6660
gtgagctaac tcacattaat tgcgttgccg tccactgccc ctttccagtc gggaaacctg 6720
tcgtgccagc tgcattaatg aatcgccaa cgcgcgggga gaggcggtt gcgtattggg 6780
cgctcttccg ctctctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg 6840
gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga 6900
aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaagg cgcgttgctg 6960
gcgtttttcc ataggctccg ccccccgtgac gagcatcaca aaaatcgacg ctcaagtcag 7020
aggtygcgaa acccgacagc actataaaga taccaggcgt ttccccctgg aagctccctc 7080
gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt tctccctcg 7140
ggaagcgtgg cgctttctca tagctcacgc tgtaggatcc tcagttcggt gtaggtcggt 7200

```
cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc 7260
ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc 7320
actggtaaca ggattagcag agcgaggatg gtaggcgggtg ctacagagtt cttgaagtgg 7380
tggcctaact acggctacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca 7440
gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgtggtagc 7500
gggtggtttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560
cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggatt 7620
ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 7680
tttaaataca tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc 7740
agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 7800
gtcgtgtaga taactacgat acgggagggc ttaccatctg gcccagtgcc tgcaatgata 7860
ccgcgagacc cagcgtcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 7920
gccgagcgca gaagtgggtc tgcaacttta tccgcctcca tccagtctat taattgttgc 7980
cgggaagcta gagtaagtag ttccgagtt aatagtttgc gcaacgttgt tgccattgct 8040
acaggcatcg tgggtgtcag ctcgctcgtt ggtatggctt cattcagctc cggttcccaa 8100
cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt 8160
cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca 8220
ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtagtac 8280
tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgtctctg cccggcgtca 8340
atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 8400
tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaacct 8460
actcgtgcac ccaactgata ttcagcatct tttactttca ccagcgttcc tgggtgagca 8520
aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggc cgacacggaa atgttgaata 8580
ctcatactct tcctttttca atattattga agcatttatc agggttattg tctcatgagc 8640
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgag cacatttccc 8700
cgaaaagtgc 8710
```

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 5
atgggatcca agatgaagcg cgcaagaccg 30

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 6
cataacgcgg ccgcttcttt attcttgggc 30

<210> 7
<211> 7148
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 7
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggtag	gcgttttgog	ctgcttcgog	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccggc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttaacgg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtagcccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggaacttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggtttttgg	agtacatcaa	tgggcgtgga	tagcgggttg	660
actcacgggg	attttccaagt	ctccaccccc	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatgggog	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttgggtacc	900
gagctcggat	ccaagatgaa	gcgcgcaaga	cogtctgaag	ataccttcaa	ccccgtgtat	960
ccatatgaca	cggaaacggg	tcctccaact	gtgccttttc	ttactcctcc	ctttgtatcc	1020
cccaatgggt	ttcaagagag	tccccctggg	gtactctctt	tgcgcctatc	cgaacctcta	1080
gttacctcca	atggcatgct	tgcgctcaaa	atgggcaacg	gcctctctct	ggacgaggcc	1140
ggcaacctta	cctcccaaaa	tgtaaccaact	gtgagccac	ctctcaaaaa	aaccaagtca	1200
aacataaacc	tggaaatatc	tgcacccctc	acagttacct	cagaagccct	aactgtggct	1260
gccgcgcac	ctctaattgt	cgcgggcaac	acactacca	tgcaatcaca	ggccccgcta	1320
accgtgcacg	actccaaact	tagcattggc	acccaaggac	ccctcacagt	gtcagaagga	1380
aagctagccc	tgcaaacatc	aggccccctc	accaccaccg	atagcagtac	ccttactatc	1440
actgcctcac	ccccctaac	tactgccact	ggtagcttgg	gcattgactt	gaaagagccc	1500
atttatacac	aaaatggaaa	actaggacta	aagtaggggg	ctcctttgca	tgtaacagac	1560
gacctaatac	ctttgaccgt	agcaactggg	ccaggtgtga	ctattaataa	tacttccctg	1620
caaactaaag	ttactggagc	cttgggtttt	gattcacaag	gcaatatgca	acttaatgta	1680
gcaggaggac	taaggattga	ttctcaaaa	agacgcctta	tacttgatgt	tagttatccg	1740
tttgatgctc	aaaaccaact	aaatctaaga	ctaggacagg	gccctctttt	tataaactca	1800
gccacaact	tggatattaa	ctacaacaaa	ggcctttact	tgtttacagc	ttcaacaact	1860
tccaaaaagc	ttgaggttaa	cctaagcact	gccaaagggt	tgatgtttga	cgctacagcc	1920
atagccatta	atgcaggaga	tgggcttgaa	tttggttcac	ctaattgcacc	aaacacaaat	1980
cccctcaaaa	caaaaattgg	ccatggccta	gaatttgatt	caaacaaggc	tatggttcct	2040
aaactaggaa	ctggccttag	ttttgacagc	acaggtgcca	ttacagtagg	aaacaaaaat	2100
aatgataagc	taactttgtg	gaccacacca	gctccatctc	ctaactgtag	actaaatgca	2160
gagaaagatg	ctaaactcac	tttggctcta	acaaaatgtg	gcagtcaaat	acttgctaca	2220
gtttcagttt	tggctgttaa	aggcagtttg	gctccaatat	ctggaacagt	tcaaagtgtc	2280
catcttatta	taagatttga	cgaaaatgga	gtgctactaa	acaattcctt	cctggaccca	2340
gaatattgga	acttttagaaa	tggagatcct	actgaaggca	cagcctatac	aaacgctgtt	2400
ggattttatgc	ctaacctatc	agcttatcca	aaatctcacg	gtaaaactgc	caaaagtaac	2460
attgtcagtc	aagtttactt	aaacggagac	aaaactaaac	ctgtaacact	aaccattaca	2520
ctaaacggta	cacaggaaac	aggagacaca	actccaagtg	catactctat	gtcattttca	2580
tgggactggg	ctggccacaa	ctacattaat	gaaatatattg	ccacatcctc	ttacactttt	2640
tcatacattg	cccaagaata	aagaagcggc	cgctcgagca	tgcacttaga	gggccctatt	2700
ctatagtgtc	acctaaatgc	tagagctcgc	tgatcagcct	cgactgtgcc	ttctagttgc	2760
cagccatctg	ttgtttgccc	ctcccccggt	ccttccttga	ccctggaagg	tgccactccc	2820
actgtccttt	cctaataaaa	tgaggaaatt	gcacgcatt	gtctgagtga	gtgtcattct	2880
attctggggg	gtgggggtggg	gcaggacagc	aagggggagg	attgggaaga	caatagcagg	2940
catgctgggg	atgcggtggg	ctctatggct	tctgaggcgg	aaagaaccag	ctggggctct	3000
aggggggtatc	cccacgcgcc	ctgtagcggc	gcattaagcg	cggcggtgtg	ggtggttacg	3060
cgcagcgtga	ccgctacact	tgccagcgcc	ctagcgcccg	ctcctttcgc	tttcttccct	3120
tcctttctcg	ccacgttcgc	cggctttccc	cgtcaagctc	taaatcgggg	catcccttta	3180
gggttccgat	ttagtgtctt	acggcacctc	gacccccaaa	aacttgatta	gggtgatgtg	3240
tcacgtagtg	ggccatcgcc	ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	3300
ttctttaata	gtggactctt	gttccaaact	ggaacaacac	tcaaccctat	ctcgggtctat	3360
tccttttgatt	tataagggat	tttggggatt	tcggcctatt	ggttaaaaaa	tgagctgatt	3420
taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	tcagttaggg	tgtggaaagt	3480
ccccaggctc	cccaggcagg	cagaagtatg	caaagcatgc	atctcaatta	gtcagcaacc	3540
aggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcactcatt	3600
tagtcagcaa	ccatagtccc	gccccctaact	ccgccccatcc	cgccccaac	tccgcccagt	3660
tccgcccatt	ctccgcccc	tggttgacta	atttttttta	tttatgcaga	ggccgaggcc	3720
gcctctgcct	ctgagctatt	ccagaagtag	tgaggaggct	tttttgagg	cctaggcttt	3780

tgcaaaaagc	tcccgggagc	ttgtatatcc	atcttcggat	ctgatcaaga	gacaggatga	3840
ggatcggttc	gcatgattga	acaagatgga	ttgcacgcag	gttctccggc	cgcttggttg	3900
gagaggtctat	tcgggctatga	ctgggcacaa	cagacaatcg	gctgctctga	tgccgccttg	3960
ttccggctgt	cagcgagggg	gcgcccgtt	ctttttgtca	agaccgacct	gtccggtgcc	4020
ctgaatgaac	tgcaggacga	ggcagcgcg	ctatcgtggc	tggccacgac	ggcggttcct	4080
tgcgcagctg	tgctcgacgt	tgtcactgaa	gcgggaagg	actggctgct	attgggcgaa	4140
gtgcgggggc	aggatctcct	gtcatctcac	cttgctcctg	ccgagaaagt	atccatcatg	4200
gctgatgcaa	tgcggcggt	gcatacgctt	gatccggcta	cctgcccatt	cgaccaccaa	4260
gcgaaacatc	gcatcgagcg	agcacgtact	cggatggaag	ccggtcttgt	cgatcaggat	4320
gatctggacg	aagagcatca	ggggctcgcg	ccagccgaac	tgttcgccag	gctcaaggcg	4380
cgcattgccg	acggcgagga	tctcgtcgtg	acccatggcg	atgcctgctt	gccgaatatc	4440
atggtggaaa	atggccgctt	ttctggattc	atcgactgtg	gccggctggg	tgtggcgag	4500
cgctatcagg	acatagcggt	ggctaccggt	gatattgctg	aagagcttgg	cggcgaatgg	4560
gctgaccgct	tcctcgtgct	ttacgggtatc	gccgctcccg	attcgcagcg	catcgcttcc	4620
tatcgctctc	ttgacgagtt	cttctgagcg	ggactctggg	gttcgaaatg	accgaccaag	4680
cgacgcccac	cctgccatca	cgagatttcg	attccaccgc	cgccttctat	gaaagggttg	4740
gcttcggaat	cgttttccgg	gacgcgggct	ggatgatcct	ccagcgcggg	gatctcatgc	4800
tggagttctt	cgcccccccc	aacttggtta	ttgcagctta	taatggttac	aaataaagca	4860
atagcatcac	aaatttcaca	aataaagcat	ttttttcact	gcattctagt	tgtggtttgt	4920
ccaaactcat	caatgtatct	tatcatgtct	gtataccgtc	gacctctagc	tagagcttgg	4980
cgtaatcatg	gtcatagctg	tttctgtgtg	gaaattgtta	tccgctcaca	attccacaca	5040
acatacagc	cggaagcata	aagtgtaaag	cctgggtgct	ctaattgagt	agctaactca	5100
cattaattgc	gttgcgctca	ctgcccgtt	tccagtcggg	aaacctgtcg	tgccagctgc	5160
attaatgaat	cggccaaacgc	gcggggagag	gcggtttgct	tattggcgcg	tcttccgctt	5220
cctcgctcac	tgactcgctg	cgctcggtcg	ttcggtcgcg	gcgagcggtg	tcagctcact	5280
caaaggcggt	aatacgggta	tccacagaat	caggggataa	cgcaggaaaag	aacatgtgag	5340
caaaaggcca	gcaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	tttttccata	5400
ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	5460
cgacaggact	ataaagatac	caggcggttc	cccgtggaag	ctccctcgct	cgctctcctg	5520
ttccgacctt	gcgcttacc	ggatacctgt	ccgcttttct	cccttcggga	agcgtggcgc	5580
tttctcaatg	ctcacgctgt	aggtatctca	gttcggtgta	ggtcggtcgc	tccaagctgg	5640
gctgtgtgca	cgaaccccc	gttcagcccg	accgctgcgc	cttatccggt	aactatcgct	5700
ttgagtccaa	cccggtaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	5760
ttagcagagc	gaggtatgta	ggcggtgcta	cagagttctt	gaagtgggtg	cctaactacg	5820
gctacactag	aaggacagta	tttggtatct	gcgctctgct	gaagccagtt	accttcggaa	5880
aaagagttgg	tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggt	ggtttttttg	5940
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	6000
ctacggggtc	tgaacgctcag	tggaaacgaa	actcacgtta	agggattttg	gtcatgagat	6060
tatcaaaaag	gatcttcacc	tagatccttt	taaattaaaa	atgaagtttt	aatcaatct	6120
aaagtatat	tgagtaaact	tggctctgaca	gttaccaatg	cttaatcagt	gaggcaccta	6180
tctcagcgat	ctgtctattt	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	6240
ctacgatacg	ggagggctta	ccatctggcc	ccagtgcctg	aatgataccg	cgagaccac	6300
gctcacccgc	tccagattta	tcagcaataa	accagccagc	cggaaaggcc	gagcgagaa	6360
gtggtcctgc	aactttatcc	gcctccatcc	agtctattaa	ttggtgccc	gaagctagag	6420
taagtagttc	gccagttaat	agtttgcgca	acgttggtgc	cattgctaca	ggcatcggtg	6480
tgtcacgctc	gtcggttggt	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	6540
ttacatgatc	ccccatgttg	tgcaaaaaag	cggttagctc	cttcggtcct	ccgatcggtg	6600
tcagaagtaa	gttgggccgca	gtgttatcac	tcattggtat	ggcagcactg	cataattctc	6660
ttactgtcat	gccatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcat	6720
tctgagaata	gtgtatgcgg	cgaccgagtt	gctcttgccc	ggcgtaata	cgggataata	6780
ccgcgccaca	tagcagaact	ttaaaagtgc	tcattcattg	aaaacgttct	tcggggcgaa	6840
aactctcaag	gatcttaccg	ctggttgagat	ccagttcgat	gtaaccact	cgtgcaccca	6900
actgatcttc	agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	6960
aaaaagccgc	aaaaaaggga	ataagggcga	cacggaatg	ttgaatactc	atactcttcc	7020
tttttcaata	ttattgaagc	atttatcgag	gttatgtct	catgagcgga	tacatatattg	7080
aatgtattta	gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	7140
ctgacgtc						7148

<210> 8

<211> 7469

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 8

```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttaggggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcg tggttgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccataa gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgcca cttggcagta catcaagtgt 480
atcatatgcc aagtagcccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggaccttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catgggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggcg 780
gtaggcgtgt acgggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagaccaa gcttggtagc 900
gagctcggat ctgaattcga gctcgtgttt gggctcgcgg ttgaggacaa actcttcgcg 960
gtctttccag tactcttggg tcggaaaccc ctggcctcc gaacggtact ccgccaccga 1020
gggacctgag cgagtcogca tcgaccggat cggaaaacct ctcgagaaag gcgtctaacc 1080
agtcacagtc gcaaggtagg ctgagcaccg tggcggggcg cagcgggtgg cggtcggggg 1140
tgtttctggc ggaggtgctg ctgatgatgt aattaaagta ggcggtcttg agacggcgga 1200
tggtcgaggt gaggtgtggc aggccttgaga tccaagatga agcgcgcaag accgtctgaa 1260
gataccttca accccgtgta tccatatgac acggaaaccc gtcctccaac tgtgcctttt 1320
cttactcctc cctttgtatc cccaatggg tttcaagaga gtcccctgg ggtactctct 1380
ttgcgcctat ccgaacctct agttacctcc aatggcatgc ttgcgtcaa aatgggcaac 1440
ggcctctctc tggacgaggc cggcaacctt acctcccaa atgtaaccac tgtgagccca 1500
cctctcaaaa aaaccaagtc aaacataaac ctggaaatat ctgcaccctt cacagttacc 1560
tcagaagccc taactgtggc tgcgcgcgca cctctaattg tcgcgggcaa cactcacc 1620
atgcaatcac aggcctcgct aaccgtgcac gactccaaac ttagcattgc caccacagga 1680
ccctcacag tgtcagaagg aaagctagcc ctgcaaacat caggccccct caccaccacc 1740
gatagcagta cccttactat cactgcctca cccctctaa ctactgccac tggtagcttg 1800
ggcattgact tgaaagagcc catttataca caaatggaa aactaggact aaagtacggg 1860
gtccttttgc atgtaacaga cgacctaaac actttgaccg tagcaactgg tccaggtgtg 1920
actattaata atacttctt gcaactaaa gttactggag ccttgggttt tgattcaca 1980
ggcaatatgc aacttaattg agcaggagga ctaaggattg attctcaaaa cagacgcctt 2040
atacttgatg ttagttatcc gtttgatgct caaaaccaac taaatctaag actaggacag 2100
ggcctcttct ttataaaact agcccacaac ttggtatata actacaacaa aggcctttac 2160
ttgtttacag cttcaaaaca ttccaaaaag cttgaggtta acctagcac tgccaagggg 2220
ttgatgtttg acgctacagc catagccatt aatgcaggag atgggcttga atttggttca 2280
cctaattcac caaacacaaa tcccctcaaa acaaaaattg gccatggcct agaatttgat 2340
tcaaacaagg ctatggttcc taaactagga actggcctta gttttgacag cacaggtgcc 2400
attacagtag gaaacaaaaa taatgataag ctaactttgt ggaccacacc agctccatct 2460
cctaactgta gactaaatgc agagaaagat gctaaactca ctttggctct aacaaaatgt 2520
ggcagtcaaa tacttgcac agtttcagtt ttggctgtta aaggcagttt ggctccaata 2580
tctggaacag ttcaaagtgc tcatcttatt ataagatttg acgaaaatgg agtgctacta 2640
aacaattcct tcttgacccc agaattttgg aactttagaa atggagatct tactgaaggc 2700
acagcctata caaacgctgt tggattttat cctaacctat cagcttatcc aaaatctcac 2760
ggtaaaactg ccaaaagtaa cattgtcagt caagtttact taaacggaga caaaactaaa 2820
cctgtaacac gcaactctta tgtcattttc atgggactgg tctggccaca actacattaa tgaaatattt 2940
gccacactct cttacacttt tctatagtgt cacctaaatg ctagagctcg ctgatcagcc 3060
tcgactgtgc cttctagttg ccagccatct gttgtttgcc cctccccgt gccttctctg 3120
accctggaag gtgccactcc cactgtcctt tcctaataaa atgaggaaat tgcacgcgat 3180
tgtctgagta ggtgtcattc tattctgggg ggtgggggtg ggaggagacag caagggggag 3240
gattgggaag acaatagcag gcatgctggg gatgcgggtg gctctatggc ttctgaggcg 3300
gaaagaacca gctggggctc taggggggtat cccacgcgcg cctgtagcgg cgcattaagc 3360
```

gcggcggggtg	tggtggttac	gcgcagcgtg	accgctacac	ttgccagcgc	cctagcgccc	3420
gctccttttcg	ctttcttccc	ttcctttctc	gccacgttcg	ccggctttcc	ccgtcaagct	3480
ctaaatcggg	gcatcccttt	aggggttcga	tttagtgctt	tacggcacct	cgaccccaaa	3540
aaacttgatt	aggggtgatg	ttcacgtagt	gggccatcgc	cctgatagac	ggtttttcgc	3600
cctttgacgt	tggagtcac	gttctttaat	agtggactct	tgttccaaac	tggaacaaca	3660
ctcaacccta	tctcgggtcta	ttcttttgat	ttataaggga	ttttggggat	ttcggcctat	3720
tggttaaaaa	atgagctgat	ttacaaaaaa	tttaacgcga	attaattctg	tggaatgtgt	3780
gtcagtttag	gtgtggaag	tccccaggct	ccccaggcag	gcagaagtat	gcaaagcatg	3840
catctcaatt	agtacgcaac	caggtgtgga	aagtccccag	gctccccagc	aggcagaagt	3900
atgcaaagca	tgcatctcaa	ttagtacga	accatagtcc	cgcccctaac	tccgccatc	3960
ccgcccctaa	ctccgcccag	ttccgcccac	tctccgcccc	atggctgact	aatttttttt	4020
atttatgcag	aggccgaggc	cgctctgccc	tctgagctat	tccagaagta	gtgaggaggc	4080
ttttttggag	gcctaggctt	ttgcaaaaag	ctcccgggag	cttgatatatc	catttttcgga	4140
tctgatcaag	agacaggatg	aggatcgttt	cgcatgattg	aacaagatgg	attgcaogca	4200
ggttctccgg	ccgcttgggt	ggagaggcta	ttcggctatg	actgggcaca	acagacaatc	4260
ggctgctctg	atgccgcccgt	gttccggctg	tcagcgcagg	ggcgcccgggt	tctttttgtc	4320
aagaccgacc	tgtccgggtgc	cctgaatgaa	ctgcaggacg	aggcagcgcg	gctatcgtgg	4380
ctggccacga	cgggcgttcc	ttgcgcagct	gtgctcgacg	ttgtcactga	agcgggaagg	4440
gactggctgc	tattgggcga	agtgcggggg	caggatctcc	tgatcatctca	ccttgctcct	4500
gccgagaaag	tatccatcat	ggctgatgca	atgcggcggc	tgcatacgct	tgatccggct	4560
acctgcccct	tgcaccacca	agcgaacat	cgcatcgagc	gagcacgtac	tccgatggaa	4620
gccgggtcttg	tccatcagga	tgatctggac	gaagagcatc	aggggctcgc	gccagccgaa	4680
ctgttcgccca	ggctcaaggc	gcgcgatccc	gacggcgagg	atctcgtcgt	gacccatggc	4740
gatgcctgct	tgccgaatat	catggtggaa	aatggccgct	tttctggatt	catcgactgt	4800
ggccggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	tggctaccog	tgatattgct	4860
gaagagcttg	gcggcgcaatg	ggctgaccgc	ttcctcgtgc	tttacgggat	cgccgctccc	4920
gattcgcagc	gcctgcctt	ctatgcctt	cttgacgagt	tcttctgagc	gggactctgg	4980
ggttcgaaat	gaccgaccaa	gcgcgcacca	acctgccatc	acgagatttc	gattccaccg	5040
ccgcctttcta	tgaaggttg	ggcttcggaa	tccgttttccg	ggacgcgggc	tggatgatcc	5100
tccagcgcg	ggatctcatg	ctggagtctt	tcgcccaccc	caacttgttt	attgcagctt	5160
ataatggtta	caaataaagc	aataagatca	caaatttcac	aaataaagca	tttttttcac	5220
tgcatcttag	ttgtggtttg	tccaaaactca	tcaatgtatc	ttatcatgtc	tgtatacogt	5280
cgacctctag	ctagagcttg	gcgtaatcat	ggctcatagct	gtttcctgtg	tgaaattgtt	5340
atccgctcac	aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	5400
cctaattgagt	gagctaactc	acattaattg	cgttgccgctc	actgcccgtc	ttccagtcgg	5460
gaaacctgtc	gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	5520
gtattgggcg	ctcttcgcgt	tctcgcctca	ctgactcgct	gcgctcggtc	gttcggctgc	5580
ggcgagcggg	atcagctcac	tcaaaggcgg	taatacgggtt	atccacagaa	tcaggggata	5640
acgcaggaaa	gaacatgtga	gcaaaaaggcc	agcaaaaaggc	caggaaccgt	aaaaaggccg	5700
cgtttgctggc	gtttttccat	aggctccgcc	cccctgacga	gcatcacaaa	aatcgacgct	5760
caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcgttt	ccccctggaa	5820
gtccctcgt	gcgctctcct	gttccgacct	tgccgcttac	cggatacctg	tccgcctttc	5880
tcccttcggg	aagcgtggcg	cttctcgaat	gctcacgctg	taggtatctc	agttcgggtg	5940
aggctcgttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	6000
ccttatccgg	taactatcgt	cttgagtcca	acccggtaag	acacgactta	tcgccactgg	6060
cagcagccac	tggttaacagg	attagcagag	cgaggatagt	aggcggtgct	acagagttct	6120
tgaagtgggtg	gcctaactac	ggctacacta	gaaggacagt	atttggtatc	tgcgctctgc	6180
tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	6240
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	6300
aagaagatcc	tttgatcttt	tctacggggt	ctgacgctca	gtggaacgaa	aactcacggt	6360
aagggttttt	ggctcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	6420
aatgaagtgtt	taaatcaatc	taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	6480
gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcatcc	atagttgcct	6540
gactccccgt	cgtgtagata	actacgatac	gggagggtt	accatctggc	cccagtgctg	6600
caatgatacc	gcgagaccca	cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	6660
ccggaagggc	cgagcgcaga	agtgttcctg	caactttatc	cgctccatc	cagtctatta	6720
attgttgccg	ggaagctaga	gtaagtgtt	cgccagttaa	tagtttgccg	aacgttggtg	6780
ccattgctac	aggcatcgtg	gtgtcacgct	cgctggtttg	tatggcttca	ttcagctccg	6840
gttcccaacg	atcaaggcga	gttacatgat	ccccatgtt	gtgcaaaaaa	gcggttagct	6900
ccttogggtcc	tccgatcggt	gtcagaagta	agttggccgc	agtgttatca	ctcatgggtta	6960
tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	7020
gtgagtactc	aaccaagtca	ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	7080

cggcgtcaat	acgggataat	accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	7140
gaaaacgttc	ttcggggcga	aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	7200
tgtaacccac	tcgtgcaccc	aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	7260
ggtgagcaaa	aacaggaagg	caaaatgccg	caaaaaagg	aataaggcgc	acacggaaat	7320
gttgaatact	catactcttc	ctttttcaat	attattgaag	catttatcag	ggttattgtc	7380
tcatgagcgg	atacatattt	gaatgtattt	agaaaaataa	acaaatagg	gttccgcgca	7440
catttccccg	aaaagtgcc	cctgacgtc				7469

<210> 9

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 9

tgcttaagcg gccgcgaagg agaagtcc

28

<210> 10

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 10

ccgagctagc gactgaaaat gag

23

<210> 11

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 11

cctctcgaga gacagcaaga cac

23

<210> 12

<211> 11152

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 12

aagcttgggc	agaaatggtt	gaactcccga	gagtgtccta	cacctagggg	agaagcagcc	60
aaggggttgt	ttcccaccaa	ggacgacctg	tctgcgcaca	aacggatgag	cccatcagac	120
aaagacatat	tcattctctg	ctgcaaaactt	ggcatagctc	tgttttgctt	ggggctattg	180
ggggaagtgt	cgttctgtgc	tcgcagggct	ctcacccttg	actcttttaa	tagctcttct	240
gtgcaagatt	acaatctaaa	caattcggag	aactcgacct	tcctcctgag	gcaaggacca	300
cagccaactt	cctcttataa	gccgcacatg	ttttgtcctt	cagaaataga	aataagaatg	360
cttgctaaaa	attatatttt	taccaataag	accaatccaa	taggtagatt	attagttact	420
atgttaagaa	atgaatcatt	atcttttagt	actattttta	ctcaaattca	gaagttagaa	480

atgggaatag	aaaatagaaa	gagacgctca	acctcaattg	aagaacaggt	gcaaggacta	540
ttgaccacag	gcctagaagt	aaaaaaggga	aaaaagagt	tttttgtcaa	aataggagac	600
aggtggtggc	aaccagggac	ttatagggga	ccttacatct	acagaccaac	agatgcccc	660
ttaccatata	caggaagata	tgacttaaat	tgggataggt	gggttacagt	caatggctat	720
aaagtgttat	atagatccct	cccttttcgt	gaaagactcg	ccagagctag	acctccttgg	780
tgtatgttgt	ctcaagaaga	aaaagacgac	atgaaacaac	aggtacatga	ttatatattat	840
ctaggaacag	gaatgcactt	ttggggaaaag	attttccata	ccaaggaggg	gacagtggct	900
ggactaatag	aacattattc	tgcaaaaact	catggcatga	gttattatga	atagccttta	960
ttggcccaac	cttgcggttc	ccagggttga	agtaagtttt	tggttacaaa	ctgttcttaa	1020
aacgaggatg	tgagacaagt	ggtttctgta	cttggtttgg	tatcaaagggt	tctgatctga	1080
gctctgagtg	ttctattttc	ctatgttctt	ttggaattta	tccaaatctt	atgtaaattgc	1140
ttatgtaaac	caagatataa	aagagtgtcg	attttttgag	taaacttgca	acagtcctaa	1200
cattcacctc	ttgtgtgttt	gtgtctgttc	gccatcccgt	ctccgctcgt	cacttatcct	1260
tcactttcca	gaggggtccc	ccgcagaccc	cggcgaccct	caggtcggcc	gactgcgcca	1320
gctggcgccc	gaacagggac	cctcggataa	gtgacccttg	tctctatttc	tactatttgg	1380
tggttgtctt	gtattgtctc	tttcttgtct	ggctatcatc	acaagagcgg	aacggactca	1440
ccatagggac	caagctagcg	actgaaaatg	agacatatta	tctgccacgg	aggtgttatt	1500
accgaagaaa	tggcgccag	tcttttgac	cagctgatcg	aagaggtact	ggctgataat	1560
cttccacctc	ctagccattt	tgaaccacct	acccttcacg	aactgtatga	tttagacgtg	1620
acggccccc	aagatcccaa	cgaggaggcg	gtttgcgaga	tttttccgga	ctctgtaatt	1680
ttggcggtgc	aggaagggat	tgacttactc	acttttccgc	cggcgcccgg	ttctccggag	1740
ccgcctcacc	tttcccgcca	gcccagacag	ccggagcaga	gagccttggg	tcccggttct	1800
atgccaaacc	ttgtaccgga	gggtgatcgat	cttacctgcc	acgaggctgg	ctttccaccc	1860
agtgacgacg	aggatgaaga	gggtgaggag	tttgtgttag	attatgtgga	gcaccccgga	1920
cacggttgca	gggtctgtca	ttatcaccgg	aggaatacgg	gggaccacga	tattatgtgt	1980
tcgctttgct	atatgaggac	ctgtggcatg	tttgtctaca	gtaagtgaag	attatgggca	2040
gtgggtgata	gagtggtggg	tttgtgtgtg	taattttttt	tttaattttt	acagttttgt	2100
ggtttaaaaga	attttgtatt	gtgatttttt	taaaagggtc	tgtgtctgaa	cctgagcctg	2160
agccccagcc	agaaccggag	cctgcaagac	ctaccgcgcg	tcctaaaatg	gcgcctgcta	2220
tccctgagacg	cccgacatca	cctgtgtcta	gagaatgcaa	tagtagtacg	gatagctgtg	2280
actccgggtcc	ttctaacaca	cctcctgaga	tacacccggt	ggtcccgtcg	tgccccatta	2340
aaccagttgc	cgtgagagtt	gggtggcgctc	gccaggtgtg	ggaatgtatc	gaggacttgc	2400
ttaacgagcc	tgggcaacct	ttggacttga	gctgtaaacg	ccccaggcca	taaggtgtaa	2460
acctgtgatt	gctgtgtgtg	ttaacgcctt	tggttgtctg	atgagttgat	gtaagtttaa	2520
taaagggtga	gataatgttt	aacttgcacg	gcgtgttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atcttggtta	catctgacct	catggaggct	tgggagtgtt	2640
tgggaagattt	ttctgtctgt	cgtaacttgc	tggaaacagag	ctctaacagt	acctcttggg	2700
tttggaggtt	tctgtggggc	tcaccccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atltgaagag	cttttgaaat	cctgtggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcatacaagc	tttgattttt	tccacaccgg	2880
ggcgcgctgc	ggctgctgtt	gcttttttga	gttttataaa	ggataaatgg	agcgaagaaa	2940
cccactctgag	cgggggggtac	ctgctggatt	ttctggccat	gcactctgtg	agagcggttg	3000
tgagacacaa	gaatcgctcg	ctactgttgt	cttcogtccg	cccgcgata	ataccgacgg	3060
aggagcagca	cgagcagcag	gaggaagcca	ggcgcgcgcg	gcaggagcag	agcccatgga	3120
acccgagagc	cggcctggac	cctcgggaat	gaatgttgta	caggtggctg	aactgtatcc	3180
agaactgaga	cgcattttga	caattacaga	ggatgggcag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtg	ttacttttca	acagatcaag	gataattgct	ctaagagct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgagccagg	3420
ggatgatttt	gaggaggcta	ttagggtata	tgcaaagggt	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaaactg	taaatatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgaggtggag	atagatacgg	aggatagggg	ggcctttaga	tgtagcatga	taaatatgtg	3600
gccgggggtg	cttggcatgg	acgggggtgt	tattatgaat	gtaaggttta	ctggcccaac	3660
ttttagcggg	acggttttcc	tggccaatac	caaccttacc	ctacacgggt	taagcttcta	3720
tgggtttaac	aatacctgtg	tggaaagcctg	gaccgatgta	agggttcggg	gctgtgcctt	3780
ttactgtctg	tggaaagggg	tggtgtgtcg	ccccaaaagc	agggcttcaa	ttaagaaatg	3840
cctctttgaa	aggtgtacct	tgggtatcct	gtctgagggt	aactccaggg	tgcgccacaa	3900
tgtggcctcc	gactgtggtt	gcttcatgct	agtgaagagc	gtggctgtga	ttaagcataa	3960
catgggtatg	ggcaactgct	aggacagggc	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	cgaaggcct	ggccagtgtt	4080
tgagcataac	atactgacct	gctgttcctt	gcatttgggt	aacaggaggg	gggtgttctt	4140
accttaccaa	tgcaatttga	gtcacactaa	gatattgctt	gagcccagaa	gcattgtccaa	4200

ggtgaacctg	aacgggggtg	ttgacatgac	catgaagatc	tggaaggtgc	tgaggtacga	4260
tgagacccgc	accaggtgca	gaccctgcga	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttggtgctgg	cctgcacccg	4380
cgctgagttt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtgggcgtgg	4440
cttaagggtg	ggaagaataa	tataagggtg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggccggggg	gcgtcagaat	gtgatgggct	ccagcattga	4620
tggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttgagg	actgcagcct	ccgccgcgcg	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtgactgac	tttgctttcc	tgagcccgct	tccaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggc	acaattggat	tctttgaccc	gggaacttaa	4860
tgtcgtttct	cagcagctgt	tggatctgcg	ccagcaggtt	tctgccctga	aggcttccct	4920
ccctcccaat	gcggtttaaa	acataaataa	aaaaccagac	tctgtttgga	tttgatcaa	4980
gcaagtgtct	tgtgtgtctt	cgagggatct	ttgtgaagga	accttacttc	tgtgggtgtg	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgttaaacta	ctgattctaa	ttgtttgtgt	atttttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tgggtggaatg	cccttaataa	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgtg	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccctc	agaattgcta	agttttttga	5340
gtcatgctgt	gttttagtaat	agaactcttg	cttgctttgc	tatttacacc	acaaaggaaa	5400
aagctgcaat	gctatacaag	aaaattatgg	aaaaatatct	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	tctttactcc	acacaggcat	agagtgtctg	5520
ctattaataa	ctatgctcaa	aaattgtgta	ccctttagctt	tttaatttgt	aaagggggta	5580
ataaggaata	tttgatgtat	agtgctttga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttggtgt	taacttggtt	attgcagctt	ataatgggta	caaataaagc	5760
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcattctag	ttgtgggttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggatccggc	tgtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcactcfaat	5940
tagtcagcaa	ccagggtgtg	aaagtcccca	ggctccccag	caggcagaag	tatgcaaagc	6000
atgcatctca	attagtccagc	aacctatgtc	ccgcccctaa	ctccgcccat	cccgccccta	6060
actccgccca	gttccgccca	ttctccgcc	catggctgac	taattttttt	tatttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttgga	6180
ggcctaggct	tttgcaaaaa	gcttggaac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgtcag	ggagaggcag	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
actggttttt	agtgcgccag	atctctataa	tctcgcgcaa	cctattttcc	cctcgaaac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaataat	acatcgtcac	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccc	taagccgtgg	cggtctggta	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgtcatg	tgcataccgt	ttgtattttc	agctacgatc	acgacaacca	6600
gcgcgagctt	aaagtgtctg	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggt	gataccgggtg	gtactgcggg	tgcgattcgt	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tcgtccgctg	gttgatgact	atgttggtga	6780
tatcccgcaa	gatactgga	ttgaacagcc	gtgggatatg	ggcgtcgtat	tcgtcccgcc	6840
aatctccggt	cgctaactct	ttcaacgcct	ggcactgccg	ggcgttggtc	tttttaactt	6900
caggcggggt	acaatagttt	ccagtaagta	ttctggaggc	tgcattccatg	acacaggcaa	6960
acctgagcga	aaccctgttc	aaaccccgct	ttaaaccatc	tgaacacctg	acgctagtcc	7020
gccgctttaa	tcacggcgca	caaccgcctg	tgcagtgggc	ccttgatggt	aaaaccatcc	7080
ctcactggta	tcgcatgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gacccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	ggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtgaagg	aaccttactt	ctgtggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaatat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgttttgt	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtggtggaat	7440
gcctttaatg	aggaaaacct	gttttgctca	gaagaaatgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactcctcca	aaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcattgctg	tgttttagtaa	tagaactctt	7620
gcttgctttg	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaattgtgt	7800
accttttagct	ttttaatttg	taaaggggtt	aataaggaat	atttgatgta	tagtgccttg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920

```

ccccacacct cccctgaacc tgaaacataa aatgaatgca attggtgttg ttaacttggt 7980
tattgcagct tataatgggt acaataaaag caatagcatc acaaatttca caaataaagc 8040
atTTTTTTca ctgcattcta gttgtgggtt gtccaaactc atcaatgtat cttatcatgt 8100
ctggatcccc aggaagctcc tctgtgtcct cataaacctt aacctcctct acttgagagg 8160
acattccaat cataggctgc ccatccaccc tctgtgtcct cctgttaatt aggtcactta 8220
acaaaaagga aattgggtag gggTTTTTca cagaccgctt tctaagggtt attttaaaat 8280
atctgggaag tcccttccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340
caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaacaccc tgctcatcaa 8400
gaagcactgt ggttgctgtg ttagtaatgt gcaaaacagg aggcacattt tccccacctg 8460
tgtaggttcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520
ctggataagc attatcctta tccaaaacag ccttggtgtc agtggttcac tgctgactgt 8580
caactgtagc atTTTTTggg gttacagttt gagcaggata tttggtcctg tagtttgcta 8640
acacaccctg cagctccaaa gggtcccccac caacagcaaa aaaatgaaaa tttgacctt 8700
gaatgggttt tccagcacca ttttcatgag tttttgtgt cctgaatgc aagttaaaca 8760
tagcagttac cccaataacc tcagttttta cagtaacagc tccccacac aaaatatttc 8820
cacaggttaa gtccctcattt aaattaggca aaggaattct tgaagacgaa agggcctcgt 8880
gatacgctta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcagggtg 8940
cacttttcgg ggaaatgtgc gcggaacccc tatttgttta ttttctaaa tacattcaaa 9000
tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa 9060
gagtatgagt attcaacatt tccgtgtgcg ccttattccc ttttttgcgg cattttgcct 9120
tcctgttttt gctcaccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg 9180
tgcacgagtg ggttacatcg aactggatct caacagcggg aagatccttg agagttttcg 9240
ccccgaagaa cgttttccaa tgaagagcac ttttaaagtt ctgctatgtg gcgcggtatt 9300
atcccggttt gacgcggggc aagagcaact cggtcgcgcg atacactatt ctcagaatga 9360
cttggttgag tactcaccag tcacagaaaa gcactttacg gatggcatga cagtaagaga 9420
attatgcagt gctgccataa ccatgagtga taacactgcg gccaaacttac ttctgacaac 9480
gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg 9540
ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac 9600
gatgcctgca gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660
agcttccccg agcttccggt cttccggtcg gctggtttat tgctgataaa tctggagccg 9720
gcgctcgccc atcattgcag cactggggcc agatggtaag ccctcccgtt 9780
gtctcgcggt ctacacgacg gggagtccag caactatgga tgaacgaaat agacagatcg 9840
tgctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tactttagat 9900
tgatttaaaa cttcattttt aatttataaa gatctagggt aagatccttt ttgataatct 9960
catgacccaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 10080
gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa 10140
aaaaccaccg ctaccagcgg tggtttggtt gccgatcaa gagctaccaa ctctttttcc 10200
gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag ttagaccgta 10260
gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaactct 10320
gttaccagtg gctgctgcca gtggcgataa gtctgtctct accgggttgg actcaagacg 10380
atagtaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca cacagcccag 10440
cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 10500
cacgcttccc gaaggagaga aggcggacag gtatccggta agcggcaggg tcggaacagg 10560
agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt 10620
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 10680
gaaaaacgcc agcaacgcgg ccttttttac gtttctggcc ttttgctggc cttttgctca 10740
catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg 10800
agctgatacc gctcgcgcga gccgaacgac cgagcgcagc gagtcagtga gcgaggaagc 10860
ggaagagcgc ctgatgcggg attttctcct taacgatctg tgccgtatct cacaccgcat 10920
atggtgcact ctcagtacaa tctgctctga tgccgcatag ttaagccagt atacactccg 10980
ctatcgctac gtgactgggt catggctgcg ccccgacacc cgccaacacc cgtgacgcg 11040
ccctgacggg cttgtctgct cccggcatcc gcttacagac aagctgtgac cgtctccggg 11100
agctgcatgt gtcagaggtt ttcaccgtca tcaccgaaac gcgcgaggca gc 11152

```

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 13

gacgcatcgg gagatctcc

19

<210> 14

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 14

ccgcctcaga agccatagag cc

22

<210> 15

<211> 14455

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 15

aagcttgggc agaaatggtt gaactcccga gagtgtccta cacctagggg agaagcagcc 60
aaggggttgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcattctctg ctgcaaaactt ggcatagctc tgctttgcct ggggctattg 180
ggggaagtgt cggttcgtgc tcgcagggtc ctcacccttg actcttttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttataa gccgcatcga ttttgcctt cagaaataga aataagaatg 360
cttgctaaaa attatatatt taccaataag accaatccaa taggtagatt attagtact 420
atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacagggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600
agggtggtggc aaccaggggac ttatagggga ccttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaaat tgggataggt gggttacagt caatggctat 720
aaagtgttat atagatccct cccttttcgt gaaagactcg ccagagctag acctccttgg 780
tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatttat 840
ctaggaacag gaatgcactt ttggggaaag attttccata ccaaggagggt gacagtggct 900
ggactaatag aacattattc tgcaaaaact catggcatga gttattatga atagccttta 960
ttggcccaac cttgcggttc ccagggtcta agtaagtttt tggttacaaa ctgttcttaa 1020
aacgaggatg tgagacaagt gggttcctga cttgggttgg tatcaaagggt tctgatctga 1080
gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaagtc 1140
ttatgtaaac caagatataa aagagtgtctg attttttgag taaacttgca acagtcctaa 1200
cattcacctc ttgtgtgttt gtgtctgttc gccatcccggt ctcgctcgt cacttatcct 1260
tcactttcca gaggttcccc ccgcagaccc cggcgacct caggctcgcc gactgcggca 1320
gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380
tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440
ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
accgaagaaa tggcgcggag tcttttggac cagctgatcg aagaggtaact ggctgataat 1560
cttccacctc ctageccattt tgaaccacct acccttcacg aactgtatga tttagacgtg 1620
acggcccccg aagatcccaa cgaggaggcg gtttcgcaga tttttccga ctctgtaatg 1680
ttggcggtgc aggaaggat tgacttactc acttttccgc cggcgcccggt ttctccggag 1740
ccgctcacc tttccgggca gcccgagcag ccggagcaga gaggcttggg tccggtttct 1800
atgccaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860
agtgcgacg aggatgaaga gggtagaggag tttgtgttag attatgtgga gcaccccggtg 1920
cacggttgca ggtcttgtca ttatcaccgg aggaatacgg gggaccaga tattatgtgt 1980
tcgctttgtc atatgaggac ctgtggcatg tttgtctaca gtaagtgaat attatgggca 2040
gtgggtgata gagtgggtggg tttgggtgtg taattttttt ttttaatttt acagttttgt 2100

ggtttaaaaga attttgtatt gtgatttttt taaaagggtcc tgtgtctgaa cctgagcctg 2160
agccccgagcc agaaccggag cctgcaagac ctaccgcgcg tcctaaaatg gcgcctgcta 2220
tcctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgtg 2280
actccgggtcc ttctaacaca cctcctgaga tacaccgggt ggtcccgctg tgccccatta 2340
aaccagttgc cgtgagagtt ttggggcgct gccaggctgt ggaatgtatc gaggacttgc 2400
ttaacgagcc tgggcaacct ttggacttga gctgtaaaacg cccagggcca taagggtgaa 2460
acctgtgatt gcgtgtgtgg ttaacgcctt tgtttgctga atgagttgat gtaagtttaa 2520
taaaggggtga gataatgttt aacttgcatg gcgtgttaaa tggggcgggg cttaaagggg 2580
atataatgcg ccgtgggcta atcttggtta catctgacct catggaggct tgggagtgtt 2640
tggaagattt ttctgctgtg cgtaacttgc tggaacagag ctctaacagt acctcttggt 2700
tttgagggtt tctgtggggc tcatcccagg caaagttagt ctgcagaatt aaggaggatt 2760
acaagtggga atttgaagag cttttgaaat cctgtggtga gctgtttgat tctttgaatc 2820
tgggtcacca ggcgcttttc caagagaagg tcatcaagac tttggatttt tccacaccgg 2880
ggcgcgctgc ggctgctgtt gcttttttga gttttataaa ggataaatgg agcgaagaaa 2940
cccatctgag cgggggggtac ctgctggatt ttctggccat gcatctgtgg agagcgggtt 3000
tgagacacaa gaatcgccct ctactgttgt cttccgtccg cccggcgata ataccgacgg 3060
aggagcagca gcagcagcag gaggaagcca ggcgcgcgcg gcaggagcag agcccatgga 3120
acccgagagc cggcctggac cctcgggaat gaattgttga cagggtggctg aactgtatcc 3180
agaactgaga cgcattttga caattacaga ggatgggcag gggctaaagg gggtaaagag 3240
ggagcggggg gcttgttgagg ctacagagga ggctaggaat ctagctttta gcttaatgac 3300
cagacaccgt cctgagtgta ttacttttca acagatcaag gataattgcg ctaatgagct 3360
tgatctgctg gcgcagaagt attccataga gcagctgacc acttactggc gcagccagg 3420
ggatgatttt gaggaggcta ttagggtata tgcaaagggt gcacttaggc cagattgcaa 3480
gtacaagatc agcaaacctt taaatatcag gaattgttgc tacatttctg ggaacggggc 3540
cgaggtggag atagatacgg aggatagggt ggcctttaga tgtagcatga taaatatgtg 3600
gccgggggtg cttggcatgg acgggggtgtt tattatgaat gtaaggttta ctggcccaa 3660
ttttagcggg acggttttcc tggccaatac caaccttate ctacacgggt taagcttcta 3720
tgggtttaac aatacctgtg tggaagcctg gaccgatgta agggttcggg gctgtgcctt 3780
ttactgctgc tggaaggggg tgggtgtctg ccccaaaagc agggcttcaa ttaagaaatg 3840
cctctttgaa aggtgtacct tgggtatcct gtctgagggt aactccaggg tgccgcacaa 3900
tgtggcctcc gactgtggtt gcttcagtgc agtgaaaagc gtggctgtga ttaagcataa 3960
catggtatgt ggcaactgcg aggacagggc ctctcagatg ctgacctgct cggacggcaa 4020
ctgtcacctg ctgaagacca ttcacgtagc cagccactct cgcaaggcct ggccagtgtt 4080
tgagcataac atactgacct gctgttcctt gcatttgggt aacaggaggg ggtgttcc 4140
accttaccaa tgcaatttga gtcacactaa gatattgctt gagcccgaga gcatgtccaa 4200
ggtgaacctg aacgggggtg ttgacatgac catgaagatc tggaagggtg tgaggtacga 4260
tgagacccgc accaggtgca gacctgcga gtgtggcggt aaacatatta ggaaccagcc 4320
tgtgatgctg gatgtgaccg aggagctgag gcccgatcac ttggtgctgg cctgcaccgg 4380
cgctgagttt ggctctagcg atgaagatac agattgaggt actgaaatgt gtggcggtg 4440
cttaaggggt ggaaagaata tataagggtg ggttcttatg tagttttgta tctgttttgc 4500
agcagccgcc gccgccatga gcaccaactc gtttgatgga agcattgtga gctcatattt 4560
gacaacgcgc atgcccccat gggccggggg gcgtcagaat gtgatgggct ccagcattga 4620
tggtcgcccc gtccgtgccc caaactctac taccttgacc tacagagccg tgtctggaac 4680
gccgttggag actgcagcct ccgcgcgcgt ttcaggcgct gcagccaccg cccgcgggat 4740
tgtgactgac tttgctttcc tgagcccgct tgcaagcagt gcagcttccc gttcatccgc 4800
ccgcgatgac aagttgacgg ctcttttggc acaattggat tctttgacct gggaaactta 4860
tgtcgtttct cagcagctgt tggatctgcg ccagcagggt tctgccctga aggcttcc 4920
ccctcccaat gcggtttaaa acataaataa aaaaccagac tctgtttgga tttggatcaa 4980
gcaagtgtct tgetgtctct cgagggatct ttgtgaagga accttacttc tgtggtgtga 5040
cataattgga caaactacct acagagattt aaagctctaa ggtaaatata aaatttttaa 5100
gtgtataatg tgttaacta ctgattctaa ttgtttgtgt cctttaatga attttagatt 5160
gaactgatga atgggagcag tgggtggaatg cctttaatga ggaaaacctg ttttgctcag 5220
aagaaatgcc atctagtgat gatgaggcta ctgctgactc tcaacattct actcctcaa 5280
aaaagaagag aaaggtagaa gaccccaagg actttccttc agaattgcta agtttttga 5340
gtcatgctgt gtttagtaat agaactcttg cttgctttgc tatttacacc acaaaggaaa 5400
aagctgcact gctatacaag aaaattatgg aaaaatatcc tgtaaccttt ataagtaggc 5460
ataacagtta taactataac atactgtttt ttcttactcc acacaggcat agagtgtctg 5520
ctattaataa ctatgctcaa aaattgtgta cctttagctt ttttaattgt aaaggggtta 5580
ataaggaata tttgatgtat agtgccttga ctagagatca taatcagcca taccacattt 5640
gtagagggtt tacttgcttt aaaaaacctc ccacacctcc ccctgaacct gaaacataaa 5700
atgaatgcaa ttgttggtgt taacttgttt attgcagctt ataatgggtta caaataaagc 5760
aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg 5820

tccaaactca	tcaatgtatc	ttatcatgtc	tggatccggc	tgtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	5940
tagtcagcaa	ccaggtgtgg	aaagtcccc	ggctccccag	caggcagaag	tatgcaaagc	6000
atgcatctca	attagtccagc	aacctagtc	ccgcccctaa	ctccgcccct	cccgccccta	6060
actccgcccc	gttccgcccc	ttctccgccc	catggctgac	taattttttt	tattttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttgga	6180
ggcctaggct	tttgcaaaaa	gcttggacac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgctcag	ggagaggcag	tgcgtaaaaa	gacgcggaact	catgtgaaat	6300
actggttttt	agtgcgccag	atctctataa	tctcgcgcaa	cctattttcc	cctcgaacac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaaaaat	acatcgtcac	6420
ctggggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccg	taagccgtgg	cggctctggta	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgtcatg	tcgataccgt	ttgtattttc	agctacgatc	acgacaacca	6600
gcgcgagctt	aaagtgtctga	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggt	gataccgggtg	gtactgcggg	tgcgatcctg	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tcgtccgctg	gttgatgact	atgttggtga	6780
tatcccgcaa	gatacctgga	ttgaacagcc	gtgggatatg	ggcgctcgat	tcgtcccgcc	6840
aatctccggt	cgctaattctt	ttcaacgcct	ggcactgcgc	ggcggtgttc	tttttaactt	6900
caggcggtgt	acaatagtgtt	ccagtaagta	ttctggaggc	tgcatccatg	acacaggcaa	6960
acctgagcga	aacctgttcc	aaaccccgct	ttaaaccatcc	tgaaacctcg	acgctagtcc	7020
gccgctttta	tcacggcgca	caaccgcctg	tgcagtcggc	ccttgatggt	aaaaccatcc	7080
ctcactggta	tcgcattgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gacccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	gggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtgaagg	aaccttactt	ctgtggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaatat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtggtggaat	7440
gccttttaatg	aggaaaacct	gttttgcctc	gaagaaatgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactctccca	aaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcattgctg	tgtttagtaa	tagaactctt	7620
gcttgctttg	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaattgtgt	7800
accttttagct	ttttaatttg	taaaggggtt	aataaggaat	atttgatgta	tagtgccttg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920
cccacacctc	ccoctgaacc	tgaaacataa	attgaatgca	attgttggtg	ttacttggtt	7980
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	8040
attttttttca	ctgcattcta	gttgtgggtt	gtccaaactc	atcaatgtat	cttatcatgt	8100
ctggatcccc	aggaagctcc	tctgtgtcct	cataaacctc	aacctcctct	acttgagagg	8160
acattccaat	cataggctgc	ccatccaccc	tctgtgtcct	cctgttaatt	aggtcactta	8220
acaaaaagga	aattgggtag	gggttttttc	cagaccgctt	tctaagggtg	atttttaaat	8280
atctgggaag	tcccttccac	tgctgtgttc	cagaagtgtt	ggtaaacagc	ccacaaatgt	8340
caacagcaga	aacatacaag	ctgtcagctt	tgcacaaggg	cccaacaccc	tgctcatcaa	8400
gaagcactgt	ggttgctgtg	ttagtaatgt	gcaaaacagg	aggcacattt	tccccacctg	8460
tgtaggttcc	aaaatatcta	gtgttttcat	ttttacttgg	atcaggaacc	cagcaactcca	8520
ctggataagc	attatcctta	tccaaaacag	ccttgtgggt	agtgttcac	tgctgactgt	8580
caactgtagc	attttttggg	gttacagttt	gagcaggata	tttggtcctg	tagtttgcta	8640
acacaccctg	cagctccaaa	ggttccccac	caacagcaaa	aaaatgaaaa	tttgaccctt	8700
gaatgggttt	tccagcacca	ttttcatgag	ttttttgtgt	ccctgaatgc	aagtttaaca	8760
tagcagttac	cccaataaacc	tcagttttaa	cagtaacagc	ttcccatatc	aaaatatatt	8820
cacaggttaa	gtcctcattt	aaattaggca	aagggaattct	tgaagacgaa	agggcctcgt	8880
gatacgcccta	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	cgtcagggtg	8940
cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	tacattcaaa	9000
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	9060
gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	cattttgcct	9120
tcctgttttt	gctcaccag	aaacgctgg	gaaagtataa	gatgctgaag	atcagttggg	9180
tgacagagt	ggttacatcg	aactggatct	caacagcggt	aagatccttg	agagttttcg	9240
ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	gcgcgggtatt	9300
atcccgtgtt	gacgccgggc	aagagcaact	cggtcgccc	atacactatt	ctcagaatga	9360
cttggttag	tactcaccag	tcacagaaaa	gcatcttacg	gatggcatga	cagtaagaga	9420
attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaacttac	ttctgacaac	9480
gatcgaggga	ccgaaggagc	taaccgcttt	tttgcaaac	atgggggatc	atgtaactcg	9540

ccttgatcgt	tgggaaccgg	agctgaatga	agccataacca	aacgacgagc	gtgacaccac	9600
gatgcctgca	gcaatggcaa	caacgttgcg	caaactatta	actggcgaa	tacttactct	9660
agcttcccgg	caacaattaa	tagactggat	ggagggcgat	aaagttgcag	gaccacttct	9720
gcgctcgccc	cttccggctg	gctgggttat	tgctgataaa	tctggagccg	gtgagcgtgg	9780
gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	tcgtagtatt	9840
ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	9900
tgcctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	9960
tgattttaaaa	cttcattttt	aattttaaaag	gatctaggtg	aagatccctt	ttgataatct	10020
catgaccaaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	10080
gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	10140
aaaaccaccg	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	ctctttttcc	10200
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	10260
gttagggcac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	tgctaatacct	10320
gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtcct	accgggttgg	actcaagacg	10380
atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	10440
cttggagcga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	10500
cacgcttccc	gaaggagaaa	aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	10560
agagcgcacg	agggagcttc	cagggggaaa	cgccctggtat	ctttatagtc	ctgtcggggt	10620
tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	10680
gaaaaacgcc	agcaacgcgg	ccttttttacg	gttccctggcc	ttttgctggc	cttttgctca	10740
catgttcttt	cctgcgttat	cccctgattc	tgtggataac	cgtattaccg	cctttgagtg	10800
agctgatacc	gctcgccgca	gccgaacgac	cgagcgcagc	gagtcagtga	gcgaggaagc	10860
ggaagagcgc	ctgatgcggg	attttctctc	tacgcattctg	tgccgtattt	cacaccgcat	10920
accgcctcag	aagccataga	gccaccgcga	tccccagcat	gcctgctatt	gtcttcccaa	10980
tcctccccct	tgtgtctctg	ccccacccca	ccccccagaa	tagaatgaca	cctactcaga	11040
caatgcgatg	caatttctct	attttatttag	gaaaggacag	tgggagtggc	accttccagg	11100
gtcaagggaag	gcacggggga	ggggcaaaca	acagatggct	ggcaactaga	aggcacagtc	11160
gaggetgate	agcgagctct	agcattttag	tgacactata	gaatagggcc	ctctagatgc	11220
atgctcgagc	ggccgcttct	ttattcttgg	gcaatgtatg	aaaaagtgtg	agaggatgtg	11280
gcaaatattt	cattaatgta	gttgtggcca	gaccagctcc	atgaaaatga	catagagtat	11340
gcacttggag	ttgtgtctcc	tgtttctctg	gtaccgttta	gtgtaatggt	tagtgttaca	11400
ggtttagttt	tgtctccggt	taagtaaact	tgactgacaa	tgttactttt	ggcagtttta	11460
ccgtgagatt	ttggataagc	tgatagggtta	ggcataaaatc	caacagcggt	tgtatagggt	11520
gtgccttcag	taagatctcc	atttctaaag	ttccaatatt	ctgggtccag	gaaggaattg	11580
tttagtagca	ctccattttc	gtcaaatctt	ataataagat	gagcactttg	aactgttcca	11640
gcatttggag	ccaaactgoc	tttaacagcc	aaaactgaaa	ctgtagcaag	tatttgactg	11700
ccacattttg	ttaagaccaa	agtgaagtta	gcatctttct	ctgcatttag	tctacagtta	11760
ggagatggag	ctggtgtggt	ccacaaagtt	agcttatcat	tatttttggt	tcctactgta	11820
atggcacctg	tgtgttcaaa	actaaggcca	gttccctagtt	taggaaccat	agccttggtt	11880
gaatcaaatt	ctaggccatg	gccaattttt	gttttgaggg	gatttggtgt	tggtgcatta	11940
ggtgaaccaa	attcaagccc	atctcctgca	ttaatggcta	tggtgtagc	gtcaaacatc	12000
aacccttggg	cagtgcttag	gttaacctca	agctttttgg	aattgtttga	agctgtaaac	12060
aagtaaaggc	ctttgttgta	gttaatatcc	aagttgtggg	ctgagtttat	aaaaagaggg	12120
ccctgtccta	gtcttagatt	tagttggttt	tgagcatcaa	acggataact	aacatcaagt	12180
ataaggcgte	tgttttgaga	atcaatcctt	agtccctctg	ctacattaag	ttgcatattg	12240
ccttgatgaat	caaaacccaa	ggctccagta	acttttagttt	gcaaggaagt	attattaata	12300
gtcacacctg	gaccagttgc	tacgggtcaaa	gtgttttaggt	cgtctgttac	atgcaaagga	12360
gccccgtact	ttagtcctag	ttttccattt	tgtgtataaa	tggtgtcttt	caagtcaatg	12420
cccaagctac	cagtgggcag	agtttagagg	ggtgaggcag	tgatagtaag	ggtactgcta	12480
tcggtgggtg	tgagggggcc	tgatgtttgc	agggtcagct	ttccttctga	cactgtgagg	12540
ggctccttgg	tggcaatgct	aagtttggag	tcgtgcacgg	ttagcggggc	ctgtgattgc	12600
atggtgagtg	tgttgcccg	gaccattaga	ggtgcggcgg	cagccacagt	tagggcttct	12660
gaggtaaactg	tgaggggtgc	agatattttc	aggtttatgt	ttgacttgg	ttttttgaga	12720
ggtgggctca	cagtggttac	attttgggag	gtaaggttgc	cggcctcgtc	cagagagagg	12780
ccgttgccca	ttttgagcgc	aagcatgcca	ttggaggtaa	ctagaggttc	ggataggcgc	12840
aaagagagta	ccccaggggg	actctcttga	aaccatttgg	gggatacaaa	gggaggagta	12900
agaaaaaggca	cagttggagg	accggtttcc	gtgtcatatg	gatacacggg	gttgaaggta	12960
tcttcagacg	gtcttgccgc	cttcatcttg	gatctcaagc	ctgccacacc	tcacctcgac	13020
catccgccgt	ctcaagaccg	cctactttta	ttacatcatc	agcagcacct	ccgccagaaa	13080
caaccccgac	cgccacccgc	tgccgcccgc	cacggtgctc	agcctacctt	gcgactgtga	13140
ctggttagac	gcctttctcg	agaggttttc	cgatccgggc	gatgcggact	cgctcaggtc	13200
cctcggtggc	ggagtaccgt	tcggaggccg	acgggtttcc	gatccaagag	tactggaaag	13260

accgcgaaga	gtttgtcctc	aaccgcgagc	ccaacagcga	gctcgaattc	agatccgagc	13320
tcggtacca	gcttgggtct	ccctatagtg	agtcgtatta	atttcgataa	gccagtaagc	13380
agtgggttct	ctagttagcc	agagagctct	gcttatatag	acctcccacc	gtacacgcct	13440
accgccatt	tgcgtaaatg	gggcggagtt	gttacgacat	tttggaagt	cccggtgatt	13500
ttggtgcaa	aacaaactcc	cattgacgtc	aatggggtg	agacttgga	atccccgtga	13560
gtcaaaccgc	tatccacgcc	cattgatgta	ctgccaaaac	cgcataacca	tggtaatagc	13620
gatgactaat	acgtagatgt	actgccaaagt	aggaaagtcc	cataaggtca	tgtactgggc	13680
ataatgccag	gcggggccatt	taccgtcatt	gacgtcaata	ggggggtac	ttggcatatg	13740
atacacttga	tgtactgcca	agtgggcagt	ttaccgtaaa	tagtccaccc	attgacgtca	13800
atggaaagt	cctattggcg	ttactatggg	aacatacgtc	attattgacg	tcaatgggag	13860
ggggtcggtg	ggcggtcagc	caggcgggcc	atttaccgta	agttatgtaa	cgcggaactc	13920
catatatggg	ctatgaacta	atgaccccg	aattgattac	tattaataac	tagtcaataa	13980
tcaatgtcaa	cgcgtatata	tggcccggtac	atcgcggaagc	agcgcaaaac	gcctaaccct	14040
aagcagattc	ttcatgcaat	tgtcggtcaa	gccttgccct	gtttagctt	aaattttgct	14100
cgcgcactac	tcagcgaccc	ccaacacaca	agcaggagc	agatactggc	ttactatgc	14160
ggcatcagag	cagattgtac	tgagagtcca	ccatagggga	tcgggagatc	tcccgatccg	14220
tctatgggtg	actctcagta	caatctgtct	tgtatccgca	tagttaagcc	agtatacact	14280
ccgctatcgc	tacgtgactg	ggcatggct	gcgccccgac	acccgcaaac	acccgctgac	14340
gcgcccgtgac	gggcttgtct	gctcccggca	tccgcttaca	gacaagctgt	gaccgtctcc	14400
gggagctgca	tgtgtcagag	gttttcaccg	tcatcaccga	aacgcgcgag	gcagc	14455

<210> 16

<211> 10610

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 16

gacggatcgg	gagatccgag	cggtacacag	aattcaggag	acacaactcc	aagtgcatac	60
tctatgtcat	tttcatggga	ctggtctggc	cacaactaca	ttaatgaaat	atttgccaca	120
tcctcttaca	ctttttcata	cattgcccaa	gaataaagaa	tcgttttgtg	tatgtttcaa	180
cgtgtttatt	tttcaattgc	agaaaatttc	aagtcatttt	tcattcagta	gtatagcccc	240
accaccacat	agcttatata	gatcacccga	ccttaatcaa	actcacagaa	ccctagtatt	300
caacctgcca	cctccctccc	aacacacaga	gtacacagtc	ctttctcccc	ggctggcctt	360
aaaaagcatc	atatcatggg	taacagacat	attcttaggt	gttatattcc	acacgggttc	420
ctgtcgagcc	aaacgctcat	cagtgatatt	aataaactcc	ccgggcagct	cacttaagtt	480
catgtcgctg	tccagctgct	gagccacagg	ctgctgtcca	acttgcgggt	gcttaacggg	540
cggcgaagga	gaagtccacg	cctacatggg	ggtagagtca	taatcgtgca	tcaggatagg	600
gcggtggtgc	tgcagcagcg	cgcgaataaa	ctgctgcgcg	cgccgctccg	tcctgcagga	660
atacaacatg	gcagtggtct	cctcagcgat	ctgtcgacc	gcccgcagca	taaggcgccct	720
tgtcctccgg	gcacagcagc	gcaccctgat	ctcacttaaa	tcagcacagt	aactgcagca	780
cagcaccaca	atattgttca	aaatcccaca	gtgcaaggcg	ctgtatccaa	agctcatggc	840
ggggaccaca	gaacccacgt	ggccatcata	ccacaagcgc	aggtagatta	agtggcgacc	900
cctcataaac	acgctggaca	taaacattac	ctcttttggc	atgttgtaat	tcaccacctc	960
ccggtaccat	ataaacctct	gattaaacat	ggcgccatcc	accaccatcc	taaaccagct	1020
ggccaaaacc	tgcccgcggg	ctatacactg	cagggaaccg	ggactggaac	aatgacagtg	1080
gagagcccag	gactcgtaac	catggatcat	catgctcgct	atgatatcaa	tgttggcaca	1140
acacaggcac	acgtgcatac	acttcctcag	gattacaagc	tcctcccggg	ttagaacccat	1200
atcccaggga	acaacccatt	cctgaatcag	cgtaaatccc	acactgcagg	gaagacctcg	1260
cacgtaactc	acgttgtgca	ttgtcaaagt	gttacattcg	ggcagcagcg	gatgatccct	1320
cagtatggta	gcgcgggttt	ctgtctcaaa	aggaggtaga	cgatccctac	tgtacggagt	1380
gcgcgcagac	aaccgagatc	gtgttggtcg	tagtgtcatg	ccaaatggaa	cgccggacgt	1440
agtcataatt	cctgaagcaa	aaccaggtgc	ggcggtgaca	aacagatctg	cgtctccggg	1500
ctcgccgctt	agatcgctct	gtgtagtgtc	tgtagtatat	ccactctctc	aaagcatcca	1560
ggcgccccct	ggcttcgggt	tctatgtaaa	ctccttcatg	cgccgctgcc	ctgataacat	1620
ccaccaccgc	agaataagcc	acaccagcc	aacctacaca	ttcgttctgc	gagtcacaca	1680
cgggaggagc	gggaagagct	ggaagaacca	tgtttttttt	tttattccaa	aagattatcc	1740
aaaacctcaa	aatgaagatc	tattaagtga	acgcgctccc	ctccggtggc	gtgggtcaaac	1800
tctacagcca	aagaacagat	aatggcattt	gtaagatgtt	gcacaatggc	ttccaaaagg	1860

caaacggccc	tcacgtccaa	gtggacgtaa	aggctaaacc	cttcagggtg	aatctcctct	1920
ataaacattc	cagcaccttc	aaccatgccc	aaataattct	catctcgcca	ccttctcaat	1980
atatctctaa	gcaaatcccc	aatattaagt	cgggccattg	taaaaatctg	ctccagagcg	2040
ccctccacct	tcagcctcaa	gcagcgaatc	atgattgcaa	aaattcaggt	tcctcacaga	2100
cctgtataag	attcaaaagc	ggaacattaa	caaaaatacc	gcgatcccgt	aggcccttc	2160
gcagggccag	ctgaacataa	tcgtgcaggt	ctgcacggac	cagcgcgggc	acttccccgc	2220
caggaacctt	gacaaaagaa	cccacactga	ttatgacacg	catactcgga	gctatgctaa	2280
ccagcgtagc	cccgatgtaa	gctttgttgc	atgggcgggc	atataaaatg	caaggtgctg	2340
ctcaaaaaat	caggcaaagc	ctcgcgcaaa	aaagaaagca	catcgtagtc	atgctcatgc	2400
agataaaggc	aggttaagctc	cggaaaccac	acagaaaaag	acaccatttt	tctctcaaac	2460
atgtctgcgg	gtttctgcat	aaacacaaaa	taaaataaca	aaaaaacatt	taaacattag	2520
aagcctgtct	tacaacagga	aaaacaaccc	ttataagcat	aagacggact	acggccatgc	2580
cggcgtgacc	gtaaaaaaac	tggtcaccgt	gattaaaaag	caccaccgac	agctcctcgg	2640
tcattgtcgg	agtcataatg	taagactcgg	taaacacatc	aggttgattc	atcggtcagt	2700
gctaaaaaag	gaccgaaata	gccccggggg	atacataccc	gcaggcgtag	agacaacatt	2760
acagccccc	taggaggtat	aacaaaatta	ataggagaga	aaaacacata	aacacctgaa	2820
aaacctcct	gcctaggcaa	aatagcacc	tccgcctcca	gaacaacata	cagcgcttca	2880
cagcggcagc	ctaacagtca	gccttaccag	taaaaagaa	aacctattaa	aaaaacacca	2940
ctcgacacgg	caccagctca	atcagtcaca	gtgtaaaaaa	gggccaagtg	cagagcgagt	3000
atatatagga	ctaaaaaatg	acgtaacggg	taaagtccac	aaaaaacacc	cagaaaaccg	3060
cacgcgaacc	tacgcccaga	aacgaaagcc	aaaaaaccca	caacttcctc	aatcgtcac	3120
ttcgcgtttc	ccacgttacg	taacttcccg	gacccctctc	cgatccccta	gggtcgactc	3180
tcagtacaat	ctgctctgat	gccgcatagt	taagccagta	tctgctccct	gcttggtgtg	3240
tggaggtcgc	tgagtatgct	gcgagctaac	tttaagctac	aacaaggcaa	ggcttgaccg	3300
acaattgcat	gaagaatctg	cttaggggta	ggcggtttgc	gctgcttcgc	gatgtacggg	3360
ccagatatac	gcgttgacat	tgattattga	ctagttatta	atagtaatca	attacggggg	3420
cattagtcca	tagcccatat	atggagttcc	gcgttacata	acttacggta	aatggccccg	3480
ctggctgacc	gcccacacg	ccccgccc	tgacgtcaat	aatgacgtat	gttcccatag	3540
taacgccaat	agggactttc	cattgacgtc	aatgggtgga	ctattttacg	taaaactgccc	3600
acttggcagt	acatcaagtg	tatcatatgc	caagtacgac	ccctattgac	gtcaatgacg	3660
gtaaatggcc	cgcttgcat	tatgccaggt	acatgacctt	atgggacttt	cctacttggc	3720
agtacatcta	cgtattagtc	atcgctatta	ccatgggtgat	gcgggttttg	cagtacatca	3780
atgggcgtgg	atagcggttt	gactcacggg	gatttccaag	tctccacccc	attgacgtca	3840
atgggagttt	gttttgccac	caaaatcaac	gggactttcc	aaaatgtcgt	aacaactccg	3900
ccccattgac	gcaaatgggc	ggtaggcgtg	tacggtgggg	ggcttatata	agcagagctc	3960
tctgggtaac	tagagaaccc	actgcttact	ggcttatatc	aattaatacg	actcactata	4020
gggagaccca	agcttggtac	cgagctcgga	tctgaattcg	agctcgctgt	tgggctcgcg	4080
gttgaggaca	aactcttcgc	ggtctttcca	gtactcttgg	atcggaacc	cgtcggcctc	4140
cgaacggtac	tccgccaccg	agggacctga	gcgagtcgcg	atcgaccgga	tcggaaaacc	4200
tctcgagaaa	ggcgtctaac	cagtcacagt	cgcaaggtag	gctgagcacc	gtggcgggcg	4260
gcagcgggtg	gcggtcgggg	ttgtttctgg	cggaggtgct	gctgatgatg	taattaaagt	4320
aggcggctct	gagacggcgg	atggtcgagg	tgaggtgtgg	caggcttgag	atccaagatg	4380
aagcgcgcaa	gaccgtctga	agataccttc	aaacccgtgt	atccatatga	cacggaacc	4440
ggctcctcaa	ctgtgccttt	tcttactcct	ccctttgtat	cccccaatgg	gtttcaagag	4500
agtccectct	gggtactctc	tttgcgctta	tccgaacctc	tagttacctc	caatggcatg	4560
cttgcgctca	aaatgggcaa	cggcctctct	ctggacgagg	cgggcaacct	tacctcccaa	4620
aatgtaacca	ctgtgagccc	acctctcaaa	aaaaccaagt	caaacataaa	cctggaaata	4680
tctgcacccc	tcacagttac	ctcagaagcc	ctaactgtgg	ctgcgcgcgc	acctctaata	4740
gtcgcgggca	acacactcac	catgcaatca	caggccccgc	taaccgtgca	cgactccaaa	4800
cttagcattg	ccaccacaag	acccctcaca	gtgtcagaag	gaaagctagc	cctgcaaaaca	4860
tcaggcccc	tcaccaccac	cgtatgcagt	acccttacta	tcaactgctc	acccctctta	4920
actactgcc	ctggtagctt	gggcattgac	ttgaaagagc	ccattttatac	acaaaatgga	4980
aaactaggac	taaagtacgg	ggctcctttg	catgtaacag	acgacctaaa	cactttgacc	5040
gtagcaactg	gtccaggtgt	gactattaat	aatacttctt	tgcaaaactaa	agttactgga	5100
gccttgggtt	ttgattcaca	aggcaatatg	caacttaagt	tagcaggagg	actaaggatt	5160
gattctcaaa	acagacgcct	tatacttgat	gttagttatc	cgtttgatgc	tcaaaacca	5220
ctaaatctaa	gactaggaca	gggcctctct	tttataaaact	cagcccacaa	cttggtatatt	5280
aactacaaca	aaggccttta	cttggtttaca	gcttcaaaaca	attccaaaaa	gcttgagggtt	5340
aacctaagca	ctgccaaggg	gttgatgttt	gacgctacag	ccatagccat	taatgcagga	5400
gatgggcttg	aatttggttc	acctaattgca	ccaaacacaa	atccccctcaa	aacaaaaatt	5460
ggccatggcc	tagaatttga	ttcaaacaag	gctatggttc	ctaaactagg	aactggcctt	5520
agttttgaca	gcacaggtgc	cattacagta	ggaacaaaaa	ataatgataa	gctaactttg	5580

tggaccacac	cagctccatc	tcctaactgt	agactaaatg	cagagaaaga	tgctaaactc	5640
acttttggct	taacaaaatg	tggcagtcaa	atacttgcta	cagtttcagt	tttggctgtt	5700
aaaggcagtt	tggctccaat	atctggaaca	gttcaaagtg	ctcatcttat	tataagattt	5760
gacgaaaatg	gagtgtact	aaacaattcc	ttcctggacc	cagaatattg	gaacttttag	5820
aatggagatc	ttactgaagg	cacagcctat	acaaacgctg	ttggatttat	gcctaacctt	5880
tcagctttatc	caaaatctca	cggtaaaact	gccaaaagta	acattgtcag	tcaagtttac	5940
ttaaacggag	acaaaactaa	acctgtaaca	ctaaccatta	cactaaacgg	tacacaggaa	6000
acaggagaca	caactccaag	tgcatactct	atgtcatttt	catgggactg	gtctggccac	6060
aactacatta	atgaaatatt	tgccacatcc	tcttacactt	tttcatacat	tgcccaagaa	6120
taaagaagcg	gccgctcgag	catgcatcta	gagggcccta	ttctatagt	tcacctaagt	6180
gctagagctc	gctgatcagc	ctcgactgtg	ctctctagt	gccagccatc	tgttggttgc	6240
ccctccccc	tgcttccctt	gacctgggaa	gggtgccactc	ccactgtcct	ttcctaataa	6300
aatgagggaaa	ttgcatcgca	ttgtctgagt	agggtgcatt	ctattctggg	gggtgggggtg	6360
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcggtg	6420
ggctctatgg	cttctgaggc	ggaaagaacc	agctggggct	ctagggggta	tccccacgcg	6480
ccctgtagcg	gcgcattaag	cgcgggcggt	gtgggtggtta	cgcgagcggt	gaccgctaca	6540
cttgccagcg	ccctagcgcc	cgctcctttc	gcttcttctc	cttcccttct	cgccacgttc	6600
gccggctttc	cccgtaagc	tctaaatcgg	ggcatccctt	tagggttccg	atttagtgct	6660
ttacggcacc	tgcaccccaa	aaaacttgat	taggggtgatg	gttcacgtag	tgggccatcg	6720
ccctgataga	cggttttttc	ccctttgacg	ttggagtcca	cgttctttta	tagtggactc	6780
ttgttccaaa	ctggaacaac	actcaaccct	atctcggtct	attcttttga	tttataaggg	6840
atthttgggga	tttcggccta	ttggttaaaa	aatgagctga	tttaacaaaa	atttaacgcg	6900
aattaattct	gtggaatgtg	tgctcagttag	gggtgtggaa	gtccccaggc	tccccaggca	6960
ggcagaagta	tgcaaagcat	gcattctcaat	tagtcagcaa	ccagggtgtg	aaagtcccca	7020
ggctccccc	caggcagaag	tatgcaaagc	atgcatctca	attagtcagc	aaccatagtc	7080
ccgccccctaa	ctccgcccct	cccgccccct	actccgcccc	gttccgcccc	ttctccgccc	7140
catggctgac	taattttttt	tatttatgca	gaggccgagg	ccgcctctgc	ctctgagcta	7200
ttccagaagt	agtgaggagg	cttttttggg	ggcctaggct	tttgcaaaaa	gctcccggga	7260
gcttgatat	ccatttttcg	atctgatcaa	gagacaggat	gaggatcggt	tcgcatgatt	7320
gaacaagatg	gattgcacgc	agggtctctc	gccgcttggg	tggagaggct	attcgctat	7380
gactgggac	aacagacaat	cggctgctct	gtgcccgcg	tggtccggct	gtcagcgag	7440
gggcggcccg	ttctttttgt	caagaccgac	ctgtccgggtg	ccctgaatga	actgcaggac	7500
gaggcagcgc	ggctatcgtg	ggtggccacg	acgggcgttc	cttgccgagc	tgtgctcgac	7560
gttgtcactg	aagcgggaag	ggactggctg	ctattgggcg	aagtgcgggg	gcaggatctc	7620
ctgtcatctc	accttgctcc	tgcgagaaaa	gtatccatca	tggtgatgc	aatgcggcgg	7680
ctgcatacgc	ttgatccggc	tacctgcccc	ttcgaccacc	aagcgaaaca	tcgcatcgag	7740
cgagcacgta	ctcggatgga	agccggtctt	atgatctgga	atgatctgga	cgaagagcat	7800
caggggctcg	cgccagccga	actgttcgcc	aggctcaagg	cgccgatgcc	cgacggcgag	7860
gatctcgtcg	tgacccatgg	cgatgcctgc	ttgccgaata	tcatggtgga	aaatggccgc	7920
ttttctggat	tcacgcactg	tggccggctg	gggtgtggcg	accgctatca	ggacatagcg	7980
ttggctaccc	gtgatattgc	tgaagagctt	ggcggcgaa	gggtgaccg	cttccctcgtg	8040
ctttacggta	tgcgcgtctc	cgattcgcag	cgcctcgctt	tctatcgctt	tcttgacgag	8100
ttcttctgag	cgggactctg	gggttcgaaa	tgaccgacca	agcgaagccc	aacctgccat	8160
cacgagattt	cgattccacc	gcgccttctt	atgaaagggt	gggtctcgga	atcgttttcc	8220
gggacgccc	ctggatgac	ctccagcgcg	gggatctcat	gctggagttc	ttcgccacc	8280
ccaacttggt	tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	8340
caaataaagc	atthttttca	ctgcattcta	gttgtgggtt	gtccaaactc	atcaatgtat	8400
cttatcatgt	ctgtataacc	tgcacctcta	gctagagctt	ggcgtaatca	tggtcatagc	8460
tgtttcctgt	gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	8520
taaagtgtaa	agcctggggt	gcctaattgag	ttagctaaact	cacattaatt	gcgttgcgct	8580
cactgcccg	tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	atcgcccaac	8640
gcgcggggg	aggcggtttg	cgtattgggc	gctcttccgc	ttctcgctc	actgactcgc	8700
tgcgctcggt	cgttcggctg	cgccgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	8760
tatccacaga	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaggc	cagcaaaagg	8820
ccaggaaccg	taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	8880
agcatcacia	aaatcgacgc	tcaagtccga	gggtggcgaaa	cccagacagga	ctataaagat	8940
accaggcggt	tccccctgga	agctccctcg	tgcgctctcc	tgttccgacc	ctgccgctta	9000
ccggatacct	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcacgct	9060
gtaggtatct	cagttcggtg	taggtcgctt	gctccaagct	gggctgtgtg	cacgaacccc	9120
ccgttcagcc	cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtc	aaccgggtaa	9180
gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	9240
taggcgggtg	tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	9300

```
tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt 9360
gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 9420
cgcgagaaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 9480
agtggaaacga aaactcacgt taagggattt tggatcatgag attatcaaaa aggatcttca 9540
cctagatcct tttaaattaa aaatgaagtt ttaaataaat cttaaagtata tatgagtaaa 9600
cttgggtctga cagttaccaaa tgcttaataca gtgaggcacc tatctcagcg atctgtctat 9660
ttcggttcac catagttgcc tgactccccg tctgttagat aactacgata cgggagggct 9720
taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt 9780
tatcagcaat aaaccagcca gccggaaggc ccgagcgtag aagtggctct gcaactttat 9840
ccgcctccat ccagtcctatt aattgttgcc ggggaagctag agtaagtagt tcgccagtta 9900
atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 9960
gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tccccatgt 10020
tgtgcaaaaa agcggtttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 10080
cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 10140
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 10200
ggcgaccgag ttgctcttgc ccggcgctcaa tacgggataa taccgcgcca catagcagaa 10260
ctttaaaagt gctcatcatt ggaaaacgtt ctccggggcg aaaactctca aggatcttac 10320
cgctgttgag atccagttcg atgtaaccca ctctgtgcacc caactgatct tcagcatctt 10380
ttactttcac cagcgtttct ggggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 10440
gaataagggc gacacggaag tggtgaatac tcatactctt cttttttcaa tattattgaa 10500
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 10560
aacaaatagg ggttcgcgcg acatttcccc gaaaagtgcc acctgacgtc 10610
```

```
<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Primer
```

```
<400> 17
tgtacaccgg atccggcgca cacc 24
```

```
<210> 18
<211> 35
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Primer
```

```
<400> 18
cacaacgagc tcaattaatt aattgccaca tcctc 35
```

```
<210> 19
<211> 4
<212> PRT
<213> adenovirus
```

```
<400> 19
Thr Leu Trp Thr
1
```

```
<210> 20
<211> 12
<212> PRT
<213> adenovirus
```

<400> 20
Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser
1 5 10

<210> 21
<211> 44
<212> PRT
<213> adenovirus

<400> 21
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20 25 30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro
35 40

<210> 22
<211> 43
<212> PRT
<213> adenovirus

<400> 22
Met Ala Lys Arg Ala Arg Leu Ser Thr Ser Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Glu Asp Glu Ser Ser Ser Gln His Pro Phe Ile Asn Pro Gly Phe
20 25 30
Ile Ser Pro Asp Gly Phe Thr Gln Ser Pro Asn
35 40

<210> 23
<211> 43
<212> PRT
<213> adenovirus

<400> 23
Met Ser Lys Arg Leu Arg Val Glu Asp Asp Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe
20 25 30
Val Ser Ser Asp Gly Phe Lys Asn Phe Pro Pro
35 40

<210> 24
<211> 42
<212> PRT
<213> adenovirus

<400> 24
Met Lys Arg Ala Arg Phe Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
1 5 10 15

Glu His Tyr Asn Pro Leu Asp Ile Pro Phe Ile Thr Pro Pro Phe Ala
20 25 30

Ser Ser Asn Gly Leu Gln Glu Lys Pro Pro
35 40

<210> 25
<211> 42
<212> PRT
<213> adenovirus

<400> 25
Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
1 5 10 15

Asp Thr Ser Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val
20 25 30

Ser Ser Asp Gly Leu Gln Glu Asn Pro Pro
35 40

<210> 26
<211> 327
<212> DNA
<213> adenovirus

<400> 26
agatctgaat tcgagctcgc tgttgggctc gcggttgagg acaaactctt cgcggtcttt 60
ccagtactct tggatcggaa acccgctcgc ctccgaacgg tactccgcca ccgagggacc 120
tgagcgaagtc cgcacgcacc ggatcggaaa acctctcgag aaaggcgtct aaccagtcac 180
agtcgcaagg taggctgagc accgtggcgg gcggcagcgg gtggcggtcg gggttgtttc 240
tggcgagggt gctgctgatg atgtaattaa agtaggcggt cttgagacgg cggatggctg 300
aggtgaggtg tggcaggctt gagatct 327

<210> 27
<211> 32480
<212> DNA
<213> adenovirus

<400> 27
catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgtttag 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaatct gaataatttt gtgttactca tagcgcgtaa tctctagcat cgatgtcgac 360
aagcttgaat tcgattaatg tgagttagct cactcattag gcaccccgag ctttacactt 420
tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga taacaatttc acacaggaaa 480
cagctatgac catgattacg aattcggcgc agcaccatgg cctgaaataa cctctgaaag 540
aggaaacttg ttaggtacct tctgaggcgg aaagaaccag ctgtggaatg tgtgtcagtt 600
agggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca tgcattctca 660
ttagtcagca accaggtgtg gaaagtcccc aggcctccca gcaggcagaa gtatgcaaag 720
catgcatctc aattagtcag caaccatagt cccgcccta actccgcca tccccccct 780
aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt ttatttatgc 840
agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag gcttttttgg 900
aggcctaggc ttttgcaaaa agcttgggat ctctataatc tcgcgcaacc tattttcccc 960
tcgaacactt tttaagccgt agataaacag gctgggacac ttcacatgag cgaaaaatac 1020
atcgtcacct gggacatgtt gcagatccat gcacgtaaac tcgcaagccg actgatgcct 1080
tctgaacaat ggaaaggcat tattgccgta agccgtggcg gtctggtacc ggtgggtgaa 1140

gaccagaaac	agcacctcga	actgagccgc	gatattgccc	agcgtttcaa	cgcgctgtat	1200
ggcgagatcg	atcccgcgtg	tttacaacgt	cgtgactggg	aaaaccctgg	cgttacccaa	1260
cttaatcgcc	ttgcagcaca	ttcccccttc	gccagctggc	gtaatagcga	agaggcccg	1320
accgatcgcc	cttcccaaca	gttgccgcagc	ctgaatggcg	aatggcgctt	tgccctggttt	1380
ccggcaccag	aagcgggtgc	ggaaagctgg	ctggagtgcg	atcttccctga	ggccgatact	1440
gtcgtcgtcc	cctcaaaactg	gcagatgcac	ggttacgatg	cgcccatcta	caccaacgta	1500
acctatccca	ttacggtcaa	tccgcgcgtt	gttcccacgg	agaatccgac	gggttggttac	1560
tcgctcacat	ttaatgttga	tgaagctggg	ctacaggaag	gccagacgcg	aattatTTTT	1620
gatggcggtta	actcggcggt	tcatctgtgg	tgcaacgggc	gctgggtcgg	ttacggccag	1680
gacagtcggt	tgccgtctga	atttgacctg	agcgcatTTT	tacgcgccgg	agaaaaccgc	1740
ctcgcggtga	tggtgctgcg	ttggagtgac	ggcagttatc	tggaagatca	ggatatgtgg	1800
cggatgagcg	gcattttccg	tgacgtctcg	ttgctgcata	aaccgactac	acaaatcagc	1860
gatttccatg	ttgccactcg	ctttaatgat	gatttcagcc	gcgctgtact	ggaggctgaa	1920
gttcagatgt	gcggcgagtt	gcgtgactac	ctacgggtaa	cagtttcttt	atggcaggggt	1980
gaaacgcagg	tcgccagcgg	caccgcgcct	ttcggcggtg	aaattatcga	tgagcgtgggt	2040
ggttatgccg	atcgcgtcac	actacgtctg	aacgtcgaaa	acccgaaact	gtggagcgcc	2100
gaaatcccga	atctctatcg	tgccgtgggt	gaactgcaca	ccgcgcacgg	cacgctgatt	2160
gaagcagaag	cctgcgatgt	cgttttccgc	gaggtgcgga	ttgaaaatgg	tctgctgctg	2220
ctgaacggca	agccgttgct	gattcgaggg	gttaaccgtc	acgagcatca	toctctgcat	2280
ggtcagggtca	tggtatgagca	gacgatgggtg	caggatatcc	tgctgatgaa	gcagaacaac	2340
tttaacgccg	tgcgctgttc	gcattatccg	aaccatccgc	tgtggtacac	gctgtgcgac	2400
cgctacggcc	tgtatgtggt	ggatgaagcc	aatatgaaa	cccacggcat	ggtgccaatg	2460
aatcgtctga	ccgatgatcc	gcgctggcta	ccgcgatga	gcgaacgcgt	aacgcgaatg	2520
gtgcagcgcg	atcgtaatca	cccagatgtg	atcatctggt	cgctggggaa	tgaatcaggc	2580
cacggcgcta	atcacgacgc	gctgtatcgc	tggtacaaat	ctgtcgatcc	ttccgcgccg	2640
gtgcagtatg	aaggcggcgg	agccgacacc	acggccaccg	atattatttg	cccgatgtac	2700
gcgcgcgtgg	atgaagacca	gcccttcccg	gctgtgcgga	aatggtccat	caaaaaatgg	2760
ctttcgctac	ctggagagac	gcgcccgtg	atcctttgcg	aatacgccca	cgcgatgggt	2820
aacagtcttg	gcggtttcgc	taaatactgg	caggcgtttc	gtcagtatcc	cggtttacag	2880
ggcggtctcg	tctgggactg	ggtggatcag	tcgctgatta	aatatgatga	aaacggcaac	2940
ccgtgggtcg	cttaacggcg	tgattttggc	gatacgccga	acgatcgcca	gttctgtatg	3000
aacgggtctg	tctttgccga	ccgcacggcg	catccagcgc	tgacgggaagc	aaaacaccag	3060
cagcagtttt	tccagttccg	tttatccggg	caaaccatcg	aagtgaccag	cgaataacctg	3120
ttccgctcata	gcgataacga	gctcctgcac	tggtatgggtg	cgctggatgg	taagccgctg	3180
gcaagcgggtg	aagtgcctct	ggatgtcgct	ccacaaggta	aacagttgat	tgaactgcct	3240
gaactaccgc	agccggagag	cgccggggcaa	ctctggctca	cagtagcgct	agtgaaccg	3300
aacgcgacgc	catggtcaga	agccgggcac	atcagcgctt	ggcagcagtg	gcgtctggcg	3360
gaaaacctca	gtgtgacgct	ccccgcgcg	tcccacgcca	tcccgcatct	gaccaccagc	3420
gaaatggatt	tttgcatcga	gctgggtaat	aagcgttggc	aatttaaccg	ccagtcaggc	3480
tttctttcac	agatgtggat	tggcgataaa	aaacaactgc	tgacgcgcgt	gcgcgatcag	3540
ttcaccocgtg	caccgctgga	taacgacatt	ggcgtaagtg	aagcgaccgc	cattgaccct	3600
aacgcctggg	tcgaacgctg	gaaggcggcg	ggccattacc	aggcgaagc	agcgttggtg	3660
cagtgcacgg	cagatacact	tgctgatgcg	gtgctgatta	cgaccgctca	cgcggtggcag	3720
catcagggga	aaaccttatt	tatcagccgg	aaaacctacc	ggattgatgg	tagtgggtcaa	3780
atggcgatta	ccgttgatgt	tgaagtggcg	agcgatacac	cgcatccggc	gcggattggc	3840
ctgaactgcc	agctggcgca	ggtagcagag	cgggtaaaact	ggctcggatt	agggccgcaa	3900
gaaaactatc	ccgacgcgct	tactgccgcc	tgttttgacc	gctgggatct	gccattgtca	3960
gacatgtata	ccccgtacgt	cttcccgcgc	gaaaacggtc	tgcgctgcgg	gacgcgcgaa	4020
ttgaattatg	gcccacacca	gtggcgcggc	gacttccagt	tcaacatcag	ccgctacagt	4080
caacagcaac	tgatggaaac	cagccatcgc	catctgctgc	acgcggaaga	aggcacatgg	4140
ctgaatatcg	acggtttcca	tatggggatt	ggtggcgacg	actcctggag	cccgtcagta	4200
tcggcggaat	tccagctgag	cgccggctgc	taccattacc	agttgggtctg	gtgtcaaaaa	4260
taataataac	cgggcaggcc	atgtctgccc	gtatttcgcg	taaggaaatc	cattatgtac	4320
tatttaaaaa	acacaaactt	ttggatgttc	ggtttattct	ttttctttta	cttttttatc	4380
atgggagcct	acttcccgtt	tttcccgcgt	tggtctacatg	acatcaacca	tatcagcaaaa	4440
agtgatacgg	gtattatttt	tgccgctatt	tctctgttct	cgctattatt	ccaaccgctg	4500
tttggctctgc	tttctgacaa	actcggaact	tgttttattgc	agcttataat	ggttacaaat	4560
aaagcaatag	catcacaaat	ttcacaaata	aagcattttt	ttcactgcac	tctagttgtg	4620
gtttgtccaa	actcatcaat	gtatcttata	atgtctggat	ccagatctgg	gcgtggctta	4680
aggggtgggaa	agaatatata	aggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	4740
gccgccgcgg	ccatgagcac	caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	4800
acgcgcacgc	ccccatgggc	cgggggtgcgt	cagaatgtga	tgggctccag	cattgatgggt	4860

cgccccgtcc	tgccccgcaaa	ctctactacc	ttgacctacg	agaccgtgtc	tggaacgccg	4920
ttgggagactg	cagcctccgc	cgccgcttca	gccgctgcag	ccaccgcccg	cgggattgtg	4980
actgacttttg	ctttcctgag	cccgccttgca	agcagtgacg	cttcccgttc	atccgcccgc	5040
gatgacaagt	tgacggctct	tttggcacaa	ttggattctt	tgaccggga	acttaatgtc	5100
gtttctcagc	agctgttgga	tctgcgccag	caggtttctg	ccctgaaggc	ttcctcccct	5160
cccaatgcgg	tttaaaacat	aaataaaaaa	ccagactctg	tttggatttg	gatcaagcaa	5220
gtgtcttgct	gtctttattt	aggggttttg	cgcgcgcggt	aggcccggga	ccagcggctc	5280
cggtcgttga	gggtcctgtg	tattttttcc	aggacgtgg	aaagggtgact	ctggatgttc	5340
agatacatgg	gcataagccc	gtctctgggg	tggaggtagc	accactgcag	agcttcatgc	5400
tgccgggtgg	tgttgtagat	gatccagtcg	tagcaggagc	gctgggcgtg	gtgcctaaaa	5460
atgtctttca	gtagcaagct	gattgccagg	ggcaggccct	tgggtgaagt	gtttacaaaag	5520
cggttaagct	gggatgggtg	catacgtggg	gatatgagat	gcatcttgga	ctgtattttt	5580
aggttggcta	tgttcccagc	catatccctc	cggggattca	tgttggtgcag	aaccaccagc	5640
acagtgtatc	cgggtgcactt	gggaaatttg	tcatgtagct	tagaaggaaa	tgcggtggaag	5700
aacttggaga	cgcccttgtg	acctccaaga	ttttccatgc	attcgtccat	aatgatggca	5760
atggggccac	ggggcgccggc	ctgggcgaag	atattttctg	gatcactaac	gtcatagtgt	5820
tgttccagga	tgagatcgtc	ataggccatt	tttacaagc	gcgggcggag	ggtgccagac	5880
tgccgtataa	tggttccatc	cggcccagg	gcgtagttac	cctcacagat	ttgcatttcc	5940
cacgctttga	gttcagatgg	ggggatcatg	tctacctgcg	gggcgatgaa	gaaaacgggt	6000
tccggggtag	gggagatcag	ctgggaagaa	agcaggttcc	tgagcagctg	cgacttaccg	6060
cagccgggtg	gcccgtaaat	cacacctatt	accgggtgca	actggtagtt	aagagagctg	6120
cagctgccgt	catccctgag	cagggggggc	acttcgttaa	gcatgtccct	gactcgcagt	6180
ttttccctga	ccaaatccgc	cagaaggcgc	tcgccgccca	gcgatagcag	ttcttgcaag	6240
gaagcaaagt	ttttcaacgg	tttgagaccg	tcgcccgtag	gcatgctttt	gagcgtttga	6300
ccaagcagtt	ccagcgggtc	ccacagctcg	gtcacctgct	ctacggcatc	tcgatccagc	6360
atatctcctc	gtttcgccgg	ttggggcgcc	tttcgctgta	cggcagtagt	cggtgctcgt	6420
ccagacgggc	cagggctcatg	tctttccacg	ggcgagggt	cctcgtcagc	gtagtctggg	6480
tcacggtgaa	gggggtgcgt	ccgggctgcg	cgctggccag	ggtgcgcttg	aggctggtec	6540
tgctgggtgct	gaagcgcgtc	cggctcttcgc	cctgcgcgtc	ggccaggtag	catttgacca	6600
tggtgtcata	gtccagcccc	tcgcggcgct	ggcccttggc	gcgcagcttg	cccttgagg	6660
aggcgccgca	cgagggggcag	tgacagcttt	tgaggcgta	gagcttgggc	gcgagaaata	6720
ccgattcccg	ggagtaggca	tcgcgcgcgc	aggccccgca	gacggtctcg	cattccacga	6780
gccaggtgag	ctctggccgt	tcgggggtcaa	aaaccagggt	tcccccatgc	tttttgatgc	6840
gtttcttacc	tctgggtttcc	atgagccggt	gtccacgctc	ggtgacgaaa	aggctgtccg	6900
tgtccccgta	tacagacttg	agaggcctgt	cctcgagcgg	tgttccgcgg	tcctcctcgt	6960
atagaaactc	ggaccactct	gagacaaaagg	ctcgcgtcca	ggccagcacg	aaggaggcta	7020
agtgggaggg	gtagcgggtcg	ttgtccacta	gggggtccac	tcgctccagg	gtgtgaagac	7080
acatgtcgcc	ctcttcggca	tcaaggaaag	tgatttggtt	gtaggtgtag	gccacgtgac	7140
cgggtgttcc	tgaagggggg	ctataaaaagg	gggtgggggc	gcgttcgtcc	tcactctctt	7200
ccgcatecgt	gtctgcgagg	gccagctggt	ggggtgagta	ctccctctga	aaagcgggca	7260
tgactttctgc	gctaagattg	tcagttttcca	aaaacgagga	ggatttgata	ttcacctggc	7320
ccgcgggtgat	gccttttgagg	gtggccgcgt	ccatctggtc	agaaaagaca	atctttttgt	7380
tgtaagcctt	ggtggcaaac	gaccggtaga	gggcgttgga	cagcaacttg	gcgatggagc	7440
gcaggggttg	gtttttgtcg	cgatcggcgc	gctccttggc	cgcatgttt	agctgcacgt	7500
attcgcgcgc	aaocgacccg	cattegggaa	agacggtggt	gcgctcgtcg	ggcaccagg	7560
gcacgcgcga	accgcggttg	tgacgggtga	caaggtcaac	gctggtggct	acctctccgc	7620
gtaggcgctc	gttggtccag	cagaggcggc	cgcccttgcg	cgagcagaat	ggcggtagg	7680
ggtctagctg	cgtctcgtcc	ggggggtctg	cgtccacgg	aaagacccc	ggcagcagg	7740
gcgcgtcgaa	gtagtctatc	ttgcatecct	gcaagtctag	cgctgctgc	catgcgcgg	7800
cggcaagcgc	gcgctcgat	gggttgagtg	ggggacccca	tggcatgggg	tggtgagcg	7860
cggaggcgta	catgccgcaa	atgtcgtaaa	cgtagagg	ctctctgagt	attccäagat	7920
atgtagggtg	gcatcttcca	ccgcggatgc	tggcgcgcac	gtaatcgat	agttcgtgcg	7980
agggagcgag	gaggtcggga	ccgaggttgc	tacgggcggg	ctgctctgct	cggaagacta	8040
tctgcctgaa	gatggcatgt	gagttggatg	atatggttgg	acgctggaag	acgttgaagc	8100
tggcgtctgt	gagacctacc	gcgtcacgca	cgaaggaggc	gtaggagtgc	cgcagcttgt	8160
tgaccagctc	ggcgggtgacc	tgacagctct	gggcgcagta	gtccagggtt	tccttgatga	8220
tgatcatactt	atcctgtccc	ttttttttcc	acagctcgcg	gttgaggaca	aactcttcgc	8280
ggtctttcca	gtactcttgg	atcggaacc	cgteggcctc	cgaacggtaa	gagcctagca	8340
tgtagaactg	gttgacggcc	tggttaggcgc	agcatccctt	ttctacgggt	agcgcgtatg	8400
cctgcgcggc	cttccggagc	gaggtgtggg	tgagcgcaaa	ggtgtccctg	accatgactt	8460
tgaggtactg	gtatttgaag	tcagtgtcgt	cgcateccgc	ctgctcccag	agcaaaaagt	8520
ccgtgcgcgtt	tttggaaacgc	ggatttggca	gggcgaaggt	gacatcgttg	aagagtatct	8580

ttcccgcgcg	aggcataaag	ttgcgtgtga	tgcggaaggg	tcccggcacc	tcggaacggt	8640
tgttaattac	ctgggcggcg	agcacgatct	cgtcaaagcc	gttgatgttg	tggcccacaa	8700
tgtaaagttc	caagaagcgc	gggatgccct	tgatggaagg	caatttttta	agttcctcgt	8760
aggtgagctc	ttcaggggag	ctgagcccgt	gctctgaaag	ggcccagtct	gcaagatgag	8820
ggttggaaag	gacgaatgag	ctccacaggt	cacgggccat	tagcatttgc	aggtggtcgc	8880
gaaaggtcct	aaactggcga	cctatggcca	ttttttctgg	ggtgatgcag	tagaaggtaa	8940
gcgggtcttg	ttcccagcgg	tcccatccaa	ggttcgcggc	taggtctcgc	gcggcagtcg	9000
ctagaggctc	atctccgcgc	aacttcatga	ccagcatgaa	gggcacgagc	tgcttcccaa	9060
aggcccccac	ccaagtatat	gtctctacat	cgtagggtgac	aaagagacgc	tcggtgcgag	9120
gatgcgagcc	gatcgggaag	aactggatct	cccgccacca	attggaggag	tggctattga	9180
tgtggtgaaa	gtagaagtcc	ctgcgacggg	ccgaacactc	gtgctggctt	ttgtaaaaac	9240
gtgcgcagta	ctggcagcgc	tgccacgggt	gtacatcctg	cacgaggttg	acctgacgac	9300
cgcgcaaaag	gaagcagcgc	gggaatttga	gccccctgcc	tggcgggttt	ggctggtggt	9360
cttctacttc	ggctgcttgc	ccttgaccgt	ctggctgctc	gaggggagtt	acggtggatc	9420
ggaccaccac	gccgcgcgag	cccaaagtcc	agatgtccgc	gcgcggcggt	cggagcttga	9480
tgacaacatc	gcgcagatgg	gagctgtcca	tggctctggag	ctcccgcggc	gtcaggtcag	9540
gcgggagctc	ctgcaggttt	acctcgcata	gacgggtcag	ggcgcgggct	agatccaggt	9600
gatacctaag	ttccaggggc	tggttggtgg	cggcgctcat	ggcttgcaag	aggccgcac	9660
cccgcggcgc	gactacggta	ccgcgcggcg	ggcggtgggc	cgcgggggtg	tccttggtatg	9720
atgcatctaa	aagcgtgtgac	gcgggcgagc	ccccggaggt	agggggggct	ccggaccgcg	9780
cgggagaggg	ggcaggggca	cgtcgggcgc	gcgcgcgggc	aggagctggt	gctgcgcgcg	9840
taggttgctg	gcgaacgcga	cgacgcggcg	ggtgatctcc	tgaatctggc	gcctctgcgt	9900
gaagacgacg	ggcccgggtga	gcttgagcct	gaaagagagt	tcgacagaat	caatttcggt	9960
gtcgttgacg	gcggcctggc	gcaaaatctc	ctgcacgtct	cctgagttgt	cttgataggg	10020
gatctcggcc	atgaactgct	cgatctcttc	ctcctggaga	tctccgcgtc	cggctcgctc	10080
cacggtggcg	gcgaggtcgt	tggaaatgcg	ggccatgagc	tgcgagaagg	cgttgaggcc	10140
tccctcgttc	cagacgcggc	tgtagaccac	gcccccttcg	gcatcgcggg	cgcgcatgac	10200
cacctgcgcg	agattgagct	ccacgtgcgc	ggcgaagacg	gcgtagtctc	gcaggcgctg	10260
aaagaggtag	ttgagggtgg	tggcggtgtg	ttctgccacg	aagaagtaca	taaccacgag	10320
tcgcaacgtg	gattcgttga	tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	10380
gtccacggcg	aagttgaaaa	actgggagtt	gcgcgcgcac	acggttaact	cctcctccag	10440
aagacggatg	agctcggcga	cagtgctcgc	cacctcgcgc	tcaaaggcta	caggggcctc	10500
ttcttcttct	tcaatctcct	cttccataag	ggcctcccct	tcttcttctt	ctggcgcgcg	10560
tgggggaggg	gggacacggc	ggcgacgacg	gcgcaccggg	aggcggtcga	caaagcgctc	10620
gatcatctcc	ccgcggcgac	ggcgcatggt	ctcggtgacg	gcgcggccgt	tctcgcgggg	10680
gcgcagttgg	aagacgcgcg	ccgtcatgtc	ccggttatgg	gttggcgggg	ggctgccatg	10740
cggcagggat	acggcgctaa	cgatgcacat	caacaattgt	tgtgtaggta	ctccgcggcc	10800
gagggacctg	acgcgactcg	catcgaccgg	atcggaatac	ctctcgagaa	aggcgctctaa	10860
ccagtcacag	tcgcaaggta	ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	10920
gttgtttctg	gcggaggtgc	tgtgatgat	gtaattaaag	taggcggtct	tgagacggcg	10980
gatggtcgac	agaagcacca	tgtccttggg	tccggcctgc	tgaatcgcca	ggcggtcggc	11040
catgccccag	gcttcgtttt	gacatcggcg	caggtctttg	tagtagtctt	gcatgagcct	11100
ttctaccggc	acttcttctt	ctccttctct	ttgtcctgca	tctcttgcat	ctatcgctgc	11160
ggcggcggcg	gagtttgccc	gtaggtggcg	ccctcttctt	cccatcgctg	tgaccccgaa	11220
gccccctatc	ggctgaagca	gggctagggt	ggcgacaacg	cgtcgggcta	atatggcctg	11280
ctgcacctgc	gtgagggtag	actggaagtc	atccatgtcc	acaaagcggg	ggtatgcgcc	11340
cgtgttgatg	gtgtaagtgc	agttggccat	aacggaccag	ttaacggtct	ggtgacccgg	11400
ctgcgagagc	tcggtgtacc	tgagacgcga	gtaagccctc	gagtcaaata	cgtagtcggt	11460
gcaagtccgc	accaggtact	ggtatcccac	caaaaagtgc	ggcggcggct	ggcggtagag	11520
gggccagcgt	aggggtggcg	gggctccggg	ggcgagatct	tccaacataa	ggcgatgata	11580
tccgtagatg	tacctggaca	tccaggtgat	gcccggcgcg	gtggtggagg	cgcgcggaag	11640
gtcgcgggac	cggttccaga	tgttgcgacg	cggcaaaaag	tgtcccatgg	tcgggacgct	11700
ctggccggtc	aggcgcgcg	aatcgttgac	gctctagacc	gtgcaaaaag	agagcctgta	11760
agcgggcact	cttccgtggt	ctgggtggata	aattcgcaag	ggtatcatgg	cggacgaccg	11820
gggttcgagc	cccgatatccg	gccgtccgcc	gtgatccatg	cggttaccgc	ccgcgtgtcg	11880
aaaccaggtg	tgcgacgtca	gacaacgggg	gagtgtcctt	tttggcttcc	ttccaggcgc	11940
ggcggtcgtc	gcgctaagct	ttttggccac	tggccgcgcg	cagcgtaagc	ggttaggctg	12000
gaaagcgaaa	gcattaagtg	gctcgtctcc	tgtagccgga	gggttatttt	ccaaggggtg	12060
agtccgcggg	cccccggttc	gagtcctcga	ccggccggac	tgcggcgaa	gggggtttgc	12120
ctccccgtca	tgaagacccc	cgcttgcaaa	ttcctccgga	aacagggagc	agcccccttt	12180
ttgcttttcc	cagatgcac	cgggtgctgc	gcagatgcgc	ccccctctc	agcagcgga	12240
agagcaagag	cagcggcaga	catgcagggc	acctcccct	cctcctaccg	cgtcaggagg	12300

ggcgacatcc	gcggttgacg	cggcagcaga	tgggtgattac	gaacccccgc	ggcgccgggc	12360
ccggcactac	ctggacttgg	aggagggcga	gggcctggcg	cggctaggag	cgccctctcc	12420
tgagcggtag	ccaagggtag	agctgaagcg	tgatagcggt	gaggcgtagc	tgccgcggca	12480
gaacctgttt	cgcgaccgcg	agggagagga	gcccagggag	atgcgggatc	gaaagttcca	12540
cgcagggcgc	gagctgcggc	atggcctgaa	tcgcgagcgg	ttgctgcgcg	aggaggactt	12600
tgagcccgcg	gcgcgaaccg	ggattagtcc	cgcgcgcgca	cacgtggcgg	ccgcccacct	12660
ggtaaccgca	tacgagcaga	cgggtgaacca	ggagattaac	tttcaaaaaa	gctttaacaa	12720
ccacgtgcgt	acgcttgtgg	cgcgcgagga	ggtggctata	ggactgatgc	atctgtggga	12780
ctttgtaagc	gcgctggagc	aaaacccaaa	tagcaagccg	ctcatggcgc	agctgttcc	12840
tatagtgcag	cacagcaggg	acaacgaggg	attcagggat	gcgctgctaa	acatagtaga	12900
gcccaggggc	cgtggcgtgc	tcgatttggat	aaacatcctg	cagagcatag	tggtgcagga	12960
gcgcagcttg	agcctggcgt	acaaggtggc	cgccatcaac	tattccatgc	ttagcctggg	13020
caagttttac	gcccgcgaaga	tataccatac	cccttacgtt	cccatagaca	aggaggtaaa	13080
gatcgagggg	ttctacatgc	gcatggcgct	gaaggtgctt	accttgagcg	acgacctggg	13140
cgtttatcgc	aacgagcgca	tccacaaggc	cgtgagcgtg	agccggcggc	gcgagctcag	13200
cgaccgcgag	ctgatgcaca	gacctgcaaa	ggccctggct	ggcacgggca	gcggcgatag	13260
agaggccgag	tcctactttg	acgcggggcg	tgacctgcgc	tgggccccaa	gccgacgcgc	13320
cctggaggca	gctggggccg	gacctgggct	ggcggtggca	cccgcgcgcg	ctggcaacgt	13380
cggcgggcgtg	gaggaatatg	acgaggacga	tgagtacgag	ccagaggacg	gcgagtacta	13440
agcgggtgatg	tttctgatca	gatgatgcaa	gacgcaacgg	acccggcggt	gcggggcgcg	13500
ctgcagagcc	agccgtccgg	ccttaactcc	acggacgact	ggcgccaggt	catggaccgc	13560
atcatgtcgc	tgactgcgcg	caatcctgac	gcgttccggc	agcagccgca	ggccaaccgg	13620
ctctccgcaa	ttctggaagc	ggtggtcccg	gcgcgcgcaa	acccccacgca	cgagaaggtg	13680
ctggcgatcg	tggcgatcg	tggcgatcg	ggggccatcc	ggccccacga	ggccggcctg	13740
gtctacgacg	cgtgcttca	gcgcgtggct	cgttacaaca	gcggcaacgt	gcagaccaac	13800
ctggaccggc	tggtggggga	tgtgcgcgag	gccgtggcgc	agcgtgagcg	cgcgcagcag	13860
cagggcaacc	tgggctccat	ggttgcaacta	aacgccttcc	tgagtacaca	gccccccaac	13920
gtgccgcggg	gacaggagga	ctacaccaac	tttgtgagcg	cactgcggct	aatgggtgact	13980
gagacaccgc	aaagtgaggt	gtaccagtc	gggcccagact	attttttcca	gaccagtaga	14040
caaggccctg	agaccgtaaa	cctgagccag	gccttcaaaa	acttgacagg	gctgtggggg	14100
gtgcgggctc	ccacaggcga	ccgcgcgacc	gtgtctagct	tgctgacgcc	caactcgcgc	14160
ctggttgcgc	tgctaatagc	gccccttcaac	gacagtggca	gcgtgtcccg	ggacacatac	14220
ctagggtcact	tgctgacact	gtaccgcgag	gccataggtc	aggcgcatgt	ggacgagcat	14280
actttccagg	agattacaag	tgtcagccgc	gcgtggggc	aggaggacac	gggacgcctg	14340
gaggcaaccc	taaactacct	gctgaccaac	cggcggcaga	agatcccctc	gttgccacagt	14400
ttaaacacgc	aggaggagcg	cattttgcgc	tactgtcagc	agagcgtgag	ccttaacctg	14460
atgcgcgacg	gggtaacgcc	cagcgtggcg	ctggacatga	ccgcgcgcaa	catggaaccg	14520
ggcatgtatg	cctcaaaccg	gccgtttatc	aaccgcctaa	tggactactt	gcacgcgcgc	14580
gccgcgcgtg	accccgagta	tttcaccaat	gccatcttga	acccgcactg	gctaccgccc	14640
cctggtttct	acaccggggg	attcgagggtg	cccgagggtg	acgatggatt	cctctgggac	14700
gacatagacg	acagcgtggt	ttccccgcaa	ccgcagaccc	tgctagagtt	gcaacagcgc	14760
gagcaggcag	aggcggcgct	gcgaaaggaa	agcttccgca	ggccaagcag	cttgtccgat	14820
ctaggcgctg	cggccccgcg	gtcagatgct	agtagcccat	ttccaagctt	gatagggtct	14880
cttaccagca	ctcgcaccac	ccgccccgcg	ctgctggggc	aggaggagta	cctaacaac	14940
tcgctgctgc	agccgcagcg	cgaaaaaac	ctgcctccgg	catttcccaa	caacgggata	15000
gagagccctag	tggacaagat	gagtagatgg	aagacgtacg	cgcaggagca	cagggacgtg	15060
ccaggcccgc	gcccgcacc	ccgtcgtcaa	aggcacgacc	gtcagcgggg	tctggtgtgg	15120
gaggacgatg	actcggcaga	cgacagcagc	gtcctggatt	tgggaggag	tggcaaccgc	15180
tttgccgacc	ttcgccccag	gctggggaga	atgtttttaa	aaaaaaaaag	catgatgcaa	15240
aataaaaaac	tcaccaaggc	catggcaccg	agcgttgggt	ttcttgtatt	ccccttagta	15300
tgccgcgcgc	ggcgatgtat	gaggaaggtc	ctcctccctc	ctacgagagt	gtggtgagcg	15360
cggcgccagt	ggcgggcgcg	ctgggttctc	ccttcgatgc	tcccctggac	ccgcccgttg	15420
tgccctccgc	gtacctgcgc	cctaccgggg	ggagaaacag	catccgttac	tctgagttgg	15480
cacccctatt	cgacaccacc	cgtgtgtacc	ttgtggacaa	caagtcaacg	gatgtggcat	15540
ccttgaacta	ccagaacgac	acagcaact	tctgacacc	ggtcattcaa	aacaatgact	15600
acagcccggg	ggaggcaagc	acacagacca	tcaatcttga	cgaccggtcg	cactggggcg	15660
gcgacctgaa	aaccatcctg	cataccaaca	tgccaaatgt	gaacgagttc	atgtttacca	15720
ataagtttaa	ggcgcggtg	atgggtgcgc	gcttgccctac	taaggacaat	caggtggagc	15780
tgaaatacga	gtgggtggag	ttcacgctgc	ccgagggcaa	ctactccgag	accatgacca	15840
tagaccttat	gaacaacgcg	atcgtggagc	actacttgaa	agtgggcaga	cagaacgggg	15900
ttctggaaag	cgacatcggg	gtaaagtttg	acacccgcaa	cttcagactg	gggtttgacc	15960
ccgtcactgg	tcttgtcatg	cctgggggtat	atacaaacga	agccttccat	ccagacatca	16020

ttttgctgcc	aggatgcg	gtggacttca	cccacagccg	cctgagcaac	ttgttgggca	16080
tccgcaagcg	gcaacccttc	caggagggt	ttaggatcac	ctacgatgat	ctggagggtg	16140
gtaacattcc	cgcactgttg	gatgtggacg	cctaccaggc	gagcttgaaa	gatgacaccg	16200
aacaggcg	gggtggcgca	ggcggcagca	acagcagtg	cagcggcgcg	gaagagaact	16260
ccaacgcggc	agcgcggca	atgcagccgg	tggaggacat	gaacgatcat	gccattcgcg	16320
gcgacacctt	tgccacacgg	gctgaggaga	agcgcgctga	ggccgaagca	gcggccgaag	16380
ctgccgcccc	cgctgcgcaa	cccaggtcg	agaagcctca	gaagaaaccg	gtgatcaaac	16440
ccctgacaga	ggacagcaag	aaacgcagtt	acaacctaat	aagcaatgac	agcaccttca	16500
cccagtaccg	cagctggtac	cttgcatata	actacggcga	ccctcagacc	ggaatccgct	16560
catggaccct	gctttgcact	cctgacgtaa	cctgcggctc	ggagcaggtc	tactggctcg	16620
tgccagacat	gatgcaagac	cccgtgacct	tccgctccac	gcgccagatc	agcaactttc	16680
cggtggtggg	cgccgagctg	ttgcccgctg	actccaagag	cttctacaac	gaccaggccg	16740
tctactccca	actcatccgc	cagtttacct	ctctgaccca	cgtgttcaat	cgctttcccg	16800
agaaccagat	tttggcgcg	ccgccagccc	ccaccatcac	caccgtcagt	gaaaacgttc	16860
ctgctctcac	agatcacggg	acgctaccgc	tgcgcaacag	catcgaggga	gtccagcgag	16920
tgaccattac	tgacgccaga	cgccgcacct	gcccctaogt	ttacaaggcc	ctgggcatag	16980
tctcgccg	cgctctatcg	agccgcactt	tttgagcaag	catgtccatc	cttatatcgc	17040
ccagcaataa	cacaggctgg	ggcctgcgct	tcccaagcaa	gatgtttggc	ggggccaaga	17100
agcgctccga	ccaacaccca	gtgcgcgtgc	gcgggcacta	ccgcgcgccc	tggggcgcg	17160
acaaacgcgg	cgcactggg	cgcaccaccg	togatgacgc	catcgacgcg	gtggtggagg	17220
aggcgcgcaa	ctacacgccc	acgcgcgcc	cagtgtccac	agtggacgcg	gccattcaga	17280
ccgtggtg	cggagcccg	cgctatgcta	aaatgaagag	acggcgagg	cgcgtagcac	17340
gtcgccaccg	cgcgcgccc	ggcactgcg	cccaacgcgc	ggcgcgccc	ctgcttaacc	17400
gcgcacgtcg	caccggccga	cggggcgcca	tgcggggcgc	tgaaggctg	gccgcgggta	17460
ttgtcactgt	gccccccagg	tccaggcgac	gagcggcgcg	cgcagcagcc	gcggccatta	17520
gtgctatgac	tcagggtcgc	aggggcaacg	tgtattgggt	gcgcgactcg	gttagcggcc	17580
tgcgcgtgcc	cgtgcgcacc	cgccccccgc	gcaactagat	tgcaagaaaa	aactacttag	17640
actcgactg	ttgtatgtat	ccagcgccg	cggcgcgcaa	cgaagctatg	tccaagcgca	17700
aaatcaaaga	agagatgctc	caggctcatcg	cgcgcgagat	ctatggcccc	ccgaagaagg	17760
aagagcagga	ttacaagccc	cgaagctaa	agcgggtcaa	aaagaaaaag	aaagatgatg	17820
atgatgaact	tgacgacgag	gtggaactgc	tgcacgctac	cgcgcccagg	cgacgggtac	17880
agtggaaagg	tgcagcgta	aaacgtgttt	tgcgaccg	caccaccgta	gtctttaogc	17940
ccggtgagcg	ctccaccgcg	acctacaagc	gcgtgtatga	tgagggtgtac	ggcgacgagg	18000
acctgcttga	gcaggccaac	gagcgccctg	gggagtttgc	ctacggaaag	cggcataaag	18060
acatgctggc	ggttgcgctg	gacgagggca	acccaacacc	tagcctaagg	cccgtaacac	18120
tgcagcaggt	gtgcgccg	cttgcaacct	ccgaagaaaa	gcgcggccta	aagcgcgagt	18180
ctggtgactt	ggcaccacc	gtgcagctga	tggtaacc	gcgccagcga	ctggaagatg	18240
tcttgaaaaa	aatgaccgtg	gaacctgggc	tggagcccga	ggtccgcgtg	cggccaatca	18300
agcaggtggc	gcccgggactg	ggcgtgcaga	ccgtggacgt	tcagataccc	actaccagta	18360
gcaccagtat	tgccaccgcc	acagagggca	tggagacaca	aacgtccccg	gttgccctcag	18420
cgggtggcgga	tgcccggtg	caggcggtcg	ctgcggccgc	gtccaagacc	tctacggagg	18480
tgcaaacgga	cccgtggatg	tttcgcgttt	cagccccccg	gcgcgcgcgc	ggttcgagga	18540
agtacggcg	cgcacgcgcg	ctactgcccg	aatatgccct	acatccttcc	attgcgccta	18600
cccccggtta	tcgtggctac	acctaccgcc	ccagaagacg	agcaactacc	cgacgcgaa	18660
ccaccactgg	aaccgcgcg	cgcgcgcgc	gtcgccagcc	cgtgctggcc	ccgatttccg	18720
tgcgcaggg	ggctcgcgaa	ggaggcagga	ccctggtgct	gccaacagcg	cgctaccacc	18780
ccagcatcgt	ttaaaagccg	gtctttgtgg	ttcttgca	tatggccctc	acctgcccgc	18840
tccgtttccc	ggtgccggga	ttccgaggaa	gaatgcaccg	taggaggggc	atggccggcc	18900
acggcctgac	ggcgggcatg	cgtcgtgcgc	accaaccggc	gcggcgcgcg	tcgcaaccgtc	18960
gcatgcgcgg	cggatatcctg	cccctcctta	ttccactgat	cgcgcggcg	attggcgccg	19020
tgcgcggaat	tgcacccgtg	gccttgcaag	cgcagagaca	ctgattaaaa	acaagttgca	19080
tgtggaaaaa	tcaaaataaa	aagtctggac	tctcacgctc	gcttggctct	gtaactattt	19140
tgtagaatgg	aagacatcaa	ctttgcgtct	ctggccccgc	gacacggctc	gcgcccgttc	19200
atgggaaact	ggcaagatat	cggcaccagc	aatatgagcg	gtggcgccct	cagctggggc	19260
tcgctgtgga	gcggcattaa	aaatttccgt	tccaccgtta	agaactatgg	cagcaaggcc	19320
tggaacagca	gcacaggcca	gatgctgagg	gataagttga	aagagcaaaa	tttccaacaa	19380
aaggtggtag	atggcctggc	ctctggcatt	agcggggtgg	tggacctggc	caaccaggca	19440
gtgcaaaaata	agattaacag	taagcttgat	ccccgccctc	ccgtagagga	gcctccaccg	19500
gccgtggaga	cagtgtctcc	agaggggctg	ggcgaaaagc	gtccgcgccc	cgacagggaa	19560
gaaactctgg	tgacgcaaat	agacgagcct	ccctcgtagc	aggaggcact	aaagcaaggc	19620
ctgccaccac	cccgtcccat	cgcgcccag	gtaccggag	tgctgggcca	gcacacacc	19680
gtaacgctgg	acctgcctcc	ccccgcccag	accagcaga	aacctgtgct	gccaggccccg	19740

accgcccgttg	ttgtaacccg	tcctagccgc	gcgtccctgc	gcccgcgcgc	cagcgggtccg	19800
cgatcgttg	ggcccgtagc	cagtggaac	tggcaaagca	cactgaacag	catcgtgggt	19860
ctgggggtgc	aatccctgaa	gcgcgcagca	tgcttctgaa	tagctaacgt	gtcgtatgtg	19920
tgtcatgtat	gcgtccatgt	cgccgccaga	ggagctgctg	agccgcgcgc	cgcccgtttt	19980
ccaagatggc	taccccttcg	atgatgccgc	agtggtctta	catgcacatc	tcggggccagg	20040
acgcctcgga	gtacctgagc	ccccggctgg	tgcagtttgc	ccgcgccacc	gagacgtact	20100
tcagcctgaa	taacaagttt	agaaacccca	cggtggcgcc	tacgcacgac	gtgaccacag	20160
accggtccca	gcgtttgacg	ctgcggttca	tccctgtgga	ccgtgaggat	actgcgtact	20220
cgtacaaggc	gcggttcacc	ctagctgtgg	gtgataaccg	tgtgctggac	atggcttcca	20280
cgtactttga	catccgcggc	gtgctggaca	ggggccctac	ttttaagccc	tactctggca	20340
ctgctcaaat	cgccctggct	cccaagggtg	cccaaatacc	ttgcgaatgg	gatgaagctg	20400
ctactgctct	tgaataaac	ctagaagaag	aggacgatga	caacgaagac	gaagtagacg	20460
agcaagctga	gcagcaaaaa	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	20520
ttacaaagga	gggtattcaa	ataggtgtcg	aaggtcaaac	acctaaatat	gccgataaaa	20580
catttcaacc	tgaacctcaa	ataggagaat	ctcagtggtg	cgaactgaa	attaatcatg	20640
cagctgggag	agtccttaaa	aagactaccc	caatgaaacc	atgttacggg	tcatatgcaa	20700
aaccacaaa	tgaataatgga	gggcaaggca	ttcttgtaaa	gcaacaaaat	ggaaagctag	20760
aaagtcaagt	ggaaatgcaa	tttttctcaa	ctactgaggc	gaccgcaggc	aatggtgata	20820
acttgactcc	taaagtggta	ttgtacagtg	aagatgtaga	tatagaaacc	ccagacactc	20880
atatttctta	catgcccact	attaaggaag	gtaactcacg	agaactaatg	ggccaacaat	20940
ctatgcccac	caggcctaata	tacattgctt	ttagggacaa	ttttattggt	ctaattgtatt	21000
acaacagcac	gggtaatatg	ggtgttctgt	cggggccaagc	atcgcagttg	aatgctgttg	21060
tagatttgca	agacagaaa	acagagcttt	cataccagct	tttgcttgat	tccattggtg	21120
atagaaccag	gtacttttct	atgtggaatc	aggctgttga	cagctatgat	ccagatgtta	21180
gaattattga	aatcatgga	actgaagatg	aacttccaaa	ttactgcttt	ccactgggag	21240
gtgtgattaa	tacagagact	cttaccagag	taaaacctaa	aacaggtcag	gaaaaatggat	21300
gggaaaaaga	tgctacagaa	ttttcagata	aaaatgaaat	aagagttgga	aataattttg	21360
ccatggaaat	caatctaata	gccaacctgt	ggagaaattt	cctgtactcc	aacatagcgc	21420
tgtatttgcc	cgacaagcta	aagtacagtc	cttccaacgt	aaaaatttct	gataacccaa	21480
acacctacga	ctacatgaac	aagcgagtg	tggtcccg	gttagtgga	tgctacatta	21540
accttgagag	acgctggtcc	cttgactata	tggacaacgt	caaccattt	aaccaccacc	21600
gcaatgctgg	cctgcgctac	cgctcaatgt	tgttgggcaa	tggtcgctat	gtgcccttcc	21660
acatccaggt	gcctcagaag	ttctttgcca	ttaaaaacct	ccttctcctg	ccgggctcat	21720
acacctacga	gtggaacttc	aggaaggatg	ttaacatggt	tctgcagagc	tccctaggaa	21780
atgacctaag	gggtgacgga	gccagcatta	agtttgatag	catttgctt	tacgccacct	21840
tcttccccat	ggcccacaac	accgctcca	cgttgaggc	catgcttaga	aacgacacca	21900
acgacagtc	ctttaacgac	tatctctccg	ccgccaaact	gctctacct	ataccgcca	21960
acgetacca	cgtgcccata	tccatccct	cccgcaactg	ggcggtttc	cgcggtggg	22020
ccttcacgcg	ccttaagact	aaggaaacct	catcactggg	ctcggtctac	gacccttatt	22080
acacctaact	tggtctata	ccctacctag	atggaacctt	ttacctcaac	cacaccttta	22140
agaaggtggc	cattaccttt	gactcttctg	tcagctggcc	tggcaatgac	cgctgcttta	22200
cccccaacga	gtttgaaatt	aagcgctcag	ttgacgggga	gggttacaac	ggtgcccagt	22260
gtaacatgac	caaagactgg	ttcctggtac	aaatgctagc	taactacaac	attggtctacc	22320
agggttcta	tatcccagag	agctacaagg	accgcatgta	ctccttcttt	agaaacttcc	22380
agcccatgag	ccgtcaggtg	gtggatgata	ctaaatacaa	ggactacca	caggtgggca	22440
tcctacacca	acacaacaac	tctggatttg	ttggctacct	tgccccacc	atgcgcgaag	22500
gacaggccta	ccctgctaac	ttcccctatc	cgttatagg	caagaccgca	gttgacagca	22560
ttaccagaa	aaagtttctt	tgcgatcgca	ccctttggcg	catcccattc	tccagtaact	22620
ttagtccat	gggcgcactc	acagacctgg	gccaaaacct	tctctacgce	aactccgccc	22680
acgcgctaga	catgactttt	gaggtggatc	ccatggacga	gccaccctt	ctttatgttt	22740
tgtttgaagt	ctttgacgtg	gtccgtgtgc	accggccgca	ccgcggcgte	atcgaaaccg	22800
tgtacctgag	cacgccttcc	tcggccggca	acgccacaac	ataaagaagc	aagcaacatc	22860
aacaacagct	gccgccatgg	gtccagtgta	gcaggaactg	aaagccattg	tcaaagatct	22920
tggttggtgg	ccatattttt	tgggcaccta	tgacaagcgc	tttccaggct	ttgtttctcc	22980
acacaagctc	gcctgcgcga	tagtcaatac	ggccggtcgc	gagactgggg	gcgtacactg	23040
gatggccttt	gcctggaacc	cgcactcaaa	aacatgctac	ctctttgagc	cctttggctt	23100
ttctgaccag	cgactcaagc	aggtttacca	gtttgagtac	gagtcactcc	tgccgcgtag	23160
cgccattgct	tcttcccccg	accgctgtat	aacgctggaa	aagtccaccc	aaagcgtaca	23220
ggggcccaac	tcggccgcct	gtggactatt	ctgctgcatg	tttctccacg	cctttgccaa	23280
ctggcccaaa	actcccattg	atcacaaccc	caccatgaac	cttattaccg	gggtacccaa	23340
ctccatgctc	aacagtcctc	aggtacagcc	cacctgcgt	cgcaaccagg	aacagctcta	23400
cagcttcctg	gagcgcact	cgcctactt	ccgcagccac	agtgcgcaga	ttaggagcgc	23460

cacttctttt	tgtcacttga	aaaacatgta	aaaataatgt	actagagaca	ctttcaataa	23520
aggcaaatgc	ttttatttgt	acactctcgg	gtgattattt	acccccaccc	ttgcggtctg	23580
cgccgtttta	aaatcaaagg	ggttctgcgg	cgcatacgta	tgcgccactg	gcagggacac	23640
gttgcgatac	tggtgtttag	tgtcccactt	aaactcaggg	acaaccatcc	gcggcagctc	23700
ggtgaagttt	tcaactccaca	ggctgcgcac	catcaccaac	gcgttttagca	ggtcggggcg	23760
cgatatcttg	aagtcgcagt	tggggcctcc	gccctgcgcg	cgcgagttgc	gatacacagg	23820
gttgcagcac	tggaaacta	tcagcgcggg	gtgggtgcacg	ctggccagca	cgctcttgtc	23880
ggagatcaga	tccgcgtcca	ggtcctccgc	gttgctcagg	gcgaacggag	tcaactttgg	23940
tagctgcctt	cccaaaaagg	gcgcgtgccc	aggcttttag	ttgcactcgc	accgtagtgg	24000
catcaaaagg	tgaccgtgcc	cggctctggg	gttaggatac	agcgcctgca	taaaagcctt	24060
gatctgccta	aaagccacct	gagcctttgc	gccttcagag	aagaacatgc	cgcaagactt	24120
gccggaaaac	tgattggccg	gacaggccgc	gtcgtgcacg	cagcaccttg	cgtcgggtgt	24180
ggagatctgc	accacatttc	ggccccaccg	gttcttcacg	atcttggcct	tgctagactg	24240
ctccttcagc	gcgcgtgccc	cgttttgcgt	cgtcacatcc	atttcaatca	cgtgctcctt	24300
atztatcata	atgcttccgt	gtagacactt	aagctcgcct	tcgatctcag	cgacgcgggtg	24360
cagccacaac	gcgcagcccg	tgggctcgtg	atgctttag	gtcacctctg	caaagcactg	24420
caggtacgcc	tgcagggaatc	gccccatcat	cgtcacaaaag	gtcttgttgc	tggtgaaggt	24480
cagctgcaac	ccgcggtgct	cctcgttcag	ccaggtcttg	catacggccg	ccagagcttc	24540
cacttgggtca	ggcagtagtt	tgaagttcgc	ctttagatcg	ttatccacgt	ggtacttgtc	24600
catcagcgcg	cgcgagcctt	ccatgccctt	ctcccaogca	gacacgatcg	gcacactcag	24660
cgggttcctc	accgtaattt	cactttccgc	ttcgtcgggc	tcttctcttt	cctcttgctg	24720
cgcataacca	cgcgccactg	ggctcgtctt	attcagccgc	cgcactgtgc	gcttacctcc	24780
tttgccatgc	ttgattagca	ccggtggggt	gctgaaaacc	accatttgta	gcgccacatc	24840
ttctctttct	tcctcgcgtg	ccacgattac	ctctgggtgat	ggcgggctgt	cgggcttggg	24900
agaaggggcg	ttctttttct	ttctggggcg	aatggccaaa	tccgcgcggc	aggtcgatgg	24960
ccgcgggctg	ggtgtgcgcg	gcaccagcgc	gtcttgtgat	gagtcttctt	cgtcctcgga	25020
ctcgatacgc	cgctcatcct	gcttttttgg	gggcgcggcg	ggaggcggcg	gcgacgggga	25080
cggggacgac	acgtcctcca	tggttggggg	acgtcgcgcg	gcaccgcgtc	cgcgctcggg	25140
ggtggtttcg	cgctgctcct	cttcccga	ggccatttcc	ttctctata	ggcagaaaaa	25200
gatcatggag	tcagtcgaga	agaaggacag	ccaaacggcc	ccctctgagt	tcgccaccac	25260
cgcctccacc	gatgcgcgca	acgcgcctac	caccttcccc	gtcgaggcac	ccccgcttga	25320
ggaggaggaa	gtgattatcg	agcaggaccc	aggttttgta	agogaagacg	acgaggaccg	25380
ctcagtagca	acagaggata	aaaagcaaga	ccaggacaac	gcagaggcaa	acgaggaaca	25440
agtcggggcg	ggggacgaaa	ggcatggcga	ctacctagat	gtgggagacg	acgtgctgtt	25500
gaagcatctg	cagcgccagt	gcgccattat	ctgcgacgcg	ttgcaagagc	gcagcgatgt	25560
gccccctcgc	atagcggatg	tcagccttgc	ctacgaacgc	cacctattct	caccgcgcgt	25620
accccccaaa	cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	25680
cgtattttgc	gtgccagagg	tgcttgccac	ctatcacatc	tttttccaaa	actgcaagat	25740
acccctatcc	tgccttgcca	accgcagccg	agcggacaag	cagctggcct	tgcggcaggg	25800
cgtgtgcata	cctgatatcg	cctcgcctca	cgaagtgcc	aaaatctttg	agggtcttgg	25860
acgcgacgag	aagcgcgcgg	caaacgctct	gcaacaggaa	aacagcgaaa	atgaaagtca	25920
ctctggagtg	ttggtggaac	tcgagggtag	caacgcgcgc	ctagccgtac	taaaacgcag	25980
catcgaggte	acccactttg	cctaccgcgg	acttaacccta	cccccaagg	tcatgagcac	26040
agtcgatgag	gagctgatcg	tgcgcctg	gcagcccctg	gagagggatg	caaatttgca	26100
agaacaaaca	gaggaggggc	taccgcag	tggcgacgag	cagctagcgc	gctggcttca	26160
aacgcgcgag	cctgcccact	tggaggagcg	acgcaacta	atgatggcgg	cagtgcctgt	26220
taccgtggag	cttgagtgc	tgcagcgggt	ctttgctgac	ccggagatgc	agcgaagct	26280
agaggaaaca	ttgcaacta	cctttcgaca	gggtacgta	cgccaggcct	gcaagatctc	26340
caacgtggag	ctctgcaacc	tggctccta	ccttgggaatt	ttgcacgaaa	accgccttgg	26400
gcaaaacgtg	cttcattcca	cgtcaagg	cgaggcgcgc	cgcgactacg	tccgcgactg	26460
cgtttactta	tttctatgct	acacctggca	gacggccatg	ggcgtttggc	agcagtgcct	26520
ggaggagtgc	aacctcaagg	agctgcagaa	actgctaaag	caaaacttga	aggacctatg	26580
gacggccttc	aacgagcgt	cgtggcgcgc	gcacctggcg	gacatcattt	tccccgaacg	26640
cctgcttaaa	accctgcaac	agggtctgcc	agacttcacc	agtcaaagca	tggtgcagaa	26700
ctttaggaac	tttatcctag	agcgtcagg	aatcttggcc	gccacctgct	gtgcacttcc	26760
tagcgacttt	gtgcccatta	agtaccgca	atgcctccg	ccgctttggg	gccactgcta	26820
cctctgcag	ctagccaact	acctgacct	ccactctgac	ataatggaag	acgtgagcgg	26880
tgacggctca	ctggagtgtc	actgtcgtg	caacctatgc	accccgacc	gctccctgg	26940
ttgcaattcg	cagctgctta	acgaaagtca	aattatcggt	acctttgagc	tgcaggggtc	27000
ctcgcctgac	gaaaagtccg	cggctccggg	gttgaaactc	actccggggc	tgtggacgtc	27060
ggcttacctt	cgcaaatctg	tacctgagga	ctaccacgcc	cacgagatta	ggttctacga	27120
agaccaatcc	cgcgcgca	atgcggagct	taccgcctgc	gtcattaccc	agggccacat	27180

tcttggccaa	ttgcaagcca	tcaacaaagc	ccgccaagag	tttctgctac	gaaagggacg	27240
gggggtttac	ttggaccccc	agtccggcga	ggagctcaac	ccaatcccc	cgccgcccga	27300
gccctatcag	cagcagccgc	gggcccttgc	ttcccaggat	ggcaccctaa	aagaagctgc	27360
agctgcccgc	gccacccacg	gacgaggagg	aatactggga	cagtcaggca	gaggagggtt	27420
tggacgagga	ggaggaggac	atgatggaag	actgggagag	cctagacgag	gaagcttccg	27480
aggtcgaaga	ggtgtcagac	gaaacaccgt	caccctcggg	cgcttcccc	tcgcccggcg	27540
cccagaaatc	ggcaaccggg	tccagcatgg	ctacaacctc	cgctcctcag	gcgccggccg	27600
cactgcccgt	tcgcccagcc	aaccgtagat	gggacaccac	tggaaaccag	gcccggtaagt	27660
ccaagcagcc	gcccgcgtta	gcccgaagag	aacaacagcg	ccaaggctac	cgctcatggc	27720
gcggggcaca	gaacgccata	gttgcttgct	tgcaagactg	tgggggcaac	atctccttcg	27780
cccgcgctt	tcttctctac	catcacggcg	tgtctgcgat	ccgtaacatc	ctgcattact	27840
accgtcatct	ctacagccca	tactgcaccg	gcggcagcgg	cagcggcagc	aacagcagcg	27900
gccacacaga	agcaaaggcg	accggatagc	aagactctga	caaagcccaa	gaaatccaca	27960
gcggcggcag	cagcaggagg	aggagcgctg	cgtctggcgc	ccaacgaacc	cgtatcgacc	28020
cgcgagctta	gaaacaggat	ttttcccaat	ctgtatgcta	tatttcaaca	gagcaggggc	28080
caagaacaag	agctgaaaat	aaaaaacagg	tctctgcgat	ccctcaccgg	cagctgcctg	28140
tatcacaaaa	gcgaagatca	gcttcggcgc	acgctggaag	acgcggaggc	tctcttcagt	28200
aaatactgcg	cgctgactct	taaggactag	tttcgcgccc	tttctcaaat	ttaagcgcg	28260
aaactacgtc	atctccagcg	gccacacccg	gcgccagcac	ctgtcgtcag	cgccattatg	28320
agcaaggaaa	ttcccacggc	ctacatgtgg	agttaccagc	cacaaatggg	acttgccggc	28380
ggagctgccc	aagactactc	aaccgcgaata	aactacatga	gcgcgggacc	ccacatgata	28440
tcccgggtca	acgggaatcc	cgcccaccga	aaccgaattc	tcttggaaaca	ggcggtctatt	28500
accaccacac	ctcgtataata	ctttaatccc	cgtagttggc	ccgctgccct	ggtgtaccag	28560
gaaagtcccg	ctcccaccac	tgtggtactt	cccagagacg	cccaggccga	agttcagatg	28620
actaactcag	gggcgcagct	tgcggggcgg	tttcgtcaca	gggtgcggtc	gcccggggcag	28680
ggtataactc	acctgacaat	cagagggcga	ggtattcagc	tcaacgacga	gtcgggtgagc	28740
tccctcgctt	gtctccgtcc	ggacgggaca	tttcagatcg	gcggcgccgg	ccgtccttca	28800
ttcacgcctc	gtcaggcaat	cctaactctg	cagacctcgt	cctctgagcc	gcgctcggga	28860
ggcattggaa	ctctgcaatt	tattgaggag	tttgtgccat	cggtctactt	taacccttcc	28920
tcgggacctc	coggccacta	tccggatcaa	tttattccta	actttgacgc	ggtaaaggac	28980
tcggcgagcg	gctacgactg	aatgttaagt	ggagaggcag	agcaactgcg	cctgaaacac	29040
ctggtccaact	gtgcgcgcca	caagtgtctt	gcccgcgact	ccggtgagtt	ttgctacttt	29100
gaattgcccg	aggatcatat	cgagggcccg	gcgcacggcg	tccggcttac	cgcccaggga	29160
gagcttgccc	gtagcctgat	tccggagttt	acccagcgcc	ccctgctagt	tgagcgggac	29220
aggggaccct	gtgttctcac	tgtgattttg	aactgtccta	accttggtat	acatcaagat	29280
tttaattaaa	gccacatcct	cttaccactt	ttcatacatt	gcccagaagt	aaagaatcgt	29340
ttgtgttatg	tttcaacgtg	tttatttttc	aattgcagaa	aatttcaagt	catttttcat	29400
tcagtagtat	agccccacca	ccacatagct	tatacagatc	accgtacctt	aatcaaactc	29460
acagaaccct	agtattcaac	ctgccacctc	cctcccaaca	cacagagtac	acagtccttt	29520
ctcccgggct	ggccttaaaa	agcatcatat	catgggtaac	agacatatct	ttaggtgtta	29580
tattccacac	ggtttcctgt	cgagccaaac	gctcatcagt	gatattaata	aactccccgg	29640
gcagctcact	taagttcatg	tcgctgtcca	gctgtgagc	cacaggctgc	tgtccaactt	29700
gcggttgctt	aacggggcgg	gaaggagaag	tccacgccta	catgggggta	gagtcataat	29760
cgtgcacag	gataggcgcg	tgggtgtgca	gcagcgcgcg	aataaactgc	tgccgcgcgc	29820
gctccgtcct	gcaggaatac	aacatggcag	tgggtctcct	agcgtatgatt	cgcaaccgcc	29880
gcagcataag	gcgccttgct	ctccgggcac	agcagcgcac	cctgatctca	cttaaatacag	29940
cacagtaact	gcagcacagc	accacaatat	gtttcaaaat	cccacagtgc	aaggcgctgt	30000
atccaaagct	catggcgggg	accacagaac	ccagctggcc	atcataccac	aagcgcaggt	30060
agattaagtg	gcgacccctc	ataaaacagc	tggacataaa	cattacctct	tttggcatgt	30120
tgtaatccac	cacctcccg	taccatataa	acctctgatt	aaacatggcg	ccatccacca	30180
ccatcctaaa	ccagctggcc	aaaacctgcc	cgccggctat	acactgcagg	gaaccgggac	30240
tggaaacaat	acagtggaga	gcccaggact	cgtaaccatg	gatcatcatg	ctcgtcatga	30300
tatcaatgtt	ggcacaacac	aggcacacgt	gcatacactt	cctcaggatt	acaagctcct	30360
cccgcgttag	aaccatatcc	cagggaaaca	cccattcctg	aatcagcgta	aatccacac	30420
tgcagggaag	acctcgcacg	taactcacgt	tgtgcattgt	caaagtgtta	cattcgggca	30480
gcagcggatg	atcctccagt	atggttagcg	gggtttctgt	ctcaaaagga	ggtagacgat	30540
ccctactgta	cggagtgcgc	cgagacaacc	gagatcgtgt	tggctcgtagt	gtcatgccaa	30600
atggaacgcc	ggacgtagtc	atatttctcg	aagcaaaacc	aggtgcgggc	gtgacaaaca	30660
gatctgcgtc	tccggtctcg	ccgcttagat	cgctctgtgt	agtagttgta	gtatatccac	30720
tctctcaaa	catccaggcg	ccccctggct	tcgggttcta	tgtaaactcc	ttcatgcgcc	30780
gctgccttga	taacatccac	caccgcagaa	taagccacac	ccagccaacc	tacacattcg	30840
ttctgcgagt	cacacacggg	aggagcggga	agagctggaa	gaaccatgtt	ttttttttta	30900

```

ttccaaaaga ttatccaaaa cctcaaaaatg aagatctatt aagtgaacgc gctccccctcc 30960
ggtggcggtg tcaaactcta cagccaaaaga acagataatg gcatttgtaa gatgttgac 31020
aatggcttcc aaaaggcaaa cggccctcac gtccaagtgg acgtaaaggc taaacccttc 31080
aggggtgaatc tcctctataa acattccagc accttcaacc atgcccaaat aattctcatc 31140
tcgccacctt ctcaatataa ctctaagcaa atcccgaata ttaagtcogg ccattgtaaa 31200
aatctgctcc agagcgccct ccaccttcag cctcaagcag cgaatcatga ttgcaaaaaa 31260
tcaggttcct cacagacctg tataagattc aaaagcggaa cattaacaaa aataccgca 31320
tcccgtaggt cccttcgcag ggccagctga acataatcgt gcaggtctgc acggaccagc 31380
gcggccactt ccccgccagg aaccttgaca aaagaaccca cactgattat gacacgcata 31440
ctcggagcta tgctaaccag cgtagccccg atgtaagctt tgttgcatgg gcggcgatat 31500
aaaatgcaag gtgctgctca aaaaatcagg caaagcctcg cgcaaaaaag aaagcacatc 31560
gtagtcatgc tcatgcagat aaaggcaggt aagctccgga accaccacag aaaaagacac 31620
catttttctc tcaaacatgt ctgcggtgtt ctgcataaac acaaaataaa ataacaaaaa 31680
aacatttaaa cattagaagc ctgtcttaca acaggaaaaa caacccttat aagcataaga 31740
cggactacgg ccatgccggc gtgaccgtaa aaaaactggt caccgtgatt aaaaagcacc 31800
accgacagct cctcggtcac gtccggagtc ataatgtaag actcggtaaa cacatcaggt 31860
tgattcatcg gtcagtgtca aaaagcgacc gaaatagccc gggggaatac ataccgcag 31920
gcgtagagac aacattacag ccccataggg aggtataaca aaattaatag gagagaaaaa 31980
cacataaaca cctgaaaaac cctcctgcct aggcataata gcaccctccc gctccagaac 32040
aacatacagc gcttcacagc ggcagcctaa cagtcagcct taccagtaaa aaagaaaacc 32100
tattaaaaaa acaccactcg acacggcacc agctcaatca gtcacagtgt aaaaaagggc 32160
caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacggttaaa gtccacaaaa 32220
aacaccaga aaaccgcacg cgaacctacg cccagaaacg aaagccaaaa aaccacaaac 32280
ttcctcaaat cgtcacttcc gttttccac gttacgtaac ttcccatttt aagaaaaacta 32340
caattcccaa cacatacaag ttactccggc ctaaaaccta cgtcaccgcg cccgttccca 32400
cgccccgcgc cacgtcacaa actccacccc ctcattatca tattggcttc aatccaaaaa 32460
aaggtatatt attgatgatg                                     32480

```

<210> 28
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 28
 ctcaacaatt gtggatccgt actcc 25

<210> 29
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 29
 gtgctcagca gatcttgcca ctgtg 25

<210> 30
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 30

ggcgcgttcg gatccactct cttcc

25

<210> 31
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 31
ctacatgcta ggcagatctc gttcggag

28

<210> 32
<211> 1240
<212> DNA
<213> adenovirus

<400> 32
ggatccactc tcttccgcat cgctgtctgc gagggccagc tgttgggggtg agtactccct 60
ctgaaaagcg ggcattgactt ctgcgctaag attgtcagtt tccaaaaacg agaggagattt 120
gatattcacc tggcccgcg gtagtccttt gaggggtggcc gcatccatct ggtcagaaaa 180
gacaatcttt ttgttgtaaa gcttggtggc aaacgacccg tagagggcgt tggacagcaa 240
cttggcgatg gagcgaggg tttgggtttt gtcgcgatcg gcgcgctcct tggccgcgat 300
gttttagctgc acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tggcgcgctc 360
gtcggggcacc aggtgcacgc gccaaacgcg gttgtgcagg gtgacaagg caacgctggt 420
ggctacctct ccgcgtaggc gctcgttggg ccagcagagg cggccgccct tgcgcgagca 480
gaatggcggg aggggttcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac 540
cccgggcagc aggcgcgcgt cgaagtagtc tatcttgcac ccttgcaagt ctacgcctg 600
ctgccatgcg cgggcggcaa gcgcgcgctc gtatgggttg agtgggggac cccatggcat 660
ggggtgggtg agcgcggagg cgtacatgcc gcaaatgtcg taaacgtaga ggggctctct 720
gagtagttcc agatatgtag ggtagcatct tccaccgcgg atgctggcgc gcacgtaatc 780
tgctcggaag actatctgcc tgaagatggc atgtgagttg gatgatatgg ttggacgctg 840
gaagacgttg aagctggcgt ctgtgagacc taccgcgtca cgcacgaagg aggcgtagga 960
gtcgcgcagc ttgttgacca gctcggcggg gacctgcacg tctagggcgc agtagtccag 1020
ggtttccttg atgatgtcat acttatcctg tccctttttt ttccacagct cgcggttgag 1080
gacaaactct tcgcggtctt tccagtactc ttggatcgga aaccgcgcgc cctccgaacg 1140
agatccgtac tccgcgcgcg agggacctga gcgagtcgcg atcgaccgga tcggaacc 1200
tctcgagaaa ggcgtctaac cagtcacagt cgcaagatct 1240

<210> 33
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 33
ggcgcgttcg gatccactct cttcc

25

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 34

gggagtagat ctcccaacag

20

<210> 35

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 35

cccttttttt tggatccctc gcgg

24

<210> 36

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 36

ctacatgcta ggcagatctc gttcggag

28

<210> 37

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 37

ctcaacaatt gttggatccg tactcc

26

<210> 38

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 38

gtgctcagca gatcttgcca ctgtg

25

<210> 39

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 39
ggcgcgttcg gatccactct cttcc 25

<210> 40
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 40
ctacatgcta ggcagatctc gttcggag 28

<210> 41
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 41
cccttttttt tggatccctc gcgg 24

<210> 42
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 42
gtgctcagca gatcttgcca ctgtg 25

<210> 43
<211> 8383
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 43
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttaggggttag gcggttttgcg ctgcttcgag atgtacgggc cagatatatc cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacgggggc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttgcca gtacatctac gtattagtca 600
tcgctattac catgggtgatg cgggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggag 780

gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttggtacc	900
gagctcggat	ccactctctt	ccgcacgcgt	gtctgcgagg	gccagctggt	ggggtgagta	960
ctccctctga	aaagcgggca	tgacttctgc	gctaagattg	tcagtttcca	aaaacgagga	1020
ggatttgata	ttcacctggc	ccgcggtgat	gcctttgagg	gtggccgcat	ccatctgggc	1080
agaaaagaca	atctttttgt	tgtcaagctt	ggtggcaaac	gacccgtaga	gggcgttgga	1140
cagcaacttg	gcgatggagc	gcagggtttg	gtttttgtcg	cgatcgggcg	gctccttggc	1200
cgcgatgttt	agctgcacgt	attcgcgcgc	aacgcaccgc	cattcgggaa	agacgggtgt	1260
gcgctcgctg	ggcaccaggt	gcacgcgcca	accgcggttg	tgcagggtga	caaggtcaac	1320
gctggtggct	acctctccgc	gtaggcgctc	gttggtccag	cagaggcggc	cgcccttgcg	1380
cgagcagaat	ggcggtgagg	ggtctagctg	cgtctcgtec	ggggggtctg	cgtccacggg	1440
aaagaccccg	ggcagcaggc	gcgcgtcgaa	gtagtctatc	ttgcatcctt	gcaagtctag	1500
cgctctgctg	catgcgcggg	cggcaagcgc	gcgctcgtat	gggttgagt	ggggacccca	1560
tggcatgggg	tgggtgagcg	cggaggcgta	catgccgcaa	atgtcgtaaa	cgtagagggg	1620
ctctctgagt	attccaagat	atgtagggtg	gcattctcca	ccgcggatgc	tggcgcgcac	1680
gtaatcgat	agttcgtgcg	agggagcgag	gaggtcggga	ccgaggttgc	tacgggcggg	1740
ctgctctgct	cggaaagacta	tctgcctgaa	gatggcatgt	gagttggatg	atatggttgg	1800
acgctggaag	acgttggaagc	tggcgtctgt	gagacctacc	gcgtcacgca	cgaaggaggc	1860
gtaggagtcg	cgcagcttgt	tgaccagctc	ggcggtgacc	tgcacgtcta	gggcgcagta	1920
gtccagggtt	tccttgatga	tgtcatactt	atcctgtccc	tttttttccc	acagctcgcg	1980
gttagggaca	aactcttcgc	ggtctttcca	gtactcttgg	atcgaaacc	cgtcggcctc	2040
cgaacgagat	ccgtaactcg	ccgcggaggg	acctgagcga	gtccgcacgc	accggatcgg	2100
aaaacctctc	gagaaaggcg	tctaaccagt	cacagtcgca	agatccaaga	tgaagcgcg	2160
aagaccgtct	gaagatacct	tcaaccccg	gtatccatat	gacacggaaa	ccggtcctcc	2220
aactgtgcct	tttcttactc	ctccctttgt	atcccccatt	gggtttcaag	agagtcccc	2280
tggggtactc	tctttgcgcc	tatccgaacc	tctagttacc	tccaatggca	tgcttgcgct	2340
caaaatgggc	aacggcctct	ctctggacga	ggcgggcaac	cttacctccc	aaaatgtaac	2400
cactgtgagc	ccacctctca	aaaaaaccaa	gtcaaacata	aaactggaaa	tatctgcacc	2460
cctcacagtt	acctcagaag	ccctaactgt	ggctgcggcc	gcacctctaa	tggtcgcggg	2520
caacacactc	accatgcaat	accagcccc	gctaaccgtg	cacgactcca	aacttagcat	2580
tgccacccaa	ggacccctca	cagtgtcaga	aggaaagcta	gccctgcaaa	catcaggccc	2640
cctcaccacc	accgatagca	gtacccttac	tatcactgcc	tcacccctc	taactactgc	2700
cactggtagc	ttgggcattg	acttgaaaga	gcccatttat	acacaaaatg	gaaaactagg	2760
actaaagtac	ggggctcctt	tgcattgtaac	agacgacctc	aacactttga	ccgtagcaac	2820
tggtccaggt	gtgactatta	ataatacttc	cttgcaaaact	aaagttactg	gagcctggg	2880
ttttgattca	caaggcaata	tgoaacttaa	tgtagcagga	ggactaagga	ttgattctca	2940
aaacagacgc	cttataactg	atgttagtta	tccgtttgat	gctcaaaacc	aactaaatct	3000
aagactagga	cagggccctc	tttttataaa	ctcagcccac	aacttgata	ttaactacaa	3060
caaaggcctt	tacttgttta	cagcttcaaa	caattccaaa	aagcttgagg	ttaacctaa	3120
cactgccaa	gggttgatgt	ttgacgctac	agccatagcc	attaatgcag	gagatgggct	3180
tgaatttggt	tcacctaatg	caccaaacc	aaatccctc	aaaacaaaa	ttggccatgg	3240
cctagaattt	gattcaaaca	aggctattgt	tctaactaa	ggaactggcc	ttagttttga	3300
cagcacaggt	gccattacag	taggaaacaa	aaataatgat	aagctaactt	tgtggaccac	3360
accagctcca	tctcctaact	gtagactaaa	tgcagagaaa	gatgctaaac	tcactttggt	3420
cttaacaaaa	tgtggcagtc	aaataacttg	tacagtttca	gttttggtg	ttaaaggcag	3480
tttggtctca	atatctggaa	cagttcaaa	tgctcatctt	attataagat	ttgacgaaaa	3540
tggagtgcta	ctaaacaatt	ccttcctgga	cccagaatat	tggaaactta	gaaatggaga	3600
tcttactgaa	ggcacagcct	atacaaacgc	tggtggattt	atgcctaacc	tatcagctta	3660
tccaaaaact	cacggtaaaa	ctgccaaaag	taacattgtc	agtcaagttt	acttaaacgg	3720
agacaaaact	aaacctgtaa	cactaacctt	tacactaaac	ggtacacagg	aaacaggaga	3780
cacaactcca	agtgcatact	ctatgtcatt	ttcatgggac	tggtctggcc	acaactacat	3840
taatgaaata	tttgccacat	cctcttacac	tttttcatac	attgcccaag	aataaaagaa	3900
gcggccgctc	gagcatgcat	ctagagggcc	ctattctata	gtgtcaccta	aatgctagag	3960
ctcgctgac	agcctcgact	gtgccttcta	gttgccagcc	atctgttggt	tgccctccc	4020
ccgtgccttc	cttgaccctg	gaaggtgcca	ctcccactgt	cctttcctaa	taaaatgagg	4080
aaattgcate	gcattgtctg	agtagggttc	attctattct	ggggggtggg	gtggggcagg	4140
acagcaagg	ggaggattgg	gaagacaata	gcaggcatgc	tggggatgcg	gtgggctcta	4200
tggcttctga	ggcggaagaa	accagctggg	gctctagggg	gtatccccac	gcgccctgta	4260
gcggcgcat	aagcgcggcg	ggtgtggtgg	ttacgcgcag	cgtgaccgct	acacttgcca	4320
gcgccctagc	gccgcgtcct	ttcgctttct	tcccttcctt	tctcgccacg	ttcgccggct	4380
ttccccgtca	agctctaaat	cggggcatcc	ctttagggtt	ccgatttagt	gctttacggc	4440
acctcgaccc	caaaaaactt	gattaggggtg	atggttcacg	tagtgggcca	tcgccctgat	4500

agacgggtttt	tcgccctttg	acgttggagt	ccacgttctt	taatagtgga	ctcttggtcc	4560
aaactggaac	aacactcaac	cctatctcgg	tctattcttt	tgatttataa	gggattttgg	4620
ggatttcggc	ctatttggtta	aaaaatgagc	tgattttaaca	aaaatttaac	gcgaattaat	4680
tctgtggaat	gtgtgtcagt	taggggtgtg	aaagtcccca	ggctccccag	gcaggcagaa	4740
gtatgcaaa	catgcatctc	aattagtcag	caaccagggtg	tggaaagtcc	ccaggctccc	4800
cagcaggcag	aagtatgcaa	agcatgcata	tcaattagtc	agcaaccata	gtcccgcccc	4860
taactccgcc	catcccgccc	ctaaactccgc	ccagttccgc	ccattctccg	ccccatggct	4920
gactaatttt	ttttattttat	gcagaggccg	aggccgcctc	tgcctctgag	ctattccaga	4980
agtagtgagg	aggctttttt	ggaggccctag	gcttttgcaa	aaagctcccc	ggagcttgta	5040
tatccatttt	cggatctgat	caagagacag	gatgaggatc	gtttcgcata	attgaacaag	5100
atggattgca	cgcaggttct	ccggccgctt	gggtggagag	gctattcggc	tatgactggg	5160
cacaacagac	aatcggtctg	tctgatgccg	ccgtgttccg	gctgtcagcg	caggggcgcc	5220
cggttctttt	tgtcaagacc	gacctgtccg	gtgccctgaa	tgaactgcag	gacgaggcag	5280
cgcggctatc	gtggctggcc	acgacggcgc	ttccttgccg	agctgtgctc	gacgttgtca	5340
ctgaagcggg	aagggactgg	ctgctattgg	gcgaagtgcc	ggggcaggat	ctcctgtcat	5400
ctcaccttgc	tcttgccgag	aaagtatcca	tcattggctga	tgcaatgcgg	cggctgcata	5460
cgttgatccc	ggctacctgc	ccattcgacc	accaagcgaa	acatcgcata	gagcgagcac	5520
gtactcggat	ggaagccggt	cttgctgata	aggatgatct	ggacgaagag	catcaggggc	5580
tcgcgccagc	cgaactgttc	gccaggctca	aggcgcgcac	gcccgcagcg	gaggatctcg	5640
tcgtgaccca	tggcgatgcc	tgcttgccga	atatcatggt	ggaaaatggc	cgtttttctg	5700
gattcatcga	ctgtggccgg	ctgggtgtgg	cggaccgcta	tcaggacata	gcgttggtta	5760
cccgatgata	tgtgaagag	cttgccggcg	aatgggctga	ccgcttcttc	gtgctttacg	5820
gtatcgccgc	tcccgatctg	cagcgcatac	ccttctatcg	ccttcttgac	gagttcttct	5880
gagcgggact	ctgggggttc	aaatgaccga	ccaagcgacg	cccaacctgc	catcacgaga	5940
tttcgattec	accgcgcgct	tctatgaaag	gttgggcttc	ggaatcggtt	tccgggacgc	6000
cggctggatg	atcctccagc	gcggggatct	catgctggag	ttcttcgccc	accccaactt	6060
gtttattgca	gcttataatg	gttacaataa	aagcaatagc	atcacaattt	tcacaataaa	6120
agcatttttt	tactgcattt	ctagtgtgag	tttgtccaaa	ctcatcaatg	tatcttatca	6180
tgtctgtata	ccgtcgacct	ctagctagag	cttgccgtaa	tcattggtcat	agctgtttcc	6240
tgtgtgaaat	tggtatccgc	tcacaatttc	acacaacata	cgagccggaa	gcataaagtg	6300
taaagcctgg	gggtgccta	gagtgaagta	actcacatta	attgcgttgc	gctcactgcc	6360
cgttttccag	tcgggaaacc	tgtcgtgcc	gctgcattaa	tgaatcggcc	aacgcgcggg	6420
gagaggcggg	ttgcgtattg	ggcgtctctc	cgttctctcg	ctcactgact	cgtgcgctc	6480
ggtcgttcgg	ctgcggcgag	cggatcagc	tcactcaaa	gcggtaatac	ggttatccac	6540
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	6600
ccgtaaaaag	gccgcgttgc	tgccgttttt	ccataggctc	cgccccctg	acgagcatca	6660
caaaaatcga	cgtcaagtc	agagggtggc	aaaccgcaca	ggactataaa	gataaccagg	6720
gtttccccct	ggaagctccc	tcgtgcgctc	tcctgttccg	accctgcgc	ttaccggata	6780
cctgtccgcc	tttctccctt	cgggaagcgt	ggcgttttct	caatgctcac	gctgtaggta	6840
tctcagttcg	gtgtagggtc	ttcgctccaa	gctgggctgt	gtgcacgaac	ccccgttca	6900
gcccagccgc	tgcgccttat	ccggtaacta	tcgtcttgag	tccaaccggg	taagacacga	6960
cttatecgca	ctggcagcag	ccactggtaa	caggattagc	agagcgagg	atgtaggcgg	7020
tgctacagag	ttcttgaaat	gggtggccta	ctacggctac	actagaagga	cagtatttgg	7080
tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	7140
caaaacaaac	accgctggta	gcgggtggtt	ttttgtttgc	aagcagcaga	ttacgcgcag	7200
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	7260
cgaaaactca	cgttaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	7320
cctttttaa	taaaaatgaa	gtttttaa	aatctaaa	atatatgagt	aaacttggtc	7380
tgacagttac	caatgcttaa	tcagtggagg	acatatctca	gcgatctgtc	tatttcgttc	7440
atoccatag	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	7500
tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atttatcagc	7560
aataaaccag	ccagccggaa	gggcccagcg	cagaagtgg	cctgcaactt	tatccgcctc	7620
catccagctc	attaattggt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	7680
gcgcaacggt	gttgccattg	ctacaggcat	cgtgggtgta	cgctcgtcgt	ttggtagggc	7740
ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	tgatcccca	tggtgtgcaa	7800
aaaagcgggt	agctccttcg	gtcctccgat	cggtgtcaga	agtaagtgtg	ccgcagtgtt	7860
atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	7920
cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	gaatagtgt	tgccgcgacc	7980
gagttgctct	tgcccgccgt	caatacggga	taataaccgc	ccacatagca	gaactttaaa	8040
agtgtcctac	attggaaaac	gttcttcggg	gcgaaaactc	tcaaggatct	taccgtgttt	8100
gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	8160
caccagcgtt	tctgggtgag	caaaaacag	aaggcaaaat	gccgcaaaaa	agggaataag	8220

```
ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 8280
tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaa 8340
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtc 8383
```

<210> 44
<211> 7960
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 44

```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcg tggctgaccg cccaacgacc 360
cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgtatttac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatcga ctcactatag ggagacccaa gctggctagc 900
gtttaaactt aagcttggtt ccgagctcgg atccactctc ttccgcctcg ctgtctgcga 960
gggccagctg ttgggggtgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020
tgtcagtttc caaaaacgag gaggatttga tattcacctg gccgcgggtg atgcctttga 1080
gggtggccgc atccatctgg tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa 1140
acgacccgta gagggcggtt gacagcaact tggcgatgga gcgcagggtt tggtttttgt 1200
cgcgatcggg gcgctccttg gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc 1260
gccattcggg aaagacgggt gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggt 1320
tgtgcagggt gacaaggtea acgctggtgg ctacctctcc gcgtaggcgc tcgttggctc 1380
agcagaggcg gccgccttgc cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt 1440
ccgggggggtc tgcgtccacg gtaaagaccc cgggcagcag gcgcgcgctc aagtagtcta 1500
tcttgcatcc ttgcaagtct agcgcctgct gccatgcgcg ggcggcaagc gcgcgctcgt 1560
atgggttgag ttgggggccc catggcatgg ggtgggtgag cgcggaggcg tacatgccgc 1620
aaatgtcgta aacgtagagg ggctctctga gtattccaag atatgtaggg tagcatcttc 1680
caccgcggat gctggcgcgc acgtaatcgt atagtctgtg cgagggagcg aggaggtcgg 1740
gaccgaggtt gctacgggcg ggctgctctg ctcggaagac tatctgcctg aagatggcat 1800
gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtct gtgagacct 1860
ccgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc tcggcgggtg 1920
cctgtcacgtc tagggcgtag tagtccaggg ttctcttgat gatgtcatac ttatcctgtc 1980
cctttttttt ccacagctcg cggttgagga caaactcttc gcggtctttc cagtactctt 2040
ggatcggaata cccgtcggcc tccgaacgag atccgtactc cgcgcgcgag ggacctgagc 2100
gagtcgcat cgaccggatc ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg 2160
caagatccaa gatgaagcgc gcaagaccgt ctgaagatac cttcaacccc gtgtatccat 2220
atgacacgga aaccggtcct ccaactgtgc cttttcttac tcctcccttt gtatccccc 2280
atgggtttca agagagtccc cctggggtag tctctttgcg cctatccgaa cctctagtta 2340
cctccaatgc catgcttgcg ctcaaaatgg gcaacggcct ctctctggac gaggcggca 2400
accttacctc ccaaatgtga accactgtga gccacctct caaaaaaacc aagtcaaa 2460
taaacctgga aatatctgca cccctcacag ttacctcaga agccctaact gtggctgccg 2520
ccgcacctct aatggctcgc ggcaacacac tcaccatgca atcacaggcc ccgctaaccg 2580
tgcacgactc caaacttagc attgccacc aaggaccctc cacagtgtca gaaggaaagc 2640
tagccctgca aacatcaggc cccctcacca ccaccgatag cagtaccctt actatcactg 2700
cctcaccccc tctaactact gccactggta gcttgggcat tgacttgaaa gagccattt 2760
atacacaata tggaataact ggactaaagt acggggctcc tttgcatgta acagacgacc 2820
taaacacttt gaccgtagca actgggtccag gtgtgactat taataatact tccttgcaaa 2880
```

ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacaggggcc	tctttttata	aactcagccc	3060
acaacttggg	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacct	agcactgcc	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcaccta	tgcaccaa	acaaatcccc	3240
tcaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	acaccagctc	catctcctaa	ctgtagacta	aatgcagaga	3420
aagatgctaa	actcactttg	gtcttaacaa	aatgtggcag	tcaaataactt	gctacagttt	3480
cagttttggc	tgttaaaggc	agtttggctc	caatatctgg	aacagttcaa	agtgtctatc	3540
ttattataag	atttgacgaa	aatggagtgc	tactaaacaa	ttccttctctg	gaccagaat	3600
attggaactt	tagaaatgga	gatcttactg	aaggcacagc	ctatacaaac	gctgttggtat	3660
ttatgcctaa	cctatcagct	tatccaaaat	ctcacggtaa	aactgccaaa	agtaacattg	3720
tcagtcaagt	ttactttaaac	ggagacaaaa	ctaaacctgt	aacactaacc	attacactaa	3780
acggtacaca	ggaaacagga	gacacaactc	caagtgcata	ctctatgtca	ttttcatggg	3840
actgggtctg	ccacaactac	attaatgaaa	tatttggccac	atcctcttac	actttttcat	3900
acattgcccc	agaataaaa	aagcggccgc	tcgagtctag	agggcccggt	taaaccgcgt	3960
gatcagcctc	gactgtgcct	tctagtgtgc	agccatctgt	tggttgcccc	tcccccgctc	4020
cttccttgac	cctggaaggt	gccactcccc	ctgtcctttc	ctaataaaaat	gaggaaattg	4080
catcgcatgg	tctgagtagg	tgtcattcta	ttctgggggg	tgggggtggg	caggacagca	4140
agggggagga	ttgggaagac	aatagcaggc	atgtctggga	tgcggtgggc	tctatggctt	4200
ctgaggcgga	aagaaccagc	tggggtctta	gggggtatcc	ccacgcgccc	tgtagcggcg	4260
cattaagcgc	ggcgggtgtg	gtgggttacgc	gcagcgtgac	cgctacactt	gccagcgcgc	4320
tagcgcgcgc	tcctttcget	ttcttccctt	cctttctcgc	cacgttcgcc	ggctttcccc	4380
gtcaagctct	aaatcggggc	atccctttag	ggttccgatt	tagtgcttta	cggcacctcg	4440
acccccaaaa	acttgattag	ggtgatggtt	cacgtagtgg	gccatcgccc	tgatagacgg	4500
ttttttcgcc	ttgacgcttg	gagtcacagt	cttttaatat	tggactcttg	ttccaaactg	4560
gaacaacact	caaccctatc	tcgggtctatt	cctttgattt	ataagggtat	ttggggattt	4620
ggcctatttg	gttaaaaaat	gagctgattt	aacaaaaatt	taacgcgaat	taattctgtg	4680
gaatgtgtgt	cagttagggt	gtggaaagtc	cccaggctcc	ccaggcaggc	agaagtatgc	4740
aaagcatgca	tctcaattag	tcagcaacca	ggtgtggaaa	gtccccaggc	tccccagcag	4800
gcagaagtat	gcaaagcatg	catctcaatt	agtcagcaac	catagtcccc	cccctaactc	4860
cgccccatcc	gccccctaact	ccgcccagtt	ccgcccattc	tcgccccat	ggctgactaa	4920
ttttttttat	ttatgcagag	gccgaggccg	cctctgcctc	tgagctattc	cagaagtatg	4980
gaggaggctt	ttttggaggc	ctaggctttt	gcaaaaagct	cccgggagct	tgtatatcca	5040
ttttcggtat	tgatcagcac	gtgttgacaa	ttaatcatcg	gcatagtata	tcggcatagt	5100
ataatacgac	aaggtgagga	actaaaccat	ggccaagtgt	accagtgccg	ttccggtgct	5160
caccgcgcgc	gacgtcgccg	gagcggtcga	gttctggacc	gaccggctcg	ggttctcccc	5220
ggacttcgtg	gaggacgact	tcgcccgtgt	ggtccgggac	gacgtgacct	tggtcatcag	5280
cgcggtccag	gaccaggtgg	tgccggacaa	caccctggcc	tgggtgtggg	tgcgcggcct	5340
ggcagagctg	tacgccaggt	ggtcggaggt	cgtgtccacg	aacttccggg	acgcctccgg	5400
gcgcggcatg	accgagatcg	gcgagcagcc	gtggggggcg	gagttcgccc	tgcgcgaccc	5460
ggcgggcaac	tgcggtgca	tcgtggccga	ggagcaggac	tgacacgtgc	tacgagattt	5520
ogattccacc	gccgccttct	atgaaaggtt	gggcttcgga	atcgttttcc	gggacgcggg	5580
ctggatgac	ctccagcgcg	gggatctcat	gctggagttc	ttcgccacc	ccaacttggt	5640
tattgcagct	tataatggtt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	5700
atttttttca	ctgcattcta	gttgtggttt	gtccaaactc	atcaatgtat	cttatcatgt	5760
ctgtataccg	tcgacctcta	gctagagctt	ggcgtaatac	tggtcatagc	tgtttctctg	5820
gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	taaagtgtaa	5880
agcctggggg	gcctaattgag	tgagctaact	cacattaatt	gcgttgcgct	cactgcccgc	5940
tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	atcgccaac	gcgcggggag	6000
aggcggtttg	cgtattgggc	gctcttccgc	ttcctcgctc	actgactcgc	tgcgctcggt	6060
cggttcggctg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	tatccacaga	6120
atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaagg	cagcaaaaag	ccaggaaacc	6180
taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	agcatcacia	6240
aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccagacagg	ctataaagat	accaggcggt	6300
tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	ccggatacct	6360
gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcacgct	gtaggtatct	6420
cagttcggtg	taggtcggtc	gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	6480
cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtc	aacccggtaa	gacacgactt	6540
atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtgc	6600

tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	tatttggtat	6660
ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	6720
acaaaccacc	gctggtagcg	gtgggttttt	tgtttgcaag	cagcagatta	cgcgagaaa	6780
aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	agtggaaacga	6840
aaactcacgt	taagggattt	tgggtcatgag	attatcaaaa	aggatcttca	cctagatcct	6900
tttaaattaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	cttgggtctga	6960
cagttaccaa	tgcttaatac	gtgaggcacc	tatctcagcg	atctgtctat	ttcgttcac	7020
catagttgcc	tgactccccg	tcgtgtagat	aactacgata	cgggagggct	taccatctgg	7080
ccccagtgt	gcaatgatac	cgcgagaccc	acgctcaccg	gctccagatt	tatcagcaat	7140
aaaccagcca	gccggaagg	ccgagcgag	aagtggctct	gcaactttat	ccgcctccat	7200
ccagtctatt	aattgttgcc	gggaagctag	agtaagtagt	tcgccagtta	atagtttgcg	7260
caacgttggt	gccattgcta	caggcatcgt	ggtgtcacgc	tcgtcgtttg	gtatggcttc	7320
attcagctcc	ggttcccaac	gatcaaggcg	agttacatga	tccccatgt	tgtgcaaaaa	7380
agcggttagc	tccttcgggtc	ctccgatcgt	tgtcagaagt	aagttggccg	cagtgttatc	7440
actcatgggt	atggcagcac	tgcataattc	tcttactgtc	atgccatccg	taagatgctt	7500
ttctgtgact	ggtgagtact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	7560
ttgctcttgc	cggcgctcaa	tacgggataa	taccgcgcca	catagcagaa	ctttaaaagt	7620
gctcatcatt	ggaaaacggt	cttcggggcg	aaaactctca	aggatcttac	cgctgttgag	7680
atccagttcg	atgtaaccca	ctcgtgcacc	caactgatct	tcagcatctt	ttactttcac	7740
cagcggttct	gggtgagcaa	aaacaggaag	gcaaaatgcc	gcaaaaaagg	gaataagggc	7800
gacacggaaa	tgttgaatac	tcatactctt	octttttcaa	tattattgaa	gcatttatca	7860
gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	7920
ggttcgcgcg	acatttcccc	gaaaagtgcc	acctgacgtc			7960

<210> 45

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 45

atgggatcca agatgaagcg cgcaagaccg

30

<210> 46

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 46

cactatagcg gccgcattct cagtcattct

30

<210> 47

<211> 7989

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 47

gacggatcgg	gagatctccc	gatcccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240

gattattgac	tagttattaa	tagtaataca	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcg	tggctgaccg	cccaacgacc	360
cccgcgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tattttacgg	aaactgccca	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgccacagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catggtgatg	cggtttttgg	agtagatcaa	tgggctgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggacttttcca	aaatgtcgtg	acaactccgc	ccatttgacg	caaatgggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctagc	900
gttttaaactt	aagcttggta	ccgagctcgg	atccactctc	ttccgcatcg	ctgtctgoga	960
gggcccagctg	ttgggggtgag	tactccctct	gaaaagcggg	catgacttct	gcgctaagat	1020
tgtcagtttc	caaaaacgag	gaggatttga	tattcacctg	gcccgcgggtg	atgcctttga	1080
gggtggccgc	atccatctgg	tcagaaaaga	caatcttttt	gttgtcaagc	ttggtggcaa	1140
acgacccgta	gagggcggtg	gacagcaact	tggcgatgga	gcgcagggtt	tgggttttgt	1200
cgcgatcggc	gcgctccttg	gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	1260
gccattcggg	aaagacgggtg	gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggg	1320
tgtgcagggt	gacaagggtca	acgctgggtg	ctacctctcc	gcgtaggcgc	tcgttgggtcc	1380
agcagaggcg	gcccgccttg	cgcgagcaga	atggcggtag	ggggtctagc	tgcgtctcgt	1440
ccgggggggtc	tgcgtccacg	gtaaagacct	cgggcagcag	gcgcgcgctc	aagtagtcta	1500
tcttgcatcc	ttgcaagtct	agcgctcgct	gccattgcgc	ggcggcaagc	gcgcgctcgt	1560
atgggttgag	tgggggaccc	actggcatgg	ggtgggtgag	cgcgaggcgc	tacatgccgc	1620
aaatgtcgtg	aacgtagagg	ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	1680
caccgcggat	gctggcgcgc	acgtaatcgt	atagttcgtg	cgaggagcgc	aggaggctcg	1740
gaccgagggt	gctacggggc	ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	1800
gtgagttgga	tgatatgggt	ggacgctgga	agacgttgaa	gctggcgtct	gtgagacctc	1860
ccgcgtcacg	cacgaaggag	gcgtaggagt	cgcgcagctt	gttgaccagc	tcggcggtga	1920
cctgcacgtc	tagggcgcag	tagtccaggg	tttcttgat	gatgtcatac	ttatcctgtc	1980
cctttttttt	ccacagctcg	cggttgagga	caaactcttc	gcggctcttc	cagtactctt	2040
ggatcggaaa	cccgtcggcc	tcogaacgag	atccgtactc	cgcgcgcgag	ggacctgagc	2100
gagtcgcgat	cgaccggatc	ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagtcg	2160
caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggctct	ccaactgtgc	cttttcttac	tcctcccttt	gtatccccc	2280
atgggtttca	agagagtcoc	cctggggtcg	tctctttgcg	cctatccgaa	cctctagtta	2340
cctccaatgg	catgctttgc	ctcaaatggg	gcaacggcct	ctctctggac	gaggccggca	2400
accttacctc	ccaaaatgta	accactgtga	gccacctct	caaaaaaacc	aagtcaaaca	2460
taaacctgga	aatatctgca	cccctcacag	ttacctcaga	agccctaact	gtggctgccg	2520
ccgcacctct	aatggtcgcg	ggcaacacac	tcacctgca	atcacaggcc	ccgctaaccg	2580
tgcacgactc	caaacttagc	attgccaccc	aaggacccct	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	cccctcacca	aacccgatag	cagtaccctt	actatcactg	2700
cctcaccccc	tctaactact	gccactggta	gcttgggcat	tgacttgaaa	gagcccattt	2760
atacacaaaa	tggaaaacta	ggactaaagt	acggggctcc	tttgcagtga	acagacgacc	2820
taaacacttt	gaccgtagca	actggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacaggggcc	tctttttata	aactcagccc	3060
acaacttggg	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacctc	agcactggca	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcacctaa	tgcaccaaac	acaaatcccc	3240
tcaaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	ggtccaaaac	cagaagccaa	ctgcataatt	gaatacggga	3420
aacaaaaccc	agatagcaaa	ctaactttta	tccttgtaaa	aaatggagga	attgtttaatg	3480
gatatgtaac	gtagatggga	gcctaagctt	acgttaaacac	cttattttaa	aacaaaaatg	3540
tctccattaa	tgtagaacta	tactttgatg	ccactgggtc	tatattacca	gactcatctt	3600
ctcttaaaac	agatctagaa	ctaaaataca	agcaaaccgc	tgactttagt	gcaagagggtt	3660
ttatgccaa	tactacagcg	tatccatttg	tccttcctaa	tgcgggaaca	cataatgaaa	3720
attatatttt	tggccaatgc	tactacaaag	caagcgatgg	tgcccttttt	ccgttggaag	3780
ttactgttat	gcttaataaa	cgctgccag	atagtcgcac	atcctatggt	atgacttttt	3840
tatggctcct	gaatgctggg	ctagctccag	aaactactca	ggcaaccctc	ataacctccc	3900
catttacctt	ttcctatatt	agagaagatg	actgattttt	aagaagcggc	cgctcgagtc	3960

tagaggggccc	gttttaaacc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	4020
tgttgttttc	ccctcccccg	tgccttcctt	gaccttgga	ggtgccactc	ccactgtcct	4080
ttcctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	4140
gggtgggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	4200
ggatgcggtg	ggctctatgg	cttctgaggc	ggaaagaacc	sncntagct	ggggtcttag	4260
ggggtatccc	cacgcgccct	gtagcggcgc	attaagcgcg	gcgggtgtgg	tggttacgcg	4320
cagcgtgacc	gctacacttg	ccagcgcctt	agcgcgcctt	cctttcgctt	tcttcccttc	4380
ctttctcgcc	acgttcgcgc	gctttccccg	tcaagctcta	aatcggggca	tcccttttag	4440
gttccgattt	agtgttttac	ggcacctcga	ccccaaaaa	cttgattagg	gtgatggttc	4500
acgtagtggg	ccatcgccct	gatagcgggt	ttttcgccct	ttgacgttgg	agtccacgtt	4560
ctttaatagt	ggactcttgt	tccaaactgg	aacaacactc	aaccctatct	cggtctattc	4620
ttttgattta	taagggattt	tggggatttc	ggcctattgg	ttaaaaaatg	agctgattta	4680
acaaaaatth	aacgcgaatt	aattctgtgg	aatgtgtgtc	agttagggtg	tggaaagtcc	4740
ccaggctccc	caggcaggca	gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	4800
gtgtggaaaag	tccccaggct	ccccagcagg	cagaagtatg	caaagcatgc	atctcaatta	4860
gtcagcaacc	atagctccgc	ccctaactcc	gcccattccc	cccctaactc	cgcccagttc	4920
cgccattctt	ccgccccatg	gctgactaat	tttttttatt	tatgcagagg	ccgaggccgc	4980
ctctgcctct	gagctattcc	agaagtagtg	aggaggcttt	tttggaggcc	taggcttttg	5040
caaaaagctc	ccgggagctt	gtatatccat	tttcggatct	gatcagcacg	tgttgacaat	5100
taatcatcgg	catagtatat	cggcatagta	taatacgaca	aggtgaggaa	ctaaaccatg	5160
gccaagttga	ccagtgcctg	tccggtgctc	accgcgcgcg	acgtcgccgg	agcggctcag	5220
ttctggaccg	accggctcgg	gttctcccgg	gactctgtgg	aggacgactt	cgccggtgtg	5280
gtccgggacg	acgtgaccct	gttcacacag	gcggtccagg	accaggtggt	gccggacaac	5340
accctggcct	gggtgtgggt	gcgcggcctg	gacgagctgt	acgccgagtg	gtcggaggtc	5400
gtgtccacga	acttccggga	cgctccgggg	ccggccatga	ccgagatcgg	cgagcagccg	5460
tggggggcggg	agttcgccct	gcgcgacccg	gccggcaact	gcgtgcactt	cgtggcccgag	5520
gagcaggact	gacacgtgct	acgagatttc	gattccaccg	ccgccttcta	tgaagggttg	5580
ggcttcggaa	tgcgtttccc	ggacgcggcg	tggatgatcc	tcagcgcggg	ggatctcatg	5640
ctggagttct	tcgcccaccc	caacttggtt	attgcagctt	ataatggtta	caaataaagc	5700
aatagcatca	caaatttcac	aaataaaagca	tttttttcac	tgcattctag	ttgtggtttg	5760
tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	cgacctctag	ctagagcttg	5820
gcgtaatcat	ggtcatagct	gtttcctgtg	tgaatgtgtt	atccgctcac	aattccacac	5880
aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	cctaattgagt	gagctaaactc	5940
acattaattg	cgttgcgctc	actgcccgcct	ttccagtcgg	gaaacctgtc	gtgccagctg	6000
cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	gtattgggcg	ctcttccgct	6060
tctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	atcagctcac	6120
tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	acgcaggaaa	gaacatgtga	6180
gcaaaaggcc	agcaaaaggc	caggaaccgt	aaaaaggccg	cgttgctggc	gtttttccat	6240
aggctccgcc	cccctgacga	gcatcacaaa	aatcgacgct	caagtccagag	gtggcgaaac	6300
ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	gctccctcgt	gcgctctcct	6360
gttccgaccc	tgcgcgttac	cggatacctg	tccgcctttc	tcccttcggg	aagcgtggcg	6420
ctttctcaat	gctcacgctg	taggtatctc	agttcggtgt	aggtcggtcg	ctccaagctg	6480
ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatcgt	6540
cttgagtcca	acccggtaag	acacgactta	tcgccactgg	cagcagccac	tggtaacagg	6600
attagcagag	cgaggatagt	aggcgggtgt	acagagttct	tgaagtgggtg	gcctaactac	6660
ggctacacta	gaaggacagt	atttggtatc	tgcgctctgc	tgaagccagt	taccttcgga	6720
aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	ctggtagcgg	tggttttttt	6780
gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	6840
tctacggggt	ctgacgctca	gtggaacgaa	aactcacgtt	aagggatttt	ggtcatgaga	6900
ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagtth	taaataaatc	6960
taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	tgaggcacct	7020
atctcagcga	tctgtctatt	tgcgttatcc	atagttgcct	gactccccgt	cgtgtagata	7080
actacgatac	gggagggtct	accatctggc	cccagtgtct	caatgatacc	gcgagaccga	7140
cgctcaccgg	ctccagattc	atcagcaata	aaccagccag	ccggaagggc	cgagcgacga	7200
agtggctcctg	caactttatc	cgctccatc	cagctcatta	attgttgccg	ggaagctaga	7260
gtaagttagtt	cgccagttaa	tagtttgccg	aacgttggtg	ccattgctac	aggcatcggt	7320
gtgtcacgct	cgctcgtttg	tatggcttca	ttcagctccg	gttcccaacg	atcaaggcga	7380
gttacatgat	cccccatggt	gtgcaaaaaa	gcggttagct	ccttcgggtc	tccgatcggt	7440
gtcagaagta	agttggccgc	agtgttatca	ctcatggtta	tggcagcact	gcataattct	7500
cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtactc	aaccaagtca	7560
ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	cgcgctcaat	acgggataat	7620
accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacgttc	ttcggggcga	7680

aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	tgtaacccac	tcgtgcaccc	7740
aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	ggtgagcaaa	aacaggaagg	7800
caaaatgccg	caaaaaaggg	aataagggcg	acacggaaat	gttgaatact	catactcttc	7860
ctttttcaat	attattgaag	catttatcag	ggttattgtc	tcatgagcgg	atacatattt	7920
gaatgtattt	agaaaaataa	acaaataggg	gttccgcgca	catttccccg	aaaagtgcc	7980
cctgacgtc						7989

<210> 48

<211> 7607

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 48

tctagaagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	gtacaggatg	60
ttctagctac	tttattagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	120
gtacaggatg	ttctagctac	tttattagat	ccgctgtacag	gatgttctag	ctactttatt	180
agatcgatct	cctggccggt	cggggtcaaa	aaccagggtt	ggctataaaa	gggggtgggg	240
gcgcgttcgt	cctcactctc	ttccgcatcg	ctgtctgcga	gggccaggat	cgatccctgag	300
aacttcaggg	tgagtttggt	gacccttgat	tgttctttct	ttttcgctat	tgtaaaattc	360
atgttatatg	gagggggcaa	agttttcagg	gtgttggtta	gaatgggaag	atgtcccttg	420
tatcaccatg	gaccctcatg	ataattttgt	ttctttcact	ttctactctg	ttgacaacca	480
ttgtctcctc	ttattttctt	ttcattttct	gtaacttttt	cgttaaactt	tagcttgcat	540
ttgtaacgaa	tttttaaaat	cacttttggt	tatttgtcag	attgtaagta	ctttctctaa	600
tcactttttt	ttcaaggcaa	tcagggtata	ttatattgta	cttcagcaca	gttttagaga	660
acaattgtta	taattaaatg	ataaggtaga	atattttctgc	atataaaatc	tggttggtg	720
ggaaatatc	ttattggtag	aaacaactac	atcctggtca	tcactcctgc	tttctcttta	780
tggttacaa	gatatacact	gtttgagatg	aggataaaat	actctgagtc	caaaccgggc	840
ccctctgcta	accatgttca	tgccttcttc	tttttcctac	agctcctggg	caacgtgctg	900
gttattgtgc	tgtctcatca	ttttggcaaa	gaattagatc	taagcttctg	cagctcgagg	960
actcggctga	ctgaaaatga	gacatattat	ctgccacgga	ggtgttatta	ccgaagaaat	1020
ggccgcaggt	cttttggacc	agctgactga	agaggactcg	gctgataatc	ttccacctcc	1080
tagccatttt	gaaccacctc	cccttcacga	actgtatgat	ttagacgtga	cgcccccgga	1140
agatcccaac	gaggaggcgg	tttcgcagat	ttttcccgac	tctgtaatgt	tgccggtgca	1200
ggaagggtat	gacttactca	cttttccgco	ggcgcccggt	tctccggagc	cgcctcacct	1260
ttcccggcag	cccagacagc	cggagcagag	agccttgggt	ccggtttcta	tgccaaacct	1320
tgtaccggag	gtgatcgatc	ttacctgcca	cgaggctggc	tttccacca	gtgacgacga	1380
ggatgaagag	ggtgaggagt	ttgtgttaga	ttatgtggag	caccccgggc	acggttgtag	1440
gtcttgcata	tatcacggga	ggaatacggg	ggaccagat	attatgtgtt	cgctttgcta	1500
tatgaggacc	tgtggcatgt	ttgtctacag	taagtgaata	ttatgggcag	tggttgatag	1560
agtgggtggg	ttgggtgtgt	aatttttttt	ttaattttta	cagttttgtg	gtttaaagaa	1620
ttttgtattg	tgattttttt	aaaaggctct	gtgtctgaac	ctgagcctga	gcccagacca	1680
gaaccggagc	ctgcaagacc	tacccgcgct	cctaaaatgg	cgctgtctat	cctgagacgc	1740
ccgacatcac	ctgtgtctag	agaatgcaat	agtagctacg	atagctgtga	ctccggtcct	1800
tctaaccacac	ctcctgagat	acaccgggtg	gtcccgctgt	gccccattaa	accagttgcc	1860
gtgagagttg	gtgggcgtcg	ccaggctgtg	gaatgtatcg	aggacttgct	taacgagcct	1920
gggcaacctt	tggaacttgag	ctgtaaaccg	cccaggccat	aagggtgtaa	cctgtgattg	1980
cgtgtgtggt	taacgccttt	gtttgctgaa	tgagttgatg	taagttaa	aaagggtgag	2040
ataatgttta	acttgcattg	cgtgttaaat	ggggcggggc	ttaaagggtg	tataatgcgc	2100
cgtgggctaa	tcttggttac	atctgacctc	atggaggctt	gggagtgttt	ggaagatttt	2160
tctgctgtgc	gtaacttgct	ggaacagagc	tctaacagta	cctcttggtt	ttggaggttt	2220
ctgtggggct	catcccaggc	aaagttagtc	tgcagaatta	aggaggatta	caagtgggaa	2280
tttgaagagc	ttttgaaatc	ctgtggtgag	ctgtttgatt	ctttgaatct	gggtcaccag	2340
gcgcctttcc	aagagaaggt	catcaagact	ttggattttt	ccacaccggg	gcgcgctgcg	2400
gctgctgttg	cttttttgag	ttttataaag	gataaatgga	gcgaagaaac	ccatctgagc	2460
gggggggtacc	tgctggattt	tctggccatg	catctgtgga	gagcggttgt	gagacacaag	2520
aatcgccctgc	tactgttgct	ttccgtccgc	ccggcgataa	taccgacgga	ggagcagcag	2580
cagcagcagg	aggaagccag	gcggcgggcg	caggagcaga	gcccatggaa	cccagagacc	2640
ggcctggacc	ctcgggaatg	aatgttgtac	aggtggctga	actgtatcca	gaactgagac	2700

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

gcattttgac	aattacagag	gatgggcagg	ggctaaagg	ggtaaagagg	gagcgggggg	2760
cttgtagggc	tacagaggag	gctaggaatc	tagcttttag	cttaatgacc	agacaccgtc	2820
ctgagtgtat	tacttttcaa	cagatcaagg	ataattgcgc	taatgagctt	gatctgctgg	2880
cgcagaagta	ttccatagag	cagctgacca	cttactggct	gcagccagg	gatgattttg	2940
aggaggctat	tagggtatat	gcaaagggtg	cacttaggcc	agattgcaag	tacaagatca	3000
gcaaacttgt	aaatatcagg	aattgtttgct	acatttctgg	gaacggggcc	gaggtggaga	3060
tagatacggg	ggataggggtg	gccttttagat	gtagcatgat	aaatatgtgg	ccgggggtgc	3120
ttggcatgga	cgggggtgggt	attatgaatg	taaggtttac	tggccccaat	tttagcggta	3180
cggttttcct	ggccaataacc	aaccttatcc	tacacgggtg	aagcttctat	gggtttaaca	3240
atacctgtgt	ggaagcctgg	accgatgtaa	gggttcgggg	ctgtgccttt	tactgctgct	3300
ggaagggggg	ggtgtgtcgc	cccaaaagca	gggttcaat	taagaaatgc	ctctttgaaa	3360
ggtgtacctt	gggtatcctg	tctgagggta	actccagggt	gcgccacaat	gtggcctccg	3420
actgtgggtg	cttcatgcta	gtgaaaagcg	tggctgtgat	taagcataac	atggtatgtg	3480
gcaactgcga	ggacagggcc	tctcagatgc	tgacctgctc	ggacggcaac	tgtcacctgc	3540
tgaagaccat	tcacgtagcc	agccactctc	gcaaggcctg	gccagtgttt	gagcataaca	3600
tactgaccgg	ctgttccttg	catttgggta	acaggagggg	ggtgttccta	ccttaccat	3660
gcaatttgag	tcacactaag	atattgcttg	agcccagag	catgtccaag	gtgaacctga	3720
acgggggtgt	tgacatgacc	atgaagatct	ggaagggtgt	gaggtacgat	gagaccgcga	3780
ccagggtgcg	accctgcgag	tgtggcggta	aacatattag	gaaccagcct	gtgatgctgg	3840
atgtgaccga	ggagctgagg	cccgatcact	tgggtgctgg	ctgcaccgcg	gctgagtttg	3900
gctctagcga	tgaagataca	gattgaggta	ctgaaatgtg	tgggcgtggc	ttaaggggtg	3960
gaaagaatat	ataaggtggg	ggtcttatgt	agttttgtat	ctgttttgca	gcagccggcg	4020
ccgccatgag	caccaactcg	tttgatggaa	gcattgtgag	ctcatatttg	acaacgcgca	4080
tgcccccatg	ggccgggggtg	cgtcagaaatg	tgatgggctc	cagcattgat	ggtcgccccg	4140
tctgccccgc	aaactctact	accttgacct	acgagaccgt	gtctggaacg	ccgttgaggga	4200
ctgcagcctc	cgccgcgctg	tcagccgctg	cagccaccgc	ccgcgggatt	gtgactgact	4260
ttgctttcct	gagcccgctt	gcaagcagtg	cagcttcccg	ttcatccgcc	cgcgatgaca	4320
agttgacggc	tcttttgcca	caattggatt	ctttgaccgg	ggaacttaac	gtcgtttctc	4380
agcagctggt	ggatctgcgc	cagcaggttt	ctgcctgtaa	ggcttctctc	cctcccaatg	4440
cgggtttaaaa	cataaataaa	aaaccagact	ctgtttggat	ttggatcaag	caagtgtctt	4500
gctgtctcag	ctgactgctt	aagtcgcaag	ccgaattgga	tccaattcgg	atcgatctta	4560
ttaaagcaga	acttgtttat	tgcagcttat	aatggttaca	aataaagcaa	tagcatcaca	4620
aatttcacaa	ataaagcatt	tttttcaactg	cattctagtt	gtggtttgtc	caaactcatc	4680
aatgtatctt	atcatgtctg	gtcgactcta	gactcttccg	cttctctcgt	cactgactcg	4740
ctgcgctcgg	tcttctcggt	gcggcgagcg	gtatcagctc	actcaaaggc	ggtaatacgg	4800
ttatccacag	aactcagggga	taacgcagga	agaacatgt	gagcaaaagg	ccagcaaaag	4860
gccaggaacc	gtaaaaaggc	cgctgtgctg	gcgtttttcc	ataggctccg	ccccctgac	4920
gagcatcaca	aaaatcgacg	ctcaagtcag	aggtggcgaa	acccgacagg	actataaaga	4980
taccaggcgt	ttccccctgg	aagctccctc	gtgcgctctc	ctgttccgac	cctgccgctt	5040
accggatacc	tgtccgcctt	tctcccttcg	ggaagcgtgg	cgctttctca	tagctcacgc	5100
tgtaggtatc	tcagttcggg	gtaggtcggt	cgctccaagc	tgggctgtgt	gcacgaacc	5160
ccggttcagc	ccgaccgctg	cgccttatcc	ggtaactatc	gtcttgagtc	caaccgggta	5220
agacacgact	tatcgccact	ggcagcagcc	actggttaaca	ggattagcag	agcgagggtat	5280
gtaggcgggtg	ctacagagtt	cttgaagtgg	tggcctaact	acggctacac	tagaaggaca	5340
gtattttggta	tctgcgctct	gctgaagcca	gttaccttcg	gaaaaagagt	tggtagctct	5400
tgatccggca	aacaaaccac	cgctggtagc	ggtggttttt	ttgtttgcaa	gcagcagatt	5460
acgcgcagaa	aaaaaggatc	tcaagaagat	cctttgatct	tttctacggg	gtctgacgct	5520
cagtggaaag	aaaactcacg	ttaagggtat	ttggtcatga	gattatcaaa	aaggatcttc	5580
acctagatcc	ttttaaatta	aaaatgaagt	tttaaatcaa	tctaaagtat	atatgagtaa	5640
acttggtctg	acagttacca	atgcttaatc	agtgaaggac	ctatctcagc	gatctgtcta	5700
tttctgttcat	ccatagttgc	ctgactcccc	gtcgtgtaga	taactacgat	acgggagggc	5760
ttaccatctg	gccccagtg	tgcaatgata	ccgcgagacc	cacgctcacc	ggctccagat	5820
ttatcagcaa	taaaccagcc	agccggaagg	gccgagcgca	gaagtgggtc	tgcaacttta	5880
tccgcctcca	tccagttctat	taattgttgc	cgggaagcta	gagtaagtag	ttcgccagtt	5940
aatagtttgc	gcaacgtttg	tgccattgct	acaggcatcg	tgggtgtcag	ctcgtcggtt	6000
gggtatggctt	cattcagctc	cggttcccaa	cgatcaaggc	gagttacatg	atcccccatg	6060
ttgtgcaaaa	aagcgggttag	ctccttcggt	cctccgatcg	ttgtcagaag	taagttggcc	6120
gcagtgttat	cactcatggg	tatggcagca	ctgcataatt	ctcttactgt	catgccatcc	6180
gtaagatgct	tttctgtgac	tgggtgagtac	tcaaccaagt	cattctgaga	atagtgtatg	6240
cggcgaccga	gttgtctctt	ccggcgctca	atacgggata	ataccgcgcc	acatagcaga	6300
actttaaaag	tgtctcatcat	tggaaaacgt	tcttcggggc	gaaaactctc	aaggatctta	6360
ccgctgttga	gatccagttc	gatgtaacct	actcgtgcac	ccaactgatc	ttcagcatct	6420

```

tttacttttca ccagcggtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
ggaataaggg cgacacggaa atgttgaata ctcatactct tccttttttca atattattga 6540
agcatttatc aggggttattg tctcatgagc ggatacatat ttgaatgtat tttagaaaaat 6600
aaacaaatag ggggttccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaaat aggcgtatca cgaggccoct ttcgtctcgc 6720
gcgtttcggt gatgacgggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttg 6840
cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca 6900
tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960
agcgtaata ttttgttaaa attcgcgtta aattttttgt aaatcagctc attttttaac 7020
caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg 7080
agtgttggtc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140
gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200
tttttggggg cgagggtgccg taaagcacta aatcggaacc ctaaaggagg cccccgattt 7260
agagcttgac ggggaaagcc ggcgaaacgtg gcgagaaagg aagggaagaa agcgaaagga 7320
gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacaccgcc 7380
gcgcttaatg cgccgctaca gggcgcgctc cattcgccat tcaggctgcg caactgttg 7440
gaaggcgcat cgggtcgggc ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct 7500
gcaaggcgat taagttgggt aacgccaggg ttttcccagt cagcagcttg taaaacgacg 7560
gccagtgaat tgtaatacga ctactatag ggcgaattaa ttcgggg 7607

```

<210> 49

<211> 11600

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 49

```

gaattccgca ttgcagagat attgtattta agtgcctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggt gtgcacctcc aagcttgggc agaaatgggt gaactcccga 120
gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgaccgc 180
tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcacaaact 240
ggcatagctc tgctttgcct ggggctattg ggggaagtgt cggttcgtgc tcgcagggct 300
ctcacccctg actcttttaa tagctcttct gtgcaagatt acaatctaaa caattcggag 360
aactcgacct tcctcctgag gcaaggacca cagccaactt cctcttataa gccgcatcga 420
ttttgtcctt cagaaataga aataagaatg cttgctaaaa attatatttt taccaataag 480
accaatccaa taggtagatt attagttact atgttaagaa atgaatcatt atcttttagt 540
actattttta ctcaaattca gaagttagaa atgggaatag aaaaatagaaa gagacgctca 600
acctcaattg aagaacagggt gcaaggacta ttgaccacag gcctagaagt aaaaaaggga 660
aaaaagagtg tttttgtcaa aataggagac aggtggtggc aaccagggac ttatagggga 720
ccttacatct acagaccaac agatgcccc ttaccatata caggaagata tgacttaaat 780
tgggataggt gggttacagt caatggctat aaagtgttat atagatccct cccttttcgt 840
gaaagactcg ccagagctag acctccttgg tgtatgttgt ctcaagaaga aaaagacgac 900
atgaaacaac aggtacatga ttatatttat ctaggaacag gaatgcactt ttggggaaaag 960
attttccata ccaaggaggg gacagtggct ggactaatag aacattattc tgcaaaaact 1020
catggcatga gttattatga atagccttta ttggcccaac cttgcggttc ccagggctta 1080
agtaagtttt tggttacaaa ctgttcttaa aacgaggatg tgagacaagt ggtttcctga 1140
cttggttttg tatcaaaggt tctgatctga gctctgagtg ttctattttc ctatgttctt 1200
ttggaattta tccaaatctt atgtaaatgc ttatgtaaac caagatataa aagagtgtctg 1260
attttttgag taaacttgca acagtcctaa cattcacctc ttgtgtgttt gtgtctgttc 1320
gccatcccggt ctccgctcgt cacttatcct tcactttcca gagggteccc ccgcagacc 1380
cggcgacct caggtcggcc gactgcggca cgtggcgccc gaacagggac cctcgataa 1440
gtgacccttg tctctatttc tactatttgg tgtttgtctt gtattgtctc tttcttgtct 1500
ggctatcatc acaagagcgg aacggactca ccatagggac caagctagcg cttctcgtcg 1560
cgtccaagac cctcaaagat ttttggcact tcgttgagcg aggcgatatc aggtatgaca 1620
gcgccctgcc gcaaggccag ctgcttgtcc gctcggctgc ggttggcacg gcaggatagg 1680
ggtatcttgc agttttggaa aaagatgtga taggtggcaa gcacctctg caccgcaaat 1740
acggggtaga agttgaggcg cgggttgggc tcgcatgtgc cgttttcttg gcgtttgggg 1800
ggtacgcgcg gtgagaatag gtggcgcttc taggcaaggc tgacatccgc tatggcgagg 1860

```

ggcacatcgc	tgcgctcttg	caacgcgctcg	cagataatgg	cgcactggcg	ctgcagatgc	1920
ttcaacagca	cgtcgtctcc	cacatctagg	tagtcgccat	gcctttcgtc	cccccgcccg	1980
acttgttcct	cgtttgccctc	tgcgttgctcc	tggtcttgct	ttttatcctc	tgttggtact	2040
gagcggtcct	cgtcgtcttc	gcttacaaaa	cctgggtcct	gctcgataat	cacttcctcc	2100
tcctcaagcg	ggggtgcctc	gacggggaag	gtggtaggcg	cgttggcggc	atcggtggag	2160
gcggtggtgg	cgaactcaga	ggggggcggtt	aggctgtcct	tcttctcgac	tgactccatg	2220
atctttttct	gcctatagga	gaaggaaatg	gccagtcggg	aagaggagca	gcgcgaaacc	2280
acccccgagc	gcggacgcgg	tgcggcgcgga	cgccccccaa	ccatggagga	cggtgcgtcc	2340
ccgtccccgt	cgccgcgcgc	tccccgggcg	cccccaaaaa	agcggatgag	gcggcggtac	2400
gagtcggagg	acgaggaaga	ctcatcacia	gacgcgctgg	tgccgcgcac	acccagcccg	2460
cggccatcga	cctcggcggc	ggattttggc	attgcgcca	agaagaaaaa	gaagcgccct	2520
tcctccaagc	ccgagcgccc	gccatcacca	gaggtaatcg	tggacagcga	ggaagaaaga	2580
gaagatgtgg	cgctacaaat	ggtgggtttc	agcaaccac	cggtgcta	caagcatggc	2640
aaaggaggta	agcgcacagt	gcggcggtcg	aatgaagacg	acccagtggc	gcgtggtatg	2700
cggacgcaag	aggaagagga	agagcccagc	gaagcggaaa	gtgaaattac	ggtgatgaac	2760
ccgctgagtg	tgccgatcgt	gtctgcgtgg	gagaagggca	tggaggctgc	gcgcgcgctg	2820
atggacaagt	accacgtgga	taacgatcta	aaggcgaaact	tcaaactact	gcctgaccaa	2880
gtggaagctc	tggcgccgct	atgcaagacc	tggtgaaacg	aggagcaccg	cggttgtagc	2940
ctgaccttca	ccagcaacaa	gacctttgtg	acgatgatgg	ggcgattcct	gcaggcgtag	3000
ctgcagtcgt	ttgcagaggt	gacctacaag	catcacgagc	ccacgggctg	cgcttggtgg	3060
ctgcaccgct	gcgctgagat	cgaaggcgag	cttaagtgtc	tacacggaag	cattatgata	3120
aataaggagc	acgtgattga	aatggatgtg	acgagcgaaa	acgggcagcg	cgcgctgaag	3180
gagcagtcct	gcaaggccaa	gatcgtgaag	aaccggtggg	gccgaaatgt	ggtgcagatc	3240
tccaacaccg	acgcaagggtg	ctgcgtgcac	gacgcggcct	gtccggccaa	tcagttttcc	3300
ggcaagtctt	gcggcatggt	cttctctgaa	ggcgcaaagg	ctcaggtggc	ttttaagcag	3360
atcaaggctt	ttatgcaggc	gctgtatcct	aacgcccaga	cogggcacgg	tcaccttttg	3420
atgccactac	ggtgcgagtg	caactcaaaag	cctgggcacg	cgcccttttt	gggaaggcag	3480
ctaccaaaag	tgactccggt	cgccctgagc	aacgcggagg	acctggacgc	ggatctgatc	3540
tccgacaaga	gcgtgctggc	cagcgtgcac	caccggcgcg	tgatagtgtt	ccagtgtgct	3600
aaccctgtgt	atcgcaactc	gcgcgcgcag	ggcgaggacc	ccaactgcga	cttcaagata	3660
tcggcgcccg	acctgctaaa	cgctgtcgag	atggtgcgca	gcctgtggag	tgaaaacttc	3720
accgagctgc	cgcgatggt	tgtgcctgag	tttaagtgga	gcactaaaca	ccagtatcgc	3780
aacgtgtccc	tgccagtggc	gcatagcgat	gcgcggcaga	acccctttga	tttttaaacg	3840
gcgcagacgg	caagggtggg	ggtaaaataat	caccgcgagag	tgtacaaata	aaagcatttg	3900
cctttattga	aagtgtctct	agtacattat	ttttacatgt	ttttcaagtg	acaaaaagaa	3960
gtggcgctcc	taatctgcgc	actgtggctg	cggaaagttag	gcgagtggcg	ctccaggaaag	4020
ctgtagagct	gttcctgggt	gcgacgcagg	gtgggctgta	cctggggact	ggtgagcatg	4080
gagttgggta	ccccggtaat	aaagttcatg	gtgggggttg	gatccatggg	agtttggggc	4140
cagttggcaa	aggcgtggag	aaacatgcag	cagaatagtc	cacaggcggc	cgagttgggc	4200
ccctgtacgc	tttgggtgga	cttttccagc	gttatacagc	ggtcggggga	agaagcaatg	4260
gcgctacggc	gcaggagtga	ctcgtactca	aactggtaaa	cctgcttgag	tcgctggtca	4320
gaaaagccaa	agggtcctaaa	gaggtagcat	gtttttgagt	gcgggttcca	ggcaaaggcc	4380
atccagtgtg	cgccccagct	ctcgcgaccg	gcctgtattga	ctatggcgca	ggcgagcttg	4440
tgtggagaaa	caaagcctgg	aaagcgcttg	tcataggtgc	ccaaaaata	tggcccacaa	4500
ccaagatctt	tgacaatggc	tttcagttcc	tgctcactgg	agcccatggc	ggcagctggt	4560
ggtgatgttg	cttgcttctt	tatgtttggt	cgttgccggc	cgagaagggc	gtgcgcaggt	4620
acacggtttc	gatgacgcgc	cggtgcggcc	ggtgcacacg	gaccacgtca	aagacttcaa	4680
acaaaacata	aagaagggtg	ggctcgtcca	tgggatccat	atatagggcc	cggtttataa	4740
ttacctcagg	tcgacctcga	gggatctttg	tgaaggaaacc	ttacttctgt	ggtgtgacat	4800
aatttgacaa	actacctaca	gagattttaa	gctctaaggt	aaatataaaa	tttttaagtg	4860
tataatgtgt	taaactactg	attctaattg	tttgtgtatt	ttagattcca	acctatggaa	4920
ctgatgaatg	ggagcagtg	tggaatgcct	ttaatgagga	aaacctgttt	tgctcagaag	4980
aaatgccatc	tagtgatgat	gaggctactg	ctgactctca	acattctact	cctccaaaaa	5040
agaagagaaa	ggtagaagac	cccaaggact	ttccttcaga	attgctaagt	tttttgagtc	5100
atgctgtgtt	tagtaataga	actccttgctt	gcttttgctat	ttacaccaca	aaggaaaaag	5160
ctgcactgct	atacaagaaa	attatggaaa	aatattctgt	aacctttata	agtaggcata	5220
acagttataa	tcataacata	ctgttttttc	ttactccaca	caggcataga	gtgtctgcta	5280
ttaataacta	tgctcaaaaa	ttgtgtacct	ttagcttttt	aatttgtaaa	ggggtaataa	5340
aggaatatatt	gatgtatagt	gccttgacta	gagatcataa	tcagccatac	cacatttgta	5400
gaggttttac	ttgcttttaa	aaacctccca	cacctccccc	tgaacctgaa	acataaaatg	5460
aatgcaattg	ttgtttgttaa	cttgttttatt	gcagcttata	atggttataa	ataaagcaat	5520
agcatcacia	atttcacaaa	taaagcattt	ttttcactgc	attctagtgt	tggtttgtcc	5580

aaactcatca	atgtatctta	tcatgtcttg	atccggctgt	ggaatgtgtg	tcagttaggg	5640
tgtggaaagt	ccccaggctc	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	5700
tcagcaacca	ggtgtggaaa	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	5760
catctcaatt	agtcagcaac	catagtcccg	cccctaactc	cgcccatccc	gcccctaact	5820
ccgcccagtt	ccgcccattc	tccgccccat	ggctgactaa	ttttttttat	ttatgcagag	5880
gccgaggccg	cctcggcctc	tgagctattc	cagaagtagt	gaggaggcct	ttttggaggc	5940
ctaggctttt	gcaaaaagct	tcacgctgcc	gcaagcactc	agggcgcaag	ggctgctaaa	6000
ggaagcggaa	cacgtagaaa	gccagtcggc	agaaacgggt	ctgaccccgg	atgaatgtca	6060
gctactgggc	tatctggaca	agggaaaaac	caagcgcaaa	gagaaagcag	gtagcttgca	6120
gtgggcttac	atggcgatag	ctagactggg	cggttttatg	gacagcaagc	gaaccggaat	6180
tgccagctgg	ggcgccctct	ggtaagggtt	ggaagccctg	caaagtaaac	tggatggctt	6240
tcttgccgcc	aaggatctga	tggcgccagg	gatcaagatc	tgatcaagag	acaggatgag	6300
gatcgtttgc	catgattgaa	caagatggat	tgacgcagcg	ttctccggcc	gcttgggtgg	6360
agaggctatt	cggctatgac	tgggcacaa	agacaatcgg	ctgctctgat	gccgccgtgt	6420
tccggctgtc	agcgcagggg	cgccccggtt	tttttgtcaa	gaccgacctg	tccggtgccc	6480
tgaatgaact	gcaggacgag	gcagcgccgc	tatctgtggc	ggccacgacg	ggcgttcctt	6540
gcgcagctgt	gctcgacgtt	gtcactgga	cggaagggga	ctggctgcta	ttgggcgaag	6600
tgccggggca	ggatctcctg	tcatctcacc	ttgctcctgc	cgagaaagta	tccatcatgg	6660
ctgatgcaat	gcggcggctg	catacgcttg	atccggctac	ctgcccattc	gaccaccaag	6720
cgaaacatcg	catcgagcga	gcacgtactc	ggatggaa	cggtcttgct	gatcaggatg	6780
atctggacga	agagcatcag	gggctcgccg	cagccgaact	gttcgccagg	ctcaaggcgc	6840
gcatgcccga	cggcgaggat	ctcgtcgtga	cccatggcga	tgctgcttgg	ccgaatatca	6900
tggtggaaaa	tggccgcttt	tgggatttca	tgcactgtgg	ccggctgggt	gtggcggaac	6960
gctatcagga	catagcgttg	gctaccctgt	atattgctga	agagcttggc	ggcgaatggg	7020
ctgaccgctt	cctcgtgctt	tacggtatcg	ccgctcccga	ttcgacgcgc	atcgccctct	7080
atcgccctct	tgacgagttc	ttctgagcgg	gactctgggg	ttcgaaatga	ccgaccaagc	7140
gacgccccac	ctgcccattc	gagattttcg	ttccaccgcc	gccttctatg	aaaggttggg	7200
cttcggaatc	gtttttccgg	acgcgcggct	gatgatectc	cagcgccggg	atctcatgct	7260
ggagttcttc	gcccaccctg	ggctcgcacc	cctcgcgagt	tggttcagct	gctgcctgag	7320
gctggacgac	ctcgcgaggt	tctaccggca	gtgcaaatcc	gtcggcatcc	aggaaaccag	7380
cagcggctat	ccgcgcattc	atgccccoga	actgcaggag	tggggaggca	cgatggccgc	7440
tttggtccc	gatctttgtg	aaggaacctt	acttctgtgg	tgtgacataa	ttggacaaac	7500
tacctacaga	gatttaaagc	tctaaggtaa	atataaaaat	tttaagtgtg	taatgtgtta	7560
aactactgat	tctaattggt	tgtgtatatt	agattccaac	ctatggaact	gatgaatggg	7620
agcagtgggt	gaatgccttt	aatgaggaaa	acctgttttg	ctcagaagaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac	attctactcc	tccaaaaaag	aagagaaagg	7740
tagaagacc	caaggacttt	ccttcagaat	tgttaagttt	tttgagtcac	gctgtgttta	7800
gtaatagaac	tcttgcttgc	tttgctatatt	acaccacaaa	ggaaaaagct	gcaactgctat	7860
acaagaaaat	tatggaaaaa	tattctgtaa	cctttataag	taggcataac	agttataatc	7920
ataacatact	gttttttctt	actccacaca	ggcatagagt	gtctgctatt	aataactagt	7980
ctcaaaaatt	gtgtaccttt	agctttttta	tttgtaaagg	ggttaataag	gaatatattga	8040
tgtatagtgc	ctgtactaga	gatcatacca	agccatacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctccccctg	aacctgaaac	ataaaatgaa	tgcaattggt	8160
gttgtttaact	tgttttattgc	agcttataat	ggttacaaat	aaagcaatag	catcacaaat	8220
ttcacaaata	aagcattttt	ttcactgcat	tctagtgttg	gtttgtccaa	actcatcaat	8280
gtatctttat	atgtctggat	ccccaggga	ctcctctgtg	tcctcataaa	ccctaacctc	8340
ctctacttga	gaggacattc	caatcatagg	ctgcccattc	accctctgtg	tcctcctgtt	8400
aatttaggtca	cttaacaaaa	aggaaattgg	gtagggggtt	ttcacagacc	gctttctaag	8460
ggtaattttta	aaatatctgg	gaagtccctt	ccactgctgt	gttccagaag	tgttggttaa	8520
cagcccacaa	atgtcaacag	cagaaacata	caagctgtca	gctttgcaca	agggcccaac	8580
accctgctca	tcaagaagca	ctgtgggtgc	tgtgttagta	atgtgcaaaa	caggaggcac	8640
attttcccca	cctgtgtagg	ttccaaaaata	tctagtgttt	tcatttttac	ttggatcagg	8700
aaccagcac	tccactggat	aagcattatc	cttatccaaa	acagccttgt	ggtcagtggt	8760
catctgctga	ctgtcaactg	tagcattttt	tgggggttaca	gtttgagcag	gatatttggg	8820
cctgtagttt	gctaacaacac	cctgcagctc	caaagggttc	ccaccaacag	caaaaaaatg	8880
aaaatttgac	ccttgcaatg	gttttccagc	accattttca	tgagtttttt	gtgtccctga	8940
atgcaagttt	aacatagcag	ttaccccaat	aacctcagtt	ttaacagtaa	cagcttccca	9000
catcaaaata	tttccacagg	ttaagtcctc	atttaaatta	ggcaaaaggaa	ttcttgaaga	9060
cgaaagggcc	tcgatgatac	cctattttta	taggttaatg	tcatgataat	aatggtttct	9120
tagacgtcag	gtggcacttt	tccgggaaat	gtgcgcggaa	cccctatttg	tttatttttc	9180
taaatacatt	caaatatgta	tccgctcatg	agacaataac	cctgataaat	gcttcaataa	9240
tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	tcgcccttat	tccttttttt	9300

gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 9360
gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 9420
cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 9480
tgtggcgcggt tattatccccg tgttgacgcc gggcaagagc aactcggtcg ccgcatacac 9540
tattctcaga atgacttgggt tgagtactca ccagtcacag aaaagcatct tacggatggc 9600
atgacagtaa gagaattatg cagtgtgcc ataaccatga gtgataacac tgcggccaac 9660
ttacttctga caacgatcgg aggaccgaag gagctaaccg cttttttgca caacatgggg 9720
gatcatgtaa ctgcgcttga tcgttgggaa cgggagctga atgaagccat accaaacgac 9780
gagcgtgaca ccacgatgcc tgcagcaatg gcaacaacgt tgcgcaaac attaaactggc 9840
gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagtt 9900
gcaggaccac ttctgcgtc ggcccttcgg gctggctgggt ttattgctga taaatctgga 9960
gccggtgagc gtgggtctcg cggatcatt gcagcactgg gccagatgg taagccctcc 10020
cgtatcgtag ttatctacac cagggggagt caggcaacta tggatgaacg aaatagacag 10080
atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 10140
tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc 10200
ctttttgata atctcatgac caaaatccct taacgtgagt ttctgttcca ctgagcgtca 10260
gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 10320
tgcttgcaaa caaaaaaac accgctacca gcggtggtt gtttgccgga tcaagagcta 10380
ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 10440
ctagtgtagc cgtagttagg ccaccaacttc aagaactctg tagcaccgcc tacataacctc 10500
gctctgctaa tcctgttacc agtggtgct gccagtgccg ataagtcgtg tcttaccggg 10560
ttggactcaa gacgatagtt accggataag gcgcagcggc cgggctgaac ggggggttcg 10620
tgcacacagc ccagcttggg gcgaacgacc tacaccgaac tgagatacct acagcgtgag 10680
ctatgagaaa gcgccacgct tcccgaaggg agaaaaggcg acaggtatcc ggtaagcggc 10740
agggtcgga caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 10800
agtctgtcg ggtttcgcca cctctgactt gagegtcgat ttttgtgatg ctctcagggg 10860
gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggctttttgc 10920
tggccttttg ctacatgtt ctttcctgcg ttatccctg attctgtgga taaccgtatt 10980
accgccttg agtgagctga taccgtcgc gcgagccgaa cgaccgagcg cagcgagtca 11040
gtgagcagg aagcggaaga gcgcctgatg cggatatttc tcttacgca tctgtgcggg 11100
atttcacacc gcatatgggt cactctcagt acaatctgct ctgatgccgc atagttaagc 11160
cagtatctgc tcctgcttg tgtgttggag gtcgctgagt agtgccgag caaaatttaa 11220
gctacaacaa ggcaaggctt gaccgacaat tgcataaga atctgcttag ggtaggcgt 11280
tttgcgctgc ttcgcatgt acgggccaga tatacgcgta tctgagggga ctagggtgtg 11340
tttaggcgaa aagcggggct tcggttgtag gcggttagga gtcccctcag gatatagtag 11400
tttcgctttt gcataggag ggggaaatgt agtcttatgc aatacacttg tagtcttgca 11460
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520
gattggtgga agtaaggtgg tacgatcgtg ccttatttag aaggcaacag acgggtctga 11580
catggattgg acgaaccact 11600

<220>

<223> Description of Artificial Sequence: plasmid

<400> 49

<210> 50

<211> 8238

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 50

gcggccgcca tcatcaataa tataccttat tttggattga agccaatatg ataatgaggg 60
ggttgagttt tgcagctggc gcggggcggt ggaacggggc gggtgacgta gtagtgtggc 120
ggaagtgtga tgttgcaagt gtggcggaac acatgtaagc gacggatgtg gcaaaagtga 180
cgtttttgggt gtgcgccggt gtacacagga agtgacaatt ttcgcgcggt tttaggcgga 240

tggtgtagta	aatttgggcg	taaccgagta	agattttggcc	atatttcgcg	gaaaactgaa	300
taagaggaag	tgaaatctga	ataattttgt	gttactcata	gocgctaata	tttgtctagg	360
gcgcggggga	ctttgaccgt	ttacgtggag	actcgccag	ggcgcgcccc	gatgtacggg	420
ccagatatac	gcgtatctga	ggggactagg	gtgtgtttag	gcgaaaagcg	gggcttcggg	480
tgtacgcggg	taggagtcgc	ctcaggatat	agtagtttcg	cttttgcata	gggaggggga	540
aatgtagtct	tatgcaatac	tcttgttagtc	ttgcaacatg	gtaacgatga	gttagcaaca	600
tgcccttaca	ggagagaaaa	agcaccgtgc	atgccgattg	gtggaagtaa	ggtggtacga	660
tcgtgcctta	ttaggaaggc	aacagacggg	tctgacatgg	attggacgaa	ccactgaatt	720
cgcattgca	gagatattgt	atttaagtgc	ctagctcgat	acaataaacg	ccatttgacc	780
attcaccaca	ttggtgtgca	cctccggccc	atatggccac	tctcttccgc	atcgctgtct	840
cggggggcca	gctgttgggc	tcgcggttga	ggacaaactc	ttcgcggtct	ttccagtagt	900
cttgatcgg	aaaccgcgcg	gcctccgaac	ggtactccgc	cgccgagggg	cctgagcgag	960
tcgcgatcga	ccggatcggg	aaacctctcg	agaaaggcgt	gtaaccagtc	acagtcgctc	1020
tagaactagt	ggatcccccg	ggctgcagga	attcgatgat	cttggtggcg	tgaaactccc	1080
gcacctcttt	ggcaagcgcc	ttgtagaagc	gcgtatggct	tcgtacccct	gccatcaaca	1140
cgcgtctgcg	ttcgaccagg	ctgcgcgttc	tcgcggccat	agcaaccgac	gtacggcggt	1200
gcgcctctgc	cggcagcaag	aagccacgga	agtccgcctg	gagcagaaaa	tgcccacgct	1260
actgcgggtt	tatatagacg	gtcctcacgg	gatggggaaa	accaccacca	cgcaactgct	1320
ggtggccctg	ggttcgcgcg	acgatatact	ctacgtaccc	gagccgatga	cttactggca	1380
ggtgctgggg	gcttcgcgaga	caatcgcgaa	catctacacc	acacaacacc	gcctcgacca	1440
gggtgagata	tcggccgggg	acgcgcgggt	ggtaatgaca	agcgcccaga	taacaatggg	1500
catgccttat	gccgtgaccg	acgcgcgttc	ggctcctcat	gtcggggggg	aggetgggag	1560
ttcacatgcc	ccgcccccg	ccctcacctt	catcttcgac	cgccatccca	tcgcgcctct	1620
cctgtgctac	ccggccgcgc	gataccttat	gggcagcatg	acccccagg	ccgtgctggc	1680
gttcgtggcc	ctcatccgcg	cgaccttgcc	cggcacaaac	atcggtttgg	gggccccttc	1740
ggaggacaga	cacatcgacc	gcctggccaa	acgccagcgc	cccggcgagc	ggcttgacct	1800
ggctatgctg	gccgcgattc	gccgcgttta	cgggctgctt	gccaatacgg	tcgggtatct	1860
gcagggcggc	gggtcgtggt	gggaggattg	gggacagctt	tcggggacgg	ccgtgcccgc	1920
ccaggggtgc	gagccccaga	gcaacgcggg	ccccgacccc	catatcgggg	acacgttatt	1980
taccctgttt	cgggcccccg	agttgctggc	ccccaacggc	gacctgtata	acgtggttgc	2040
ctgggacctg	cgcgtcttgg	ccaaacgcgc	ccgtcccatg	cacgtcttta	tcctggatta	2100
cgaccaatcg	cccgcgggct	gccgggacgc	cctgctgcaa	cttacctccg	ggatggtcca	2160
gacccacgtc	accaccccag	gctccatacc	gacgatctgc	gacctggcgc	gcacgtttgc	2220
ccgggagatg	ggggaggcta	actgactcga	gaagcttggg	cccatcgatc	aagcttatcg	2280
ataccgtcga	aacttgttta	ttgcagctta	taatggttac	aaataaagca	atagcatcac	2340
aaatttcaca	aataaagcat	ttttttcaat	gcattctagt	tgtgggtttg	ccaaactcat	2400
caatgtatct	tatcatgtct	ggatccgacc	tcggatctgg	aagggtgctga	ggtacgatga	2460
gacccgcacc	aggtgcagac	cctgcgagtg	tgccggtaaa	catattagga	accagcctgt	2520
gatgctggat	gtgaccgagg	agctgaggcc	cgatcacttg	gtgctggcct	gcacccgcgc	2580
tgagtttggc	tctagcgatg	aagatacaga	ttgagggtact	gaaatgtgtg	ggcgtggctt	2640
aagggtggga	aagaatatat	aagggtgggg	tcttatgtag	ttttgtatct	gttttgacgc	2700
agccgcgcgc	gccatgagca	ccaactcgtt	tgatgggaag	attgtgagct	catatttgac	2760
aacgcgcgat	ccccatggg	ccgggggtgc	tcagaatgtg	atgggctcca	gcattgatgg	2820
tcgccccgct	ctgcccgcaa	actctactac	cttgacctac	gagaccgtgt	ctggaacgcc	2880
gttgagagact	gcagcctccg	ccgcgcgttc	agccgcgtga	gccaccgccc	gcgggattgt	2940
gactgacttt	gctttcctga	gccgcgttgc	aagcagtgca	gcttcccgtt	catccgcccc	3000
cgatgacaag	ttgacggctc	ttttggcaca	attggattct	ttgacccggg	aacttaattg	3060
cgtttctcag	cagctgttgg	atctgcgcga	gcaggtttct	gccctgaagg	cttccctccc	3120
tcccaatgcg	gtttaaaaa	taaaataaaa	accagactct	gtttggattt	ggatcaagca	3180
agtgtcttgc	tgtctttatt	taggggtttt	gcgcgcgcgc	taggcccggg	accagcggtc	3240
tcggctcggtg	agggtcctgt	gtattttttc	caggacgtgg	taaagggtgac	tctggatggt	3300
cagatacatg	ggcataagcc	cgtctctggg	gtggaggtag	caccactgca	gagcttcatg	3360
ctgcgggggtg	gtggtgtaga	tgatccagtc	gtagcaggag	cgctgggcgt	ggtgcctaaa	3420
aatgtctttc	agtagcaagc	tgattgccag	gggcaggccc	ttggtgtaag	tgttttacaaa	3480
gcgggttaagc	tgggatgggt	gcatacgtgg	ggatatgaga	tgcatcttgg	actgtatttt	3540
taggttggct	atgttcccag	ccatatccct	ccgggggatc	atgttgtgca	gaaccaccag	3600
cacagtgtat	ccggtgcact	tgggaaattt	gtcatgtagc	ttagaaggaa	atgctgtgaa	3660
gaacttgag	acgcccttgt	gacctccaag	attttccatg	cattcgtcca	taatgatggc	3720
aatgggcccc	cgggcggcgg	cctgggcgaa	gatattttctg	ggatcactaa	cgtcatagtt	3780
gtgttccagg	atgagatcgt	cataggccat	ttttacaaa	cgcgggcgga	gggtgccaga	3840
ctgcgggtata	atggttccat	ccggcccagg	ggcgtagtta	ccctcacaga	tttgcatttc	3900
ccacgccttg	agttcagatg	gggggatcat	gtctacctgc	ggggcgatga	agaaaacggg	3960

ttccggggta	ggggagatca	gctgggaaga	aagcagggtc	ctgagcagct	gcgacttacc	4020
gcagccgggtg	ggcccgtaaa	tcacacctat	taccggctgc	aactggtagt	taagagagct	4080
gcagctgccg	tcattccctga	gcaggggggc	cacttcgtta	agcatgtccc	tgactcgcac	4140
gtttttccctg	accaaataccg	ccagaaggcg	ctcgccgccc	agcgatagca	gttcttgcaa	4200
ggaagcaaaag	tttttcaacg	gtttgagacc	gtccgcgcta	ggcatgcttt	tgagcgtttg	4260
accaagcagt	tccaggcggt	cccacagctc	ggtcacctgc	tctacggcat	ctcgatccag	4320
catatctcct	cgtttcgcgg	gttggggcgg	ctttcgctgt	acggcagtag	tcgggtgctcg	4380
tccagacggg	ccagggtcat	gtctttccac	gggcgcaggg	tcctcgtcag	cgtagtctgg	4440
gtcacgggtga	aggggtgcgc	tccgggctgc	gcgctggcca	gggtgcgctt	gaggctgggc	4500
ctgctgggtgc	tgaagcgctg	ccggtcttcg	ccctgcgcgt	cggccaggta	gcatttgacc	4560
atggtgtcat	agtccagccc	ctccgcggcg	tggcccttgg	cgcgcagctt	gcccttgagg	4620
gaggcgccgc	acgaggggca	gtgcagactt	ttgagggcgt	agagcttggg	cgcgagaaat	4680
aocgattccg	gggagtaggc	atccgcgcgc	caggcccccgc	agacggtctc	gcattccacg	4740
agccagggtga	gctctggccg	ttcgggggtca	aaaaccagggt	ttcccccatg	ctttttgatg	4800
cgtttctttac	ctctgggttc	catgagccgg	tgtccacgct	cgggtgacgaa	aaggctgtcc	4860
gtgtccccgt	atacagactt	gagaggcctg	tcctcgagcg	gtgttccgcg	gtcctcctcg	4920
tatagaaact	cggaccactc	tgagacaaag	gctcgcgtcc	aggccagcac	gaaggaggct	4980
aagtgggagg	ggtagcggtc	gttgtccact	aggggggtcca	ctcgctccag	ggtgtgaaga	5040
cacatgtcgc	cctcttcggc	atcaagggaag	gtgattgggt	tgtaggtgta	ggccacgtga	5100
ccgggtgttc	ctgaaggggg	gctataaaag	gggggtgggg	cgcgttcgtc	ctcactctct	5160
tccgcatcgc	tgtctgcgag	ggccagctgt	tgggtgaggt	actccctctg	aaaagcgggc	5220
atgacttctg	cgctaagatt	gtcagtttcc	aaaaacgagg	aggatttgat	attcacctcg	5280
cccgcggtga	tgcttttgag	ggtggccgca	tcctctcgtt	cagaaaaagac	aatctttttg	5340
ttgtcaagct	tcgagggggg	gcccgggtacc	cagcttttgt	tccctttagt	gaggggtaat	5400
tgccgcttg	gcgtaatcat	ggtcatagct	gtttcctgtg	tgaattgttt	atccgctcac	5460
aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	cctaagtgtg	5520
gagctaactc	acattaattg	cgttgcgctc	actgcccgtc	ttccagtcgg	gaaacctgtc	5580
gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	ggcgttttgc	gtattgggcg	5640
ctcttcgcgt	tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	5700
atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	acgcaggaaa	5760
gaacatgtga	gcaaaaaggcc	agcaaaaaggc	caggaaccgt	aaaaaggccg	cgttgctggc	5820
gtttttccat	aggctccgcc	ccccctgacga	gcatcacaaa	aatcgacgct	caagtacagag	5880
gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	gctccctcgt	5940
gcgctctcct	gttccgaccc	tgccgcttac	cggataacctg	tcgccttttc	tccttcgggg	6000
aagcgtggcg	ctttctcata	gtcacgctg	taggtatctc	agttcgggtg	aggtcggtcg	6060
ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatcccg	6120
taactatcgt	cttgagtcga	acccggttaag	acacgactta	tcgccactgg	cagcagccac	6180
tggttaacagg	attagcagag	cgagggtatgt	aggcggtgct	acagagttct	tgaagtgggtg	6240
gcctaactac	ggctacacta	gaaggacagt	atttggtatc	tgcgctctgc	tgaagccagt	6300
taccttcgga	aaaagagttg	gtagctcttg	atccggcaaaa	caaaccaccg	ctggtagcgg	6360
tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	6420
tttgatctttt	tctacggggt	ctgacgctca	gtggaacgaa	aactcacggt	aagggatttt	6480
ggtcatgaga	ttatcaaaaa	ggatctttcac	ctagatcctt	ttaaattaaa	aatgaagtgt	6540
taaatacaatc	taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	6600
tgaggcacct	atctcagcga	tctgtctatt	tcgttcatcc	atagttgcct	gactccccgt	6660
cgtgtagata	actacgatac	gggagggctt	accatctggc	cccagtgctg	caatgatacc	6720
gcgagaccca	cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	ccggaagggc	6780
cgagcgcaga	agtggtcctg	caactttatc	cgccctccatc	cagtcctatta	attgttgccc	6840
ggaagctaga	gtaagtgtt	cgccagttta	tagtttgccg	aacgttgttg	ccattgctac	6900
aggcatcggtg	gtgtcacgct	cgctcgtttg	tatggcttca	ttcagctccg	gttcccaacg	6960
atcaaggcga	gttacatgat	cccccatggt	gtgcaaaaaa	gcggttagct	ccttcgggtcc	7020
tccgatcggtt	gtcagaagta	agttggccgc	agtgttatca	ctcatgggtta	tggcagcact	7080
gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtaact	7140
aaccaagtca	ttctgagaat	agtgtatgag	gcgacagagt	tgctcttgcc	cgcgctcaat	7200
acgggataat	accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacggtt	7260
ttcggggcga	aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	tgtaaccacg	7320
tcgtgcaccc	aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	ggtgagcaaa	7380
aacaggaagg	caaaatgcgc	caaaaaaggg	aataaggcg	acacggaaat	gttgaatact	7440
catactcttc	ctttttcaat	attattgaag	catttatcag	ggttatgtgc	tcatgagcgg	7500
atacatattt	gaatgtattt	agaaaaataa	acaaataggg	gttccgcgca	catttccccg	7560
aaaagtgccca	cctgacgcgc	cctgtagcgc	cgcattaagc	gcggcggttg	tgggtggttac	7620
gcgcagcgtg	accgctacac	ttgccagcgc	cctagcgcgc	gctcctttcg	ctttcttccc	7680

```

ttcctttctc gccacgttcg ccggctttcc ccgtcaagct ctaaactcggg ggctcccttt 7740
agggttccga tttagtgtt tacggcacct cgaccccaaa aaacttgatt aggggtgatgg 7800
ttcacgtagt gggccatcgc cctgatagac ggtttttcgc cctttgacgt tggagtccac 7860
gttctttaat agtggactct tgttccaaac tggacaaca ctcaacccta tctcgggtcta 7920
ttcttttgat ttataaggga ttttgcgatt tcggcctatt ggttaaaaaa tgagctgatt 7980
taacaaaaat ttaacgcgaa ttttaacaaa atattaacgc ttacaatttc cattcgccat 8040
tcaggctgcg caactgttgg gaagggcgat ccgtgcgggc ctcttcgcta ttacgccagc 8100
tggcgaaagg gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt 8160
cacgacgttg taaaacgcg gccagtgagc gcgcgtaata cgactcacta tagggcgaat 8220
tgagctcca ccgcggtg 8238

```

<210> 51
 <211> 11
 <212> DNA
 <213> adenovirus

<400> 51
 cgcgatccc g 11

<210> 52
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 52
 ctgacaaact cagatcttgt ttattg 26

<210> 53
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 53
 gtcgactcta gaggatccag a 21

<210> 54
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 54
 ccgactcta gatggcaacc atggcgctac 30

<210> 55
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 55
ggaggggaag cttggccctc agccagcctc t 31

<210> 56
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 56
tgtcttgat ccaagatgaa gcgcgcccgc cccagcgaag atgacttc 48

<210> 57
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 57
aaacacggcg gccgctcttt cattcttg 28

<210> 58
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 58
cgcgctgact cttaggacta gtttc 25

<210> 59
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 59
gcgcttaatt aacatcatca ataataacc ttatattt 37

<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 60
tgaagcgcgc aagaccgtct gaag 24

<210> 61
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 61
cataacactg cagattcttt attcttgg 28

<210> 62
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 62
ggtacacagg aaacaggagg ttccggaggt ggaggagaca caactcc 47

<210> 63
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic peptide

<400> 63
Gly Gly Ser Gly Gly Gly
1 5

<210> 64
<211> 7231
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 64
ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggtag gcgttttgcg 120
ctgcttcgcg atgtacgggc cagatatacg cgttgacatt gattattgac tagttattaa 180
tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg cgttacataa 240
cttacggtaa atggcccggc tggctgaccg cccaacgacc cccgcccatt gacgtcaata 300
atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggag 360
tatttacggg aaactgccc cttggcagta catcaagtgt atcatatgcc aagtacgccc 420
cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta catgacctta 480
tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac catggtgatg 540
cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg atttccaagt 600
ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg ggactttcca 660
aaatgtcgtg acaactccgc ccattgacg caaatgggcg gtaggcgtgt acggtgggag 720

gtctatataa	gcagagctct	ctggctaact	agagaaccca	ctgcttactg	gcttatcgaa	780
attaatacga	ctcactatag	ggagacccaa	gctggctage	gtttaaactt	aagcttggta	840
ccgagctcgg	atccactctc	ttccgcctcg	ctgtctgcga	gggccagctg	ttgggggtgag	900
tactccctct	gaaaagcggg	catgacttct	gcgctaagat	tgtcagtttc	caaaaacgag	960
gaggatttga	tattcacctg	gcccgcggtg	atgcctttga	gggtggccgc	atccatcttg	1020
tcagaaaaga	caatcttttt	gttgtaagc	ttggtggcaa	acgaccgta	gagggcggtg	1080
gacagcaact	tggcgatgga	gcgcagggtt	tggtttttgt	cgcgatcggc	gcgctccttg	1140
gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	gccattcggg	aaagacggtg	1200
gtgcgcctgt	cgggcaccag	gtgcacgcgc	caaccgcggt	tgtgcagggt	gacaaggtea	1260
acgctggtgg	ctacctctcc	gcgtaggcgc	tcgttggtcc	agcagaggcg	gcccgccttg	1320
cgcgagcaga	atggcggtag	ggggctctagc	tgcgtctcgt	ccgggggggtc	tgcgtccacg	1380
gtaaaagacc	cgggcagcag	gcgcgcgtcg	aagtagtcta	tcttgcatoc	ttgcaagtct	1440
agcgcttgct	gcatgcgcg	ggcggcaagc	gcgcgctcgt	atgggttgag	tgggggaccc	1500
catggcatgg	ggtgggtgag	cgcgaggcgc	tacatgccgc	aaatgtcgta	aacgtagagg	1560
ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	caccgcggat	gctggcgcg	1620
acgtaatcgt	atagttcgtg	cgagggagcg	aggaggctcg	gaccgagggt	gctacggggc	1680
ggctgctctg	ctcggaagac	tatctgacct	aagatggcat	gtgagttgga	tgatatggtt	1740
ggacgctgga	agacgttgaa	gctggcgtct	gtgagacctc	ccgcgtcacg	cacgaaggag	1800
gcgtaggagt	cgcgagcgtt	gttgaccagc	tcggcggtga	cctgcacgtc	tagggcgag	1860
tagtccaggg	tttccttgat	gatgtcatac	ttatcctgtc	cctttttttt	ccacagctcg	1920
cggttgagga	caaactcttc	gcggtctttc	cagtactctt	ggatcggaaa	cccgtcggcc	1980
tccgaacgag	atccgtactc	cgccgcgcag	ggacctgagc	gagtcggcat	cgaccggatc	2040
ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagtcg	caagatccaa	gatgaagcgc	2100
gcccggccca	gcgaagatga	cttcaaccct	gtctaccctc	atggctacgc	gcggaatcag	2160
aatatccctc	tcctcactgc	cccccttgct	tcctcogatg	gattcaaaaa	cttccccctc	2220
ggggtactgt	cactcaaaact	ggctgatcca	atcaccatta	ccaatgggga	tgtatccctc	2280
aaggtgggag	gtggtctcac	tttgcaagat	ggaagcctaa	ctgtaaacc	taaggctcca	2340
ctgcaagtta	atactgataa	aaaacttgag	cttgcatatg	ataatccatt	tgaaagtagt	2400
gctaataaac	ttagttttaa	agtaggacat	ggattaaaag	tattagatga	aaaaagtgtc	2460
gcggggttaa	aagattttaa	tggaactt	gtgggtttta	caggaaaagg	aataggcact	2520
gaaaattttag	aaaatacaga	tggtagcagc	agaggaattg	gtataaatgt	aagagcaaga	2580
gaagggttga	catttgacaa	tgatggatac	ttggtagcat	ggaacccaaa	gtatgacacg	2640
cgcacacttt	ggacaacacc	agacacatct	ccaaactgca	caattgctca	agataaggac	2700
tctaaactca	ctttgggtact	tacaaagtgt	ggaagtcaaa	tattagctaa	tgtgtctttg	2760
attgtggtcg	caggaaaagta	ccacatcata	aataataaga	caaatccaaa	aataaaaagt	2820
tttactatta	aactgctatt	taataagaac	ggagtgcctt	tagacaactc	aaatcttgga	2880
aaagcttatt	ggaacttttag	aagtggaaat	tccaatgttt	cgacagctta	tgaaaaagca	2940
attggtttta	tgctaatttt	ggtagcgtat	ccaaaaccca	gtaattctaa	aaaatatgca	3000
agagacatag	tttatggaa	tatatatctt	ggtggaaaac	ctgatcagcc	agcagtcatt	3060
aaaactacct	ttaaccaaga	aactggatgt	gaatactcta	tcacatttaa	ctttagttgg	3120
tccaaaacct	atgaaaatgt	tgaatttgaa	accacctctt	ttaccttctc	ctatatgtcc	3180
caagaatgaa	agagcggccg	ctcgagtcta	tgaggcccg	ttaaaccgcg	tgatcagcct	3240
cgactgtgcc	ttctagtctg	cagccatctg	ttgtttggcc	ctcccccg	ccttccttga	3300
ccctggaagg	tgccactccc	actgtccttt	cctaataaaa	tgaggaaatt	gcatcgcat	3360
gtctgagtag	gtgtcattct	attctggggg	gtgggggtgg	gcaggacagc	aagggggagg	3420
attgggaaga	caatagcagg	catgctgggg	atgcgggtgg	ctctatggct	tctgaggcgg	3480
aaagaaccag	ctggggctct	agggggtatc	cccacgcgcc	ctgtagcggc	gcattaagcg	3540
cggcggtgtg	ggtggttaag	cgcagcgtga	ccgctacact	tgccagcgcc	ctagcggccc	3600
ctcctttcgc	ttctctccct	tcctttctcg	ccacgttcgc	cggctttccc	cgtcaagctc	3660
taaatcgggg	catcccttta	gggttccgat	ttagtgtttt	acggcacctc	gaccccaaaa	3720
aacttgatta	gggtgatggt	tcacgtagt	ggccatcgcc	ctgatagacg	gtttttcgcc	3780
ctttgacgtt	ggagtccacg	ttctttaata	gtggactctt	gttccaaact	ggaacaacac	3840
tcaaccctat	ctcgggtctat	tccttttgatt	tataagggat	tttggggatt	tcggcctatt	3900
ggttaaaaaa	tgagctgatt	taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	3960
tcagtttagg	tgtggaaagt	ccccaggctc	cccagcgagg	cagaagtatg	caaagcatgc	4020
atctcaatta	gtcagcaacc	aggtgtggaa	agtcgccagg	ctccccagca	ggcagaagta	4080
tgcaaaagcat	gcatctcaat	tagtcagcaa	ccatagtccc	gccccctaact	ccgcccattc	4140
cgcgccctaac	tcgcgccagt	tcgcgccatt	ctccgcccga	tggtgacta	atttttttta	4200
tttatgcaga	ggccgaggcc	gcctctgcct	ctgagctatt	ccagaagtag	tgaggaggct	4260
tttttgagg	cctaggtctt	tgcaaaaagc	tcccgggagc	ttgtatatcc	attttcggat	4320
ctgatcagca	cgtgttgaca	attaatcatc	ggcatagtat	atcggcatag	tataatacga	4380
caaggtgag	aactaaacca	tggccaagtt	gaccagtgc	gttccgggtg	tcaccgcgcg	4440

```

cgacgtcgcc ggagcggtcg agttctggac cgaccggctc gggttctccc gggacttcgt 4500
ggaggacgac ttgcgcggtg tggtcgggga cgacgtgacc ctgttcatca gcgcggtcca 4560
ggaccaggtg gtgcgcggaca acaccctggc ctgggtgtgg gtgcgcggcc tggacgagct 4620
gtacgcgcgag tggtcggagg tcgtgtccac gaacttccgg gacgcctccg ggccggccat 4680
gaccgagatc ggcgagcagc cgtgggggcg ggagttcgcc ctgcgcgacc cggccggcaa 4740
ctgcgtgcac ttctgtggccg aggagcagga ctgacacgtg ctacgagatt tcgattccac 4800
cgccgccttc tatgaaaggt tgggcttcgg aatcgttttc cgggaocgcg gctggatgat 4860
cctccagcgc ggggatctca tgctggagtt cttcgccac cccaacttgt ttattgcagc 4920
ttataatggt tacaaataaa gcaatagcat cacaaatttc acaaataaag cttttttttc 4980
actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg tctgtatacc 5040
gtcgacctct agctagagct tggcgtaatc atggtcatag ctgtttcctg tgtgaaattg 5100
ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgtg aagcctgggg 5160
tgccaatgta gtgagctaac tcacattaat tgcgttgcgc tccactgccg ctttccagtc 5220
gggaaacctg tctgtccagc tgcattaatg atcgggcca cgcgcgggga gaggcggttt 5280
gcgtattggg cgtctcttcg cttcctcget cactgactcg ctgcgctcgg tcgttcggct 5340
gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga 5400
taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 5460
cgcgttgctg gcgttttttc ataggctccg cccccctgac gagcatcaca aaaatcgacg 5520
ctcaagtcag aggtggcgaa acccgagcag actataaaga taccaggcgt tccccctgg 5580
aagctccctc gtgcgctctc ctgttccgag cctgcgctt accggatacc tgtccgcctt 5640
tctcccttcg ggaagcgtgg cgttttctca atgctcacgc tgtaggtatc tcagttcggg 5700
gtaggtcgtt cgtctcaagc tgggctgtgt gcacgaaccc ccggttcagc ccgaccgctg 5760
cgcccttatc ggtaactatc gtcttgatc caacccggtg agacacgact tatcgccact 5820
ggcagcagcc actggtaaca ggattagcag agcgagggtg gtaggcggtg ctacagagtt 5880
gctgaagcca gttaccttcg gaaaagagtt tggtagctct tgatccggca acaaaaccac 5940
cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 6000
tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg 6060
ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta 6120
aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttgggtctg acagttacca 6180
atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 6240
ctgactcccc gtctgtaga taactacgat acgggaggggc ttaccatctg gccccagtgc 6300
tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 6360
agccggaagg gccgagcgca gaagtgttcc tgcaacttta tccgcctcca tccagtctat 6420
taattgttgc cggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 6480
tgccattgct acaggcatcg tgggtgtcacg ctcgctcgttt ggtatggctt cattcagctc 6540
cggttcccaa cgatacaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 6600
ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 6660
tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 6720
tggtagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 6780
cccggcgta atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 6840
tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 6900
gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 6960
tgggtagaca aaacacggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7020
atgttgaaata ctcatactct tcttttttca atattattga agcatttatc agggttattg 7080
tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 7140
cacatttccc cgaaaagtcg cacctgacgt c 7200
7231

```

<210> 65
 <211> 8484
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

```

<400> 65
ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggttag gcgttttgcg 120
ctgcttcgcg atgtacgggc cagatatacg cggtgacatt gattattgac tagttattaa 180
tagtaatcaa ttacgggggc attagttcat agcccatata tggagttccg cgttacataa 240

```

cttacggtaa	atggcccgcg	tggctgaccg	cccaacgacc	cccgcccatt	gacgtcaata	300
atgacgtatg	ttcccatagt	aacgcccaata	gggaattttcc	attgacgtca	atgggtggac	360
tatttacggg	aaactgcccc	cttggcagta	catcaagtgt	atcatatgcc	aagtacgcc	420
cctattgacg	tcaatgacgg	taaatggccc	gocctggcatt	atgcccagta	catgacctta	480
tgggactttc	ctacttggca	gtacatctac	gtattagtca	tcgctattac	catgggtgatg	540
cggttttggc	agtacatcaa	tggcggtgga	tagcggtttg	actcacgggg	atttccaagt	600
ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	aaaatcaacg	ggactttcca	660
aaatgtcgta	acaactccgc	cccattgacg	caaatgggcg	gtaggcgtgt	acggtgggag	720
gtctatataa	gcagagctct	ctggctaact	agagaaccca	ctgcttactg	gcttatcgaa	780
attaatacga	ctcactatag	ggagacccaa	gctggctagc	gtttaaactt	aagcttggtg	840
ccgagctcgg	atccactctc	ttccgcacgc	ctgtctgcga	gggccagctg	ttggggtgag	900
tactccctct	gaaaagcggg	catgactttc	gcgctaagat	tgtcagtttc	caaaaacgag	960
gaggatttga	tattcacctg	gcccgcggtg	atgcctttga	gggtggccgc	atccatctgg	1020
tcagaaaaga	caatcttttt	gttgtcaagc	ttggtggcaa	acgacccgta	gagggcggtg	1080
gacagcaact	tggcgatgga	gcgcagggtt	tggtttttgt	cgcgatcggc	gcgctccttg	1140
gcccgcgatg	ttagctgcac	gtattcgcg	gcaacgcacc	gccattcggg	aaagacgggtg	1200
gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggg	tgtgcagggt	gacaaggtca	1260
acgctgggtg	ctacctctcc	gcgtaggcgc	tcgttgggtc	agcagaggcg	gccgcctctg	1320
cgcgagcaga	atggcggtag	ggggtctagc	tgcgtctcgt	ccgggggggtc	tgcgtccacg	1380
gtaaagaccc	cgggcagcag	gcgcgcgctg	aagtagtcta	tcttgcaccc	ttgcaagtct	1440
agcgctgct	gccatgcgcg	ggcggaagc	gcgcgctcgt	atgggttgag	tgggggaccc	1500
catggcatgg	ggtgggtgag	cgcggaaggc	tacatgccgc	aaatgtcgta	aacgtagagg	1560
ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	caccgcggat	gctggcgcg	1620
acgtaatcgt	atagttcgtg	cgaggagcgc	aggaggtcgc	gaccgaggtt	gctacggggc	1680
ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	gtgagttgga	tgatatgggt	1740
ggacgctgga	agacgttgaa	gctggcgtct	gtgagacctt	ccgcgtcacg	cacgaaggag	1800
gcgtaggagt	cgcgacgctt	gttgaccagc	tcggcggtga	cctgcacgtc	tagggcgcg	1860
tagtccaggg	tttccttgat	gatgtcatat	ttatcctgtc	cctttttttt	ccacagctcg	1920
cggttgagga	caaactcttc	gcggtctttc	cagtactctt	ggatcgga	cccgtcggcc	1980
tccgaacgag	atccgtactc	cgccgcgag	ggacctgagc	gagtcgcgat	cgaccggatc	2040
ggaaaacctc	tcgagaaagg	cgcttaacca	gtcacagtgc	caagatccaa	gatgaagcgc	2100
gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	atgacacgga	aaccggctct	2160
ccaactgtgc	cttttcttac	tctctccttt	gtatcccca	atgggtttca	agagagtccc	2220
cctgggggtac	tctctttgcg	cctatccgaa	cctctagtta	cctccaatgg	catgcttgcg	2280
ctcaaaatgg	gcaacggcct	ctctctggac	gaggccggca	accttacctc	ccaaaatgta	2340
accactgtga	gcccacctct	caaaaaaacc	aagtcaaaca	taaacctgga	aatatctgca	2400
ccctcacag	ttacctcaga	agccctaact	gtggctgccc	ccgcacctct	aatggctcgc	2460
ggcaacacac	tcaccatgca	atcacaggcc	ccgctaaccg	tgcacgactc	caaacttagc	2520
attgccaccc	aaggacccct	cacagtgtca	gaaggaaagc	tagccctgca	aacatcaggc	2580
ccctcacca	ccaccgatag	cagtaccctt	actatcactg	cctcaccccc	tctaactact	2640
gccactggta	gcttgggcat	tgacttgaaa	gagcccattt	atacacaaaa	tggaaaacta	2700
ggactaaagt	acggggctcc	tttgcagtga	acagacgacc	taaactcttt	gaccgtagca	2760
actggtccag	gtgtgactat	taataatact	tccctgcaaa	ctaaagttac	tggagccttg	2820
ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	gaggactaag	gattgattct	2880
caaaacagac	gccttatact	tgatgttagt	tatccgtttg	atgctcaaaa	ccaactaaat	2940
ctaagactag	gacagggccc	tctttttata	aactcagccc	acaacttgga	tattaactac	3000
aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	aaaagcttga	ggttaacctt	3060
agcactgcca	aggggttgat	gtttgacgct	acagccatag	ccattaatgc	aggagatggg	3120
cttgaatttg	gttcacctaa	tgacccaac	acaaatcccc	tcaaaacaaa	aattggccat	3180
ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	taggaactgg	ccttagtttt	3240
gacagcacag	gtgccattac	agtaggaac	aaaaataatg	ataagctaac	tttgtggacc	3300
acaccagctc	catctcctaa	ctgtagacta	aatgcagaga	aagatgctaa	actcactttg	3360
gtcttaacaa	aatgtggcag	tcaataactt	gctacagttt	cagttttggc	tgttaaaggc	3420
agtttggtc	caatatctgg	aacagttcaa	agtgtctatc	ttattataag	atttgacgaa	3480
aatggagtgc	tactaaacaa	ttccttccctg	gaccagaat	attggaactt	tagaaatgga	3540
gatcttactg	aaggcacagc	ctatacaaac	cgctgtggat	ttatgcctaa	cctatcagct	3600
tatccaaaat	ctcacggtaa	aactgccaaa	agtaacattg	tcagtcaagt	ttacttaaac	3660
ggagacaaaa	ctaaacctgt	aacactaacc	attacactaa	acggtacaca	ggaaacagga	3720
gacacaactc	caagtgcata	ctctatgtca	ttttcatggg	actggtctgg	ccacaactac	3780
attaatgaaa	tatttgccac	atcctcttac	actttttcat	acattgcccc	agaataaaaag	3840
aagcgccgcg	tcgagtctag	cgataatcaa	cctctggatt	acaaaatttg	tgaaagattg	3900
actggtattc	ttaactatgt	tgctcctttt	acgctatgtg	gatacgtcgc	tttaatgcct	3960

ttgtatcatg	ctattgcttc	cogtatggct	ttcattttct	cctccttgta	taaatacctgg	4020
ttgctgtctc	tttatgagga	gttgtggccc	gttgtcaggc	aacgtggcgt	ggtgtgcact	4080
gtgtttgctg	acgcaacccc	cactggttgg	ggcattgcca	ccacctgtca	gctcctttcc	4140
gggactttcg	ctttccccct	cctatttgcc	acggcggaac	tcacgcgcgc	ctgccttgcc	4200
cgctgtcgga	caggggctcg	gctgttgggc	actgacaatt	ccgtggtgtt	gtcggggaag	4260
ctgacgtcct	ttccatggct	gctcgccctgt	gttgccacct	ggattctgcg	cgggacgtcc	4320
ttctgctacg	tcccttcggc	cctcaatcca	gcggaccttc	cttccccgcg	cctgctgccc	4380
gctctgcggc	ctcttcgcgc	tcttcgcctt	cgccctcaga	cgagtcggat	ctcccttttg	4440
gccgcctccc	cgctgatcg	ctagagggcc	cgttttaaacc	cgctgatcag	cctcgactgt	4500
gccttctagt	tgccagccat	ctgttgtttg	ccccctcccc	gtgccttcc	tgaccctgga	4560
aggtgccact	cccactgtcc	tttctaata	aaatgaggaa	attgcatcgc	attgtctgag	4620
taggtgtcat	tctattctgg	gggggtgggg	ggggcaggac	agcaaggggg	aggattggga	4680
agacaatagc	aggcatgctg	gggatgcggg	gggctctatg	gcttctgagg	cggaaagaac	4740
cagctggggc	tctagggggg	atccccacgc	gccctgtagc	ggcgcattaa	gcgcggcggg	4800
tgtggtggtt	acgcgcagcg	tgaccgctac	acttgccagc	gccctagcgc	ccgctccttt	4860
cgctttcttc	ccttcctttc	tgcgccagtt	cgccggcttt	ccccgtcaag	ctcctaaatcg	4920
gggcatccct	ttagggttcc	gatttagtgc	tttacggcac	ctcgacccca	aaaaacttga	4980
ttagggtgat	ggttcacgta	gtggggccatc	gccctgatag	acggtttttc	gcccttttgac	5040
gttgaggctc	acgttcttta	atagtggact	cttggttcaa	actggaacaa	cactcaaccc	5100
tatctcggtc	tattcttttg	atattataagg	gattttgggg	atttcggcct	attggttaaa	5160
aaatgagctg	atttaacaaa	aatttaacgc	gaattaattc	tgtggaatgt	gtgtcagtta	5220
gggtgtggaa	agtccccagg	ctccccaggc	aggcagaagt	atgcaaaagca	tgcactctcaa	5280
ttagtacgca	accaggtgtg	gaaagctccc	aggctcccca	gcaggcagaa	gtatgcaaaag	5340
catgcacttc	aattagtcag	caaacatagt	ccgcgcccta	actccgccca	tccgcgccct	5400
aactccgccc	agtccgccc	attctccgcc	ccatggctga	ctaatttttt	ttattttatgc	5460
agaggccgag	gccgcctctg	cctctgagct	attccagaag	tagtgaggag	gctttttttg	5520
aggcctaggc	ttttgcaaaa	agctcccggg	agcttgtata	tccatttttc	gatctgatca	5580
gcacgtgttg	acaattaatc	atcggcatag	tatatcgcca	tagtataata	cgacaagggtg	5640
aggaactaaa	ccatggccaa	gttgaccagt	gccgttccgg	tgctcaccgc	gcgcgacgtc	5700
gccggagccg	tcgagttctg	gaccgaaccg	ctcggttctc	cccgggactt	cgtggaggac	5760
gacttcgcgc	gtgtggtcgc	ggacgacgtg	accctgttca	tcagcgcggt	ccaggaccag	5820
gtggtgccc	acaacaccct	ggcctgggtg	tgggtgcgcg	gcctggacga	gctgtacgcc	5880
gagtggctcg	aggtcgtgtc	cacgaacttc	cgggacgcct	ccgggccggc	catgaccgag	5940
atcggcgagc	agccgtgggg	gcgggagttc	gccctgcgcg	acccggccgg	caactgcgtg	6000
cacttcgtgg	ccgaggagca	ggactgacac	gtgtctacag	atttcgatcc	caccgcgcgc	6060
ttctatgaaa	ggttgggctt	cgggaatcggt	ttccgggacg	ccggctggat	gatcctccag	6120
cgggggatc	tcattgctga	gttcttgcgc	caccccaact	tgtttattgc	agcttataat	6180
ggttacaaat	aaagcaatag	catcacaat	ttcacaata	aagcattttt	ttcactgcat	6240
tctagtgtgt	gtttgtccaa	actcatcaat	gtatcttata	atgtctgtat	accgtcgacc	6300
tctagctaga	gcttggcgta	atcatggtoa	tagctgtttc	ctgtgtgaaa	ttgttatccg	6360
ctcacaattc	cacacaacat	acgagccgga	agcataaagt	gtaaaagcct	gggtgcctaa	6420
tgagtgaagt	aactcacatt	aattgcgttg	cgtcactgc	ccgctttcca	gtcgggaaac	6480
ctgtcgtgcc	agctcgtatta	atgaatcggc	caacgcgcgc	ggagaggcgc	tttgctatt	6540
gggcgtctct	ccgcttcctc	gctcactgac	tcgtgcgcgt	cggtcgttcg	gctgcggcga	6600
gcggtatcag	ctcactcaaa	ggcggtata	cggttatcca	cagaatcagg	ggataacgca	6660
ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	accgtaaaaa	ggccgcgttg	6720
ctggcgtttt	tccataggct	ccgccccctc	gacgagcatc	acaaaaatcg	acgctcaagt	6780
cagagggtgg	gaaacccgac	aggactataa	agataaccag	cgtttccccc	tggaaagctc	6840
ctcgtgcgct	ctcctgttcc	gaccctgccc	cttaccggat	acctgtccgc	ctttctccct	6900
tcgggaagcg	tggcgctttc	tcaatgctca	cgctgtaggt	atctcagttc	ggtgtaggtc	6960
gttcgctcca	agctgggctg	tgtgcacgaa	cccccgcttc	agcccgaccg	ctgcgcctta	7020
tccggtaact	atcgtcttga	gtccaaaccg	gtaagacacg	acttatcgcc	actggcagca	7080
gccactggta	acaggattag	cagagcgagg	tatgtaggcg	gtgctacaga	gttcttgaag	7140
tggtggccta	actacggcta	cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	7200
ccagttacct	tcggaaaaag	agttggtagc	tcttgatccg	gcaaaacaa	caccgctggt	7260
agcgggtggt	tttttgtttg	caagcagcag	attacgcgca	gaaaaaaaag	atctcaagaa	7320
gatacctttg	tcttttctac	ggggtctgac	gctcagtggg	acgaaaactc	acgttaaggg	7380
atthtggta	tgagattatc	aaaaaggatc	ttcacctaga	tccttttaaa	ttaaaaatga	7440
agtttttaaa	caatctaaag	tatatatgag	taaacttggt	ctgacagtta	ccaatgctta	7500
atcagtgagg	cacctatctc	agcgatctgt	ctatttgcgt	catccatagt	tgctgactc	7560
cccgctcgtg	agataactac	gatacgggag	ggcttaccat	ctggccccag	tgctgcaatg	7620
ataccgcgag	acccacgctc	accggctcca	gatttatcag	caataaacca	gccagccgga	7680

```

agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc tattaattgt 7740
tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt 7800
gctacaggca tcgtgggtgc acgctcgtcg tttggtagtg cttcattcag ctccggttcc 7860
caacgatcaa ggcgagttac atgatcccc atgttggtgca aaaaagcggg tagctccttc 7920
ggtcctccga tcgttggtcag aagtaagtgt gccgcagtgt tatcactcat gggtatggca 7980
gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt gactgggtgag 8040
tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg 8100
tcaatacggg ataataccgc gccacatagc agaactttaa aagtgtcat cattggaaaa 8160
cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa 8220
cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga 8280
gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa ggcgcacacg gaaatgttga 8340
atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg 8400
agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt 8460
ccccgaaaag tgccacctga cgtc                                     8484

```

<210> 66

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 66

gtcactcgag gactcggctg actgaaaatg agacatatta tctgccacgg acc 53

<210> 67

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 67

cgagatcgat cacctccggg acaagggttg gcatag 36

<210> 68

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 68

catgaagatc tggaaggtgc tgagggtacga tgagacc 37

<210> 69

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 69

gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c 51

<210> 70
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 70
cacgaattcg tcagcgcttc tcgtcgcgtc caagaccc 38

<210> 71
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 71
caccgccggg aggcggcggc gacggggacg gg 32

<210> 72
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<400> 72
atgggatcca agatgaagcg cgcaagaccg 30

<210> 73
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<400> 73
cataacctgc aggattcttt attcttgggc 30

<210> 74
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<400> 74
ggtacacagg aaacaggagg ttccggaggt ggaggagaca caactcc 47

<210> 75

<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 75
atgggatcca agatgaagcg cgcaagaccg 30

<210> 76
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 76
cactatagcg gccgcattct cagtcattct 30